<SEC-DOCUMENT>0001193125-18-342511.txt : 20181206
<SEC-HEADER>0001193125-18-342511.hdr.sgml : 20181206
<ACCEPTANCE-DATETIME>20181204215918
ACCESSION NUMBER:		0001193125-18-342511
CONFORMED SUBMISSION TYPE:	PREM14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20181204
FILED AS OF DATE:		20181205
DATE AS OF CHANGE:		20181204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PREM14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		181218575

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>PREM14A
<SEQUENCE>1
<FILENAME>d646626dprem14a.htm
<DESCRIPTION>PRELIMINARY PROXY STATEMENT PERTAINING TO A MERGER
<TEXT>
<HTML><HEAD>
<TITLE>Preliminary Proxy Statement pertaining to a Merger</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE&nbsp;14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Filed by the Registrant&nbsp;&nbsp;&#9746;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by
a Party other than the Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-2</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s)
Filing Proxy Statement, if other than the Registrant) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(4)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Common stock, par value $0.001 per share, of Pacific Biosciences of California, Inc. (the &#147;common stock&#148;)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">As of November&nbsp;26, 2018, there were outstanding: (1) 149,342,128 shares of common stock; (2) 20,402,654 shares of common
stock issuable upon the exercise of stock options with an exercise price below $8.00; (3) 323,750 shares of common stock underlying restricted stock units; and (4) 586,096 shares of common stock underlying performance-based restricted stock
units.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule
<FONT STYLE="white-space:nowrap">0-11</FONT> (set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">The maximum aggregate value was determined based upon the sum of: (1) 149,342,128 shares of common stock multiplied by $8.00
per share; (2)&nbsp;stock options to purchase 20,402,654 shares of common stock with an exercise price per share below $8.00 multiplied by $3.59 per share (the difference between $8.00 and the weighted average exercise price of $4.41 per share); (3)
323,750 shares of common stock underlying restricted stock units multiplied by $8.00 per share; and (4) 586,096 shares of common stock underlying performance-based restricted stock units multiplied by $8.00 per share. In accordance with
Section&nbsp;14(g) of the Securities Exchange Act of 1934, as amended, the filing fee was determined by multiplying the sum calculated in the preceding sentence by $0.0001212.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction: $1,275,306,363.64</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Total fee paid: $154,567.13</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8.5pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>PRELIMINARY PROXY STATEMENT&#151;SUBJECT TO COMPLETION
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g646626g53x69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>], 2018 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Pacific Biosciences Stockholder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend a special meeting of stockholders, which we refer to as the
&#147;special meeting,&#148; of Pacific Biosciences of California, Inc., which we refer to as &#147;Pacific Biosciences,&#148; to be held on [&#9679;], 2019, at [&#9679;], Pacific time, at the offices of Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
Professional Corporation, located at 650 Page Mill Road, Palo Alto, California 94304. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the special meeting, you will be asked to
consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of November&nbsp;1, 2018, as it may be amended from time to time, which we refer to as the &#147;merger agreement,&#148; by and among Pacific Biosciences, Illumina,
Inc., which we refer to as &#147;Illumina,&#148; and FC Ops Corp. We refer to the acquisition of Pacific Biosciences by Illumina as the &#147;merger.&#148; At the special meeting, you will also be asked to consider and vote on (1)&nbsp;a proposal
for the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (2)&nbsp;a proposal
to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to its named executive officers in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, you will be entitled to receive $8.00 in cash, without interest and subject to any applicable withholding taxes,
for each share of common stock that you own (unless you have properly exercised your appraisal rights), which represents a premium of approximately (1)&nbsp;77&nbsp;percent to the closing price of the common stock on November&nbsp;1, 2018 (the last
trading day before the announcement of the merger); (2)&nbsp;75&nbsp;percent to the volume-weighted average price per share of the common stock for the 30&nbsp;trading day period up to and including November&nbsp;1, 2018; and
(3)&nbsp;79&nbsp;percent to the volume-weighted average price per share of the common stock for the 90&nbsp;trading day period up to and including November&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pacific Biosciences&#146; Board of Directors, after considering the factors more fully described in the enclosed proxy statement, has
unanimously: (1)&nbsp;determined that the merger agreement, the merger and the other transactions contemplated by the merger agreement are fair to, advisable and in the best interests of Pacific Biosciences and its stockholders; and (2)&nbsp;adopted
and approved the merger agreement, the merger and the other transactions contemplated by the merger agreement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pacific
Biosciences&#146; Board of Directors unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the merger agreement; (2) &#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to
solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3) &#147;FOR&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive
officers in connection with the merger. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enclosed proxy statement provides detailed information about the special meeting, the
merger agreement and the merger. A copy of the merger agreement is attached as Annex A to this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement also
describes the actions and determinations of Pacific Biosciences&#146; Board of Directors in connection with its evaluation of the merger agreement and the merger. We encourage you to read this proxy statement and its annexes, including the merger
agreement, carefully and in their entirety, as they contain important information. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not you plan to attend the special meeting in person, please sign, date and
return, as promptly as possible, the enclosed proxy card (a prepaid reply envelope is provided for your convenience) or grant your proxy electronically over the internet or by telephone (using the instructions found on the proxy card). If you attend
the special meeting and vote in person by ballot, your vote will revoke any proxy that you have previously submitted. If you fail to return your proxy or to attend the special meeting in person, your shares will not be counted for purposes of
determining whether a quorum is present at the special meeting and will have the same effect as a vote against the adoption of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held through a bank, broker or other nominee, you are considered the &#147;beneficial owner&#148; of shares held in
&#147;street name.&#148; If you hold your shares in &#147;street name&#148; you should instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instruction form that you will receive from your bank, broker or
other nominee. Your bank, broker or other nominee cannot vote on any of the proposals to be considered at the special meeting without your instructions. Without your instructions, your shares will not be counted for purposes of a quorum or voted at
the meeting, and that will have the same effect as voting against the adoption of the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your vote is very important,
regardless of the number of shares that you own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions or need assistance voting your shares, please contact our
proxy solicitor: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501 Madison Avenue, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders may call toll-free: (888) <FONT STYLE="white-space:nowrap">750-5834</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Pacific Biosciences&#146; Board of Directors, thank you for your support. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Hunkapiller, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the
Board of Directors, President and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement is dated [&#9679;], 2018, and, together with the enclosed form of proxy
card, is first being mailed on or about [&#9679;], 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>PRELIMINARY PROXY STATEMENT&#151;SUBJECT TO COMPLETION
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g646626g53x69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON [</B>&#9679;<B></B><B>], 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice is hereby given that a special meeting of stockholders of Pacific Biosciences of California, a Delaware corporation (which is referred
to as &#147;Pacific Biosciences&#148;), will be held on [&#9679;], 2019, at [&#9679;], Pacific time, at the offices of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, located at 650 Page Mill Road, Palo Alto, California 94304,
for the following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated as of
November&nbsp;1, 2018, as it may be amended from time to time, by and among Pacific Biosciences, Illumina, Inc. and FC Ops Corp. (this agreement is referred to as the &#147;merger agreement&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. To consider and vote on any proposal to adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit
additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. To consider and
vote on the proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to its named executive officers in connection with the merger; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. To transact any other business that may properly come before the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders as of the close of business on [&#9679;], are entitled to notice of the special meeting and to vote at the special meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pacific Biosciences&#146; Board of Directors unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the merger
agreement; (2) &#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special
meeting; and (3) &#147;FOR&#148; the compensation that will or may become payable by Pacific Biosciences to its named executive officers in connection with the merger. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences stockholders who do not vote in favor of the proposal to adopt the merger agreement will have the right to seek appraisal
of the &#147;fair value&#148; of their shares of common stock (exclusive of any elements of value arising from the accomplishment or expectation of the merger and together with interest (as described in the accompanying proxy statement) to be paid
on the amount determined to be &#147;fair value&#148;) in lieu of receiving the per share merger consideration if the merger is completed, as determined in accordance with Section&nbsp;262 of the Delaware General Corporation Law (which we refer to
as the &#147;DGCL&#148;). To do so, a Pacific Biosciences stockholder must properly demand appraisal before the vote is taken on the merger agreement and comply with all other requirements of Delaware law, including Section&nbsp;262 of the DGCL,
which are summarized in the accompanying proxy statement, and must meet certain conditions. Section&nbsp;262 of the DGCL is reproduced in its entirety in Annex C to the accompanying proxy statement and is incorporated in this notice by reference.
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not you plan to attend the special meeting in person, please sign, date and
return, as promptly as possible, the enclosed proxy card (a prepaid reply envelope is provided for your convenience) or grant your proxy electronically over the internet or by telephone (using the instructions found on the proxy card). If you attend
the special meeting and vote in person by ballot, your vote will revoke any proxy that you have previously submitted. If you fail to return your proxy or to attend the special meeting in person, your shares will not be counted for purposes of
determining whether a quorum is present at the special meeting and will have the same effect as a vote against the adoption of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held through a bank, broker or other nominee, you are considered the &#147;beneficial owner&#148; of shares held in
&#147;street name.&#148; If you hold your shares in &#147;street name,&#148; you should instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instruction form that you will receive from your bank, broker
or other nominee. Your bank, broker or other nominee cannot vote on any of the proposals to be considered at the special meeting without your instructions. Without your instructions, your shares will not be counted for purposes of a quorum or voted
at the meeting, and that will have the same effect as voting against the adoption of the merger agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board of Directors,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen M. Moore</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Vice President, General
Counsel and Corporate Secretary</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: [&#9679;], 2018</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Menlo Park,
CA</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Whether or not you plan to attend the special meeting in person, we encourage you to submit your proxy as promptly as possible:
(1)&nbsp;over the internet; (2)&nbsp;by telephone; or (3)&nbsp;by signing and dating the enclosed proxy card (a prepaid reply envelope is provided for your convenience). You may revoke your proxy or change your vote at any time before your proxy is
voted at the special meeting. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held through a bank, broker or other nominee, you are considered the
&#147;beneficial owner&#148; of shares held in &#147;street name.&#148; If you hold your shares in &#147;street name,&#148; you should instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instruction form
that you will receive from your bank, broker or other nominee. Your bank, broker or other nominee cannot vote on any of the proposals to be considered at the special meeting without your instructions. Without your instructions, your shares will not
be counted for purposes of a quorum or voted at the meeting, and that will have the same effect as voting against the adoption of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, voting in person by ballot at the special meeting will revoke any proxy that you previously submitted. If
you hold your shares through a bank, broker or other nominee, you must obtain a &#147;legal proxy&#148; from the bank, broker or other nominee that holds your shares in order to vote in person by ballot at the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We encourage you to read the accompanying proxy statement and its annexes, including all documents incorporated by reference into the
accompanying proxy statement, carefully and in their entirety. If you have any questions concerning the merger, the special meeting or the accompanying proxy statement, would like additional copies of the accompanying proxy statement, or need help
voting your shares, please contact our proxy solicitor: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501 Madison Avenue, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders may call toll-free: (888) <FONT STYLE="white-space:nowrap">750-5834</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_1">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_2">Parties Involved in the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_3">Effect of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_4">Effect on Pacific Biosciences if the Merger is Not Complete</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_5">Per Share Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_6">The Special Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_7">Recommendation of the Pacific Biosciences Board and Reasons for the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_8">Opinion of Centerview Partners LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_9">Treatment of Equity Awards in the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_10">Employee Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_11">Interests of Pacific Biosciences&#146; Directors and Executive Officers in the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_12">Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_13">Material U.S. Federal Income Tax Consequences of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_14">Regulatory Approvals Required for the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_15">No Solicitation of Other Offers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_16">Change in the Pacific Biosciences Board&#146;s Recommendation</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_17">Conditions to the Closing of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_18">Termination of the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_19">Termination Fees and Remedies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_20">QUESTIONS AND ANSWERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_21">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_22">THE SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_23">Date, Time and Place</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_24">Purpose of the Special Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_25">Record Date; Shares Entitled to Vote; Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_26">Vote Required; Abstentions and Broker <FONT STYLE="white-space:nowrap">Non-Votes
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_27">Shares Held by Pacific Biosciences&#146; Directors and Executive
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_28">Voting of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_29">Revocability of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_30">The Pacific Biosciences Board&#146;s Recommendation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_31">Adjournment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_32">Solicitation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_33">Anticipated Date of Completion of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_34">Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_35">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_36">Important Notice Regarding the Availability of Proxy Materials for the Stockholder
 Meeting to be Held on [&#9679;], 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_37">Householding of Special Meeting Materials</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_38">Questions and Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_39">THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_40">Parties Involved in the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_41">Effect of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_42">Effect on Pacific Biosciences if the Merger is Not Completed</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_43">Per Share Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_44">Background of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_45">Recommendation of the Pacific Biosciences Board and Reasons for the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_46">Opinion of Centerview Partners LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_47">Financial Forecasts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_48">Interests of Pacific Biosciences&#146; Directors and Executive Officers in the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_49">Payments Upon Termination Following Change of Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_50">Closing and Effective Time of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_51">Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_52">Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_53">Material U.S. Federal Income Tax Consequences of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_54">Regulatory Approvals Required for the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_55">PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_56">PROPOSAL 2: ADJOURNMENT OF THE SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_57">PROPOSAL 3: APPROVAL, ON A <FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY
 BASIS, OF CERTAIN MERGER-RELATED EXECUTIVE COMPENSATION ARRANGEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_58">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_59">Closing and Effective Time of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_60">Effects of the Merger; Certificate of Incorporation; Bylaws; Directors and Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_61">Conversion of Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_62">Payment Agent, Exchange Fund and Exchange and Payment
Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_63">Representations and Warranties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_64">Conduct of Business Pending the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_65">No Solicitation of Other Offers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_66">The Pacific Biosciences Board&#146;s Recommendation; Adverse Recommendation Change
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_67">Stockholder Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_68">Employee Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_69">Efforts to Close the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_70">Indemnification and Insurance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_71">Conditions to the Closing of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_72">Termination of the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_73">Termination Fees and Remedies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_74">Specific Performance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_75">Fees and Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_76">No Third Party Beneficiaries</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_77">Amendment and Waiver</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_78">Governing Law; Venue</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_79">Waiver of Jury Trial</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_80">THE VOTING AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_81">Voting Provisions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_82">Restrictions on Transfer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_83">Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_84">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_85">FUTURE STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_86">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_87">MISCELLANEOUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_88">Annex A&#151;Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_89">Annex B&#151;Fairness Opinion</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_90">Annex C&#151;Section&nbsp;262 of the DGCL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_91">Annex D&#151;Voting Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc646626_92">Annex E&#151;Proxy Card </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_1"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Except as otherwise specifically noted in this proxy statement, &#147;Pacific Biosciences,&#148; &#147;we,&#148; &#147;our,&#148;
&#147;us&#148; and similar words refer to Pacific Biosciences of California, Inc., including, in certain cases, our subsidiaries. Throughout this proxy statement, we refer to Pacific Biosciences&#146; Board of Directors as the &#147;Pacific
Biosciences Board.&#148; Throughout this proxy statement, we refer to Illumina, Inc. as &#147;Illumina&#148; and FC Ops Corp. as &#147;Merger Sub.&#148; In addition, throughout this proxy statement we refer to the Agreement and Plan of Merger, dated
as of November&nbsp;1, 2018, as it may be amended from time to time, by and among Pacific Biosciences, Illumina and Merger Sub, as the &#147;merger agreement.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this proxy statement related to the proposed merger of Merger Sub (a wholly owned
subsidiary of Illumina) with and into Pacific Biosciences. We refer to the transaction as the &#147;merger.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This proxy
statement may not contain all of the information that is important to you. To understand the merger more fully and for a complete description of its legal terms, you should carefully read this proxy statement, including the annexes to this proxy
statement and the other documents to which we refer in this proxy statement. You may obtain the information incorporated by reference in this proxy statement without charge by following the instructions in the section of this proxy statement
captioned &#147;Where You Can Find More Information.&#148; A copy of the merger agreement is attached as Annex A to this proxy statement. We encourage you to read the merger agreement, which is the legal document that governs the merger, carefully
and in its entirety. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_2"></A>Parties Involved in the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pacific Biosciences of California, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule,
Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) Technology, Pacific Biosciences&#146; products enable: <I>de novo</I> genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic
structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic
variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#146; technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences&#146; common stock is listed on the Nasdaq Stock Market (which we refer to as &#147;Nasdaq&#148;) under the symbol
&#147;PACB.&#148; Pacific Biosciences&#146; corporate offices are located at 1305 O&#146;Brien Drive, Menlo Park, California 94025, and its telephone number is (650) <FONT STYLE="white-space:nowrap">521-8000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Illumina, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina is the global leader in sequencing- and array-based solutions for genetic analysis. Illumina&#146;s products and services serve
customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. Illumina&#146;s customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as
well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina&#146;s portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to
accelerate and simplify genetic analysis. This portfolio addresses the range of genomic complexity, price points, and throughput, enabling customers to select the best solution for their research or clinical challenge. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina&#146;s common stock is listed on Nasdaq under the symbol &#147;ILMN.&#148;
Illumina&#146;s principal executive offices are located at 5200 Illumina Way, San Diego, California 92122, and its telephone number is (858) <FONT STYLE="white-space:nowrap">202-4500.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>FC Ops Corp. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub is a wholly owned subsidiary of Illumina and was formed on October&nbsp;29, 2018, solely for the purpose of engaging in the
transactions contemplated by the merger agreement. Merger Sub has not engaged in any business activities other than incidental to its formation and in connection with the transactions contemplated by the merger agreement. Upon completion of the
merger, Merger Sub will cease to exist and Pacific Biosciences will continue as the surviving corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub&#146;s principal
executive offices are located at c/o Illumina, Inc., 5200 Illumina Way, San Diego, California 92122, and its telephone number is (858) <FONT STYLE="white-space:nowrap">202-4500.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_3"></A>Effect of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the merger agreement, and in accordance with the DGCL, at the effective time of the merger:
(1)&nbsp;Merger Sub will merge with and into Pacific Biosciences; (2)&nbsp;the separate existence of Merger Sub will cease; and (3)&nbsp;Pacific Biosciences will continue as the surviving corporation in the merger and as a wholly owned subsidiary of
Illumina. Throughout this proxy statement, we use the term &#147;surviving corporation&#148; to refer to Pacific Biosciences as the surviving corporation following the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the merger, Pacific Biosciences will cease to be a publicly traded company. If the merger is completed, you will not own any
shares of capital stock of the surviving corporation as a result of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time at which the merger becomes effective (which we
refer to as the &#147;effective time of the merger&#148;) will occur upon the filing of a certificate of merger with, and acceptance of that certificate by, the Secretary of State of the State of Delaware (or at a later time as Pacific Biosciences,
Illumina and Merger Sub may agree and specify in such certificate of merger). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_4"></A>Effect on Pacific Biosciences if the Merger is
Not Completed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger agreement is not adopted by Pacific Biosciences stockholders, or if the merger is not completed for any
other reason, Pacific Biosciences stockholders will not receive any payment for their shares of common stock in connection with the merger. Instead: (1)&nbsp;Pacific Biosciences will remain an independent public company; (2)&nbsp;our common stock
will continue to be listed and traded on Nasdaq and registered under the Securities Exchange Act of 1934 (which we refer to as the &#147;Exchange Act&#148;); and (3)&nbsp;we will continue to file periodic reports with the Securities and Exchange
Commission (which we refer to as the &#147;SEC&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_5"></A>Per Share Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the merger agreement, at the effective time of the merger, each outstanding share of Pacific
Biosciences&#146; common stock (which we refer to as &#147;common stock&#148;) (other than shares: (1)&nbsp;held by Pacific Biosciences as treasury stock; (2)&nbsp;owned by Illumina or Merger Sub; (3) owned by any direct or indirect wholly owned
subsidiaries of Pacific Biosciences or Illumina (other than Merger Sub); or (4)&nbsp;stockholders who have properly and validly exercised, and not withdrawn or otherwise lost, their appraisal rights under Delaware law) will be canceled and
automatically converted into the right to receive $8.00 in cash, without interest and less any applicable withholding taxes. We refer to this amount as the &#147;per share merger consideration.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the closing of the merger, a sufficient amount of cash will be deposited with
a designated payment agent to pay the aggregate per share merger consideration. Once a Pacific Biosciences stockholder has provided the payment agent with his, her or its stock certificates (or an affidavit of loss in lieu of a stock certificate) or
customary agent&#146;s message with respect to book-entry shares, appropriate letter of transmittal and the other items specified by the payment agent, then the payment agent will pay the stockholder the appropriate portion of the aggregate per
share merger consideration. For more information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;Payment Agent, Exchange Fund, and Exchange and Payment Procedures.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the merger is completed, you will have the right to receive the per share merger consideration for each share of common stock that you
own, but you will no longer have any rights as a stockholder (except that Pacific Biosciences stockholders who properly and validly exercise and perfect, and do not validly withdraw or otherwise lose, their appraisal rights will have the right to
receive a payment for the &#147;fair value&#148; of their shares as determined pursuant to an appraisal proceeding as contemplated by Delaware law, as described below under the section of this proxy statement captioned &#147;The
Merger&#151;Appraisal Rights&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_6"></A>The Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Date, Time and Place </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A special meeting of Pacific Biosciences stockholders will be held on [&#9679;], 2019, at [&#9679;], Pacific time, at the offices of Wilson
Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, 650 Page Mill Road, Palo Alto, California 94304. We refer to the special meeting, and any adjournment, postponement or other delay of the special meeting, as the &#147;special
meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Purpose </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the special meeting, we will ask stockholders to vote on proposals to: (1)&nbsp;adopt the merger agreement; (2)&nbsp;adjourn the special
meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3)&nbsp;approve, on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Record Date; Shares Entitled to Vote </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are entitled to vote at the special meeting if you owned shares of common stock as of the close of business on [&#9679;] (which we refer to
as the &#147;record date&#148;). For each share of common stock that you owned as of the close of business on the record date, you will have one vote on each matter submitted for a vote at the special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the
record date, there were [&#9679;] shares of common stock outstanding and entitled to vote at the special meeting. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall
constitute a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposals to be voted on at the special meeting require the following votes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal 1: Approval of the proposal to adopt the merger agreement requires the affirmative vote of the holders
of a majority of the outstanding shares of common stock entitled to vote at the special meeting. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal 2: Approval of the proposal to adjourn the special meeting to a later date or dates to solicit
additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting requires the affirmative vote of holders of a majority of the shares of common stock present in person or represented by proxy at the
special meeting and entitled to vote on the proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal 3: Approval of the proposal to approve the compensation that will or may become payable by Pacific
Biosciences to our named executive officers in connection with the merger requires the affirmative vote of holders of a majority of the shares of common stock present in person or represented by proxy at the special meeting and entitled to vote on
the proposal. This vote will be on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting
and Proxies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any stockholder of record entitled to vote at the special meeting may vote in one of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by proxy, by returning a signed and dated proxy card (a prepaid reply envelope is provided for your convenience);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by proxy, by granting a proxy electronically over the internet or by telephone (using the instructions found on
the proxy card); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in person, by appearing at the special meeting and voting by ballot. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is voted at the special meeting by
(1)&nbsp;signing another proxy card with a later date and returning it prior to the special meeting; (2)&nbsp;submitting a new proxy electronically over the internet or by telephone after the date of the earlier submitted proxy; (3)&nbsp;delivering
a written notice of revocation to our Corporate Secretary; or (4)&nbsp;attending the special meeting and voting in person by ballot. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
you are a beneficial owner and hold your shares of common stock in &#147;street name&#148; through a bank, broker or other nominee, you should instruct your bank, broker or other nominee on how you wish to vote your shares of common stock using the
instructions provided by your bank, broker or other nominee. Under applicable stock exchange rules, banks, brokers or other nominees have the discretion to vote on routine matters, but not on <FONT STYLE="white-space:nowrap">non-routine</FONT>
matters. <B>The proposals to be considered at the special meeting are <FONT STYLE="white-space:nowrap">non-routine</FONT> matters, and banks, brokers and other nominees cannot vote on these proposals without your instructions. Therefore, it is
important that you cast your vote or instruct your bank, broker or nominee on how you wish to vote your shares.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your
shares of common stock in &#147;street name,&#148; you should contact your bank, broker or other nominee for instructions regarding how to change your vote. You may also vote in person by ballot at the special meeting if you obtain a &#147;legal
proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares at the special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_7"></A>Recommendation of the Pacific Biosciences Board and Reasons for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board, after considering various factors described in the section of this proxy statement captioned &#147;The
Merger&#151;Recommendation of the Pacific Biosciences Board and Reasons for the Merger,&#148; has unanimously: (1)&nbsp;determined that the merger agreement, the merger and the other transactions contemplated by the merger agreement are fair to,
advisable and in the best interests of Pacific Biosciences and its stockholders; and (2)&nbsp;adopted and approved the merger agreement, the merger and the other transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the merger agreement; (2)
&#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3) &#147;FOR&#148; the compensation that will or
may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_8"></A>Opinion of
Centerview Partners LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences retained Centerview Partners LLC (which we refer to as
&#147;<B></B>Centerview<B></B>&#148;) as financial advisor to the Pacific Biosciences Board in connection with the merger<B> </B>and the other transactions contemplated by the merger agreement. In connection with this engagement, the Pacific
Biosciences Board requested that Centerview evaluate the fairness, from a financial point of view, to the holders of shares of Pacific Biosciences common stock (other than common stock (1)&nbsp;held by Pacific Biosciences as treasury stock,
(2)&nbsp;owned by Illumina or Merger Sub, (3)&nbsp;owned by any direct or indirect wholly owned subsidiaries of Pacific Biosciences or Illumina (other than Merger Sub) or (4)&nbsp;shares that are held by Pacific Biosciences stockholders who have
properly exercised their respective demand for, and not effectively withdrawn, waived or lost their rights to, appraisal pursuant to Section&nbsp;262 of the Delaware General Corporation Law with respect to such shares (the shares referred to in
clauses (1)&nbsp;and (2), together with any shares of Pacific Biosciences common stock held by any affiliate of Pacific Biosciences or Illumina, are collectively referred to as &#147;<B></B>excluded shares<B></B>&#148;)) of the per share merger
consideration proposed to be paid to such holders pursuant to the merger agreement. On November&nbsp;1, 2018, Centerview rendered to the Pacific Biosciences Board its oral opinion, which was subsequently confirmed by delivery of a written opinion
dated November&nbsp;1, 2018, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the
merger consideration proposed to be paid to the holders of shares of Pacific Biosciences common stock (other than excluded shares) pursuant to the merger agreement was fair, from a financial point of view, to such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Centerview&#146;s written opinion, dated November&nbsp;1, 2018, which describes the assumptions made, procedures followed,
matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex B to this proxy statement and is incorporated by reference. <B>Centerview&#146;s financial advisory
services and opinion were provided for the information and assistance of the Pacific Biosciences Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the merger, and
Centerview&#146;s opinion addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of shares of Pacific Biosciences common stock (other than excluded shares) of the merger consideration to be paid to such
holders pursuant to the merger agreement. Centerview&#146;s opinion did not address any other term or aspect of the merger agreement or the merger and does not constitute a recommendation to any Pacific Biosciences stockholder or any other person as
to how such stockholder or other person should vote with respect to the merger or otherwise act with respect to the merger or any other matter.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of Centerview&#146;s written opinion should be read carefully in its entirety for a description of the assumptions made,
procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_9">
</A>Treatment of Equity Awards in the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that Pacific Biosciences&#146; equity awards that are
outstanding immediately prior to the effective time of the merger will be treated in the following manner in connection with the merger: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, each award covering options to acquire shares of common stock (which we refer to
as a &#147;company option&#148;) that is outstanding immediately prior to the effective </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time of the merger, whether vested or unvested, with an exercise price per share below the per share merger consideration (which we refer to as an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;in-the-money</FONT></FONT> company option&#148;) will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the excess of the per share merger consideration over the
applicable per share exercise price of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option, multiplied by (2)&nbsp;the aggregate number of shares of common stock subject to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option immediately before the effective time of the merger. Any company option that is not an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option will be canceled as of the effective time of the merger without any amount payable in exchange. Holders of unvested company options (including company options that are not <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options) will be given an opportunity to exercise any unvested company option prior to, and contingent upon, the consummation of the transactions
contemplated by the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company RSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately before the effective time of the merger, each award covering restricted stock units that are not company PRSUs (as defined
below) (which we refer to as a &#147;company RSU&#148;) that is outstanding immediately prior to the effective time of the merger and with vesting based only on continued service will be canceled and converted into the right to receive a cash amount
equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the total number of shares of common stock subject to such company RSU award immediately before the effective time of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company PRSUs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
or immediately before the effective time of the merger, each award covering restricted stock units with vesting that includes the achievement of performance-based criteria (which we refer to as a &#147;company PRSU&#148;) that is outstanding
immediately prior to the effective time of the merger will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the number of shares of common
stock that would be payable if such company PRSU award had vested at target performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2010 Employee Stock Purchase Plan (which we refer to as the &#147;ESPP&#148;) (and all outstanding rights thereunder) will be terminated no
later than as of immediately prior to the effective time of the merger, contingent upon the consummation of the transactions contemplated by the merger agreement. From and after the date of the merger agreement, no new participants are permitted to
participate in the ESPP and participants may not increase their payroll deductions or purchase elections from those in effect on the date of the merger agreement. Except for any offering or purchase period under the ESPP that is in effect on the
date of the merger agreement (which we refer to as the &#147;final offering period&#148;), no new offering or purchase period will be authorized, continued or commenced following the date of the merger agreement. In addition, from and after the date
of the merger agreement, both the maximum number of shares of common stock that a participant in the ESPP can purchase and the total number of shares of common stock available under the ESPP will not be increased. Unless otherwise agreed between
Illumina and us, the final offering period will terminate no later than as of immediately following the next scheduled purchase date (to occur on March&nbsp;1, 2019), and the exercise date under the final offering period will accelerate and occur on
such termination date with respect to any then-outstanding purchase rights. Additionally, shares of common stock purchased under the terms of the ESPP for the final offering period will be canceled at the effective time of the merger in exchange for
the right to receive the per share merger consideration in accordance with the merger agreement. As promptly as practicable following the purchase of shares of common stock under the final offering period, Pacific Biosciences will return to each
participant the funds, if any, that remain in such participant&#146;s account after such purchase. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_10"></A>Employee Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period commencing on the effective time of the merger and ending one year later (or, if shorter, during the period of employment),
Illumina will provide each employee of Pacific Biosciences or any of its subsidiaries immediately before the effective time of the merger whose employment with the surviving corporation, Illumina or any of their respective affiliates continues after
the effective time of the merger (whom we refer to as &#147;continuing employees&#148;) with (1)&nbsp;an aggregate base salary or base wages and cash target bonus opportunity no less than the aggregate base salary or base wages and cash target bonus
opportunity provided to such continuing employee immediately before the effective time of the merger; and (2)&nbsp;benefits (other than any equity or equity-based and change in control or transaction-based compensation or benefits or severance pay
or benefits) that are substantially comparable in the aggregate to either (i)&nbsp;those offered to similarly situated employees of Illumina or its affiliates; or (ii)&nbsp;those offered by Pacific Biosciences to the continuing employees as of
immediately before the effective time of the merger. The determination of the employee benefits under clause (2)&nbsp;will be made by Illumina, based on Illumina&#146;s evaluation of the nature and scope of the continuing employees&#146; duties,
principal locations, grade level and performance, among other things. However, Illumina will not have any obligation to issue, or adopt any plans or arrangements providing for the issuance of, shares of capital stock, warrants, options, stock
appreciation rights or other rights in respect of any shares of capital stock of any entity or any securities convertible into, or exchangeable or exercisable for, such shares pursuant to any such plans or arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any employee benefit plan maintained by Illumina in which any continuing employee will participate on or after the effective
time of the merger (which we refer to as &#147;Illumina benefit plans&#148;), (other than (1)&nbsp;any retiree healthcare or life insurance plans or programs maintained by Illumina and (2)&nbsp;any equity compensation arrangement) Illumina will
recognize all service with us or any subsidiary of ours provided before the effective time of the merger by continuing employees who are active Pacific Biosciences employees immediately before the closing of the merger for purposes of vesting and
eligibility (but not benefit accrual), to the extent such continuing employees otherwise would be eligible to participate or vest under the terms of such Illumina benefit plans. The service of a continuing employee before the effective time of the
merger will not be recognized for the purpose of any entitlement to participate in, or receive benefits with respect to, (1)&nbsp;any retiree medical programs or other retiree welfare benefit programs maintained by Illumina or its affiliates; or
(2)&nbsp;for purposes of early retirement subsidies under any Illumina benefit plan. In no event will these benefits result in any duplication of benefits for the same period of service. In addition, Illumina will use commercially reasonable efforts
to (1)&nbsp;waive any limitations on benefits relating to <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions to the same extent such limitations are waived under any comparable plan of Pacific Biosciences applicable to such continuing
employee before the effective time of the merger; and (2)&nbsp;recognize, for purposes of satisfying the deductibles, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets, <FONT
STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments under its medical, dental and vision plans, the deductibles, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets, <FONT STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments recognized under the corresponding
employee plan with respect to a continuing employee (and his or her eligible dependents) for the plan year in which the effective time of the merger occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless Illumina chooses otherwise, effective as of the date immediately before the closing date of the merger, Pacific Biosciences will
terminate its 401(k) plan, subject to the completion of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_11"></A>Interests of Pacific Biosciences&#146; Directors and
Executive Officers in the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the Pacific Biosciences Board that you vote to approve the
proposal to adopt the merger agreement, you should be aware that our directors and executive officers may have interests in the merger that are different from, or in addition to, your interests as a stockholder. In (1)&nbsp;evaluating and
negotiating the merger agreement, (2)&nbsp;approving the merger agreement and the merger and (3)&nbsp;recommending that the merger agreement be adopted by Pacific Biosciences stockholders, the Pacific
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biosciences Board was aware of and considered these interests to the extent that they existed at the time, among other matters. These interests include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accelerated vesting, at or immediately prior to the effective time of the merger, of company options, company
RSUs, and company PRSUs, and the treatment of outstanding rights under the ESPP, as described in more detail under the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive
Officers in the Merger&#151;Treatment of Equity-Based Awards;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entitlement of each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips to receive payments and
benefits pursuant to his or her change in control severance agreement previously entered into with Pacific Biosciences (each, a &#147;change in control agreement&#148;) if, on or within 12 months following the merger, Pacific Biosciences terminates
his or her employment with Pacific Biosciences for a reason other than &#147;cause,&#148; his or her death or &#147;disability,&#148; or he or she resigns for &#147;good reason,&#148; in each case, as set forth in the applicable change in control
agreement. These payments and benefits include: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing payments of base salary in effect immediately before the termination of his or her employment or, if
greater, the base salary as in effect immediately before the merger, from the date of termination of employment of (1)&nbsp;in the case of Dr.&nbsp;Hunkapiller, 12 months; and (2)&nbsp;in the case of Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, six
months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100&nbsp;percent of the unvested portion of his or her then-outstanding equity awards will vest immediately and,
to the extent applicable, become exercisable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as applicable, Pacific Biosciences-paid or Pacific Biosciences-reimbursed premiums for continuation coverage
pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (which we refer to as &#147;COBRA&#148;) for himself or herself and his or her eligible dependents (as applicable), subject to his or her timely election to continue such
coverage, for up to 12 months (for Dr.&nbsp;Hunkapiller) or six&nbsp;months (for Ms.&nbsp;Barnes and Mr.&nbsp;Phillips) following termination of employment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued indemnification and insurance coverage for our directors and executive officers from the surviving
corporation and Illumina under the terms of the merger agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the decision of the Pacific Biosciences Board to approve cash bonuses to Dr.&nbsp;Hunkapiller and Ms.&nbsp;Barnes
in the amount of $1,030,000 and $617,500, respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If the proposal to adopt the merger agreement is approved,
the common stock held by our directors and executive officers will be treated in the same manner as the common stock held by all other Pacific Biosciences stockholders. For more information, see the section of this proxy statement captioned
&#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger.&#148; </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_12"></A>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is consummated, Pacific Biosciences stockholders who (1)&nbsp;do not vote in favor of the adoption of the merger agreement;
(2)&nbsp;continuously hold such shares through the effective time of the merger; (3)&nbsp;properly perfected appraisal of their shares; (4)&nbsp;meet certain other conditions and statutory requirements described in this proxy statement; and
(5)&nbsp;do not withdraw their demands or otherwise lose their rights to appraisal will be entitled to seek appraisal of their shares in connection with the merger under Section&nbsp;262 of the DGCL. This means that these stockholders will be
entitled to have their shares appraised by the Delaware Court of Chancery and to receive payment in cash of the &#147;fair value&#148; of their shares of common stock, exclusive of any elements of value arising from the accomplishment or expectation
of the merger, together with (unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown) interest on the amount determined by the Delaware Court of Chancery to be fair value from the effective date of the
merger through the date of payment of </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the judgment at a rate of five percent over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger
and the date of payment of the judgment (except that, if at any time before the entry of judgment in the proceeding, the surviving corporation makes a voluntary cash payment to each stockholder seeking appraisal an amount in cash, interest will
accrue thereafter only upon the sum of (i)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery, and (ii)&nbsp;interest theretofore accrued, unless paid at that
time). The surviving corporation is under no obligation to make such voluntary cash payment prior to such entry of judgment. Due to the complexity of the appraisal process, stockholders who wish to seek appraisal of their shares are encouraged to
seek the advice of legal counsel with respect to the exercise of appraisal rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stockholders considering seeking appraisal should
be aware that the fair value of their shares as determined pursuant to Section&nbsp;262 of the DGCL could be more than, the same as or less than the value of the consideration that they would receive pursuant to the merger agreement if they did not
seek appraisal of their shares. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only a stockholder of record may submit a demand for appraisal. To exercise appraisal rights, the
stockholder of record must (1)&nbsp;submit a written demand for appraisal to Pacific Biosciences before the vote is taken on the proposal to adopt the merger agreement; (2)&nbsp;not vote, in person or by proxy, in favor of the proposal to adopt the
merger agreement; (3)&nbsp;continue to hold the subject shares of common stock of record through the effective time of the merger; and (4)&nbsp;strictly comply with all other procedures for exercising appraisal rights under the DGCL. The failure to
follow exactly the procedures specified under the DGCL may result in the loss of appraisal rights. In addition, the Delaware Court of Chancery will dismiss appraisal proceedings in respect of Pacific Biosciences unless certain conditions are
satisfied by the stockholders seeking appraisal, as described further below. The requirements under Section&nbsp;262 of the DGCL for exercising appraisal rights are described in further detail in this proxy statement, and a copy of Section&nbsp;262
of the DGCL, the relevant section of the DGCL regarding appraisal rights, is attached as Annex C to this proxy statement. If you hold your shares of common stock through a bank, broker or other nominee and you wish to exercise appraisal rights, you
should consult with your bank, broker or other nominee to determine the appropriate procedures for the making of a demand for appraisal on your behalf by your bank, broker or other nominee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_13"></A>Material U.S. Federal Income Tax Consequences of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, the receipt of cash by a U.S. Holder (as defined under the section of this proxy statement captioned
&#147;The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger&#148;) in exchange for such U.S. Holder&#146;s shares of common stock in the merger generally will result in the recognition of gain or loss in an amount measured by
the difference, if any, between the amount of cash that such U.S. Holder receives in the merger and such U.S. Holder&#146;s adjusted tax basis in the shares of common stock surrendered in the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (as defined under the section of this proxy statement captioned &#147;The
Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger&#148;) generally will not be subject to U.S. federal income tax with respect to the exchange of common stock for cash in the merger unless such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has certain connections to the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information, see the
section of this proxy statement captioned &#147;The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger.&#148;<B> Stockholders should consult their own tax advisors concerning the U.S. federal income tax consequences relating to
the merger in light of their particular circumstances and any consequences arising under U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax laws or the laws of any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxing jurisdiction.</B> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_14"></A>Regulatory Approvals Required for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, the merger cannot be completed until the waiting periods (and any extensions thereof, if any) applicable to the
merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (which we refer to as the &#147;HSR Act&#148;) and the competition laws of the European Union or one or more competent European Union member states have expired or otherwise been
terminated, or all requisite consents pursuant thereto have been obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_15"></A>No Solicitation of Other Offers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, from the date of the merger agreement until the effective time of the merger (or the earlier termination of the
merger agreement), Pacific Biosciences has agreed to cease and cause to be terminated any activities, discussions or negotiations conducted on or prior to the date of the merger agreement with any person and its representatives (other than Illumina,
Merger Sub and their respective representatives) relating to an acquisition proposal (as defined under the section of this proxy statement captioned &#147;The Merger Agreement&#151;No Solicitation of Other Offers&#148;), and to instruct each such
person and its representatives that is in possession of confidential information furnished by or on behalf of Pacific Biosciences or its subsidiaries prior to the date of the merger agreement (and all analyses and other materials prepared by or on
behalf of such person and its representatives (other than Illumina, Merger Sub and their respective representatives) that contain, reflect or analyze that information) to return or destroy all such information as promptly as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the merger agreement, from the date of the merger agreement until the effective time of the merger (or the earlier
termination of the merger agreement), Pacific Biosciences and its subsidiaries and certain of its and their respective directors and executive officers will not, and Pacific Biosciences will not authorize or direct any of its or its
subsidiaries&#146; employees, consultants or other representatives to, directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate, propose, seek or take any action for the purpose of the making, submission or announcement of,
or knowingly facilitate, assist, induce or encourage the making, submission or announcement of, any proposal that constitutes, or that would reasonably be expected to lead to an acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, engage in, participate in or maintain or continue any discussions or negotiations with, furnish any <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to Pacific Biosciences or any of its subsidiaries or afford access to the business, properties, assets, books, records or other <FONT STYLE="white-space:nowrap">non-public</FONT>
information of Pacific Biosciences or any of its subsidiaries to, or otherwise knowingly cooperate in any way with, or knowingly assist, participate in, facilitate, induce or encourage, any effort by any person (other than Illumina, Merger Sub, and
their respective representatives) concerning an acquisition proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make an adverse recommendation change; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve any transaction, or any person becoming an &#147;interested stockholder,&#148; under Section&nbsp;203 of
the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submit any acquisition proposal or any related matter to the vote of Pacific Biosciences stockholders; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize or commit to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding these restrictions, prior to the adoption of the merger agreement by Pacific Biosciences stockholders, Pacific Biosciences
may, directly or indirectly through one or more of their representatives: (1)&nbsp;contact any person or its representatives that has made (and not withdrawn) a bona fide written acquisition proposal that was not solicited in breach of the <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above to the extent necessary to clarify the terms and conditions of such acquisition proposal; (2)&nbsp;engage in discussions or negotiations with any person or its representatives
that has made (and not withdrawn) a bona fide written acquisition proposal that was </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not solicited in breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above, but only if the Pacific Biosciences Board (or a committee thereof) has reasonably
determined in good faith (after consultation with its financial advisor and outside legal counsel) that such acquisition proposal either constitutes a superior proposal (as defined under the section of this proxy statement captioned &#147;The Merger
Agreement&#151;No Solicitation of Other Offers&#148;) or is reasonably expected to lead to a superior proposal; or (3)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to Pacific Biosciences or any of its
subsidiaries to any person or its representatives that has made or delivered to Pacific Biosciences a written acquisition proposal that was not solicited in breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above
pursuant to a written confidentiality agreement, but only if, in the case of (1)&nbsp;through (3), the Pacific Biosciences Board (or a committee thereof) has determined in good faith (after consultation with its financial advisor and outside legal
counsel) that&nbsp;the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable law. For more information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;No Solicitation of Other
Offers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences is not entitled to terminate the merger agreement to enter into an agreement for a superior proposal
unless it complies with certain procedures as set forth in the merger agreement. If Pacific Biosciences terminates the merger agreement in order to accept a superior proposal, it must pay a $43.0&nbsp;million termination fee to Illumina. For more
information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;The Pacific Biosciences Board&#146;s Recommendation; Adverse Recommendation Change.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_16"></A>Change in the Pacific Biosciences Board&#146;s Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board may not withdraw its recommendation that Pacific Biosciences stockholders adopt the merger agreement or take
certain similar actions other than, under certain circumstances, if it (or a committee of the Pacific Biosciences Board) determines in good faith, after consultation with its financial advisor and outside legal counsel, that failure to do so would
be inconsistent with the Pacific Biosciences Board&#146;s fiduciary duties pursuant to applicable law and the Pacific Biosciences Board (or a committee thereof) complies with the terms of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the Pacific Biosciences Board cannot withdraw its recommendation that Pacific Biosciences stockholders adopt the merger agreement or
take certain similar actions unless it complies with certain procedures in the merger agreement, including engaging in good faith negotiations with Illumina during a specified period. If Pacific Biosciences or Illumina terminates the merger
agreement under certain circumstances, including because the Pacific Biosciences Board withdraws its recommendation that Pacific Biosciences stockholders adopt the merger agreement, then Pacific Biosciences must pay a $43.0&nbsp;million termination
fee to Illumina. For more information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;The Pacific Biosciences Board&#146;s Recommendation; Adverse Recommendation Change.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_17"></A>Conditions to the Closing of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Illumina, Merger Sub and Pacific Biosciences, as applicable, to consummate the merger are subject to the satisfaction or
waiver (where permitted by applicable law) of certain conditions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adoption of the merger agreement by the requisite affirmative vote of Pacific Biosciences stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expiration or termination of the waiting period under the HSR Act and the affirmative approval or clearance
under the competition laws of the European Union or one or more competent European Union member states; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of (1)&nbsp;any applicable law in certain jurisdictions (which we refer to as &#147;key
jurisdictions&#148;) and (2)&nbsp;any injunction, order or decree that a governmental authority in any key jurisdiction has </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
enacted, issued, promulgated, enforced or entered, that, in each case, remains in effect and makes illegal, enjoins or otherwise prohibits the consummation of the merger or the other transactions
contemplated by the merger agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the obligations of Illumina and Merger Sub to consummate the merger
are subject to the satisfaction or waiver of each of the following additional conditions, any of which may be waived exclusively by Illumina: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences having performed in all material respects all obligations under the merger agreement required
to be performed and complied with by it prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of the representations and warranties of Pacific Biosciences in the merger agreement, subject to
materiality or de minimis qualifiers, as of the effective time of the merger or the date in respect of which such representation or warranty was specifically made; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt by Illumina and Merger Sub of a customary closing certificate of Pacific Biosciences;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any Company Material Adverse Effect (as such term is defined in the section of this proxy
statement captioned &#147;The Merger Agreement&#151;Representations and Warranties&#148;) having occurred after the date of the merger agreement that is continuing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of (1)&nbsp;any applicable law in certain jurisdictions (which we refer to as &#147;specified
jurisdictions or other jurisdictions&#148;) and (2)&nbsp;any injunction, order or decree that a governmental authority in any specified jurisdiction or other jurisdiction has enacted, issued, promulgated, enforced or entered, that, in each case,
remains in effect and makes illegal, enjoins or otherwise prohibits the consummation of the merger or the other transactions contemplated by the merger agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the obligation of Pacific Biosciences to consummate the merger is subject to the satisfaction or waiver (where permitted by
applicable law) of each of the following additional conditions, any of which may be waived exclusively by Pacific Biosciences: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina and Merger Sub having complied in all material respects all obligations under the merger agreement
required to be performed by Illumina and Merger Sub prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of the representations and warranties of Illumina and Merger Sub in the merger agreement, subject to
materiality or de minimis qualifiers, as of the effective time of the merger or the date in respect of which such representation or warranty was specifically made; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt by Pacific Biosciences of a customary closing certificate of Illumina and Merger Sub.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_18"></A>Termination of the Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement may be terminated at any time prior to the effective time of the merger, whether before or after the adoption of the
merger agreement by Pacific Biosciences stockholders (except as otherwise provided in the merger agreement), in the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by mutual written agreement of Pacific Biosciences and Illumina; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Pacific Biosciences or Illumina if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger has not been consummated on or before November&nbsp;1, 2019 (which we refer to as the
&#147;termination date&#148;), except that a party may not terminate the merger agreement pursuant to this provision if such party&#146;s action or failure to act constitutes a breach of the merger agreement and has resulted in the failure to
satisfy the conditions to the closing of the merger or the failure to consummate the merger by the termination date; or </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences stockholders do not adopt the merger agreement at the special meeting, except that a party
may not terminate the merger agreement pursuant to this provision if such party&#146;s action or failure to act constitutes a breach of the merger agreement and results in the failure to obtain the approval of the Pacific Biosciences stockholders at
the special meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Pacific Biosciences if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after a <FONT STYLE="white-space:nowrap">30-day</FONT> cure period, Illumina or Merger Sub has materially
breached or failed to perform any of its respective representations, warranties, covenants or other agreements in the merger agreement such that the related closing condition would not be satisfied; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the adoption of the merger agreement by Pacific Biosciences stockholders: (1)&nbsp;the Pacific
Biosciences Board has made an adverse recommendation change in compliance with the terms of the merger agreement in order to enter into a definitive, written agreement in respect of a superior proposal; and (2)&nbsp;Pacific Biosciences pays to
Illumina a $43.0&nbsp;million termination fee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Illumina if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) after a <FONT STYLE="white-space:nowrap">30-day</FONT> cure period, Pacific Biosciences has materially
breached or failed to perform any of its representations, warranties, covenants or other agreements in the merger agreement such that the related closing condition would not be satisfied; or (2)&nbsp;Pacific Biosciences has materially breached its <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions, as described in more detail under the sections of this proxy statement captioned &#147;The Merger Agreement&#151;No Solicitation of Other Offers&#148; and &#147;The Merger
Agreement&#151;The Pacific Biosciences Board&#146;s Recommendation; Adverse Recommendation Change&#148;; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Pacific Biosciences Board has effected an adverse recommendation change. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_19"></A>Termination Fees and Remedies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to pay Illumina a termination fee of $43.0&nbsp;million if the merger agreement is terminated in specified
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In specified circumstances in which the transaction is terminated, (1)&nbsp;Illumina has agreed to pay Pacific Biosciences
a termination fee of $98.0&nbsp;million; or (2)&nbsp;Pacific Biosciences may be entitled to a specific remedy, in each case as described in more detail under the section of this proxy statement captioned &#147;The Merger Agreement&#151;Termination
Fees and Remedies.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delisting and Deregistration of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, our common stock will no longer be traded on Nasdaq and will be deregistered under the Exchange Act. We will no
longer be required to file periodic reports, current reports and proxy and information statements with the SEC on account of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting
Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the merger agreement, Illumina entered into a voting agreement (which we refer to as the
&#147;voting agreement&#148;) with the following individuals, each of whom is a director or executive officer of Pacific Biosciences: Susan K. Barnes, David Botstein, Ph.D., William W. Ericson, Christian Henry, Michael Hunkapiller, Ph.D., Randall
Livingston, John Milligan, Ph.D., Marshall Mohr, Kathy Ordo&ntilde;ez, Michael Phillips, and Lucy Shapiro, Ph.D. The voting agreement generally obligates these individuals to vote all shares of common stock owned by them in favor of adoption of the
merger agreement and against any action, proposal, agreement or transaction involving an acquisition proposal (as such term is defined in the section of this proxy statement captioned &#147;The Merger Agreement&#151;No Solicitation of Other
Offers&#148;). These individuals owned, in the aggregate, approximately 2% of our common stock as of November&nbsp;26, 2018. For more information, see the section of this proxy statement captioned &#147;The Voting Agreement.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_20"></A>QUESTIONS AND ANSWERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following questions and answers address some commonly asked questions regarding the merger, the merger agreement and the special
meeting. These questions and answers may not address all questions that are important to you. We encourage you to carefully read the more detailed information contained elsewhere in this proxy statement, including the annexes to this proxy statement
and the other documents to which we refer in this proxy statement. You may obtain the information incorporated by reference in this proxy statement without charge by following the instructions in the section of this proxy statement captioned
&#147;Where You Can Find More Information.&#148; </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why am I receiving these materials? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On November&nbsp;1, 2018, we announced that Pacific Biosciences entered into the merger agreement. Under the
merger agreement, Illumina will acquire Pacific Biosciences for $8.00 in cash per share of common stock. In order to complete the merger, Pacific Biosciences stockholders must vote to adopt the merger agreement at the special meeting. This approval
is a condition to the consummation of the merger. See the section of this proxy statement captioned &#147;The Merger Agreement&#151;Conditions to the Closing of the Merger.&#148; The Pacific Biosciences Board is furnishing this proxy statement and
form of proxy card to the holders of shares of common stock in connection with the solicitation of proxies of Pacific Biosciences stockholders to be voted at the special meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This proxy statement, which you should read carefully, contains important information about the merger, the merger agreement, the special
meeting and the matters to be voted on at the special meeting. The enclosed materials allow you to submit a proxy to vote your shares of common stock without attending the special meeting and to ensure that your shares of common stock are
represented and voted at the special meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Your vote is very important. Even if you plan to attend the special meeting, we encourage
you to submit a proxy as soon as possible. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the proposed merger and what effects will it have on Pacific Biosciences? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The proposed merger is the acquisition of Pacific Biosciences by Illumina. If the proposal to adopt the merger
agreement is approved by Pacific Biosciences stockholders and the other closing conditions under the merger agreement are satisfied or waived, Merger Sub will merge with and into Pacific Biosciences, with Pacific Biosciences continuing as the
surviving corporation. As a result of the merger, Pacific Biosciences will become a wholly owned subsidiary of Illumina, and our common stock will no longer be publicly traded and will be delisted from Nasdaq. In addition, our common stock will be
deregistered under the Exchange Act, and we will no longer file periodic reports with the SEC. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What am I being asked to vote on at the special meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are being asked to vote on the following proposals: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to adopt the merger agreement pursuant to which Merger Sub will merge with and into Pacific Biosciences, and
Pacific Biosciences will become a wholly owned subsidiary of Illumina; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to
solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will
or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When and where is the special meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The special meeting will take place on [&#9679;], 2019, at [&#9679;], Pacific time, at the offices of Wilson
Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, 650 Page Mill Road, Palo Alto, California 94304. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who is entitled to vote at the special meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Pacific Biosciences stockholders as of the close of business on [&#9679;], which is the record date for the
special meeting, are entitled to vote their shares of common stock at the special meeting. As of the close of business on the record date, there were [&#9679;] shares of common stock outstanding and entitled to vote at the special meeting. Each
share of common stock is entitled to one vote per share on each matter properly brought before the special meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I attend the special meeting and vote in person? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. Subject to the requirements described in this proxy statement, all Pacific Biosciences&#146; stockholders
of record as of the record date may attend the special meeting and vote in person. Seating will be limited. All attendees will need to present a form of government-issued photo identification to be admitted to the special meeting. Beneficial owners
of shares held in &#147;street-name&#148; will also need to present proof of ownership of shares of common stock, such as a bank or brokerage account statement. No cameras, recording equipment, electronic devices, large bags, briefcases or packages
will be permitted in the special meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Even if you plan to attend the special meeting in person, to ensure that your
shares will be represented at the special meeting, we encourage you to sign, date and return the enclosed proxy card (a prepaid reply envelope is provided for your convenience) or grant your proxy electronically over the internet or by telephone
(using the instructions found on the proxy card). If you attend the special meeting and vote in person by ballot, your vote will revoke any proxy previously submitted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If, as of the record date, you are a beneficial owner of shares held in &#147;street name,&#148; you may not vote your shares in person at the
special meeting unless you provide a &#147;legal proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares in person at the special meeting. Otherwise, you should instruct your bank, broker or other nominee how to
vote your shares in accordance with the voting instruction form that you will receive from your bank, broker or other nominee. Your bank, broker or other nominee cannot vote on any of the proposals to be considered at the special meeting without
your instructions. Without your instructions, your shares will not be counted for purposes of a quorum or voted at the meeting, which will have the same effect as voting against the adoption of the merger agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will I receive if the merger is completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon completion of the merger, you will be entitled to receive $8.00 in cash, without interest and less any
applicable withholding taxes, for each share of common stock that you own, unless you have properly exercised, and not validly withdrawn or subsequently lost, your appraisal rights under the DGCL, and certain other conditions under the DGCL are
satisfied. For example, if you own 100 shares of common stock, you will receive $800.00 in cash in exchange for your shares of common stock, without interest and less any applicable withholding taxes. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How does the per share merger consideration compare to the market price of the common stock prior to the
public announcement of the merger agreement? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The per share merger consideration represents a premium of a premium of approximately (1)&nbsp;77&nbsp;percent
to the closing price of the common stock on November&nbsp;1, 2018 (the last trading day before the announcement of the merger); (2)&nbsp;75&nbsp;percent to the volume-weighted average price per share of the common stock for the 30&nbsp;trading day
period up to and including November&nbsp;1, 2018; and (3)&nbsp;79&nbsp;percent to the volume-weighted average price per share of the common stock for the 90&nbsp;trading day period up to and including November&nbsp;1, 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We encourage you to read this proxy statement, the annexes to this proxy statement and the documents that we
refer to in this proxy statement carefully and consider how the merger affects you. Then, even if you expect to attend the special meeting, please sign, date and return, as promptly as possible, the enclosed proxy card (a prepaid reply envelope is
provided for your convenience), or grant your proxy electronically over the internet or by telephone (using the instructions found on the proxy card), so that your shares can be voted at the special meeting. If you hold your shares in &#147;street
name,&#148; please refer to the voting instruction forms provided by your bank, broker or other nominee to vote your shares. Please do not send your stock certificates with your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Should I send in my stock certificates now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. After the merger is completed, you will receive a letter of transmittal containing instructions for how to
send your stock certificates or surrender your book-entry shares to the payment agent in order to receive the appropriate cash payment for the shares of common stock represented by your stock certificates. Unless you are seeking appraisal, you
should use the letter of transmittal to exchange your stock certificates or book-entry shares for the cash payment to which you are entitled. Please do not send your stock certificates with your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I sell or transfer my shares of common stock after the record date but before the special
meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The record date for the special meeting is earlier than the date of the special meeting and the expected
effective date of the merger. If you sell or transfer your shares of common stock after the record date but before the special meeting, unless special arrangements (such as provision of a proxy) are made between you and the person to whom you sell
or transfer your shares and each of you notifies Pacific Biosciences in writing of such special arrangements, you will transfer the right to receive the per share merger consideration, if the merger is completed, to the person to whom you sell or
transfer your shares, but you will retain your right to vote those shares at the special meeting. <B>Even if you sell or transfer your shares of common stock after the record date, we encourage you to sign, date and return the enclosed proxy card (a
prepaid reply envelope is provided for your convenience) or grant your proxy electronically over the internet or by telephone (using the instructions found on the proxy card).</B> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How does the Pacific Biosciences Board recommend that I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Pacific Biosciences Board unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the
merger agreement; (2) &#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the
special meeting; and (3) &#147;FOR&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why am I being asked to cast a vote to approve the compensation that will or may become payable by Pacific
Biosciences to our named executive officers in connection with the merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SEC rules require Pacific Biosciences to seek approval, on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, of compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. Approval of the compensation that will or may
become payable by Pacific Biosciences to our named executive officers in connection with the merger is not required to consummate the merger. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the compensation that will or may become payable by Pacific Biosciences to our named executive
officers in connection with the merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The compensation that will or may become payable by Pacific Biosciences to our named executive officers in
connection with the merger is certain compensation that is tied to or based on the merger and payable to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
certain of Pacific Biosciences&#146; named executive officers pursuant to underlying plans and arrangements that are contractual in nature. Compensation that will or may become payable by
Illumina to our named executive officers in connection with or following the merger is not subject to this advisory vote. For further information, see the section of this proxy statement captioned &#147;Proposal 3: Approval of, on a non-binding,
advisory basis, Certain Merger-Related Executive Compensation Arrangements.&#148; </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen if Pacific Biosciences stockholders do not approve the compensation that will or may become
payable by Pacific Biosciences to its named executive officers in connection with the merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approval of the compensation that will or may become payable by Pacific Biosciences to our named executive
officers in connection with the merger is not a condition to consummation of the merger. The vote to approve the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger is an
advisory vote and will not be binding on Pacific Biosciences or Illumina. The underlying plans and arrangements providing for such compensation are contractual in nature and are not, by their terms, subject to stockholder approval. Accordingly, if
the merger agreement is adopted by Pacific Biosciences stockholders and the merger is consummated, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger will or may be
paid to Pacific Biosciences&#146; named executive officers even if Pacific Biosciences stockholders do not approve such compensation. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if the merger is not completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the merger agreement is not adopted by Pacific Biosciences stockholders or if the merger is not completed
for any other reason, Pacific Biosciences stockholders will not receive any payment for their shares of common stock. Instead: (1)&nbsp;Pacific Biosciences will remain an independent public company; (2)&nbsp;the common stock will continue to be
listed and traded on Nasdaq and registered under the Exchange Act; and (3)&nbsp;we will continue to file periodic reports with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to pay Illumina a termination fee of $43.0&nbsp;million if the merger agreement is terminated in specified
circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In specified circumstances in which the transaction is terminated, (1)&nbsp;Illumina has agreed to pay Pacific Biosciences
a termination fee of $98.0&nbsp;million; or (2)&nbsp;Pacific Biosciences may be entitled to a specific remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more information, see
the section of this proxy statement captioned &#147;The Merger Agreement&#151;Termination Fees and Remedies.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What vote is required to approve the proposal to adopt the merger agreement? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The affirmative vote of the holders of a majority of the outstanding shares of common stock is required to
adopt the merger agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The failure of any stockholder of record to (1)&nbsp;submit a signed proxy card;
(2)&nbsp;grant a proxy over the internet or by telephone; or (3)&nbsp;vote in person by ballot at the special meeting will have the same effect as a vote &#147;AGAINST&#148; the proposal to adopt the merger agreement. If you hold your shares in
&#147;street name,&#148; the failure to instruct your bank, broker or other nominee how to vote your shares will have the same effect as a vote &#147;AGAINST&#148; the proposal to adopt the merger agreement. Abstentions will have the same effect as
a vote &#147;AGAINST&#148; the proposal to adopt the merger agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What vote is required to approve (1)&nbsp;the proposal to adjourn the special meeting, if necessary or
appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (2)&nbsp;the proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory
basis, the compensation that will or may become payable by Pacific Biosciences to its named executive officers in connection with the merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approval of the proposal to adjourn the special meeting to a later date or dates to solicit additional proxies
if there are insufficient votes to adopt the merger agreement at the time of the special meeting requires the affirmative vote of holders of a majority of the shares of common stock issued and outstanding, present in person or represented by proxy,
at the special meeting and entitled to vote on the proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Approval of the proposal to approve, on a <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger requires the affirmative vote of holders of a
majority of the shares of common stock present in person or represented by proxy at the special meeting and entitled to vote on the proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The failure of any stockholder of record to: (1)&nbsp;submit a signed proxy card; (2)&nbsp;grant a proxy over the internet or by telephone; or
(3)&nbsp;vote in person by ballot at the special meeting will not have any effect on the proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger
agreement at the time of the special meeting, or the proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive
officers in connection with the merger, except to the extent that such failure affects obtaining a quorum at the meeting. If you hold your shares in &#147;street name,&#148; the failure to instruct your bank, broker or other nominee how to vote your
shares will not have any effect on these proposals, except to the extent that such failure affects obtaining a quorum at the meeting. In all cases, abstentions will have the same effect as a vote &#147;AGAINST&#148; these proposals. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Are there any stockholders who have already committed to vote in favor of the merger?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Yes.<B> </B>Concurrently with the execution of the merger agreement, Illumina entered into the voting
agreement with the following individuals, each of whom is a director or executive officer of Pacific Biosciences: Susan&nbsp;K. Barnes, David Botstein, Ph.D., William W. Ericson, Christian Henry, Michael Hunkapiller, Ph.D., Randall Livingston, John
Milligan, Ph.D., Marshall Mohr, Kathy Ordo&ntilde;ez, Michael Phillips and Lucy Shapiro, Ph.D. The voting agreement generally obligates these individuals to vote all shares of common stock owned by them in favor of adoption of the merger agreement
and against any action, proposal, agreement or transaction involving an acquisition proposal. These individuals owned, in the aggregate, approximately 2% of our common stock as of November&nbsp;26, 2018. For more information, see the section of this
proxy statement captioned &#147;The Voting Agreement.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the difference between holding shares as a stockholder of record and as a beneficial owner?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A.,
you are considered, with respect to those shares, to be the &#147;stockholder of record.&#148; If you are a stockholder of record, this proxy statement and your proxy card have been sent directly to you by or on behalf of Pacific Biosciences. As a
stockholder of record, you may attend the special meeting and vote your shares in person by ballot. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are
held through a bank, broker or other nominee, you are considered the &#147;beneficial owner&#148; of shares of common stock held in &#147;street name.&#148; If you are a beneficial owner of shares of common stock held in &#147;street name,&#148;
this proxy statement has been forwarded to you by your bank, broker or other nominee who is considered, with respect to those shares, to be the stockholder of record. As the beneficial owner, you have the right to direct your bank, broker or other
nominee how to vote your shares by following their instructions for voting. You are also invited to attend the special meeting. However, because you are not the stockholder of record, you may not vote your shares in person by ballot at the special
meeting unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
you provide a &#147;legal proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares at the special meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How may I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a stockholder of record (that is, if your shares of common stock are registered in your name with
Computershare Trust Company, N.A., our transfer agent), there are four ways to vote: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by signing, dating and returning the enclosed proxy card (a prepaid reply envelope is provided for your
convenience); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by visiting the internet address on your proxy card; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by calling the toll-free (within the U.S. or Canada) phone number on your proxy card; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the special meeting and voting in person by ballot. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A control number, located on your proxy card, is designed to verify your identity and allow you to vote your shares of common stock and to
confirm that your voting instructions have been properly recorded when voting electronically over the internet or by telephone. Although there is no charge for voting your shares, if you vote electronically over the internet or by telephone, you may
incur costs such as internet access and telephone charges for which you will be responsible. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Even if you plan to attend the special
meeting in person, you are strongly encouraged to vote your shares of common stock by proxy. If you are a stockholder of record or if you obtain a &#147;legal proxy&#148; to vote shares that you beneficially own, you may still vote your shares of
common stock in person by ballot at the special meeting even if you have previously voted by proxy. If you are present at the special meeting and vote in person by ballot, your vote will revoke any previously submitted proxy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; through a bank, broker or other nominee, you may vote through your bank, broker or other
nominee by completing and returning the voting instruction form provided by your bank, broker or other nominee, or, if such a service is provided by your bank, broker or other nominee, electronically over the internet or by telephone. To vote over
the internet or by telephone through your bank, broker or other nominee, you should follow the instructions on the voting instruction form provided by your bank, broker or nominee. However, because you are not the stockholder of record, you may not
vote your shares in person by ballot at the special meeting unless you provide a &#147;legal proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares at the special meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is a proxy? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy is your legal designation of another person, referred to as a &#147;proxy,&#148; to vote your shares of
common stock. The written document describing the matters to be considered and voted on at the special meeting is called a &#147;proxy statement.&#148; The document used to designate a proxy to vote your shares of common stock is called a
&#147;proxy card.&#148; You may follow the instructions on the proxy card to designate a proxy by telephone or by the Internet in the same manner as if you had signed, dated and returned a proxy card. Michael Hunkapiller, Ph.D. and Susan K. Barnes,
with full powers of substitution and resubstitution, are the proxy holders for the special meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If my broker holds my shares in &#147;street name,&#148; will my broker vote my shares for me?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. Your bank, broker or other nominee is permitted to vote your shares on any proposal currently scheduled to
be considered at the special meeting only if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided by your bank, broker or other nominee to vote your shares. Without instructions, your shares will not
be counted for the purpose of a quorum or voted on such proposals, which will have the same effect as if you voted &#147;AGAINST&#148; adoption of the merger agreement, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
but will have no effect on the adjournment proposal or the proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become
payable by Pacific Biosciences to our named executive officers in connection with the merger. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I change my vote after I have mailed my signed and dated proxy card? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is
voted at the special meeting by: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing another proxy card with a later date and returning it to us prior to the special meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submitting a new proxy electronically over the internet or by telephone after the date of the earlier submitted
proxy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering a written notice of revocation to our Corporate Secretary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending the special meeting and voting in person by ballot. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares of common stock in &#147;street name,&#148; you should contact your bank, broker or other nominee for instructions
regarding how to change your vote. You may also vote in person at the special meeting if you obtain a &#147;legal proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares at the special meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If a stockholder gives a proxy, how are the shares voted? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your
shares in the way that you direct. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you sign and date your proxy card but do not mark the boxes showing how your
shares should be voted on a matter, the shares represented by your properly signed proxy will be voted as recommended by the Pacific Biosciences Board with respect to each proposal. This means that they will be voted: (1) &#147;<B>FOR</B>&#148; the
adoption of the merger agreement; (2) &#147;<B>FOR</B>&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at
the time of the special meeting; and (3) &#147;<B>FOR</B>&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What should I do if I receive more than one set of voting materials? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We encourage you to sign, date and return each proxy card and voting instruction form (or grant your proxy
electronically over the internet or by telephone) that you receive to ensure that all of your shares are voted. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may
receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction forms, if your shares are registered differently or are held in more than one account. For example, if
you hold your shares in more than one brokerage account, you will receive a separate voting instruction form for each brokerage account in which you hold shares. If you are a stockholder of record and your shares are registered in more than one
name, you will receive more than one proxy card. Please vote all voting materials that you receive. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Where can I find the voting results of the special meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If available, Pacific Biosciences may announce preliminary voting results at the conclusion of the special
meeting. Pacific Biosciences intends to publish final voting results in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed with the SEC following the special meeting. All reports that Pacific Biosciences files with the
SEC are publicly available when filed. See the section of this proxy statement captioned &#147;Where You Can Find More Information.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will I be subject to U.S. federal income tax upon the exchange of common stock for cash pursuant to the
merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a U.S. Holder (as defined under the section of this proxy statement captioned &#147;The
Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger&#148;), the exchange of common stock for cash pursuant to the merger will be a taxable transaction for U.S. federal income tax purposes, which generally will require a U.S.
Holder to recognize gain or loss for U.S. federal income tax purposes in an amount equal to the difference, if any, between the amount of cash received by such U.S. Holder in the merger and such U.S. Holder&#146;s adjusted tax basis in the shares of
common stock surrendered in the merger. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (as defined in the
section of this proxy statement captioned &#147;The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger&#148;) generally will not be subject to U.S. federal income tax with respect to the exchange of common stock for cash in the
merger unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has certain connections to the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Because
particular circumstances may differ, we recommend that you consult your own tax advisor to determine the U.S. federal income tax consequences relating to the merger in light of your own particular circumstances and any consequences arising under
U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax laws or the laws of any state, local or foreign taxing jurisdiction. A more complete description of material U.S. federal income tax consequences of the merger is provided in the
section of this proxy statement captioned &#147;The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will the holders of company options, company RSUs, and company PRSUs receive in the merger?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At or immediately prior to the effective time of the merger, each <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the excess of the per share merger consideration over the applicable per
share exercise price of the canceled <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option, multiplied by (2)&nbsp;the aggregate number of shares of common stock subject to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> option immediately before the effective time of the merger. Any company option that is not an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option will be canceled as of the effective time of the merger without any amount payable in exchange and will have no further force or effect.
Holders of unvested company options (including company options that are not <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options) will be given an opportunity to exercise such unvested company
options prior to, and contingent upon, the consummation of the transactions contemplated by the merger agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At or
immediately prior to the effective time of the merger, each company RSU award will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the
total number of shares of common stock subject to such company RSU award immediately prior to the effective time of the merger. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At or
immediately prior to the effective time of the Merger, each company PRSU award will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the
number of shares of common stock that would be payable if such company PRSU award had vested at target performance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to the ESPP? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Our ESPP (and all outstanding rights thereunder) will be terminated no later than as of immediately
prior to the effective time of the merger, contingent upon the consummation of the transactions contemplated by the merger agreement. From and after the date of the merger agreement, no new participants are permitted to participate in the ESPP and
participants may not increase their payroll deductions or purchase elections from those in effect on the date of the merger agreement. Except for the final offering period, no new offering or purchase period will be authorized, continued or
commenced following the date of the merger </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
agreement. In addition, from and after the date of the merger agreement, both the maximum number of shares of common stock that a participant in the ESPP can purchase and the total number of
shares of common stock available under the ESPP will not be increased. Unless otherwise agreed between Illumina and us, the final offering period will terminate no later than as of immediately following the next scheduled purchase date (to occur on
March&nbsp;1, 2019), and the exercise date under the final offering period will accelerate and occur on such termination date with respect to any then-outstanding purchase rights. Additionally, shares of common stock purchased under the terms of the
ESPP for the final offering period will be canceled at the effective time of the merger in exchange for the right to receive the per share merger consideration in accordance with the merger agreement. As promptly as practicable following the
purchase of shares of common stock under the final offering period, Pacific Biosciences will return to each participant the funds, if any, that remain in such participant&#146;s account after such purchase. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When do you expect the merger to be completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We currently expect to complete the merger in <FONT STYLE="white-space:nowrap">mid-2019.</FONT> However, the
exact timing of completion of the merger, if at all, cannot be predicted because the merger is subject to the closing conditions specified in the merger agreement, many of which are outside of our control. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What governmental and regulatory approvals are required? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the terms of the merger agreement, the merger cannot be completed until the waiting period applicable to
the merger under the HSR Act has expired or been terminated. Additionally, under the terms of the merger agreement, the merger cannot be completed until affirmative approval or clearance required under the antitrust laws of the European Union or one
or more competent European Union member states have been obtained. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Am I entitled to appraisal rights under the DGCL? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the merger is consummated, Pacific Biosciences stockholders who (1)&nbsp;do not vote in favor of the
adoption of the merger agreement; (2)&nbsp;continuously hold such shares through the effective time of the merger; (3)&nbsp;properly perfect appraisal of their shares; (4)&nbsp;meet certain other conditions and statutory requirements described in
this proxy statement; and (5)&nbsp;do not withdraw their demands or otherwise lose their rights to appraisal will be entitled to seek appraisal of their shares in connection with the merger under Section&nbsp;262 of the DGCL. This means that such
stockholders will be entitled to have their shares appraised by the Delaware Court of Chancery and to receive payment in cash of the &#147;fair value&#148; of their shares of common stock, exclusive of any elements of value arising from the
accomplishment or expectation of the merger, together with (unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown) interest on the amount determined by the Delaware Court of Chancery to be fair value from
the effective date of the merger through the date of payment of the judgment at a rate of five percent over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of
the merger and the date of payment of the judgment (except that, if at any time before the entry of judgment in the proceeding, the surviving corporation makes a voluntary cash payment to each stockholder seeking appraisal, interest will accrue
thereafter only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery, and (2)&nbsp;interest theretofore accrued, unless paid at that time). The
surviving corporation is under no obligation to make such voluntary cash payment prior to such entry of judgment. Stockholders who wish to seek appraisal of their shares are in any case encouraged to seek the advice of legal counsel with respect to
the exercise of appraisal rights due to the complexity of the appraisal process. The DGCL requirements for exercising appraisal rights are described in additional detail in this proxy statement, which description is qualified in its entirety by the
relevant section of the DGCL regarding appraisal rights attached as Annex C to this proxy statement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do any of Pacific Biosciences&#146; directors or officers have interests in the merger that may differ from
those of Pacific Biosciences stockholders generally? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. In considering the recommendation of the Pacific Biosciences Board with respect to the proposal to adopt
the merger agreement, you should be aware that our directors and executive officers may have interests in the merger that are different from, or in addition to, the interests of Pacific Biosciences stockholders generally. In: (1)&nbsp;evaluating and
negotiating the merger agreement; (2)&nbsp;approving the merger agreement and the merger; and (3)&nbsp;unanimously recommending that the merger agreement be adopted by Pacific Biosciences stockholders, the Pacific Biosciences Board was aware of and
considered these interests to the extent that they existed at the time, among other matters. For more information, see the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive
Officers in the Merger.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have any questions concerning the merger, the special meeting or this proxy statement, would like
additional copies of the accompanying proxy statement or need help submitting your proxy or voting your shares of common stock, please contact our proxy solicitor: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501
Madison Avenue, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders may call toll-free: (888) <FONT STYLE="white-space:nowrap">750-5834</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_21"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement, the documents to which we refer you in this proxy statement and information included in oral statements or other written
statements made or to be made by us or on our behalf contain &#147;forward-looking statements&#148; that do not directly or exclusively relate to historical facts, including, without limitation, statements relating to the completion of the merger.
You can typically identify forward-looking statements by the use of forward-looking words, such as &#147;may,&#148; &#147;should,&#148; &#147;could,&#148; &#147;project,&#148; &#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;plan,&#148; &#147;forecast&#148; and other words of similar import. Stockholders are cautioned that any forward-looking statements are not guarantees of future performance and
may involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks detailed in our filings with the SEC,
including in our most recent filings on Forms <FONT STYLE="white-space:nowrap">10-K</FONT> and <FONT STYLE="white-space:nowrap">10-Q,</FONT> factors and matters described or incorporated by reference in this proxy statement, and the following
factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to complete the merger due to the failure of Pacific Biosciences stockholders to adopt the merger
agreement or failure to satisfy the other conditions to the completion of the merger, including that a governmental entity may prohibit, delay or refuse to grant a necessary regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the merger agreement may be terminated in circumstances that require us to pay a termination fee of
$43.0&nbsp;million; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us and others related to the merger
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks that the merger affects our ability to retain or recruit employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that receipt of the <FONT STYLE="white-space:nowrap">all-cash</FONT> per share merger consideration will
be taxable to Pacific Biosciences stockholders that are treated as U.S. Holders (as defined under the section of this proxy statement captioned &#147;The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger&#148;) for U.S. federal
income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, if the merger is completed, Pacific Biosciences stockholders will forego the opportunity to
realize the potential long-term value of the successful execution of Pacific Biosciences&#146; current strategy as an independent company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Pacific Biosciences could, at a later date, engage in unspecified transactions, including
restructuring efforts, special dividends or the sale of some or all of Pacific Biosciences&#146; assets to one or more as yet unknown purchasers, that could conceivably produce a higher aggregate value than that available to Pacific Biosciences
stockholders in the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that under the terms of the merger agreement, Pacific Biosciences is unable to solicit other acquisition
proposals during the pendency of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the announcement or pendency of the merger on our business relationships, customers, operating
results and business generally, including risks related to the diversion of the attention of Pacific Biosciences management or employees during the pendency of the merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the costs, fees, expenses and charges related to the merger agreement or the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the proposed merger will not be consummated in a timely manner, exceeding the expected costs of the
merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that our stock price may decline significantly if the merger is not completed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks related to obtaining the requisite stockholder approval to the merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, all of the forward-looking statements that we make in this proxy statement are qualified by the information contained or
incorporated by reference in this proxy statement, including: (1)&nbsp;the information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained under this caption; and (2)&nbsp;the information contained under the caption &#147;Risk Factors,&#148; and information in our consolidated financial statements and notes thereto
included in our most recent filings on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q.</FONT> No assurance can be given that these are all of the factors that could cause actual results to
vary materially from the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by applicable law, we undertake no obligation to publicly update
forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders are advised to consult any future disclosures that we make on related subjects as may be detailed in our other filings made from time to
time with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_22"></A>THE SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This proxy statement is being provided to Pacific Biosciences stockholders as part of a solicitation by the Pacific Biosciences Board of
proxies for use at the special meeting. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_23"></A>Date, Time and Place </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will hold the special meeting on [&#9679;], 2019, at [&#9679;], Pacific time, at the offices of Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
Professional Corporation, 650 Page Mill Road, Palo Alto, California 94304. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_24"></A>Purpose of the Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the special meeting, we will ask stockholders to vote on proposals to (1)&nbsp;adopt the merger agreement; (2)&nbsp;adjourn the special
meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3)&nbsp;approve, on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_25"></A>Record Date; Shares Entitled to Vote; Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only Pacific Biosciences stockholders as of the close of business on the record date are entitled to notice of, and to vote at, the special
meeting. A list of stockholders of record entitled to vote at the special meeting will be available at our corporate offices located at 1305 O&#146;Brien Drive, Menlo Park, California 94025, during regular business hours for a period of no less than
10 days before the special meeting and at the place of the special meeting during the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the record date, there were
[&#9679;] shares of common stock outstanding and entitled to vote at the special meeting. Each share of common stock is entitled to one vote per share on each matter properly brought before the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence in person or represented by proxy of the holders of a majority of the shares of common stock issued and outstanding and entitled
to vote at the special meeting will constitute a quorum at the special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_26"></A>Vote Required; Abstentions and Broker <FONT
STYLE="white-space:nowrap">Non-Votes</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the proposal to adopt the merger agreement requires the affirmative vote of
the holders of a majority of the outstanding shares of common stock entitled to vote on the proposal. Adoption of the merger agreement by Pacific Biosciences&#146; stockholders is a condition to the closing of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the proposal to adjourn the special meeting to a later date or dates to solicit additional proxies if there are insufficient votes
to adopt the merger agreement at the time of the special meeting requires the affirmative vote of the holders of a majority of the shares of common stock present in person or represented by proxy at the special meeting and entitled to vote on the
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, of the compensation that will or may become
payable by Pacific Biosciences to our named executive officers in connection with the merger requires the affirmative vote of the holders of a majority of the shares of common stock present in person or represented by proxy at the special meeting
and entitled to vote on the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stockholder abstains from voting, that abstention will have the same effect as if the
stockholder voted: (1) &#147;AGAINST&#148; the proposal to adopt the merger agreement; (2) &#147;AGAINST&#148; any proposal to adjourn the special meeting to a later date to solicit additional proxies if there are insufficient votes to adopt the
merger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement at the time of the special meeting; and (3) &#147;AGAINST&#148; the proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, compensation that will
or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. Abstentions will be counted as present for purposes of determining whether a quorum exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> generally occurs when a bank, broker or other nominee holding shares on
your behalf does not vote on a proposal because the bank, broker or other nominee has not received your voting instructions and lacks discretionary power to vote your shares. We do not expect any &#147;broker
<FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> at the special meeting, but if there are any, they will be counted for the purpose of determining whether a quorum is present. If there are broker
<FONT STYLE="white-space:nowrap">non-votes,</FONT> each broker <FONT STYLE="white-space:nowrap">non-vote</FONT> will count as a vote &#147;AGAINST&#148; the proposal to adopt the merger agreement, but will have no effect on: (1)&nbsp;the proposal to
adjourn the special meeting to a later date to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; or (2)&nbsp;the proposal to approve, on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_27"></A>Shares Held by Pacific Biosciences&#146; Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the record date, our directors and executive officers beneficially owned and were entitled to vote, in the aggregate, [&#9679;] shares of
common stock, representing approximately [&#9679;] percent of the shares of common stock outstanding as of the record date. Our directors and executive officers have informed us that they intend to vote all of their shares of common stock: (1)
&#147;<B>FOR</B>&#148; the adoption of the merger agreement; (2) &#147;<B>FOR</B>&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to
adopt the merger agreement at the time of the special meeting; and (3) &#147;<B>FOR</B>&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the merger agreement, Illumina entered into the voting agreement with the following individuals, each of
whom is a director or executive officer of Pacific Biosciences: Susan K. Barnes, David Botstein, Ph.D., William W. Ericson, Christian Henry, Michael Hunkapiller, Ph.D., Randall Livingston, John Milligan, Ph.D., Marshall Mohr, Kathy Ordo&ntilde;ez,
Michael Phillips and Lucy Shapiro, Ph.D. The voting agreement generally obligates these individuals to vote all shares of common stock owned by them in favor of adoption of the merger agreement and against any action, proposal, agreement or
transaction involving an acquisition proposal. These individuals owned, in the aggregate, approximately 2% of our common stock as of November&nbsp;26, 2018. For more information, see the section of this proxy statement captioned &#147;The Voting
Agreement.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_28"></A>Voting of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are registered in your name with our transfer agent, Computershare Trust Company, N.A., you may vote your shares by returning a
signed and dated proxy card (a prepaid reply envelope is provided for your convenience), or you may vote in person by ballot at the special meeting. Additionally, you may grant a proxy electronically over the internet or by telephone by following
the instructions on your proxy card. You must have the enclosed proxy card available, and follow the instructions on the proxy card, in order to grant a proxy electronically over the internet or by telephone. Based on your proxy cards or internet
and telephone proxies, the proxy holders will vote your shares according to your directions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you attend the special meeting and wish
to vote in person, you will be given a ballot at the special meeting. All attendees will need to present a form of government-issued photo identification to be admitted to the special meeting. Beneficial owners of shares held in &#147;street
name&#148; will also need to present proof of ownership of shares of common stock, such as a bank or brokerage account statement and must also provide a &#147;legal proxy&#148; from their bank or broker in order to vote in person at the special
meeting. You are encouraged to vote by proxy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
even if you plan to attend the special meeting in person. If you attend the special meeting and vote in person by ballot, your vote will revoke any previously submitted proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares represented by properly signed and dated proxies received will, if received before the special meeting, be voted at the special
meeting in accordance with the instructions of the stockholder. Properly signed and dated proxies that do not contain voting instructions will be voted: (1) &#147;FOR&#148; adoption of the merger agreement; (2) &#147;FOR&#148; the adjournment of the
special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3) &#147;FOR&#148; the compensation that will
or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in
&#147;street name&#148; through a bank, broker or other nominee, you may vote through your bank, broker or other nominee by completing and returning the voting instruction form provided by your bank, broker or other nominee. You may also attend the
special meeting and vote in person by ballot if you have a &#147;legal proxy&#148; from your bank, broker or other nominee giving you the right to vote your shares at the special meeting. If available, you may vote over the internet or telephone
through your bank, broker or other nominee by following the instructions on the voting instruction form provided by your bank, broker or other nominee. If you do not: (1)&nbsp;return your bank&#146;s, broker&#146;s or other nominee&#146;s voting
instruction form; (2)&nbsp;vote over the internet or by telephone through your bank, broker or other nominee, if possible; or (3)&nbsp;attend the special meeting and vote in person with a &#147;legal proxy&#148; from your bank, broker or other
nominee, it will have the same effect as if you voted &#147;AGAINST&#148; the proposal to adopt the merger agreement. It will not have any effect on the proposals: (1)&nbsp;to adjourn the special meeting, if necessary or appropriate, to solicit
additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; or (2)&nbsp;to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may
become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_29"></A>Revocability of
Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is voted at the
special meeting by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing another proxy card with a later date and returning it to us prior to the special meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submitting a new proxy electronically over the internet or by telephone after the date of the earlier submitted
proxy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering a written notice of revocation to our Corporate Secretary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending the special meeting and voting in person by ballot. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have submitted a proxy, your appearance at the special meeting, in the absence of voting in person or submitting an additional proxy or
revocation, will not have the effect of revoking your prior proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares of common stock in &#147;street name,&#148;
you should contact your bank, broker or other nominee for instructions regarding how to change your vote. You may also vote in person at the special meeting if you obtain a &#147;legal proxy&#148; from your bank, broker or other nominee giving you
the right to vote your shares at the special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any adjournment, postponement or other delay of the special meeting, including for
the purpose of soliciting additional proxies, will allow Pacific Biosciences stockholders who have already sent in their proxies to revoke them at any time prior to their use at the special meeting as adjourned, postponed or delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_30"></A>The Pacific Biosciences Board&#146;s Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board, after considering various factors described in the section of this proxy statement captioned &#147;The
Merger&#151;Recommendation of the Pacific Biosciences Board and Reasons for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger,&#148; has unanimously: (1)&nbsp;determined that the merger agreement, the merger and the other transactions contemplated by the merger agreement are fair to, advisable and in the best
interests of Pacific Biosciences and its stockholders; and (2)&nbsp;adopted and approved the merger agreement, the merger and the other transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the merger agreement; (2)
&#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and (3)
&#147;FOR&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_31"></A>Adjournment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the proposals to (1)&nbsp;adopt the merger agreement and (2)&nbsp;approve, on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger, Pacific Biosciences stockholders are also
being asked to approve a proposal to adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional votes or proxies in favor of the proposal to adopt the merger agreement if there are insufficient votes at
the time of the special meeting to approve the merger agreement. If a quorum is not present, the chairperson of the special meeting or the stockholders entitled to vote at the special meeting, present in person or represented by proxy, may adjourn
the special meeting, from time to time, without notice other than announcement at the meeting, until a quorum is present or represented. In addition, the special meeting could be postponed before it commences, subject to the terms of the merger
agreement. If the special meeting is adjourned or postponed, Pacific Biosciences stockholders who have already submitted their proxies will be able to revoke them at any time before they are voted at the special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_32"></A>Solicitation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expense of soliciting proxies will be borne by Pacific Biosciences. We have retained Innisfree M&amp;A Incorporated, a professional proxy
solicitation firm, to assist in the solicitation of proxies, and provide related advice and informational support during the solicitation process, for a fee of $20,000, plus reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. We will indemnify Innisfree M&amp;A Incorporated against losses arising out of its provisions of these services on our behalf. In addition, we
may reimburse banks, brokers and other nominees representing beneficial owners of shares of common stock for their expenses in forwarding soliciting materials to such beneficial owners. Proxies may also be solicited by our directors, officers and
employees, personally or by telephone, email, fax or over the internet. No additional compensation will be paid for such services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_33">
</A>Anticipated Date of Completion of the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to complete the merger in
<FONT STYLE="white-space:nowrap">mid-2019.</FONT> However, the exact timing of completion of the merger, if at all, cannot be predicted because the merger is subject to the closing conditions specified in the merger agreement, many of which are
outside of our control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_34"></A>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is consummated, stockholders who (1)&nbsp;do not vote in favor of the adoption of the merger agreement; (2)&nbsp;continuously
hold such shares through the effective time of the merger; (3)&nbsp;properly perfect appraisal of their shares; (4)&nbsp;meet certain other conditions and statutory requirements described in this proxy statement; and (5)&nbsp;do not withdraw their
demands or otherwise lose their rights to appraisal will be entitled to seek appraisal of their shares in connection with the merger under Section&nbsp;262 of the DGCL. This means that such stockholders will be entitled to seek appraisal of their
shares by the Delaware Court of Chancery and to receive payment in cash of the &#147;fair value&#148; of their shares of common stock, exclusive of any elements of value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arising from the accomplishment or expectation of the merger, together with (unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown) interest on the
amount determined by the Delaware Court of Chancery to be fair value from the effective date of the merger through the date of payment of the judgment at a rate of five percent over the Federal Reserve discount rate (including any surcharge) as
established from time to time during the period between the effective date of the merger and the date of payment of the judgment (except that, if at any time before the entry of judgment in the proceeding, the surviving corporation makes a voluntary
cash payment to each stockholder seeking appraisal, interest will accrue thereafter only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery,
and (2)&nbsp;interest theretofore accrued, unless paid at that time). The surviving corporation is under no obligation to make such voluntary cash payment prior to such entry of judgment. Due to the complexity of the appraisal process, stockholders
who wish to seek appraisal of their shares are encouraged to seek the advice of legal counsel with respect to the exercise of appraisal rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stockholders considering seeking appraisal should be aware that the fair value of their shares as determined pursuant to Section&nbsp;262
of the DGCL could be more than, the same as or less than the value of the consideration that they would receive pursuant to the merger agreement if they did not seek appraisal of their shares. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only a stockholder of record may submit a demand for appraisal. To exercise appraisal rights, the stockholder of record must (1)&nbsp;submit a
written demand for appraisal to Pacific Biosciences before the vote is taken on the proposal to adopt the merger agreement; (2)&nbsp;not vote, in person or by proxy, in favor of the proposal to adopt the merger agreement; (3)&nbsp;continue to hold
the subject shares of common stock of record through the effective time of the merger; and (4)&nbsp;strictly comply with all other procedures for exercising appraisal rights under the DGCL. The failure to follow exactly the procedures specified
under the DGCL may result in the loss of appraisal rights. In addition, the Delaware Court of Chancery will dismiss appraisal proceedings in respect of Pacific Biosciences unless certain conditions are satisfied by the stockholders seeking
appraisal, as described further below. The requirements under Section&nbsp;262 of the DGCL for exercising appraisal rights are described in further detail in this proxy statement, which description is qualified in its entirety by Section&nbsp;262 of
the DGCL, the relevant section of the DGCL regarding appraisal rights, a copy of which is attached as Annex C to this proxy statement. If you hold your shares of common stock through a bank, broker or other nominee and you wish to exercise appraisal
rights, you should consult with your bank, broker or other nominee to determine the appropriate procedures for the making of a demand for appraisal on your behalf by your bank, broker or other nominee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_35"></A>Other Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we know of no other matters to be voted on at the special meeting. If any other matters properly come before the special meeting,
your shares of common stock will be voted in accordance with the discretion of the appointed proxy holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_36"></A>Important
Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on [</B>&#9679;<B></B><B>], 2019 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
proxy statement is available on our website at www.pacb.com under the Investor Relations tab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_37"></A>Householding of Special
Meeting Materials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a procedure approved by the SEC called &#147;householding.&#148; Under this procedure, stockholders
who have the same address and last name will receive only one copy of this proxy statement unless one or more of these stockholders notifies us that they wish to continue receiving individual copies. This procedure reduces printing costs, postage
fees and the use of natural resources. Each stockholder who participates in householding will continue to be able to access or receive a separate proxy card. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you wish to receive a separate set of our disclosure documents at this time, please
notify us by sending a written request to Investor Relations, Pacific Biosciences of California, Inc., 1305 O&#146;Brien Drive, Menlo Park, California 94025 or by <FONT STYLE="white-space:nowrap">e-mail</FONT> to ir@pacificsciences.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder who has multiple accounts in your name or you share an address with other stockholders and would like to receive a
single set of our disclosure documents for your household, you may notify your broker, if your shares are held in a brokerage account. If you hold registered shares, you may contact our Corporate Secretary using the contact method above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_38"></A>Questions and Additional Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions concerning the merger, the special meeting or this proxy statement, would like additional copies of this proxy
statement or need help submitting your proxy or voting your shares of common stock, please contact our proxy solicitor: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A
Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501 Madison Avenue, 20th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders may call toll-free: (888) <FONT STYLE="white-space:nowrap">750-5834</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_39"></A>THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and obligations of the parties to the merger agreement are governed by the specific terms and conditions of the merger agreement
and not by any summary or other information in this proxy statement. Therefore, this discussion of the merger is qualified in its entirety by reference to the merger agreement, a copy of which is attached as Annex A to this proxy statement and
incorporated into this proxy statement by reference. You should read the entire merger agreement carefully as it is the legal document that governs the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_40"></A>Parties Involved in the Merger </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pacific Biosciences of California, Inc. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1305 O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Menlo
Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(650) <FONT STYLE="white-space:nowrap">521-8000</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule,
Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) Technology, Pacific Biosciences&#146; products enable: <I>de novo</I> genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic
structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic
variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#146; technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences&#146; common stock is listed on Nasdaq under the symbol &#147;PACB.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Illumina, Inc. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5200 Illumina Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego,
California 92122 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">202-4500</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina is the global leader in sequencing- and array-based solutions for genetic analysis. Illumina&#146;s products and services serve
customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. Illumina&#146;s customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as
well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina&#146;s portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to
accelerate and simplify genetic analysis. This portfolio addresses the range of genomic complexity, price points, and throughput, enabling customers to select the best solution for their research or clinical challenge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina&#146;s common stock is listed on Nasdaq under the symbol &#147;ILMN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>FC Ops Corp. </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o
Illumina, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5200 Illumina Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, California 92122 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">202-4500</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub is a wholly owned subsidiary of Illumina and was formed on October&nbsp;29, 2018, solely for the purpose of engaging in the
transactions contemplated by the merger agreement. Merger Sub has not engaged in any business activities other than incidental to its formation and in connection with the transactions contemplated by the merger agreement. Upon completion of the
merger, Merger Sub will cease to exist and Pacific Biosciences will continue as the surviving corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_41"></A>Effect of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the merger agreement, and in accordance with the DGCL, at the effective time of the merger,
(1)&nbsp;Merger Sub will merge with and into Pacific Biosciences; (2)&nbsp;the separate existence of Merger Sub will cease; and (3)&nbsp;Pacific Biosciences will continue as the surviving corporation in the merger and a wholly owned subsidiary of
Illumina. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the merger, Pacific Biosciences will cease to be a publicly traded company, will be delisted from Nasdaq, its
common stock will be deregistered under the Exchange Act, and it will no longer file periodic reports with the SEC. If the merger is completed, you will not own any shares of capital stock of the surviving corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective time of the merger will occur upon the filing of a certificate of merger with, and acceptance of that certificate by, the
Secretary of State of the State of Delaware (or at a later time as we, Illumina and Merger Sub may agree and specify in such certificate of merger). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_42">
</A>Effect on Pacific Biosciences if the Merger is Not Completed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger agreement is not adopted by Pacific Biosciences
stockholders, or if the merger is not completed for any other reason, Pacific Biosciences stockholders will not receive any payment for their shares of common stock in connection with the merger. Instead, (1)&nbsp;Pacific Biosciences will remain an
independent public company; (2)&nbsp;our common stock will continue to be listed and traded on Nasdaq and registered under the Exchange Act; and (3)&nbsp;we will continue to file periodic reports with the SEC. In addition, if the merger is not
completed, we expect that: (1)&nbsp;our management will operate the business in a manner similar to that in which it is being currently operated; and (2)&nbsp;Pacific Biosciences stockholders will continue to be subject to the same risks and
opportunities to which they are currently subject, including risks related to the highly competitive industry in which Pacific Biosciences operates and adverse economic conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if the merger is not completed, and depending on the circumstances that caused the merger not to be completed, the price of our
common stock may decline significantly. If that were to occur, it is uncertain when, if ever, the price of our common stock would return to the price at which it trades as of the date of this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance as to the effect of the merger not being completed on the future value of your shares of common stock.
If the merger is not completed, the Pacific Biosciences Board will continue to evaluate and review, among other things, Pacific Biosciences&#146; business, operations, strategic direction and capitalization, and will make whatever changes it deems
appropriate. If the merger agreement is not adopted by Pacific Biosciences stockholders or if the merger is not completed for any other reason, Pacific Biosciences&#146; business, prospects or results of operation may be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to pay Illumina a termination fee of $43.0&nbsp;million if the merger agreement is terminated in specified
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In specified circumstances in which the transaction is terminated, (1)&nbsp;Illumina has agreed to pay Pacific Biosciences
a termination fee of $98.0&nbsp;million; or (2)&nbsp;Pacific Biosciences may be entitled to a specific remedy, as described in more detail under the section of this proxy statement captioned &#147;The Merger Agreement&#151;Termination Fees and
Remedies.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_43"></A>Per Share Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the merger agreement, at the effective time of the merger: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each share of common stock that is (1)&nbsp;held by Pacific Biosciences as treasury stock or (2)&nbsp;owned by
Illumina or Merger Sub (which we refer to as the &#147;canceled shares&#148;) will be canceled and retired without any payment thereto; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each share of common stock that is owned by any direct or indirect subsidiary of Pacific Biosciences or Illumina
(other than Merger Sub) as of immediately prior to the effective time of the merger (which we refer to as the &#147;subsidiary-owned shares&#148;) will be converted into such number of shares of stock of the surviving corporation such that each such
subsidiary owns the same percentage of the outstanding capital stock of the surviving corporation immediately following the effective time of the merger as such subsidiary-owned in Pacific Biosciences immediately prior to the effective time of the
merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each share of common stock that is issued and outstanding as of immediately prior to the effective time of the
merger (other than canceled shares, subsidiary-owned shares and shares of common stock held by Pacific Biosciences stockholders who have (1)&nbsp;neither voted in favor of the adoption of the merger agreement nor consented thereto in writing; and
(2)&nbsp;properly and validly exercised their statutory rights of appraisal in respect of such shares in accordance with the Delaware law) will be converted into the right to receive cash in an amount equal to $8.00, without interest thereon, less
any applicable withholding taxes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each certificate formerly representing any shares of common stock or any book-entry shares that represented
shares of common stock immediately prior to the effective time of the merger will automatically be canceled and retired and all such shares will cease to exist and will thereafter only represent the right to receive the merger consideration.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the closing of the merger, a sufficient amount of cash will be deposited with a designated payment agent
to pay the aggregate per share merger consideration. Once a Pacific Biosciences stockholder has provided the payment agent with his, her or its stock certificates (or an affidavit of loss in lieu of a stock certificate) or customary agent&#146;s
message with respect to book-entry shares, appropriate letter of transmittal and other items specified by the payment agent, then the payment agent will pay the stockholder the appropriate portion of the aggregate per share merger consideration. For
more information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;Payment Agent, Exchange Fund and Exchange and Payment Procedures.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the merger is completed, each Pacific Biosciences stockholder will have the right to receive the per share merger consideration for each
share of common stock that such stockholder owned, as described in the section of this proxy statement captioned &#147;The Merger Agreement&#151;Conversion of Shares,&#148; but will no longer have any rights as a Pacific Biosciences stockholder
(except that Pacific Biosciences stockholders who properly and validly exercise and perfect, and do not validly withdraw or subsequently lose, their appraisal rights will have the right to receive payment for the &#147;fair value&#148; of their
shares, determined pursuant to an appraisal proceeding contemplated by Delaware law as described below under the section of this proxy statement captioned &#147;The Merger&#151;Appraisal Rights&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_44"></A>Background of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following chronology summarizes the key meetings and events that led to the signing of the Merger Agreement. This chronology does not
purport to catalogue every conversation of or among the Pacific Biosciences Board or its committees, Pacific Biosciences&#146; representatives, and other parties. Other than as described below, there have been no material contacts between Pacific
Biosciences and Illumina in the past two years. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board regularly evaluates Pacific Biosciences&#146; strategic
direction and ongoing business plans with a view toward strengthening Pacific Biosciences&#146; business and enhancing stockholder value. As part of this evaluation, the Pacific Biosciences Board has, from time to time, considered a variety of
strategic alternatives. These have included, among others, (1)&nbsp;the continuation of Pacific Biosciences&#146; current business plan as a standalone entity; (2)&nbsp;investment in, and development of, new products; (3)&nbsp;potential expansion
opportunities through partnerships or other commercial relationships; (4)&nbsp;the sale of Pacific Biosciences or one or more of its business units; and (5)&nbsp;strategic investments in Pacific Biosciences and other capital raising activities. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As active participants in the DNA sequencing space, Pacific Biosciences and Illumina, and
their respective management teams, are well known to each other. From time to time, members of each of Pacific Biosciences management and Illumina management have discussed partnerships, strategic collaborations and other ways that the two companies
could work together. Prior to September 2017, these discussions never advanced beyond the introductory stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From September 2013 until
December 2016, Pacific Biosciences and F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd (which we refer to as &#147;Roche&#148;) collaborated on the development and supply of diagnostic products for use with Pacific Biosciences&#146;
DNA sequencing technology. In December 2016, Roche elected to terminate that relationship for convenience even though Pacific Biosciences had achieved all development milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in August 2017 and continuing into 2018, Pacific Biosciences, with the assistance of an internationally recognized investment
banking firm, contacted 23 parties (including Illumina and Roche) concerning their interest in a strategic partnership with Pacific Biosciences. The principal motivations for these discussions were to (1)&nbsp;expand the distribution of Pacific
Biosciences&#146; DNA sequencing products; and (2)&nbsp;ensure that Pacific Biosciences had access to sufficient cash resources to continue its research and development and commercialization efforts. Although the Pacific Biosciences Board was most
focused on identifying a strategic partner to assist Pacific Biosciences in pursuing its standalone strategy, the Pacific Biosciences Board approached these discussions with an open mind as to potential outcomes, including the potential sale of
Pacific Biosciences. For various reasons, most of these companies declined to pursue discussions with Pacific Biosciences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with these strategic partnership discussions, members of Pacific Biosciences management, including Michael W. Hunkapiller, Ph.D., the chairman, president and chief executive officer of Pacific Biosciences, met in September 2017 and November 2017
with members of Illumina management. During these conversations, the members of each of Pacific Biosciences management and Illumina management discussed ways that the two companies could work together. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, Illumina informed a representative of Pacific Biosciences that Illumina was still considering a potential strategic
partnership with Pacific Biosciences. Illumina also stated that it was then most interested in a <FONT STYLE="white-space:nowrap">co-promotion</FONT> or <FONT STYLE="white-space:nowrap">co-development</FONT> relationship in specific areas rather
than a broad or exclusive relationship with Pacific Biosciences in the clinical market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, Dr.&nbsp;Hunkapiller and Kathy
Ordo&ntilde;ez, a member of the Pacific Biosciences Board who was also then serving as the chief commercial officer of Pacific Biosciences, met with members of Illumina management, including Francis deSouza, Illumina&#146;s president and chief
executive officer. At this meeting, the parties discussed opportunities for the two companies to work together in the clinical market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
various times in April, May and June 2018, Susan Barnes, Pacific Biosciences&#146; executive vice president and chief financial officer, met with a member of Illumina management. These meetings involved discussions of ways that Pacific Biosciences
and Illumina might work together, including (1)&nbsp;a strategic partnership; (2)&nbsp;distribution by Illumina of Pacific Biosciences&#146; products into the clinical market; (3)&nbsp;distribution by Illumina of Pacific Biosciences&#146; products
in the United States and Europe; (4)&nbsp;collaboration on future joint research and development projects; and (5)&nbsp;collaboration on various human sequencing projects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2018, Dr.&nbsp;Hunkapiller discussed with a member of Illumina management and certain other Illumina employees various
technical aspects of Pacific Biosciences and Illumina collaborating on human sequencing projects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At various times in July, August and
September 2018, Ms.&nbsp;Barnes spoke with one or more members of Illumina management. These meetings involved discussions of ways that Pacific Biosciences and Illumina might work together. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences
management in attendance. The members of the Pacific Biosciences Board discussed the strategic alternatives available to Pacific Biosciences. The Pacific Biosciences Board directed Pacific Biosciences management to continue to explore (1)&nbsp;a
potential equity offering in the United States; (2)&nbsp;a potential strategic partnership in the Chinese market coupled with an investment by one or more Chinese investors; and (3)&nbsp;a potential strategic partnership with, or acquisition of
Pacific Biosciences by, various companies, including Illumina. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;19, 2018, Dr.&nbsp;Hunkapiller, William W. Ericson, Pacific
Biosciences&#146; lead independent director, and Ms.&nbsp;Barnes met with members of Illumina management, including Mr.&nbsp;deSouza, to further discuss aspects of Pacific Biosciences&#146; current research and development program and ways in which
Pacific Biosciences and Illumina could work together in the clinical market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2018, the Pacific Biosciences Board met,
with members of Pacific Biosciences management and representatives of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, outside counsel to Pacific Biosciences (which we refer to as &#147;Wilson Sonsini&#148;), in attendance. The
members of the Pacific Biosciences Board discussed Pacific Biosciences&#146; cash forecasts and financing alternatives. The members of the Pacific Biosciences Board continued the July&nbsp;6, 2018, discussion regarding (1)&nbsp;a potential equity
offering in the United States; (2)&nbsp;a potential strategic partnership in the Chinese market coupled with an investment by one or more Chinese investors; and (3)&nbsp;a potential strategic partnership with various companies, including Illumina.
The Pacific Biosciences Board directed Pacific Biosciences management to continue to explore these alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2018,
members of Pacific Biosciences management, including Dr.&nbsp;Hunkapiller and Ms.&nbsp;Barnes, met with members of Illumina management, including Mr.&nbsp;deSouza, to discuss ways in which Pacific Biosciences and Illumina could work together in the
clinical market. During this meeting, members of Pacific Biosciences management informed Illumina management that Pacific Biosciences was actively continuing its efforts to find a strategic partner with the goal of finalizing a transaction before
the end of 2018. Accordingly, members of Pacific Biosciences management communicated the importance of Illumina providing a partnership or other transaction proposal in the near future. In response, members of Illumina management informed Pacific
Biosciences that Illumina would not be in a position to proceed with any type of discussions until after a meeting of Illumina&#146;s board of directors in September 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;30, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of Wilson
Sonsini in attendance. The members of the Pacific Biosciences Board discussed (1)&nbsp;financing alternatives; and (2)&nbsp;a potential strategic partnership with various companies, including Illumina. The Pacific Biosciences Board approved
proceeding with an underwritten public equity offering with an aggregate offering price of up to $69&nbsp;million (inclusive of a 15&nbsp;percent over-allotment option). The Pacific Biosciences Board also instructed Pacific Biosciences management to
continue to pursue a strategic partnership in the Chinese market coupled with an investment by one or more Chinese investors. The Pacific Biosciences Board believed that this investment, together with the proceeds of the public equity offering,
would provide Pacific Biosciences with an adequate amount of capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By September 2018, Pacific Biosciences had identified a preferred
strategic partner for the Chinese market (which we refer to as &#147;Party A&#148;) and was actively discussing a commercial partnership with Party A. Party A was one of the 23 companies previously contacted concerning a strategic partnership. In
addition, Pacific Biosciences was in discussions regarding an investment into Pacific Biosciences by one or more Chinese investors, with this investment to occur at approximately the same time as Pacific Biosciences entered into a commercial
partnership with Party A. We refer to the possible commercial partnership with Party A and the associated investment by one or more Chinese investors together as the &#147;Partnership Transaction.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;11, 2018, Pacific Biosciences and Illumina entered into a confidentiality agreement (which replaced an expiring
confidentiality agreement that covered previous discussions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2018, Pacific Biosciences completed a $69&nbsp;million equity offering
(inclusive of a 15&nbsp;percent over-allotment option) at price of $4.25 per share of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
<FONT STYLE="white-space:nowrap">mid-September</FONT> 2018, Mr.&nbsp;deSouza and Dr.&nbsp;Hunkapiller spoke. During this conversation, Mr.&nbsp;deSouza stated that Illumina might prefer to acquire Pacific Biosciences rather than enter into any type
of strategic partnership, but that no final decision had been reached. This discussion was highly preliminary and possible prices at which Illumina would be prepared to acquire Pacific Biosciences were not discussed. This conversation was the first
time that Illumina had expressed an interest in an acquisition of Pacific Biosciences. Mr.&nbsp;deSouza stated that he would speak with Dr.&nbsp;Hunkapiller again after a meeting of Illumina&#146;s board of directors later in September 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2018, Mr.&nbsp;deSouza requested an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting with Dr.&nbsp;Hunkapiller.
That meeting occurred later on September&nbsp;25, 2018. Also in attendance were Mr.&nbsp;Ericson (in his capacity as Pacific Biosciences&#146; lead independent director) and Ms.&nbsp;Barnes. At that meeting, Mr.&nbsp;deSouza, on behalf of Illumina,
provided Pacific Biosciences with a <FONT STYLE="white-space:nowrap">non-binding</FONT> letter expressing an interest in an <FONT STYLE="white-space:nowrap">all-cash</FONT> acquisition of Pacific Biosciences for $7.00 per share of common stock. This
letter also requested that Pacific Biosciences agree to negotiate exclusively with Illumina for a period of 30 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;26, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of Wilson Sonsini in attendance. The representatives of Wilson Sonsini discussed with the members of the Pacific
Biosciences Board their fiduciary duties as directors. The members of the Pacific Biosciences Board discussed the September&nbsp;25, 2018, letter from Illumina. The Pacific Biosciences Board concluded that (1)&nbsp;Illumina&#146;s proposal warranted
additional consideration; and (2)&nbsp;it was not presently interested in considering exclusive negotiations with Illumina. In order to assist with its review of Illumina&#146;s acquisition proposal, the Pacific Biosciences Board discussed the
retention of a financial advisor. The Pacific Biosciences Board instructed Pacific Biosciences management to contact Centerview Partners LLC (which we refer to as &#147;Centerview&#148;) to determine Centerview&#146;s ability to serve as Pacific
Biosciences&#146; financial advisor. The members of the Pacific Biosciences Board were familiar with Centerview&#146;s qualifications, expertise, international reputation and knowledge of the industry in which Pacific Biosciences operates, as well
as Centerview&#146;s experience in similar situations. The Pacific Biosciences Board also elected to form a committee of directors (which we refer to as the &#147;Transactions Committee&#148;) to oversee this exploration. The Transactions Committee
was formed in light of (1)&nbsp;the potentially significant workload that could be involved in considering a sale of Pacific Biosciences; (2)&nbsp;the possibility that Pacific Biosciences management might need feedback and direction on relatively
short notice; and (3)&nbsp;the benefits of having independent directors oversee and direct the process of considering a sale. The Transactions Committee was authorized, among other things, to (1)&nbsp;explore, evaluate, consider, review and
negotiate the terms and conditions of any transaction relating to any sale of Pacific Biosciences, and to take such other actions with respect to any such transaction as the Transactions Committee deemed necessary, appropriate or advisable;
(2)&nbsp;determine whether any sale of Pacific Biosciences is fair to, and in the best interests of, Pacific Biosciences and Pacific Biosciences stockholders; and (3)&nbsp;recommend to the Pacific Biosciences Board what action, if any, should be
taken by Pacific Biosciences with respect to any such transaction. The Pacific Biosciences Board retained the power and authority to approve the final decision on a sale of Pacific Biosciences. The Pacific Biosciences Board appointed
Mr.&nbsp;Ericson, Randy Livingston and John Milligan, Ph.D. as the members of the Transactions Committee. The Pacific Biosciences Board did not provide for the payment of any additional compensation to the members of the Transactions Committee. The
Pacific Biosciences Board was of the consensus that Mr.&nbsp;Ericson and Dr.&nbsp;Hunkapiller should meet with members of Illumina management to further discuss Pacific Biosciences and its technology in an effort to prompt Illumina to increase the
value of its acquisition proposal. The Pacific Biosciences Board instructed Pacific Biosciences management to continue to pursue discussions regarding the Partnership Transaction with the goal of signing a definitive agreement by early November
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on September&nbsp;26, 2018, a member of Pacific Biosciences management contacted a representative of Centerview. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;27, 2018, Dr.&nbsp;Hunkapiller and Mr.&nbsp;deSouza discussed
Illumina&#146;s September&nbsp;25, 2018, acquisition proposal of $7.00 in cash per share of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout October 2018,
Pacific Biosciences management and its advisors remained in active discussions concerning the Partnership Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2,
2018, Mr.&nbsp;Ericson (in his capacity as a member of the Transactions Committee) and Dr.&nbsp;Hunkapiller met with members of Illumina management, including Mr.&nbsp;deSouza. During this meeting, Mr.&nbsp;Ericson and Dr.&nbsp;Hunkapiller expressed
the view that the Pacific Biosciences Board would likely not accept Illumina&#146;s September&nbsp;25, 2018, acquisition proposal of $7.00 in cash per share of common stock. Mr.&nbsp;Ericson and Dr.&nbsp;Hunkapiller encouraged Illumina to submit a
revised proposal with a higher <FONT STYLE="white-space:nowrap">per-share</FONT> value. They also informed Illumina that Pacific Biosciences was in discussions concerning the Partnership Transaction and would continue to pursue those discussions so
as to maximize the number of strategic options available to Pacific Biosciences (but Pacific Biosciences did not share the identity of Party A with Illumina). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of Wilson Sonsini
in attendance. The members of the Transactions Committee discussed (1)&nbsp;the proposed terms of Centerview&#146;s engagement; and (2)&nbsp;the possibility of contacting companies other than Illumina regarding their interest in an acquisition of
Pacific Biosciences. The members of the Transactions Committee reviewed the strategic partnership discussions already undertaken by Pacific Biosciences. The Transactions Committee expressed concern that contacting these companies again regarding an
acquisition of Pacific Biosciences carried a significant risk of unwanted public disclosure and speculation that Pacific Biosciences was pursuing a sale. The Transactions Committee also expressed concern that any such disclosure and speculation
would be harmful to Pacific Biosciences&#146; business and competitive position, as well as to its relationships with employees, customers and suppliers. The Transactions Committee determined to have additional discussions with Centerview concerning
an appropriate response to Illumina&#146;s acquisition proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, a representative of Illumina&#146;s financial
advisor spoke with a representative of Centerview about Illumina&#146;s interest in acquiring Pacific Biosciences. The representative of Centerview stated that Illumina should consider increasing the value of its acquisition proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;7, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance. The representatives of Centerview reviewed for, and discussed with, the Transactions Committee a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s September&nbsp;25, 2018,
acquisition proposal of $7.00 in cash per share of common stock. The Transactions Committee determined not to contact Illumina until after the upcoming meeting of the Pacific Biosciences Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;8, 2018, Pacific Biosciences formally engaged Centerview to serve as its financial advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance for a portion of the meeting. The members of the Transactions Committee provided the members of the Pacific Biosciences Board with an update on discussions with Illumina. The representatives of Centerview
reviewed for, and discussed with, the Pacific Biosciences Board a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s September&nbsp;25, 2018, acquisition proposal of $7.00 in cash per share of common stock. The Pacific
Biosciences Board directed the Transactions Committee to proceed with a negotiation strategy that encouraged Illumina to increase the value of its acquisition proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance. The Transactions Committee determined to wait for Illumina to make a revised acquisition proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2018, the Transactions Committee met, with members of Pacific
Biosciences management and representatives of each of Centerview and Wilson Sonsini in attendance. The representatives of Wilson Sonsini discussed with the Transactions Committee the antitrust and competition law implications of an acquisition of
Pacific Biosciences by Illumina. The representatives of Centerview again reviewed for, and discussed with, the Transactions Committee a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s September&nbsp;25, 2018,
acquisition proposal of $7.00 in cash per share of common stock. The Transactions Committee instructed Centerview to contact Illumina&#146;s financial advisor to determine when Illumina would make a revised acquisition proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on October&nbsp;12, 2018, Pacific Biosciences entered into a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet with Party A
concerning aspects of the Partnership Transaction. Party A and Pacific Biosciences had the goal of entering into the Partnership Transaction before November&nbsp;10, 2018. The parties wished to consummate the Partnership Transaction before
November&nbsp;10, 2018, so that the Partnership Transaction was not required to be filed with the Committee on Foreign Investment in the United States (which we refer to as &#147;CFIUS&#148;). The United States Department of the Treasury has
recently issued new regulations to implement the Foreign Investment Risk Review Modernization Act. This legislation expanded the jurisdiction of CFIUS to include many non-controlling investments and made a filing with CFIUS mandatory in connection
with those investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;13, 2018, a representative of Centerview spoke with a representative of Illumina&#146;s financial
advisor concerning Illumina&#146;s September&nbsp;25, 2018, acquisition proposal of $7.00 in cash per share of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;15, 2018, a representative of Centerview spoke with a representative of Illumina&#146;s financial advisor. During this conversation, the representative of Illumina&#146;s financial advisor stated that Illumina was prepared to increase
the value of its acquisition proposal to $7.50 in cash per share of common stock. Illumina subsequently confirmed this acquisition proposal in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on October&nbsp;15, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance. The representatives of Centerview reviewed for, and discussed with, the Pacific Biosciences Board a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s October&nbsp;15, 2018,
acquisition proposal of $7.50 in cash per share of common stock. The Transactions Committee authorized Centerview to make a counterproposal to Illumina of $8.25 in cash per share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2018, a representative of Centerview proposed to a representative of Illumina&#146;s financial advisor that Illumina
increase the value of its acquisition proposal to $8.25 in cash per share of common stock. In response, the representative of Illumina&#146;s financial advisor stated that Illumina was prepared to increase the value of its acquisition proposal to
$7.75 in cash per share of common stock, but that a higher per share price would require additional discussions by Illumina&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on October&nbsp;16, 2018, and following discussions with certain members of each of Pacific Biosciences management and the Transactions
Committee, a representative of Centerview informed a representative of Illumina&#146;s financial advisor that Pacific Biosciences believed that a higher per share price was warranted and that Illumina&#146;s board of directors should be consulted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Still later on October&nbsp;16, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives
of each of Centerview and Wilson Sonsini in attendance. The members of Transactions Committee discussed Illumina&#146;s October&nbsp;16, 2018, acquisition proposal of $7.75 in cash per share of common stock and the earlier conversation between
representatives of each of Centerview and Illumina&#146;s financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2018, at the request of Illumina,
members of Pacific Biosciences management and representatives of Centerview discussed Pacific Biosciences&#146; expected results for the third quarter of 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(which at the time were not publicly available) with members of Illumina management and representatives of Illumina&#146;s financial advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance. The members of the Transactions Committee discussed Illumina&#146;s October&nbsp;16, 2018, acquisition proposal of $7.75 in cash per share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on October&nbsp;20, 2018, a representative of Centerview spoke with a representative of Illumina&#146;s financial advisor. During this
conversation, the representative of Illumina&#146;s financial advisor stated that Illumina was prepared to increase the value of its acquisition proposal to $8.00 in cash per share of common stock. During this conversation, the representative of
Illumina&#146;s financial advisor conveyed that Illumina was unlikely to further increase the value of its acquisition proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;21, 2018, the Transactions Committee met, with members of Pacific Biosciences management and representatives of each of Centerview and Wilson Sonsini in attendance. The members of the Transactions Committee discussed Illumina&#146;s
October&nbsp;20, 2018, acquisition proposal of $8.00 in cash per share of common stock. The Transactions Committee determined that it supported proceeding with additional discussions with Illumina and the negotiation of the merger agreement. The
Transactions Committee instructed Wilson Sonsini to begin discussions with outside legal counsel to Illumina concerning the antitrust and competition law aspects of an acquisition. In addition, the Transactions Committee approved making a proposal
to Illumina under which Illumina would owe Pacific Biosciences a reverse termination fee of 10&nbsp;percent of the deal value in connection with a failure of the acquisition to be completed due to necessary antitrust and competition law approvals
not being obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on October&nbsp;21, 2018, legal counsel to Illumina provided Wilson Sonsini with an initial draft of the merger
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At various points during the week of October&nbsp;22, 2018, Illumina and its legal counsel and Pacific Biosciences and Wilson
Sonsini discussed a number of matters related to the execution and completion of the transaction, including due diligence, negotiation of the terms of the merger agreement and regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;24, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of each of
Centerview and Wilson Sonsini in attendance. The representatives of Centerview reviewed for, and discussed with, the Pacific Biosciences Board a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s October&nbsp;20, 2018,
acquisition proposal of $8.00 in cash per share of common stock. With the representatives of Centerview and Wilson Sonsini, the members of the Pacific Biosciences Board discussed the possibility of contacting companies other than Illumina regarding
their interest in an acquisition of Pacific Biosciences. In that regard, the Pacific Biosciences Board reviewed the results, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">company-by-company</FONT></FONT> basis, of the
strategic partnership discussions that had begun in August 2017. With respect to each company, the Pacific Biosciences Board considered its financial capability and perceived current level of strategic interest in an acquisition of Pacific
Biosciences. The Pacific Biosciences Board considered that during the strategic partnership discussions, only one company other than Illumina had expressed any interest in acquiring Pacific Biosciences (and that interest was highly preliminary), and
that company had subsequently determined not to pursue an acquisition. Given these earlier strategic partnership discussions, the Pacific Biosciences Board believed that contacting these companies again regarding an acquisition of Pacific
Biosciences carried a significant risk of unwanted public disclosure and speculation that Pacific Biosciences was pursuing a sale. The Pacific Biosciences Board believed that any such disclosure and speculation would be harmful to Pacific
Biosciences&#146; business and competitive position, as well as to its relationships with employees, customers and suppliers. The Pacific Biosciences Board also believed that any public speculation that Pacific Biosciences was pursuing a sale had
the potential to significantly impact Illumina&#146;s willingness to enter into an acquisition on the terms and at the per share price then being discussed. The Pacific Biosciences Board was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concerned that any failure to promptly accept Illumina&#146;s acquisition proposal created a meaningful risk that Illumina would withdraw that proposal and would not pursue it in the future. The
Pacific Biosciences Board considered that any merger agreement with Illumina would, among other things, permit Pacific Biosciences, under certain circumstances, to (1)&nbsp;furnish information to, and conduct negotiations with, third parties
regarding unsolicited acquisition proposals; and (2)&nbsp;terminate the merger agreement to enter into an alternative acquisition agreement. In light of these considerations, the Pacific Biosciences Board concluded not to contact any of these
companies concerning an acquisition of Pacific Biosciences. The representatives of Wilson Sonsini discussed with the Pacific Biosciences Board the process surrounding obtaining necessary antitrust and competition law approvals in connection with an
acquisition of Pacific Biosciences by Illumina. It was the consensus of the Pacific Biosciences Board that Pacific Biosciences and Illumina should continue to work toward an acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the week of October&nbsp;29, 2018, representatives of each of Wilson Sonsini and outside legal counsel to Illumina met numerous times
to negotiate the terms of the merger agreement. The principal areas of negotiation were (1)&nbsp;the commitments of the parties related to obtaining necessary antitrust and competition law approvals; (2)&nbsp;the remedies available to Pacific
Biosciences in connection with a failure of the acquisition to be completed due to necessary antitrust and competition law approvals not being obtained; and (3)&nbsp;the amount of the termination fee payable by Pacific Biosciences in order to accept
a superior acquisition proposal from a third party and the circumstances in which that fee would be payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2018,
the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of each of Centerview and Wilson Sonsini in attendance. The representatives of Wilson Sonsini reviewed the terms of the latest draft of the merger
agreement. The representatives of Centerview reviewed for, and discussed with, the Pacific Biosciences Board a summary of Centerview&#146;s preliminary financial analysis of Illumina&#146;s October&nbsp;20, 2018, acquisition proposal of $8.00 in
cash per share of common stock. The Pacific Biosciences Board instructed Centerview to use the Forecasts (in addition to historical financial data) for purposes of its financial analysis. Members of Pacific Biosciences management discussed Pacific
Biosciences&#146; cash needs through the time when Pacific Biosciences management expected Pacific Biosciences to become cash-flow positive. The Pacific Biosciences Board considered Pacific Biosciences&#146; cash needs should an acquisition of
Pacific Biosciences by Illumina not be consummated, and the impact that receipt of a reverse termination fee would have on those needs. The Pacific Biosciences Board instructed Wilson Sonsini to continue to negotiate the remedies available to
Pacific Biosciences in connection with a failure of the acquisition to be completed due to, among other things, necessary antitrust and competition law approvals not being obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Early on November&nbsp;1, 2018, the Pacific Biosciences Board met, with members of Pacific Biosciences management and representatives of each
of Centerview and Wilson Sonsini in attendance. The representatives of Wilson Sonsini discussed with the members of the Pacific Biosciences Board their fiduciary duties as directors. The representatives of Centerview reviewed for, and discussed
with, the Pacific Biosciences Board the financial analysis of Centerview of the merger consideration based on the Forecasts. The representatives of Centerview rendered Centerview&#146;s oral opinion, which was subsequently confirmed by delivery of a
written opinion dated November&nbsp;1, 2018, that, as of such date and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken in preparing its
opinion, the merger consideration to be paid to the holders of shares of common stock (other than Excluded Shares) pursuant to the merger agreement was fair, from a financial point of view, to such holders. The representatives of Wilson Sonsini
reviewed with the members of the Pacific Biosciences Board the key terms of the merger agreement. The members of the Pacific Biosciences Board discussed potential reasons for and against entering into the merger with Illumina. The Pacific
Biosciences Board then recessed the meeting until later in the day while the final terms of the merger agreement were negotiated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later
on November&nbsp;1, 2018, the Pacific Biosciences Board reconvened, with members of Pacific Biosciences management and representatives of each of Centerview and Wilson Sonsini in attendance. The representatives of Wilson Sonsini reviewed with the
members of the Pacific Biosciences Board the key terms of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the merger agreement, which was now in final form. The Pacific Biosciences Board, after considering the factors more fully described in this proxy statement, (1)&nbsp;determined that the merger
agreement, the merger and the other transactions contemplated by the merger agreement are fair to, advisable and in the best interests of Pacific Biosciences and its stockholders; and (2)&nbsp;adopted and approved the merger agreement, the merger
and the other transactions contemplated by the merger agreement. The merger agreement was subsequently signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Still later on
November&nbsp;1, 2018, after the close of trading of the common stock on Nasdaq, Pacific Biosciences and Illumina publicly announced the signing of the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_45"></A>Recommendation of the Pacific Biosciences Board and Reasons for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of the Pacific Biosciences Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board has unanimously: (1)&nbsp;determined that the merger agreement, the merger and the other transactions
contemplated by the merger agreement are fair to, advisable and in the best interests of Pacific Biosciences and its stockholders; and (2)&nbsp;adopted and approved the merger agreement, the merger and the other transactions contemplated by the
merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Pacific Biosciences Board unanimously recommends that you vote: (1) &#147;FOR&#148; the adoption of the merger
agreement; (2) &#147;FOR&#148; the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special
meeting; and (3) &#147;FOR&#148; the compensation that will or may become payable by Pacific Biosciences to our named executive officers in connection with the merger. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Reasons for the Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating the merger agreement, the merger and the other transactions contemplated by the merger agreement, the Pacific Biosciences Board
consulted with Pacific Biosciences management, Wilson Sonsini and Centerview. In recommending that Pacific Biosciences stockholders vote &#147;FOR&#148; the adoption of the merger agreement, the Pacific Biosciences Board considered a number of
factors, including the following (which factors are not necessarily presented in order of relative importance), each of which the Pacific Biosciences Board believed supported its determination and recommendation. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Financial Condition, Results of Operations and Prospects of Pacific Biosciences</I>. The current, historical
and projected financial condition, results of operations and business of Pacific Biosciences, as well as Pacific Biosciences&#146; prospects and risks if it were to remain an independent company. The Pacific Biosciences Board considered Pacific
Biosciences&#146; current business plans, including (1)&nbsp;the risks and uncertainties associated with achieving and executing on Pacific Biosciences&#146; business plans in the short and long term; (2)&nbsp;the impact of general market, customer
and competitive trends on Pacific Biosciences; and (3)&nbsp;the general risks of market conditions that could reduce the price of the common stock. Among the potential risks identified by the Pacific Biosciences Board were: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences&#146; competitive positioning and prospects as a standalone company. Included in this was the
consideration of Pacific Biosciences&#146; size, as well as its strategic and financial resources, relative to those of its competitors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences&#146; liquidity position and ongoing financing needs, including the uncertainty and potential
inability to raise additional or replacement equity or debt financing on terms acceptable to it. In this regard, the Pacific Biosciences Board considered the potentially lengthy time before Pacific Biosciences was projected to be cash-flow positive.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The current status of Pacific Biosciences&#146; product commercialization efforts, including the planned
introduction in 2019 of a new sequencing technology. The Pacific Biosciences Board believed that, as with any new technology, there was significant uncertainty as to final time to market and market acceptance of this new technology.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The small size of Pacific Biosciences&#146; commercial organization and the need to significantly expand the size
and scope of that organization through strategic partnerships or substantial investment. In that regard, a strategic partnership with another company carried significant execution and counterparty risk. At the same time, an organic expansion of the
commercial organization would require substantial investment and could take an extended period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The need for continued research and development investment in Pacific Biosciences&#146; DNA sequencing business.
This investment would require significant additional capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The historical execution of Pacific Biosciences management and its ability to continue to drive the business
toward positive cash flow. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Certainty of Value</I>. The consideration to be received by Pacific Biosciences stockholders in the merger
consists entirely of cash, which provides liquidity and certainty of value. The receipt of cash consideration eliminates uncertainty and risk for Pacific Biosciences stockholders related to the continued execution of Pacific Biosciences&#146;
business. The Pacific Biosciences Board also considered that the merger was not subject to any financing condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Best Value Reasonably Obtainable</I>. The belief of the Pacific Biosciences Board that the per share merger
consideration represents the best value reasonably obtainable for the shares of common stock, taking into account the Pacific Biosciences Board&#146;s familiarity with the business, operations, prospects, business strategy, assets, liabilities and
general financial condition of Pacific Biosciences on a historical and prospective basis. The Pacific Biosciences Board also considered that the per share merger consideration of $8.00 (an increase from Illumina&#146;s initial proposal of $7.00 per
share) constituted a premium of approximately (1)&nbsp;77 percent to the closing price of the common stock on November&nbsp;1, 2018 (the last trading day before the announcement of the merger); (2)&nbsp;75 percent to the volume-weighted average
price per share of the common stock for the 30 trading day period up to and including November&nbsp;1, 2018; and (3)&nbsp;79 percent to the volume-weighted average price per share of the common stock for the 90 trading day period up to and including
November&nbsp;1, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fairness Opinion of Centerview</I>. The opinion of Centerview rendered to the Pacific Biosciences Board on
November&nbsp;1, 2018, which was subsequently confirmed by delivery of a written opinion dated November&nbsp;1, 2018, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and
qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the merger consideration to be paid to the holders of shares of Pacific Biosciences common stock (other than Excluded Shares) pursuant to the merger
agreement was fair, from a financial point of view, to such holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential Strategic Alternatives</I>. The (1)&nbsp;possible alternatives to the merger, including the
possibility of continuing to operate Pacific Biosciences as an independent entity or of pursuing the Partnership Transaction, and the desirability and perceived risks of those alternatives; (2)&nbsp;potential benefits to Pacific Biosciences
stockholders of these alternatives and the timing and likelihood of effecting such alternatives; and (3)&nbsp;Pacific Biosciences Board&#146;s assessment that none of these alternatives was reasonably likely to present superior opportunities for
Pacific Biosciences to create greater value for Pacific Biosciences stockholders, taking into account risks of execution as well as business, competitive, financial, industry, market and regulatory risks. The Pacific Biosciences Board believed that
the strategic partnership discussions already undertaken had provided Pacific Biosciences with significant insight into the willingness of various companies to partner, or pursue another transaction, with Pacific Biosciences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Negotiations with Illumina and Terms of the Merger Agreement</I>. The terms of the merger agreement, which was
the product of arms&#146;-length negotiations, and the belief of the Pacific Biosciences Board that the merger agreement contained customary terms. These terms include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences&#146; ability, under certain circumstances, to furnish information to, and conduct
negotiations with, third parties regarding unsolicited acquisition proposals. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Pacific Biosciences Board&#146;s view that the terms of the merger agreement would be unlikely to deter third
parties from making a superior proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Pacific Biosciences Board&#146;s ability, under certain circumstances, to withdraw or modify its
recommendation that Pacific Biosciences stockholders vote in favor of the adoption of the merger agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Pacific Biosciences Board&#146;s ability, under certain circumstances, to terminate the merger agreement to
enter into an alternative acquisition agreement. In that regard, the Pacific Biosciences Board believed that the termination fee payable by Pacific Biosciences in such instance was reasonable, consistent with or below similar fees payable in
comparable transactions, and not preclusive of other offers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The limited conditions to Illumina&#146;s obligation to consummate the merger, making the merger reasonably
likely to be consummated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The reverse termination fee of $98.0&nbsp;million payable by Illumina in certain circumstances and the other
remedies available to Pacific Biosciences in connection with certain terminations of the merger agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The consummation of the merger not being subject to a financing condition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Business Reputation of Illumina</I>. The business reputation, management and financial resources of Illumina.
The Pacific Biosciences Board believed that these factors supported the conclusion that a transaction with Illumina could be completed in an orderly manner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Appraisal Rights</I>. The appraisal rights in connection with the merger available to Pacific Biosciences
stockholders who timely and properly exercise such appraisal rights under Delaware law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recommending that Pacific
Biosciences stockholders vote &#147;FOR&#148; the adoption of the merger agreement, the Pacific Biosciences Board also considered a number of uncertainties and risks and other potentially negative factors, including the following (which factors are
not necessarily presented in order of relative importance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Stockholder Participation in Future Growth or Earnings</I>. The nature of the merger as a cash transaction
means that Pacific Biosciences stockholders will not participate in the future earnings or growth of Pacific Biosciences, and will not benefit from any appreciation in value of the combined company. The Pacific Biosciences Board also considered the
other potential alternative strategies available to Pacific Biosciences, which, despite significant uncertainty, had the potential to result in a more successful and valuable company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Timing and Regulatory Risks</I>. The amount of time that it could take to complete the merger and the
uncertainty and related disruption that could arise during that time. In that regard, the Pacific Biosciences Board considered that the merger is subject to antitrust and competition law approvals in the United States and other jurisdictions. These
approvals may take significant time to obtain and may not be obtained at all. In addition, if these approvals are not obtained, then Illumina is permitted, under certain circumstances, to terminate the merger agreement and pay Pacific Biosciences
the reverse termination fee of $98.0&nbsp;million. This reverse termination fee may not be sufficient to compensate Pacific Biosciences for the damage suffered by its business as a result of the pendency of the merger or of the strategic initiatives
forgone by Pacific Biosciences during this period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk Associated with Failure to Consummate the Merger</I>. The possibility that the merger might not be
consummated, and if it is not consummated, (1)&nbsp;Pacific Biosciences&#146; directors, senior management and other employees will have expended extensive time and effort and will have experienced significant distractions from their work during the
pendency of the transaction; (2)&nbsp;Pacific Biosciences will have incurred significant transaction costs; (3)&nbsp;Pacific Biosciences&#146; continuing business relationships with customers, licensors, business partners and employees may be
adversely affected; (4)&nbsp;the trading price of the common stock could be adversely affected; (5)&nbsp;the reverse termination fee of $98.0&nbsp;million </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
payable by Illumina will not be available in all instances in which the merger agreement is terminated; (6)&nbsp;the other contractual and legal remedies available to Pacific Biosystems in the
event of termination of the merger agreement may be insufficient, costly to pursue or both; and (7)&nbsp;the market&#146;s perceptions of Pacific Biosciences&#146; prospects could be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Interim Restrictions on Pacific Biosciences&#146; Business Pending the Completion of the Merger</I>. The
restrictions on the conduct of Pacific Biosciences&#146; business prior to the consummation of the merger, including the requirement that Pacific Biosciences conduct its business in the ordinary course, subject to specific limitations, which may
delay or prevent Pacific Biosciences from undertaking strategic initiatives before the completion of the merger that, absent the merger agreement, Pacific Biosciences might have pursued. The Pacific Biosciences Board also considered the restrictions
on soliciting other acquisition proposals prior to the consummation of the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Effects of Merger Announcement</I>. The effect of the public announcement of the merger agreement, including
(1)&nbsp;effects on Pacific Biosciences&#146; sales, employees, customers, operating results and stock price; (2)&nbsp;the impact of the public announcement of the merger on Pacific Biosciences&#146; ability to attract and retain key management,
sales and marketing, and technical personnel; and (3)&nbsp;the potential for litigation in connection with the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Termination Fee Payable by Pacific Biosciences</I>. The requirement that Pacific Biosciences pay Illumina a
termination fee of $43.0&nbsp;million under certain circumstances following termination of the merger agreement, including if the Pacific Biosciences Board terminates the merger agreement to accept a superior proposal. The Pacific Biosciences Board
considered the potentially discouraging impact that this termination fee could have on another company&#146;s interest in making a competing proposal to acquire Pacific Biosciences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Taxable Consideration</I>. The receipt of cash in exchange for shares of common stock pursuant to the merger
will be a taxable transaction for U.S. federal income tax purposes for many of PacBio stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Interests of Pacific Biosciences&#146; Directors and Executive Officers</I>. Pacific Biosciences&#146;
directors and executive officers may have interests in the merger that are different from, or in addition to, those of Pacific Biosciences&#146; other stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is not meant to be exhaustive, but summarizes the material factors considered by the Pacific Biosciences Board in its
consideration of the merger. After considering these and other factors, the Pacific Biosciences Board concluded that the potential benefits of the merger outweighed the uncertainties and risks. In view of the variety of factors considered by the
Pacific Biosciences Board and the complexity of these factors, the Pacific Biosciences Board did not find it practicable to, and did not, quantify or otherwise assign relative weights to the foregoing factors in reaching its determination and
recommendations. Moreover, each member of the Pacific Biosciences Board applied his or her own personal business judgment to the process and may have assigned different weights to different factors. The Pacific Biosciences Board adopted and approved
the merger agreement, the merger and the other transactions contemplated by the merger agreement and recommended that Pacific Biosciences stockholders adopt the merger agreement based upon the totality of the information presented to, and considered
by, the Pacific Biosciences Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_46"></A>Opinion of Centerview Partners LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2018, Centerview rendered to the Pacific Biosciences Board its oral opinion, subsequently confirmed in a written opinion
dated November&nbsp;1, 2018, that, as of such date and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion,
the merger consideration to be paid to the holders of shares of common stock (other than excluded shares) pursuant to the merger agreement was fair, from a financial point of view, to such holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Centerview&#146;s written opinion, dated November&nbsp;1, 2018, which
describes the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex B and is incorporated herein by reference. <B>The
summary of the written opinion of Centerview set forth below is qualified in its entirety by the full text of Centerview&#146;s written opinion attached as Annex B.</B> <B>Centerview&#146;s financial advisory services and opinion were provided for
the information and assistance of the Pacific Biosciences Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the merger, and Centerview&#146;s opinion only addressed the
fairness, from a financial point of view, as of the date thereof, to the holders of shares of common stock (other than excluded shares) of the merger consideration to be paid to such holders pursuant to the merger agreement. Centerview&#146;s
opinion</B> <B>did not address any other term or aspect of the merger agreement or the merger and does not constitute a recommendation to any Pacific Biosciences stockholder or any other person as to how such stockholder or other person should vote
with respect to the merger or otherwise act with respect to the merger or any other matter.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of Centerview&#146;s
written opinion should be read carefully in its entirety for a description of the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering the opinion described above and performing its related financial analyses, Centerview reviewed, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a draft of the merger agreement dated November&nbsp;1, 2018 (which is referred to as the &#147;<B></B>draft
merger agreement<B></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Pacific Biosciences for the years ended
December&nbsp;31, 2017, December&nbsp;31, 2016, and December&nbsp;31, 2015; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain interim reports to stockholders and Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> of Pacific Biosciences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain publicly available research analyst reports for Pacific Biosciences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other communications from Pacific Biosciences to Pacific Biosciences stockholders; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and
prospects of Pacific Biosciences, including the Forecast, prepared by Pacific Biosciences management and furnished to Centerview by Pacific Biosciences for purposes of Centerview&#146;s analysis (the Forecast as well as the foregoing internal
information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Pacific Biosciences are collectively referred to as the &#147;<B></B>internal data<B></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview also participated in discussions with members of Pacific Biosciences management and representatives of Pacific Biosciences
regarding their assessment of the internal data. In addition, Centerview reviewed publicly available financial and stock market data, including valuation multiples, for Pacific Biosciences and compared that data with similar data for certain other
companies, the securities of which are publicly traded, in lines of business that Centerview deemed relevant. Centerview also compared certain of the proposed financial terms of the merger with the financial terms, to the extent publicly available,
of certain other transactions that Centerview deemed relevant, and conducted such other financial studies and analyses and took into account such other information as Centerview deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal,
regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by Centerview for purposes of its opinion and, with Pacific Biosciences&#146; consent, Centerview relied upon such information as being complete and accurate.
In that regard, Centerview assumed, at Pacific Biosciences&#146; direction, that the internal data (including, without limitation, the Forecast) were reasonably prepared on bases reflecting the best currently available estimates and judgments of
Pacific Biosciences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management as to the matters covered thereby and Centerview relied, at Pacific Biosciences&#146; direction, on the internal data for purposes of Centerview&#146;s analysis and opinion. Centerview
expressed no view or opinion as to the internal data or the assumptions on which it was based. In addition, at Pacific Biosciences direction, Centerview did not make any independent evaluation or appraisal of any of the assets or liabilities
(contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Pacific Biosciences, nor was Centerview furnished with any such evaluation or appraisal, and was not asked to conduct, and did not conduct, a
physical inspection of the properties or assets of Pacific Biosciences. Centerview assumed, at Pacific Biosciences&#146; direction, that the final executed merger agreement would not differ in any respect material to Centerview&#146;s analysis or
opinion from the draft merger agreement reviewed by Centerview. Centerview also assumed, at Pacific Biosciences&#146; direction, that the merger will be consummated on the terms set forth in the merger agreement and in accordance with all applicable
laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to Centerview&#146;s analysis or Centerview&#146;s opinion and that,
in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the merger, no delay, limitation, restriction, condition or other change will be imposed, the effect of which would be material
to Centerview&#146;s analysis or Centerview&#146;s opinion. Centerview did not evaluate and did not express any opinion as to the solvency or fair value of Pacific Biosciences, or the ability of Pacific Biosciences to pay its obligations when they
come due, or as to the impact of the merger on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. Centerview is not a legal, regulatory, tax or accounting advisor, and Centerview expressed no
opinion as to any legal, regulatory, tax or accounting matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview&#146;s opinion expressed no view as to, and did not address,
Pacific Biosciences&#146; underlying business decision to proceed with or effect the merger, or the relative merits of the merger as compared to any alternative business strategies or transactions that might be available to Pacific Biosciences or in
which Pacific Biosciences might engage. Centerview&#146;s opinion was limited to and addressed only the fairness, from a financial point of view, as of the date of Centerview&#146;s written opinion, to the holders of the shares of common stock
(other than excluded shares) of the merger consideration to be paid to such holders pursuant to the merger agreement. For purposes of its opinion, Centerview was not asked to, and Centerview did not, express any view on, and its opinion did not
address, any other term or aspect of the merger agreement or the merger, including, without limitation, the structure or form of the merger, or any other agreements or arrangements contemplated by the merger agreement or entered into in connection
with or otherwise contemplated by the merger, including, without limitation, the fairness of the merger or any other term or aspect of the merger to, or any consideration to be received in connection therewith by, or the impact of the merger on, the
holders of any other class of securities, creditors or other constituencies of Pacific Biosciences or any other party. In addition, Centerview expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any
other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Pacific Biosciences or any party, or class of such persons in connection with the merger, whether relative to the merger consideration to be
paid to the holders of shares of common stock (other than excluded shares) pursuant to the merger agreement or otherwise. Centerview&#146;s opinion was necessarily based on financial, economic, monetary, currency, market and other conditions and
circumstances as in effect on, and the information made available to Centerview as of, the date of Centerview&#146;s written opinion, and Centerview does not have any obligation or responsibility to update, revise or reaffirm its opinion based on
circumstances, developments or events occurring after the date of Centerview&#146; written opinion. Centerview&#146;s opinion does not constitute a recommendation to any Pacific Biosciences stockholder or any other person as to how such stockholder
or other person should vote with respect to the merger or otherwise act with respect to the merger or any other matter. Centerview&#146;s financial advisory services and its written opinion were provided for the information and assistance of the
Pacific Biosciences Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the merger. The issuance of Centerview&#146;s opinion was approved by the Centerview Partners LLC
Fairness Opinion Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Centerview&#146;s Financial Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses prepared and reviewed with the Pacific Biosciences Board in connection with
Centerview&#146;s opinion, dated November&nbsp;1, 2018. <B>The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, Centerview, nor does
the order of the financial analyses described represent the relative importance or weight given to those financial analyses by Centerview. Centerview may have deemed various assumptions more or less probable than other assumptions, so the reference
ranges resulting from any particular portion of the analyses summarized below should not be taken to be Centerview&#146;s view of the actual value of Pacific Biosciences. Some of the summaries of the</B> <B>financial analyses set forth below include
information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses
performed by Centerview. Considering the data in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such
analyses or factors, could create a misleading or incomplete view of the processes underlying Centerview&#146;s financial analyses and its opinion. </B>In performing its analyses, Centerview made numerous assumptions with respect to industry
performance, general business and economic conditions and other matters, many of which are beyond the control of Pacific Biosciences or any other parties to the merger. None of Pacific Biosciences, Illumina, Merger Sub or Centerview or any other
person assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be
significantly more or less favorable than as set forth below. In addition, analyses relating to the value of Pacific Biosciences do not purport to be appraisals or reflect the prices at which Pacific Biosciences may actually be sold. Accordingly,
the assumptions and estimates used in, and the results derived from, the financial analyses, are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on
market data, is based on market data as it existed on or before October&nbsp;31, 2018 (the last trading day before the public announcement of the merger) and is not necessarily indicative of current market conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Company Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview reviewed and compared certain financial information for Pacific Biosciences to corresponding financial information for the following
publicly traded companies that Centerview deemed comparable, based on its experience and professional judgment, to Pacific Biosciences: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Large Cap
Companies </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Agilent Technologies, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Becton, Dickinson and Company </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Danaher Corporation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mettler-Toledo International Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Thermo Fisher Scientific Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Waters Corporation </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Small/Mid Cap Companies </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accelerate Diagnostics, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Bio-Techne</FONT> Corporation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bioMerieux </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bruker Corporation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DiaSorin </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Haemonetics Corporation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Luminex Corporation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NanoString Technologies, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PerkinElmer, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Qiagen N.V. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quidel Corporation </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although none of the selected companies is directly comparable to Pacific Biosciences, the companies listed above were chosen by Centerview,
among other reasons, because they are publicly traded life science tools and/or diagnostic companies with certain operational, business and/or financial characteristics that, for purposes of Centerview&#146;s analysis, may be considered similar to
those of Pacific Biosciences. However, because none of the selected companies is exactly the same as Pacific Biosciences, Centerview believed that it was inappropriate to, and therefore did not, rely solely on the quantitative results of the
selected public company analysis. Accordingly, Centerview also made qualitative judgments, based on its experience and professional judgment, concerning differences between the operational, business and/or financial characteristics of Pacific
Biosciences and the selected companies, which could affect the public trading values of each, in order to provide a context in which to consider the results of the quantitative analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview calculated and compared financial multiples for the selected companies based on information it obtained from Pacific Biosciences
management, public<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>filings, FactSet (a data source containing historical and estimated financial data) and other Wall Street research. With respect to each of the selected companies, Centerview
calculated enterprise value (calculated as the market value of common equity (determined using the treasury stock method and taking into account outstanding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT>
options, warrants, RSUs/PSUs and other convertible securities, plus the book value of debt and certain liabilities less cash and cash equivalents and other investments)) (which is referred to as &#147;EV&#148;), as a multiple of Wall Street research
analyst consensus estimated revenues for such selected companies for calendar years 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are
summarized as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Large Cap Companies</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV / Revenue&nbsp;Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019E&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020E&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Small/Mid Cap Companies</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV / Revenue&nbsp;Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019E&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020E&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, Centerview applied a range of (1) 4.0x to 6.0x estimated 2019
revenue multiples derived from the selected companies to Pacific Biosciences&#146; estimated calendar year 2019 revenue of $144&nbsp;million, based on the Forecast, which resulted in an implied per share equity value range for the shares of common
stock of approximately $4.30 to $5.95, rounded to the nearest $0.05; and (2) 3.5x to 5.5x estimated 2020 revenue multiples derived from the selected companies to Pacific Biosciences&#146; estimated calendar year 2020 revenue of $221&nbsp;million,
based on the Forecast, which resulted in an implied per share equity value range for the Shares of approximately $5.45 to $7.90, rounded to the nearest $0.05. Centerview then compared these ranges to the $8.00 per share merger consideration proposed
to be paid to the holders of common stock (other than excluded shares) pursuant to the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Selected Precedent
Transactions Analysis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview reviewed and analyzed certain information relating to selected transactions involving publicly traded
life science tools and/or diagnostic companies that Centerview, based on its experience and judgment as a financial advisor, deemed relevant to consider in relation to Pacific Biosciences and the merger. These transactions were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Announced</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquiror</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/19/18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Foundation Medicine, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Roche Holdings, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/06/16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cepheid Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Danaher Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/08/16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Affymetrix, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Thermo Fisher Scientific Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/22/14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sigma-Aldrich Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Merck KGaA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">04/15/13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Life Technologies Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Thermo Fisher Scientific Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/17/12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">IRIS International, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Danaher Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/08/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Caliper Life Sciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PerkinElmer, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">07/11/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cellestis Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Qiagen N.V.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/18/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Celera Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quest Diagnostics Incorporated</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">02/07/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Beckman Coulter, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Danaher Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12/13/10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dionex Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Thermo Fisher Scientific Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">07/27/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Varian, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Agilent Technologies, Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No company or transaction used in this analysis is identical or directly comparable to Pacific Biosciences or
the merger. The target companies included in the selected transactions above were selected, among other reasons, because they have certain characteristics that, for the purposes of this analysis, may be considered similar to certain characteristics
of Pacific Biosciences. The reasons for and the circumstances surrounding each of the selected precedent transactions analyzed were diverse and there are inherent differences in the business, operations, financial conditions and prospects of Pacific
Biosciences and the companies included in the selected precedent transactions analysis. Accordingly, Centerview believed that it was inappropriate to, and therefore did not, rely solely on the quantitative results of the selected transactions
analysis. This analysis involves complex considerations and qualitative judgments concerning differences in financial and operating characteristics and other factors that could affect the public trading, acquisition or other values of the selected
target companies and Pacific Biosciences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial data for the precedent transactions was based on publicly available information at
the time of the announcement of the relevant transactions that Centerview obtained from public filings, FactSet and Wall Street research. Using publicly available information, Centerview calculated, for each selected transaction, among other things,
the enterprise value implied for the applicable target company based on the consideration payable in the selected transaction (which is referred to as &#147;TEV&#148;) as a multiple of the target company&#146;s (1)&nbsp;forward projected revenue one
year following the transaction announcement; and (2)&nbsp;forward projected revenue two years following the transaction announcement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>TEV&nbsp;/&nbsp;Forward&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on this analysis and other considerations that Centerview deemed relevant in its professional judgment
and expertise, Centerview applied a range of (1) 3.5x to 5.5x <FONT STYLE="white-space:nowrap">one-year</FONT> forward revenue multiples derived from the target companies in the selected precedent transactions, to Pacific Biosciences&#146; estimated
<FONT STYLE="white-space:nowrap">one-year</FONT> forward revenue of $144&nbsp;million as of December&nbsp;31, 2018, as derived from the Forecast, which resulted in an implied per share equity value range for the shares of common stock of
approximately $3.90 to $5.55, rounded to the nearest $0.05; and (2) 3.0x to 5.0x <FONT STYLE="white-space:nowrap">two-year</FONT> forward revenue multiples derived from the precedent transactions to Pacific Biosciences&#146; estimated <FONT
STYLE="white-space:nowrap">two-year</FONT> forward revenue of $221&nbsp;million as of December&nbsp;31, 2018, as derived from the Forecast, which resulted in an implied per share equity value range for the shares of common stock approximately $4.80
to $7.30, rounded to the nearest $0.05. Centerview then compared these ranges to the $8.00 per share merger consideration proposed to be paid to the holders of common stock (other than excluded shares) pursuant to the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview performed a discounted cash flow analysis of Pacific Biosciences based on the Forecasts. A discounted cash flow analysis is a
traditional valuation methodology used to derive a valuation of an asset or set of assets by calculating the &#147;present value&#148; of estimated future cash flows of the asset or set of assets. &#147;Present value&#148; refers to the current
value of future cash flows or amounts and is obtained by discounting those future cash flows or amounts by a discount rate that takes into account macroeconomic assumptions, estimates of risk and the opportunity cost of capital of the future cash
flows or amounts, expected returns and other appropriate factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing this analysis, Centerview calculated a range of equity
values for Pacific Biosciences by discounting to present value as of December&nbsp;31, 2018, using discount rates ranging from 11% to 13% (reflecting Centerview&#146;s analysis of Pacific Biosciences&#146; weighted average cost of capital) and the <FONT
STYLE="white-space:nowrap">mid-year</FONT> convention: (1)&nbsp;the forecasted, <FONT STYLE="white-space:nowrap">after-tax</FONT> unlevered free cash flows of Pacific Biosciences over the period beginning on January&nbsp;1, 2019 and ending on
December&nbsp;31, 2028, as set forth in the Forecast; and (2)&nbsp;a range of implied terminal values of Pacific Biosciences at the end of the Forecast period calculated by applying an illustrative range of enterprise value to earnings before
interest, taxes, depreciation and amortization (which is referred to as &#147;EBITDA&#148;) multiples of 12.0x to 16.0x, which Centerview selected utilizing its professional judgment and experience, to Pacific Biosciences&#146; estimated forward
EBITDA as of December&nbsp;31, 2028, as set forth in the Forecasts. In performing this analysis, Centerview adjusted for (i)&nbsp;Pacific Biosciences&#146; estimated net cash balance of $136&nbsp;million as of December&nbsp;31, 2018; (ii) the net
present value of standalone tax savings from federal net operating losses of $50&nbsp;million, or $0.30 per share, based on the estimated utilization of Pacific Biosciences&#146; net operating losses; and (iii)&nbsp;at the direction of Pacific
Biosciences management, an assumed $50&nbsp;million equity financing at $4.25 per share (which is referred to as the &#147;equity financing&#148;). Centerview divided the result of the foregoing calculations by the number of fully-diluted
outstanding shares of common stock (determined using the treasury stock method and taking into account outstanding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> options and RSUs/PSUs and including
shares to be issued in the equity financing) as of October&nbsp;30, 2018, based on the internal data to derive a range of implied values per share of common stock of approximately $6.75 to $9.20, rounded to the nearest $0.05. Centerview compared
this range to the $8.00 per share merger consideration proposed to be paid to the holders of common stock (other than excluded shares) pursuant to the merger agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Factors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview noted for the Pacific Biosciences Board the additional factors solely for informational purposes, including, among other things, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Historical closing trading prices of the shares of common stock during the
<FONT STYLE="white-space:nowrap">52-week</FONT> period ended October&nbsp;31, 2018 (the last trading day before the public announcement of the merger), which reflected low and high stock closing prices for Pacific Biosciences during such period of
approximately $2.05 to $5.55 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock price targets for the shares of common stock in publicly available Wall Street research analyst reports,
which indicated low and high stock price targets for common stock ranging from $3.50 to $8.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An analysis of premiums paid in the selected transactions involving publicly traded life science tools and/or
diagnostic companies, as set forth in the section of this proxy statement captioned &#147;&#151;Opinion of the Centerview Partners LLC&#151;Selected Precedent Transactions Analysis,&#148; for which premium data was available. The premiums in this
analysis were calculated by comparing the per share acquisition price in each transaction to the closing price of the target company&#146;s common stock for the date one day prior to the date on which the trading price of the target&#146;s common
stock was perceived to be affected by a potential transaction. Based on the analysis above and other considerations that Centerview deemed relevant in its professional judgment, Centerview applied a range of 30 percent to 50 percent to closing stock
price on October&nbsp;31, 2018 (the last trading day before the public announcement of the merger) of $4.45, which resulted in an implied price range of approximately $5.80 to $6.70 per share, rounded to the nearest $0.05. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of a financial opinion is a complex analytical process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and,
therefore, a financial opinion is not readily susceptible to summary description. In arriving at its opinion, Centerview did not draw, in isolation, conclusions from or with regard to any factor or analysis that it considered. Rather, Centerview
made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the analyses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview&#146;s financial analyses and opinion were only one of many factors taken into consideration by the Pacific Biosciences Board in
its evaluation of the merger. Consequently, the analyses described above should not be viewed as determinative of the views of the Pacific Biosciences Board or Pacific Biosciences management with respect to the merger consideration or as to whether
the Pacific Biosciences Board would have been willing to determine that a different consideration was fair. The consideration for the merger was determined through <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between
Pacific Biosciences and Illumina and was approved by the Pacific Biosciences Board. Centerview provided advice to Pacific Biosciences during these negotiations. Centerview did not, however, recommend any specific amount of consideration to Pacific
Biosciences or the Pacific Biosciences Board or that any specific amount of consideration constituted the only appropriate consideration for the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview is a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial
advisory and merchant banking activities. In the two years prior to the date of its written opinion, Centerview was not (except for the current engagement) engaged to provide financial advisory or other services to Pacific Biosciences, and
Centerview has not received any compensation from Pacific Biosciences. In the two years prior to the date of its written opinion on November&nbsp;1, 2018, Centerview was not engaged to provide financial advisory or other services to Illumina or
Merger Sub, and Centerview has not received any compensation from Illumina. Centerview may provide financial advisory and other services to or with respect to Pacific Biosciences or Illumina or their respective affiliates in the future, for which
Centerview </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may receive compensation. Certain (1)&nbsp;of Centerview&#146;s and its affiliates&#146; directors, officers, members and employees, or family members of such persons; (2)&nbsp;of
Centerview&#146;s affiliates or related investment funds; and (3)&nbsp;investment funds or other persons in which any of the foregoing may have financial interests or with which they may <FONT STYLE="white-space:nowrap">co-invest,</FONT> may at any
time acquire, hold, sell or trade, in debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, Pacific Biosciences, Illumina or any of their respective affiliates, or
any other party that may be involved in the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board selected Centerview as its financial advisor in
connection with the merger based on Centerview&#146;s reputation and experience. Centerview is an internationally recognized investment banking firm that has substantial experience in transactions similar to the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Centerview&#146;s services as the financial advisor to the Pacific Biosciences Board, Pacific Biosciences has agreed to pay
Centerview an aggregate fee of $18.5&nbsp;million, $2&nbsp;million of which was payable upon the rendering of Centerview&#146;s opinion and $16.5&nbsp;million of which is payable contingent upon consummation of the merger. In addition, Pacific
Biosciences has agreed to reimburse certain of Centerview&#146;s expenses arising, and to indemnify Centerview against certain liabilities that may arise, out of Centerview&#146;s engagement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_47"></A>Financial Forecasts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences does not, as a matter of course, make public projections as to its future financial performance. However, Pacific
Biosciences management regularly prepares internal financial forecasts regarding its future operations for subsequent fiscal years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with Pacific Biosciences&#146; strategic planning process, Pacific Biosciences management prepared and provided to the Pacific Biosciences Board various forward-looking financial information for fiscal years 2018 through 2028. This
financial information is collectively referred to as the &#147;Forecasts.&#148; Pacific Biosciences also provided the Forecasts to Centerview. A summary of the Forecasts is set forth in the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Forecasts were not prepared with a view toward public disclosure or to complying with accounting principles generally accepted in the
United States (which we refer to as &#147;GAAP&#148;). In addition, the Forecasts were not prepared with a view toward complying with the guidelines established by the SEC or by the American Institute of Certified Public Accountants with respect to
prospective financial information. In addition, the Forecasts assume that Pacific Biosciences would continue as a standalone company and do not reflect the impact of the merger (if it is completed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The projections were prepared by, and are the responsibility of, Pacific Biosciences management. In the opinion of Pacific Biosciences
management, the Forecasts (1)&nbsp;were prepared on a reasonable basis; (2)&nbsp;reflected the best currently available estimates and judgments; and (3)&nbsp;presented, to Pacific Biosciences management&#146;s knowledge, the expected future
financial performance of Pacific Biosciences within the parameters and under the assumptions specified in preparing the Forecasts. Because the Forecasts reflect estimates and judgments, they are susceptible to sensitivities and assumptions, as well
as multiple interpretations based on actual experience and business developments. The Forecasts also cover multiple years and such information by its nature becomes less predictive with each succeeding year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Pacific Biosciences&#146; independent registered public accounting firm nor any other independent accountants have (1)&nbsp;compiled,
reviewed, audited, examined or performed any procedures with respect to the Forecasts; (2)&nbsp;expressed any opinion or any other form of assurance on such information or the achievability of such information; or (3)&nbsp;assumed any responsibility
for the Forecasts. Pacific Biosciences&#146; independent registered public accounting firm disclaims any association with the Forecasts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Forecasts are forward-looking statements. Although the Forecasts are presented with
numerical specificity, they reflect numerous assumptions and estimates as to future events made by Pacific Biosciences management that Pacific Biosciences management believed were reasonable at the time that the Forecasts were prepared, taking into
account the relevant information available to Pacific Biosciences management at that time. However, the Forecasts are not fact and should not be relied upon as being necessarily indicative of future results. Important factors that may affect actual
results and cause the Forecasts not to be achieved include, among others, (1)&nbsp;general economic conditions; (2)&nbsp;the accuracy of certain accounting assumptions; (3)&nbsp;changes in actual or projected cash flows; (4)&nbsp;competitive
pressures; and (5)&nbsp;changes in tax laws. Additional factors that may impact Pacific Biosciences and its business can be found in the various risk factors included in Pacific Biosciences&#146; periodic filings with the SEC. All of these factors
are difficult to predict, and many of them are outside of Pacific Biosciences&#146; control. As a result, there can be no assurance that the Forecasts will be realized, and actual results may be materially better or worse than those contained in the
Forecasts. The Forecasts may differ from publicized analyst estimates and forecasts and do not take into account any events or circumstances after the date that they were prepared, including the announcement of the merger.<B> Pacific Biosciences
does not intend to update or otherwise revise the Forecasts to reflect circumstances existing after the date they were made or to reflect the occurrence of future events, even if any or all of the assumptions underlying the Forecasts are shown to be
in error or no longer appropriate.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By including the Forecasts in this proxy statement, neither Pacific Biosciences nor any of its
representatives has made or makes any representation to any person regarding Pacific Biosciences&#146; ultimate performance as compared to the information contained in the Forecasts. The inclusion of the Forecasts should not be regarded as an
indication that the Pacific Biosciences Board, Pacific Biosciences or any other recipient of the Forecasts considered, or now considers, the Forecasts to be predictive of actual future results. Further, the inclusion of the Forecasts in this proxy
statement does not constitute an admission or representation by Pacific Biosciences that the information presented is material. The summary of the Forecasts is not being included in this proxy statement to influence the decision of any Pacific
Biosciences stockholder on how to vote at the special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pacific Biosciences stockholders are cautioned not to place undue
reliance on the Forecasts, as Pacific Biosciences may not achieve the Forecasts whether or not the merger is completed. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Forecasts </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>(Dollars in millions)(1)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2027E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2028E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Goods Sold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SG&amp;A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBIT</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals may not foot due to rounding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at the direction of the Pacific Biosciences&#146; management, Centerview
calculated, from the Forecasts, unlevered free cash flow as set forth below for use in Centerview&#146;s discounted cash flow analysis (see the section of the proxy statement captioned &#147;&#151;Discounted Cash Flow Analysis&#148;). The
calculation of unlevered free cash flow includes estimated capital expenditures, depreciation and amortization, and changes in net working capital. At the direction of Pacific Biosciences&#146; management, the calculation also includes an adjustment
for the net present value of standalone tax savings from federal net operating losses of $50.0 million, or $0.30 per share, based on the estimated utilization of Pacific Biosciences&#146; net operating losses, and an assumed $50.0&nbsp;million
equity financing at $4.25 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>($ in millions)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2019E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2020E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2027E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY<BR>2028E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered free cash flow is defined as the Company&#146;s free cash flow before interest payments and is
calculated as earnings before interest, taxes, depreciation and amortization, less capital expenditures, less changes in net working capital and less tax expense. Unlevered free cash flow is a non-GAAP financial measure. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_48"></A>Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the Pacific Biosciences Board that you vote to approve the proposal to adopt the merger agreement, you
should be aware that our directors and executive officers have interests in the merger that are different from, or in addition to, the interests of Pacific Biosciences stockholders . In (1)&nbsp;evaluating and negotiating the merger agreement;
(2)&nbsp;approving the merger agreement and the merger; and (3)&nbsp;recommending that the merger agreement be adopted by Pacific Biosciences stockholders, the Pacific Biosciences Board was aware of and considered these interests to the extent that
they existed at the time, among other matters. The Pacific Biosciences Board was aware of and considered these interests to the extent that they existed at the time, among other matters, in approving the merger agreement and the merger and
recommending that the merger agreement be adopted by Pacific Biosciences stockholders. These interests are more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Insurance and Indemnification of Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the merger agreement, directors and officers of Pacific Biosciences will be entitled to certain ongoing
indemnification and coverage under directors&#146; and officers&#146; liability insurance policies. For more information, see the section of this proxy statement captioned &#147;The Merger Agreement&#151;Indemnification and Insurance.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Equity-Based Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Treatment of Company Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;26, 2018, there were outstanding company options to purchase 20,402,654 shares of common stock with an exercise price below
$8.00 per share, of which company options to purchase 1,560,834 shares of common stock were held by our directors and of which company options to purchase 5,491,258 shares of common stock were held by our executive officers (including
Mr.&nbsp;Corcoran who was an executive officer during Pacific Biosciences&#146; 2017 fiscal year but no longer is an executive officer for Pacific Biosciences&#146; 2018 fiscal year and whose employment with Pacific Biosciences terminated on
November&nbsp;23, 2018). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, each <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the excess of the per share merger consideration over the applicable per
share exercise price of such canceled company option, multiplied by (2)&nbsp;the aggregate number of shares of common stock subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option
immediately before the effective time of the merger. Any company option that is not an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option will be canceled as of the effective time of the merger without any amount payable in exchange. Holders of unvested company options (including company options that are not <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options) will be given an opportunity to exercise any unvested company options prior to, and contingent upon the consummation of the transactions
contemplated by the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Treatment of Company RSUs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;26, 2018, there were outstanding company RSU awards that cover 323,750 shares of common stock, of which company RSUs
covering 43,750 shares of common stock were held by our directors and of which company RSUs covering 108,750 shares of common stock were held by our executive officers. As a result of the termination of his employment on November&nbsp;23, 2018,
Mr.&nbsp;Corcoran no longer holds any company RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, each company RSU award
will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the total number of shares of common stock subject to such company RSU award
immediately prior to the effective time of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Treatment of Company PRSUs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;26, 2018, there were outstanding company PRSU awards that cover 586,096 shares of common stock (at target), of which
company PRSU awards covering 87,500 shares of common stock (at target) were held by our directors and of which company PRSU awards covering 217,355 shares of common stock (at target) were held by our executive officers. As a result of the
termination of his employment on November&nbsp;23, 2018, Mr.&nbsp;Corcoran no longer holds any company PRSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to
the effective time of the Merger, each company PRSU award will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the per share merger consideration, multiplied by (2)&nbsp;the number of shares of
common stock that would be payable if such company PRSU award had vested at target performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Treatment of the ESPP </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP (and all outstanding rights thereunder) will be terminated no later than as of immediately prior to the effective time of the Merger,
contingent upon the consummation of the transactions contemplated by the merger agreement. From and after the date of the merger agreement, no new participants are permitted to participate in the ESPP and participants may not increase their payroll
deductions or purchase elections from those in effect on the date of the merger agreement. Except for the final offering period, no new offering or purchase period will be authorized, continued or commenced following the date of the merger
agreement. In addition, from and after the date of the merger agreement, both the maximum number of shares of common stock that a participant in the ESPP can purchase and the total number of shares of common stock available under the ESPP will not
be increased. Unless otherwise agreed between Illumina and us, the final offering period will terminate no later than as of immediately following the next scheduled purchase date (to occur on March&nbsp;1, 2019), and the exercise date under the
final offering period will accelerate and occur on such termination date with respect to any then-outstanding purchase rights. Additionally, shares of common stock purchased under the terms of the ESPP for the final offering period will be canceled
at the effective time of the Merger in exchange for the right to receive the per share merger consideration in accordance with the merger agreement. As promptly as practicable following the purchase of shares of common stock under the final offering
period, Pacific Biosciences will return to each participant the funds, if any, that remain in such participant&#146;s account after such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Interests of Pacific Biosciences&#146; Executive Officers and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth for each Pacific Biosciences executive officer and director, as of November&nbsp;26, 2018, (1) the
number of shares of common stock held; (2)&nbsp;the number of shares of common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options; and (3)&nbsp;the number of shares of common stock subject to company RSUs
and company PRSUs (at target). The table sets forth the values of these shares of common stock and equity awards based on the per share merger consideration (minus the applicable exercise price in the case of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Equity Interests of Pacific Biosciences&#146; Executive
Officers and <FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Held<BR>(#)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>Shares<BR>Held<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Subject
to<BR><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-Money</FONT></FONT><BR>Options<BR>(#)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-Money</FONT></FONT><BR>Company<BR>Options<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Subject to<BR>Company<BR>RSUs and<BR>Company<BR>PRSUs<BR>(#)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>Shares<BR>Subject to<BR>Company<BR>RSUs and<BR>Company<BR>PRSUs<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hunkapiller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,198,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,798,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan K. Barnes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,779,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,436,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,394,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,224,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Corcoran(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,087,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Phillips</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,601,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">597,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,791,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,751,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Botstein, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Ericson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randy Livingston</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marshall Mohr</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">846,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">846,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Milligan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy Ordo&ntilde;ez(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,628,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lucy Shapiro, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This number includes the number of shares of common stock directly held by the individual as of
November&nbsp;26, 2018. For additional information regarding beneficial ownership of common stock, see the section of this proxy statement captioned &#147;Security Ownership of Certain Beneficial Owners and Management.&#148; The value shown with
respect to the shares is determined as the product of (1)&nbsp;the corresponding number of shares of common stock in the &#147;Number of Shares Held&#148; column, multiplied by (2)&nbsp;the per share merger consideration. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This number represents the number of shares of common stock subject to outstanding, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options, whether vested or unvested, held by the individual. The value shown with respect to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options is determined as the excess of (1)&nbsp;the total number of shares of common stock subject to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options multiplied by the per share merger consideration, over (2)&nbsp;the aggregate exercise price for such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts are the total number of shares subject to outstanding company RSUs and company PRSUs (at target)
for which the corresponding company RSU or company PRSU consideration will be payable in connection with the merger. The value shown with respect to company RSUs and company PRSUs is determined as the product of the per share merger consideration,
multiplied by (a)&nbsp;for company RSUs, the total number of shares of common stock subject to company RSUs; and (b)&nbsp;for company PRSUs, the number of shares of common stock subject to company PRSUs based on target performance. The aggregate
maximum number of shares subject to the company PRSUs held by each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes, Mr.&nbsp;Phillips, and Ms.&nbsp;Ordo&ntilde;ez that may become eligible to vest under such awards is 112,500, 98,438, 37,294, and 98,438,
respectively. For additional information regarding the company RSUs and company PRSUs, see the section of the proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Officers in the Merger&#151;Golden
Parachute Compensation.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Corcoran resigned from his role as Senior Vice President, Market Development, and his employment
terminated on November&nbsp;23, 2018. As a result, the unvested portion of his <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
company RSUs and company PRSUs terminated. The values shown with respect to his in-the-money company options, company RSUs and company PRSUs do not include such terminated amounts.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Ordo&ntilde;ez is Pacific Biosciences&#146; former Chief Commercial Officer. She remains a director of
Pacific Biosciences. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_49"></A>Payments Upon Termination Following Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Change in Control Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences entered into change in control agreements with Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips. Pacific
Biosciences also previously entered into a change in control agreement with Ms.&nbsp;Ordo&ntilde;ez and Mr.&nbsp;Corcoran. In connection with Ms.&nbsp;Ordo&ntilde;ez&#146; resignation from her role as Chief Commercial Officer and Executive Vice
President on October&nbsp;30,&nbsp;2018, she is no longer eligible to receive any severance benefits under that agreement. Additionally, as a result of Mr.&nbsp;Corcoran&#146;s resignation on November&nbsp;23, 2018, he is no longer eligible to
receive any severance benefits under his change in control agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in control agreements with Dr.&nbsp;Hunkapiller,
Ms.&nbsp;Barnes, and Mr.&nbsp;Phillips provide that if, on or within 12 months following a change in control (as defined in the change in control agreements), Pacific Biosciences terminates his or her employment with Pacific Biosciences for a reason
other than &#147;cause,&#148; his or her death or &#147;disability,&#148; or he or she resigns for &#147;good reason,&#148; in each case, as set forth in the applicable change in control agreement, he or she would be entitled to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing payments of base salary in effect immediately before the termination of his or her employment or, if
greater, the base salary as in effect immediately before the merger, for a period of (1)&nbsp;in the case of Dr.&nbsp;Hunkapiller, 12 months; and (2)&nbsp;in the case of Ms.&nbsp;Barnes, and Mr.&nbsp;Phillips, six months, in each case from the date
of termination of employment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100&nbsp;percent of the unvested portion of his or her then-outstanding equity awards will vest immediately and,
to the extent applicable, become exercisable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences-paid or Pacific Biosciences-reimbursed premiums for continuation coverage as applicable,
pursuant to COBRA for himself or herself and his or her eligible dependents (as applicable), subject to his or her timely election to continue such coverage, for up to 12 months (for Dr.&nbsp;Hunkapiller) or six&nbsp;months (for Ms.&nbsp;Barnes and
Mr.&nbsp;Phillips) following termination of employment, except that, in the case of Dr.&nbsp;Hunkapiller, if we determine in our sole discretion that we cannot provide the COBRA benefits without potentially violating applicable law, then we will
provide instead a taxable monthly payment in an amount equal to the monthly COBRA premium, regardless of whether he elects COBRA continuation coverage. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to receive the severance benefits under the change in control agreement, the executive officer must execute and not revoke a
separation and release of claims agreement in favor of Pacific Biosciences. The executive officer also is required to comply with the terms of his or her confidential information and invention assignment agreement previously entered into with
Pacific Biosciences, including obligations relating to <FONT STYLE="white-space:nowrap">non-solicitation</FONT> of Pacific Biosciences employees for a period of 12 months following the termination of his or her employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each severance agreement provides that, if any payment or benefits to the applicable named executive officer (including the payments and
benefits under his or her severance agreement) would constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code and therefore would be subject to an excise tax under Section&nbsp;4999 of the
Internal Revenue Code, then such payments and benefits will be either (1)&nbsp;reduced to the largest portion of the payments and benefits that would result in no portion of the payments and benefits being subject to the excise tax; or (2)&nbsp;not
reduced, whichever, after taking into account all applicable federal, state, and local employment taxes, income taxes and the excise tax, results in his or her receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater
payments and benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the change in control agreements for each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and
Mr.&nbsp;Phillips, the following definitions are used: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Cause&#148; generally means (1)&nbsp;conviction of any felony; (2)&nbsp;conviction of any crime involving
moral turpitude or dishonesty that causes, or is likely to cause, material harm to us; (3)&nbsp;participation in a fraud or willful act of dishonesty against us that causes, or is likely to cause, material harm to us; (4)&nbsp;intentional and
material damage to our property; or (5)&nbsp;material breach of our proprietary information and inventions agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Disability&#148; means an executive is unable to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Good reason&#148; generally means an executive&#146;s termination of employment within thirty days
following the expiration of any cure period (discussed below) following the occurrence of one or more of the following, without his or her express written consent: (1) (i) for each of Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, a material reduction of
his or her duties, authority, or responsibilities, relative to the executive&#146;s duties, authority, or responsibilities as in effect immediately prior to such reduction; provided, however, that a reduction in duties, authority, responsibilities
solely by virtue of our being acquired and made part of a larger entity (for example, where he or she retains essentially the same responsibility and duties of the subsidiary, business unit or division substantially containing our business following
a change in control) shall not constitute good reason; (ii)&nbsp;for Dr.&nbsp;Hunkapiller, a material reduction of his duties, authority, or responsibilities, relative to his duties, authority, or responsibilities as in effect immediately prior to
such reduction, or any change which results in his ceasing to serve as Pacific Biosciences&#146; chief executive officer, except that ceasing to serve as president of Pacific Biosciences or executive chairman of the Pacific Biosciences Board will
not constitute good reason; (2)&nbsp;for each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, a material reduction by Pacific Biosciences in his or her annualized base pay as in effect immediately prior to such reduction (in other
words, a reduction of more than 10&nbsp;percent of his or her annualized base compensation in any one year, other than a reduction applicable to executives generally that does not adversely affect him or her to a greater extent than other
similarly-situated executives); (3) for each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, the relocation of his or her principal place of performing his or her duties as an employee of Pacific Biosciences by more than 50 miles; or
(4)&nbsp;for each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, Pacific Biosciences&#146; failure to obtain the assumption of the change in control agreement by a successor; except that, in order for an event to qualify as good
reason, he or she must not terminate employment without first providing Pacific Biosciences with written notice of the acts or omissions constituting the grounds for good reason within 90 days of the initial existence of the grounds for good reason
and a reasonable cure period of not less than 30 days following the date of such notice. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the merger will
constitute a &#147;change in control&#148; under the change in control agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PRSU Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Dr.&nbsp;Hunkapiller, Mses. Barnes and Ordo&ntilde;ez, and Mr.&nbsp;Phillips holds awards of company PRSUs that provide that, if a
&#147;change in control&#148; (as defined in the applicable Pacific Biosciences equity incentive plan) occurs during the applicable performance period (or during the period after the end of the applicable performance period but before the applicable
determination date), then effective as of immediately before the completion of the change in control, all of the applicable performance goals automatically will be deemed to have been achieved at the target level, such that 100&nbsp;percent of the
target number of shares subject to the award will be considered eligible to vest based on the individual&#146;s continued status as a service provider through the applicable vesting date, and the applicable performance goals no longer will apply to
the award. Mr.&nbsp;Corcoran no longer holds any company PRSUs due to the termination of his employment on November&nbsp;23, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
closing of the merger will constitute a &#147;change in control&#148; for the purposes of the company PRSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Director Equity Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Ordo&ntilde;ez holds company option awards granted under our 2010 Outside Director Equity Incentive Plan (which we refer to as the
&#147;director plan&#148;). In the event of a &#147;change in control,&#148; as defined in our director plan, these awards will vest in full and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the merger will constitute a &#147;change in control&#148; under the director plan. As described above, all <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options, including those granted under the director plan, will be canceled and converted into the right to receive cash consideration in an amount set
forth in the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and Chief Financial Officer Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1,&nbsp;2018, the Pacific Biosciences Board approved cash bonuses to Dr.&nbsp;Hunkapiller and Ms.&nbsp;Barnes in the amount of
$1,030,000 and $617,500, respectively. These amounts were approved as compensation for their services as Pacific Biosciences&#146; chief executive officer and chief financial officer, respectively, in light of each of these executive officers
previously having received $1 as cash compensation for their services during the year. These amounts were intended to recognize their commitment to the best interests of Pacific Biosciences and to provide compensation commensurate with their roles
at, and services provided to, Pacific Biosciences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Golden Parachute Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the information required by Item 402(t) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> published
by the SEC regarding certain compensation that each of Pacific Biosciences&#146; named executive officers may receive that is based on, or that otherwise relates to, the merger. Pacific Biosciences&#146; &#147;named executive officers&#148; for
purposes of the disclosure in this proxy statement are Dr.&nbsp;Hunkapiller, Mses. Barnes and Ordo&ntilde;ez, and Messrs. Corcoran and&nbsp;Phillips. For additional details regarding the terms of the payments quantified below, see the sections of
this proxy statement captioned &#147;&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger&#151;Treatment of Equity-Based Awards&#148; and &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors
and Executive Officers in the Merger&#151;Payments Upon Termination Following Change of Control.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figures in the table are
estimated based on (1)&nbsp;assumed compensation and benefit levels as of November 26, 2018; (2) an assumed effective date of November&nbsp;26, 2018, for the merger, which is the latest practicable date with respect to the date of this proxy
statement; and (3)&nbsp;the assumed termination of the named executive officer&#146;s employment without cause on the day immediately following such effective date for the merger. The amounts reported below are estimates based on multiple
assumptions that may or may not actually occur or be accurate on the relevant date. Accordingly, the ultimate values to be received by a named executive officer in connection with the merger may differ from the amounts set below. Pacific
Biosciences&#146; named executive officers will not receive pension, <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation, or tax reimbursements in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by applicable SEC rules, all amounts below that are determined using the per share value of the common stock have been calculated
based on the per share merger consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Golden Parachute Compensation </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Perquisites/<BR>Benefits<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Payments<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hunkapiller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,030,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,370,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,400,377</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan K. Barnes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">617,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,889,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,506,963</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy Ordo&ntilde;ez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,866,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,866,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Corcoran(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Phillips</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">829,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,007,511</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A portion of the amounts for Dr.&nbsp;Hunkapiller and Ms.&nbsp;Barnes, consisting of $1,030,000 and $617,500,
respectively, were paid in November&nbsp;2018 in order to compensate our chief executive officer and chief financial officer for their services to Pacific Biosciences, in light of their previously having received $1 as cash compensation for the
year. These compensation amounts would be considered &#147;single trigger&#148; payments since they were not made in connection with any termination of employment. The remaining amount for each of Dr.&nbsp;Hunkapiller and Ms.&nbsp;Barnes, and the
full amount for Mr.&nbsp;Phillips, represent the &#147;double-trigger&#148; cash severance payments to which he or she may become entitled under the applicable change in control agreement, as described in further detail in the section of this proxy
statement captioned &#147;&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger&#151;Payments Upon Termination Following Change of Control.&#148; The amounts represent continuing payments of severance at a rate
equal to his or her base salary rate, in the case of Dr.&nbsp;Hunkapiller, for 12 months (or $1), and in the case of Ms.&nbsp;Barnes and Mr.&nbsp;Phillips, six months (or $0.50 and $168,400, respectively), from the date of such termination of
employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount includes the &#147;single-trigger&#148; vesting acceleration of 100&nbsp;percent of the unvested
portion of his or her outstanding equity awards to which each named executive officer may become entitled pursuant to the treatment of equity awards under the merger agreement. The following table quantifies the value of such payments and the number
of shares to which the payment relate: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name(a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Subject
to<BR>Unvested,<BR><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-money</FONT></FONT><BR>Company<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value
of<BR>Unvested,<BR><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-money</FONT></FONT><BR>Company<BR>Options<BR>($)(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>Subject<BR>to<BR>Company<BR>RSUs (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><BR><BR><BR>Value of<BR>Company<BR>RSUs<BR>($)(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>Subject to<BR>Company<BR>PRSUs at<BR>Target&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>Company<BR>PRSUs at<BR>Target<BR>($)(d)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hunkapiller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan K. Barnes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy Ordo&ntilde;ez</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Corcoran</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Phillips</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the &#147;single trigger&#148; vesting acceleration pursuant to the terms of the merger
agreement, the equity awards held by each of Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes, and Mr.&nbsp;Phillips have &#147;double trigger&#148; vesting acceleration of 100&nbsp;percent of the unvested portion pursuant to his or her change in control
agreement as described in further detail in the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger&#151;Payments Upon Termination Following Change of
Control.&#148; For additional information regarding Ms.&nbsp;Ordo&ntilde;ez&#146; equity awards, please see the section of this proxy statement captioned &#147;&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the
Merger&#151;Payments Upon Termination Following Change of Control.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents a cash amount equal to (1)&nbsp;the product of (i)&nbsp;the per share merger
consideration, multiplied by (ii)&nbsp;the aggregate number of shares subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money,</FONT></FONT> unvested company options held by the named executive officer (as set
forth in the column immediately to the left of this column), minus (2)&nbsp;the aggregate exercise price of such company options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents a cash amount equal to the product of (1)&nbsp;the per share merger consideration,
multiplied by (2)&nbsp;the total number of shares of common stock subject to such company RSUs held by the named executive officer (as set forth in the column immediately to the left of the applicable column). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents a cash amount equal to the product of (1)&nbsp;the per share merger consideration,
multiplied by (2)&nbsp;the number of shares of common stock subject to company PRSUs held by the named executive officer that would be payable if such company PRSU were to vest at target performance (as set forth in the column immediately to the
left of the applicable column). The aggregate maximum number of shares subject to the company PRSUs held by each of Dr.&nbsp;Hunkapiller, Mses. Barnes and Ordo&ntilde;ez, and Mr.&nbsp;Phillips that may become eligible to vest under such awards is
112,500, 98,438, 98,438, and 37,294, respectively. The difference in number of shares subject to PRSUs between target </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
performance and maximum performance relate to certain company PRSUs held by the named executive officer for which the applicable performance period will end on December&nbsp;31, 2018. On the date
of certification by the Pacific Biosciences Board or its compensation committee of the applicable performance under such PRSU awards, which generally will occur during the first calendar quarter of 2019, the applicable number of shares of common
stock subject to the company PRSU award will vest subject to the individual&#146;s continued service through such date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents 12 months for Dr.&nbsp;Hunkapiller and in the case of Ms.&nbsp;Barnes and
Mr.&nbsp;Phillips, six months of reimbursement or payment for continued coverage under COBRA for the named executive officer and his or her covered dependents. These amounts are a &#147;double-trigger&#148; severance benefit that each of
Dr.&nbsp;Hunkapiller, Ms.&nbsp;Barnes and Mr.&nbsp;Phillips may become entitled to receive under the applicable change in control agreement, as described in further detail in the section of this proxy statement captioned &#147;&#151;Interests of
Pacific Biosciences&#146; Directors and Executive Officers in the Merger&#151;Payments Upon Termination Following Change of Control.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the change in control agreements, amounts are subject to reduction in the event the named executive
officer would be better off on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis being cut back than paying the excise tax under Section&nbsp;4999 of the Internal Revenue Code. This amount assumes no such reductions will be applied.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Due to the termination of Mr.&nbsp;Corcoran&#146;s employment on November&nbsp;23, 2018, Mr.&nbsp;Corcoran no
longer is eligible to receive any &#147;single trigger&#148; or &#147;double trigger&#148; payments or benefits in connection with the merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_50"></A>Closing and Effective Time of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the merger will take place (1)&nbsp;on a date that is as soon as possible, but no later than the third business day after the
satisfaction or waiver (to the extent permitted under the Merger Agreement) of the last to be satisfied or waived of the closing conditions of the merger (described in the section of this proxy statement captioned &#147;The Merger
Agreement&#151;Conditions to the Closing of the Merger&#148;), other than conditions that by their terms are to be satisfied at the closing of the merger, but subject to the satisfaction or waiver of each of such conditions; or (2)&nbsp;at such
other time agreed to by Pacific Biosciences and Illumina. On the closing date, the parties will file a certificate of merger with the Secretary of State of the State of Delaware as provided under the DGCL. The merger will become effective upon the
filing and acceptance of such certificate of merger, or at a later time agreed to in writing by the parties and specified in such certificate of merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_51"></A>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is consummated, Pacific Biosciences stockholders who do not vote in favor of the adoption of the merger agreement, who properly
demand an appraisal of their shares, who continuously hold such shares through the effective time of the merger, who otherwise comply with the procedures of Section&nbsp;262 of the DGCL and who do not withdraw their demands or otherwise lose their
rights to appraisal may, subject to the conditions thereof, are entitled to seek appraisal of their shares in connection with the merger under Section&nbsp;262 of the DGCL, which we refer to as &#147;Section&nbsp;262.&#148; Unless the context
requires otherwise, all references in Section&nbsp;262 and in this summary to a &#147;stockholder&#148; or to a &#147;holder of shares&#148; are to a record holder of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is not a complete statement of the law pertaining to appraisal rights under the DGCL and is qualified in its entirety
by the full text of Section&nbsp;262, which is attached to this proxy statement as Annex C and incorporated into this proxy statement by reference. The following summary does not constitute any legal or other advice and does not constitute a
recommendation that Pacific Biosciences stockholders exercise their appraisal rights under Section&nbsp;262. Only a holder of record of shares of common stock is entitled to demand appraisal of the shares registered in that holder&#146;s name. A
person having a beneficial interest in shares of common stock held of record in the name of another person, such as a bank, broker or other nominee, must act promptly to cause the record holder to demand an appraisal of such holder&#146;s shares.
<B>If you hold your shares of our common stock through a bank, broker or other nominee and you wish to exercise appraisal rights, you should consult with your bank, broker or the other nominee to ensure that appraisal rights are exercised.
Stockholders should carefully review the full text of Section</B><B></B><B>&nbsp;262 as well as the information discussed below.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;262, if the merger is completed, holders of record of shares of common
stock who (1)&nbsp;submit a written demand for appraisal of such stockholder&#146;s shares to Pacific Biosciences prior to the vote on the adoption of the merger agreement; (2)&nbsp;do not vote in favor of the adoption of the merger agreement;
(3)&nbsp;continuously are the record holders of such shares through the effective time of the merger; and (4)&nbsp;otherwise comply with the procedures and satisfy certain ownership thresholds set forth in Section&nbsp;262 may be entitled to have
their shares of common stock appraised by the Delaware Court of Chancery and to receive payment in cash of the &#147;fair value&#148; of the shares of common stock, exclusive of any element of value arising from the accomplishment or expectation of
the merger, together with (unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown) interest on the amount determined by the Delaware Court of Chancery to be fair value from the effective date of the merger
through the date of payment of the judgment at a rate of five percent over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of
payment of the judgment (except that, if at any time before the entry of judgment in the proceeding, the surviving corporation makes a voluntary cash payment to each stockholder seeking appraisal, interest will accrue thereafter only upon the sum of
(i)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery; and (ii)&nbsp;interest theretofore accrued, unless paid at that time). However, after an appraisal petition
has been filed, the Delaware Court of Chancery, at a hearing to determine stockholders entitled to appraisal rights, will dismiss appraisal proceedings as to all Pacific Biosciences stockholders who asserted appraisal rights unless (1)&nbsp;the
total number of shares of common stock for which appraisal rights have been pursued or perfected exceeds one percent of the outstanding shares of common stock as measured in accordance with subsection (g)&nbsp;of Section&nbsp;262; or (2)&nbsp;the
value of the merger consideration in respect of such shares exceeds $1&nbsp;million. We refer to these conditions as the &#147;ownership thresholds.&#148; Unless the Delaware Court of Chancery, in its discretion, determines otherwise for good cause
shown, interest on an appraisal award will accrue and compound quarterly from the effective time of the merger through the date the judgment is paid at five percent over the Federal Reserve discount rate (including any surcharge) as established from
time to time during such period (except that, if at any time before the entry of judgment in the proceeding, the surviving corporation makes a voluntary cash payment to each stockholder seeking appraisal, interest will accrue thereafter only upon
the sum of (i)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery; and (ii)&nbsp;interest theretofore accrued, unless paid at that time). The surviving corporation
is under no obligation to make such voluntary cash payment prior to such entry of judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;262, where a merger
agreement is to be submitted for adoption at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, must notify each of its stockholders of record as of the record date for notice of such meeting that appraisal
rights are available and include in the notice a copy of Section&nbsp;262. This proxy statement constitutes Pacific Biosciences&#146; notice to Pacific Biosciences stockholders that appraisal rights are available in connection with the merger, and
the full text of Section&nbsp;262 is attached to this proxy statement as Annex C. In connection with the merger, any holder of shares of common stock who wishes to exercise appraisal rights, or who wishes to preserve such holder&#146;s right to do
so, should review Annex C carefully. Failure to strictly comply with the requirements of Section&nbsp;262 in a timely and proper manner may result in the loss of appraisal rights under the DGCL. A stockholder who loses his, her or its appraisal
rights will be entitled to receive the merger consideration described in the merger agreement without interest and less any applicable withholding taxes. Moreover, because of the complexity of the procedures for exercising the right to seek
appraisal of shares of common stock, Pacific Biosciences believes that if a stockholder considers exercising such rights, that stockholder should seek the advice of legal counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders wishing to exercise the right to seek an appraisal of their shares of common stock must do <B>ALL</B> of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder must not vote in favor of the proposal to adopt the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder must deliver to Pacific Biosciences a written demand for appraisal before the vote on the merger
agreement at the special meeting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder must continuously hold the shares from the date of making the demand through the effective time
of the merger (a stockholder will lose appraisal rights if the stockholder transfers the shares before the effective time of the merger); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a stockholder (or any person who is the beneficial owner of shares of common stock held either in a voting trust
or by a nominee on behalf of such person) or the surviving corporation must file a petition in the Delaware Court of Chancery demanding a determination of the value of the stock of all such stockholders within 120 days after the effective time of
the merger (the surviving corporation is under no obligation to file any petition and has no intention of doing so). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, after an appraisal petition has been filed, the Delaware Court of Chancery, at a hearing to determine stockholders entitled to appraisal rights, will dismiss appraisal proceedings as to all Pacific Biosciences stockholders who asserted
appraisal rights unless one of the ownership thresholds is met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because a proxy that does not contain voting instructions will, unless
revoked, be voted in favor of the adoption of the merger agreement, a Pacific Biosciences stockholder who votes by proxy and who wishes to exercise appraisal rights must vote against the adoption of the merger agreement, abstain, or not vote his,
her or its shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Filing Written Demand </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A stockholder wishing to exercise appraisal rights must deliver to Pacific Biosciences, before the vote on the adoption of the merger agreement
at the special meeting, a written demand for the appraisal of such stockholder&#146;s shares. In addition, that stockholder must not vote or submit a proxy in favor of the adoption of the merger agreement. A vote in favor of the adoption of the
merger agreement, in person at the special meeting or by proxy (whether by mail or via the Internet or telephone), will constitute a waiver of your appraisal rights in respect of the shares so voted and will nullify any previously filed written
demands for appraisal. A stockholder exercising appraisal rights must hold of record the shares on the date the written demand for appraisal is made and must continue to hold the shares of record through the effective time of the merger. A proxy
that is submitted and does not contain voting instructions will, unless revoked, be voted in favor of the adoption of the merger agreement, and it will constitute a waiver of the stockholder&#146;s right of appraisal and will nullify any previously
delivered written demand for appraisal. Therefore, a stockholder who submits a proxy and who wishes to exercise appraisal rights must submit a proxy containing instructions to vote against the adoption of the merger agreement or abstain from voting
on the adoption of the merger agreement. Neither voting against the adoption of the merger agreement nor abstaining from voting or failing to vote on the proposal to adopt the merger agreement will, in and of itself, constitute a written demand for
appraisal satisfying the requirements of Section&nbsp;262. The written demand for appraisal must be in addition to and separate from any proxy or vote on the adoption of the merger agreement. A proxy or vote against the adoption of the merger
agreement will not constitute a demand. A stockholder&#146;s failure to make the written demand prior to the taking of the vote on the adoption of the merger agreement at the special meeting will constitute a waiver of appraisal rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only a holder of record of shares of common stock is entitled to demand appraisal rights for the shares registered in that holder&#146;s name.
A demand for appraisal in respect of shares of common stock should be executed by or on behalf of the holder of record, and must reasonably inform Pacific Biosciences of the identity of the holder and that the stockholder intends thereby to demand
an appraisal of such stockholder&#146;s shares. If the shares are owned of record in a fiduciary or representative capacity, such as by a trustee, guardian or custodian, such demand must be executed by or on behalf of the record owner, and if such
shares are owned of record by more than one person, as in a joint tenancy and tenancy in common, the demand should be executed by or on behalf of all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may
execute a demand for appraisal on behalf of a holder of record; however, the agent must identify the record owner or owners and expressly disclose that, in executing the demand, the agent is acting as agent for the record owner or owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS WHO HOLD THEIR SHARES IN &#147;STREET NAME&#148; BY A BANK, BROKER, TRUST OR
OTHER NOMINEE AND WHO WISH TO EXERCISE APPRAISAL RIGHTS SHOULD CONSULT WITH THEIR BANK, BROKER, TRUST OR OTHER NOMINEE, AS APPLICABLE, TO DETERMINE THE APPROPRIATE PROCEDURES FOR THE BANK, BROKER, TRUST OR OTHER NOMINEE TO MAKE A DEMAND FOR
APPRAISAL OF THOSE SHARES. A PERSON HAVING A BENEFICIAL INTEREST IN SHARES HELD OF RECORD IN THE NAME OF ANOTHER PERSON, SUCH AS A BANK, BROKER, TRUST OR OTHER NOMINEE, MUST ACT PROMPTLY TO CAUSE THE RECORD HOLDER TO FOLLOW PROPERLY AND IN A TIMELY
MANNER THE STEPS NECESSARY TO PERFECT APPRAISAL RIGHTS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All written demands for appraisal pursuant to Section&nbsp;262 should be mailed
or delivered to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1305 O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo
Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time within 60 days after the effective date of the Merger, any holder of shares of common stock may withdraw his, her or its demand
for appraisal and accept the per share merger consideration offered pursuant to the merger agreement, without interest and less any applicable withholding taxes, by delivering to Pacific Biosciences, as the surviving corporation, a written
withdrawal of the demand for appraisal. However, any such attempt to withdraw the demand made more than 60 days after the effective time of the merger will require written approval of the surviving corporation. Notwithstanding the foregoing, no
appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the Delaware Court of Chancery, and such approval may be conditioned upon such terms as the Delaware Court of Chancery deems just;
provided, however, that this shall not affect the right of any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#146;s demand for appraisal and to accept the merger
consideration within 60 days after the effective time of the merger. If Pacific Biosciences, as the surviving corporation, does not approve a request to withdraw a demand for appraisal when that approval is required, or, except with respect to any
stockholder who withdraws such stockholder&#146;s demand in accordance with the proviso in the immediately preceding sentence, if the Delaware Court of Chancery does not approve the dismissal of an appraisal proceeding with respect to a stockholder,
the stockholder will be entitled to receive only the appraised value determined in any such appraisal proceeding, which value could be less than, equal to or more than the per share merger consideration being offered pursuant to the merger
agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Notice by the Surviving Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, within 10 days after the effective time of the merger, the surviving corporation will notify each record holder of
shares of common stock who has properly made a written demand for appraisal pursuant to Section&nbsp;262, and who has not voted in favor of the adoption of the merger agreement, that the merger has become effective and the effective date thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Filing a Petition for Appraisal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the effective time of the merger, but not thereafter, the surviving corporation or any holder of shares of common stock
who has complied with Section&nbsp;262 and is entitled to appraisal rights under Section&nbsp;262 (or the beneficial owner of such shares) may commence an appraisal proceeding by filing a petition in the Delaware Court of Chancery, with a copy
served on the surviving corporation in the case of a petition filed by a stockholder, demanding a determination of the fair value of the shares held by all dissenting stockholders entitled to appraisal. The surviving corporation is under no
obligation, and has no present intention, to file a petition, and stockholders should not assume that the surviving corporation will file a petition or initiate any negotiations with respect to the fair value of the shares of common stock.
Accordingly, any holders of shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock who desire to have their shares appraised should initiate all necessary action to perfect their appraisal rights in respect of their shares of common stock within the time and in the
manner prescribed in Section&nbsp;262. The failure to file such a petition within the period specified in Section&nbsp;262 could nullify a previous written demand for appraisal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the effective time of the merger, any holder of shares of common stock who has complied with the requirements for an
appraisal of such holder&#146;s shares pursuant to Section&nbsp;262 will be entitled, upon written request, to receive from the surviving corporation a statement setting forth the aggregate number of shares not voted in favor of the adoption of the
merger agreement and with respect to which Pacific Biosciences has received demands for appraisal, and the aggregate number of holders of such shares. The surviving corporation must mail this statement to the requesting stockholder within 10 days
after receipt by the surviving corporation of the written request for such a statement or within 10 days after the expiration of the period for delivery of demands for appraisal, whichever is later. A beneficial owner of shares of common stock held
either in a voting trust or by a nominee on behalf of such person may, in such person&#146;s own name, file a petition seeking appraisal or request from the surviving corporation the foregoing statements. As noted above, however, the demand for
appraisal can only be made by a stockholder of record. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a petition for an appraisal is duly filed by a holder of shares of common stock
and a copy thereof is served upon the surviving corporation, the surviving corporation will then be obligated within 20 days after such service to file with the Delaware Register in Chancery a duly verified list containing the names and addresses of
all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached. The Delaware Court of Chancery may order that notice of the time and place fixed for the hearing of such
petition be given to the surviving corporation, and all of the stockholders shown on the verified list at the addresses stated therein. Any such notice shall also be given by one or more publications at least one week before the day of the hearing
in a newspaper of general circulation published in the City of Wilmington, Delaware or any other publication which the Delaware Court of Chancery deems advisable. The costs of any such notice are borne by the surviving corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After notice to dissenting stockholders as required by the court, at the hearing on such petition, the Delaware Court of Chancery will
determine the stockholders who have complied with Section&nbsp;262 and who have become entitled to appraisal rights thereunder. The Delaware Court of Chancery may require the stockholders who demanded appraisal for their shares to submit their stock
certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings. If any stockholder fails to comply with the direction, the Delaware Court of Chancery may dismiss the proceedings as to such stockholder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware Court of Chancery will dismiss appraisal proceedings as to all Pacific Biosciences stockholders who assert appraisal rights
unless (1)&nbsp;the total number of shares for which appraisal rights have been pursued and perfected exceeds one percent of the outstanding shares of common stock as measured in accordance with subsection (g)&nbsp;of Section&nbsp;262 or
(2)&nbsp;the value of the merger consideration in respect of the shares for which appraisal rights have been pursued and perfected exceeds $1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Delaware Court of Chancery determines the holders of common stock entitled to appraisal, and that at least one of the ownership
thresholds above has been satisfied in respect of the Pacific Biosciences stockholders seeking appraisal rights, then the appraisal proceeding will be conducted in accordance with the rules of the Delaware Court of Chancery, including any rules
specifically governing appraisal proceedings. Through such proceeding, the Delaware Court of Chancery will determine the &#147;fair value&#148; of the shares of common stock, exclusive of any element of value arising from the accomplishment or
expectation of the merger, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining fair value, the Delaware Court of Chancery will take into account all relevant factors. Unless the Delaware Court
of Chancery in its discretion determines otherwise for good cause shown, interest from the effective date of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger through the date of payment of the judgment will be compounded quarterly and will accrue at five percent over the Federal Reserve discount rate (including any surcharge) as established
from time to time during the period between the effective date of the merger and the date of payment of the judgment. The surviving corporation has the right, at any time prior to the Delaware Court of Chancery&#146;s entry of judgment in the
proceedings, to make a voluntary cash payment to each stockholder seeking appraisal. If the surviving corporation makes a voluntary cash payment pursuant to subsection (h)&nbsp;of Section&nbsp;262, interest will accrue thereafter only on the sum of
(1)&nbsp;the difference, if any, between the amount paid by the surviving corporation in such voluntary cash payment and the fair value of the shares as determined by the Delaware Court of Chancery; and (2)&nbsp;interest accrued before such
voluntary cash payment, unless paid at that time. In <I>Weinberger v. UOP, Inc.</I>, the Supreme Court of Delaware discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#147;proof of value
by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#148; should be considered, and that &#147;[f]air price obviously requires consideration of all relevant factors
involving the value of a company.&#148; The Delaware Supreme Court stated that, in making this determination of fair value, the court must consider market value, asset value, dividends, earnings prospects, the nature of the enterprise and any other
facts that could be ascertained as of the date of the merger that throw any light on future prospects of the merged corporation. Section&nbsp;262 provides that fair value is to be &#147;exclusive of any element of value arising from the
accomplishment or expectation of the merger.&#148; In <I>Cede</I><I></I><I>&nbsp;&amp; Co. v. Technicolor, Inc.</I>, the Delaware Supreme Court stated that such exclusion is a &#147;narrow exclusion [that] does not encompass known elements of
value,&#148; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <I>Weinberger</I>, the Supreme Court of Delaware also stated that &#147;elements of future value, including the
nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders considering seeking appraisal should be aware that the fair value of their shares as so determined by the Delaware Court of
Chancery could be more than, the same as or less than the consideration they would receive pursuant to the merger if they did not seek appraisal of their shares and that an opinion of an investment banking firm as to the fairness from a financial
point of view of the consideration payable in a merger is not an opinion as to, and may not in any manner address, fair value under Section&nbsp;262. <B>Although Pacific</B> <B>Biosciences</B> <B>believes that the per share merger consideration is
fair, no representation is made as to the outcome of the appraisal of fair value as determined by the Delaware Court of Chancery, and stockholders should recognize that such an appraisal could result in a determination of a value higher or lower
than, or the same as, the per share merger consideration</B>. Neither Pacific Biosciences nor Illumina anticipates offering more than the per share merger consideration to any stockholder exercising appraisal rights, and each of Pacific Biosciences
and Illumina reserves the rights to make a voluntary cash payment pursuant to subsection (h)&nbsp;of Section&nbsp;262 and to assert, in any appraisal proceeding, that for purposes of Section&nbsp;262, the &#147;fair value&#148; of a share of common
stock is less than the per share merger consideration. If a petition for appraisal is not timely filed, or if neither of the ownership thresholds above has been satisfied in respect of the Pacific Biosciences stockholders seeking appraisal rights,
then the right to an appraisal will cease. The costs of the appraisal proceedings (which do not include attorneys&#146; fees or the fees and expenses of experts) may be determined by the Delaware Court of Chancery and taxed upon the parties as the
Delaware Court of Chancery deems equitable under the circumstances. Upon application of a stockholder, the Delaware Court of Chancery may also order that all or a portion of the expenses incurred by any stockholder in connection with the appraisal
proceeding, including, without limitation, reasonable attorney&#146;s fees and the fees and expenses of experts, be charged pro rata against the value of all the shares entitled to an appraisal. In the absence of such determination or assessment,
each party bears its own expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any stockholder who demands appraisal of his, her or its shares of common stock under
Section&nbsp;262 fails to perfect, or loses or validly withdraws, such holder&#146;s right to appraisal, the stockholder&#146;s shares of common stock will be deemed to have been converted at the effective time of the merger into the right to
receive the per share merger consideration as provided in the merger agreement. A stockholder will fail to perfect, or effectively lose, such holder&#146;s right to appraisal if no petition for appraisal is filed within 120 days after the effective
time of the merger, if neither of the ownership thresholds above has been satisfied in respect of the Pacific Biosciences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders seeking appraisal rights or if the stockholder delivers to the surviving corporation a written withdrawal of such holder&#146;s demand for appraisal and an acceptance of the per
share merger consideration as provided in the merger agreement in accordance with Section&nbsp;262. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the effective time of
the merger, no stockholder who has demanded appraisal rights in compliance with Section&nbsp;262 will be entitled to vote such shares of common stock for any purpose or to receive payment of dividends or other distributions on the stock (except
dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger); provided, however, that if no petition for an appraisal is filed within the time provided in Section&nbsp;262, if
neither of the ownership thresholds above has been satisfied in respect of the CA stockholders seeking appraisal rights or if such stockholder delivers to the surviving corporation a written withdrawal of such stockholder&#146;s demand for an
appraisal and an acceptance of the merger, either within 60 days after the effective date of the merger or thereafter with the written approval of the surviving corporation, then the right of such stockholder to an appraisal will cease.
Notwithstanding the foregoing, no appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just;
provided, however, that the foregoing shall not affect the right of any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#146;s demand for appraisal and to accept the
terms offered upon the merger or consolidation within 60 days after the effective date of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply strictly with all
of the procedures set forth in Section&nbsp;262 may result in the loss of a stockholder&#146;s statutory appraisal rights. In that event, you will be entitled to receive the per share merger consideration for your dissenting shares in accordance
with the merger agreement, without interest and less any applicable withholding taxes. Consequently, any stockholder wishing to exercise appraisal rights is encouraged to consult legal counsel before attempting to exercise those rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_52"></A>Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be accounted for as a &#147;purchase transaction&#148; for financial accounting purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_53"></A>Material U.S. Federal Income Tax Consequences of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax consequences of the merger that may be relevant to U.S. Holders and <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (each as defined below) of shares of common stock whose shares are converted into the right to receive cash pursuant to the merger. This discussion is based upon the Internal Revenue Code of 1986
(which we refer to as the &#147;Code&#148;) Treasury Regulations promulgated under the Code, court decisions, published positions of the Internal Revenue Service (which we refer to as the &#147;IRS&#148;) and other applicable authorities, all as in
effect on the date of this proxy statement and all of which are subject to change or differing interpretations, possibly with retroactive effect. This discussion is limited to holders who hold their shares of common stock as &#147;capital
assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is
for general information only and does not address all of the tax consequences that may be relevant to holders in light of their particular circumstances. For example, this discussion does not address: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences that may be relevant to holders who may be subject to special treatment under U.S. federal
income tax laws, such as financial institutions; <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; S corporations, partnerships and any other entity or arrangement treated as a partnership or pass-through entity for U.S. federal
income tax purposes; insurance companies; mutual funds; dealers in stocks and securities; traders in securities that elect to use the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting
for their securities; regulated investment companies; real estate investment trusts; entities subject to the U.S. anti-inversion rules; holders who hold their common stock as &#147;qualified small business stock&#148; for purposes of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Sections 1045 and 1202 of the Code; <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that own (directly or by attribution) more than five percent of our common stock; or certain former
citizens or long-term residents of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to holders holding the shares as part of a hedging, constructive sale or conversion, straddle or
other risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to holders who received their shares of common stock in a compensatory transaction or pursuant
to the exercise of options or warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to U.S. Holders whose &#147;functional currency&#148; is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to holders who hold their common stock through a bank, financial institution or other entity, or
a branch thereof, located, organized or resident outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences arising from the Medicare tax on net investment income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to holders subject to special tax accounting rules as a result of any item of gross income with
respect to the shares of common stock being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal estate, gift or alternative minimum tax consequences, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax consequences to holders that do not vote in favor of the merger and who properly demand appraisal of their
shares under Section&nbsp;262 of the DGCL. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including an entity or arrangement, domestic or foreign,
treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of shares of common stock, then the tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the
partner and the partnership. Partnerships holding shares of common stock and partners therein should consult their tax advisors regarding the consequences of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been or will be obtained from the IRS regarding the U.S. federal income tax consequences of the merger described below. If the
IRS contests a conclusion set forth herein, no assurance can be given that a holder would ultimately prevail in a final determination by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS PROVIDED FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE LEGAL ADVICE TO ANY HOLDER. A HOLDER SHOULD CONSULT ITS
OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES RELATING TO THE MERGER IN LIGHT OF ITS PARTICULAR CIRCUMSTANCES AND ANY CONSEQUENCES ARISING UNDER FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS OR THE LAWS
OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of shares of common stock that is for U.S. federal income tax
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States or any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;that is subject to the primary supervision of a court within the United States and the control
of one or more United States persons as defined in section 7701(a)(30) of the Code; or (2)&nbsp;that has a valid election in effect under applicable Treasury regulations to be treated as a United States person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The receipt of cash by a U.S. Holder in exchange for shares of common stock pursuant to the
merger will be a taxable transaction for U.S. federal income tax purposes. In general, such U.S. Holder&#146;s gain or loss will be equal to the difference, if any, between the amount of cash received and the U.S. Holder&#146;s adjusted tax basis in
the shares surrendered pursuant to the merger. A U.S. Holder&#146;s adjusted tax basis generally will equal the amount that such U.S. Holder paid for the shares. Such gain or loss will be capital gain or loss and will be long-term capital gain or
loss if such U.S. Holder&#146;s holding period in such shares is more than one year at the time of the completion of the merger. A reduced tax rate on capital gain generally will apply to long-term capital gain of a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder (including individuals). The deductibility of capital losses is subject to limitations. If a U.S. Holder acquired different blocks of shares of common stock at different times and
different prices, such holder must determine its adjusted tax basis and holding period separately with respect to each block of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, the term <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a beneficial owner of
shares of common stock that is neither a U.S. Holder nor a partnership for U.S. federal income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any gain realized by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder pursuant to the merger generally will not be subject to U.S. federal income tax unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a trade or business of such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder in the United States), in which case such gain generally will be subject to U.S. federal income tax at rates generally applicable to U.S. persons, and, if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a corporation, such gain
may also be subject to the branch profits tax at a rate of 30&nbsp;percent (or a lower rate under an applicable income tax treaty); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States
for 183 days or more in the taxable year of the completion of the merger, and certain other specified conditions are met, in which case such gain will be subject to U.S. federal income tax at a rate of 30&nbsp;percent (or a lower rate under an
applicable income tax treaty). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding (at a current rate of 24 percent) may apply to the proceeds received by a holder pursuant to the
merger. Backup withholding generally will not apply to (1)&nbsp;a U.S. Holder that furnishes a correct taxpayer identification number and certifies that such U.S. Holder is not subject to backup withholding on IRS Form
<FONT STYLE="white-space:nowrap">W-9</FONT> (or a substitute or successor form); or (2)&nbsp;a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that (i)&nbsp;provides a certification of such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on the appropriate series of IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> (or a substitute or successor form); or (ii)&nbsp;otherwise establishes an exemption from backup
withholding. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against the holder&#146;s U.S. federal income tax liability, if the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_54"></A>Regulatory Approvals Required for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General Efforts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, Illumina, Merger Sub and Pacific Biosciences agreed to use reasonable best efforts to take, or cause to be taken,
all actions and to do, or cause to be done, and assist and cooperate with the other parties hereto in doing, all things necessary, proper or advisable under applicable law to consummate the merger, including: (1)&nbsp;preparing and filing as
promptly as practicable with any governmental authority or other third parties all documentation to effect all necessary filings, notices, petitions, statements, registrations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submissions of information, applications and other documents; and (2)&nbsp;obtaining and maintaining all permits required to be obtained from any governmental authority or other third party that
are necessary, proper or advisable to consummate the transactions contemplated by the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed
to, at the request of Illumina, divest, hold separate or otherwise take or commit to take any action with respect to, any of the businesses, services, or assets of Pacific Biosciences or any of its subsidiaries, if requested to do so by Illumina, if
and to the extent such action is necessary to obtain clearance of the merger pursuant to the HSR Act or any other competition laws applicable to the merger, but only so long as any such action is conditioned upon the consummation of merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, neither Illumina nor any of its subsidiaries is required to (and Pacific Biosciences may not, without
Illumina&#146;s prior written consent)&nbsp;(1) enter into any settlement, undertaking, consent decree, stipulation or agreement with any governmental authority in connection with the merger; (2)&nbsp;agree, propose, negotiate, offer, sell, divest,
lease, license, transfer, dispose of or otherwise encumber or hold separate (including by establishing a trust, licensing any intellectual property rights or otherwise), or take any other action (including by providing its consent to permit Pacific
Biosciences or any of its subsidiaries to take any of the foregoing actions), or otherwise proffer or agree to do any of the foregoing, with respect to any of the businesses, assets or properties of Illumina, Pacific Biosciences or the surviving
corporation or any of their respective affiliates or subsidiaries; (3)&nbsp;terminate any existing relationships or contractual rights or obligations; or (4)&nbsp;otherwise offer to take or offer to commit to take any action that would limit
Illumina&#146;s or any of its affiliates&#146; freedom of action with respect to, or ability to retain, operate or otherwise exercise full rights of ownership with respect to, businesses, assets or properties of Illumina, Pacific Biosciences, the
surviving corporation, or any of their respective affiliates or subsidiaries (or equity interests held by Illumina or any of its affiliates in entities with businesses, assets or properties). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>HSR Act and U.S. Antitrust Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the HSR Act, the merger cannot be completed until Illumina and Pacific Biosciences file&nbsp;a Notification and Report Form with the
Federal Trade Commission (which we refer to as the &#147;FTC&#148;) and the Antitrust Division of the Department of Justice (which we refer to as the &#147;DOJ&#148;), and the applicable waiting period has expired or been terminated. The parties
filed a notification and report form with the FTC and DOJ on November 29, 2018. A transaction notifiable under the HSR Act may not be completed until the expiration of a 30 calendar day waiting period following the parties&#146; filing of their
respective HSR Act notification forms (which waiting period, in relation to the merger, would expire at 11:59&nbsp;p.m., Eastern time, on December&nbsp;31, 2018) or the early termination of that waiting period. The FTC or the DOJ may extend the <FONT
STYLE="white-space:nowrap">30-calendar</FONT> day waiting period by issuing a request for additional information or documentary material (which we refer to as a &#147;second request&#148;). If either the FTC or the DOJ issues a second request, the
waiting period is extended until 30 days after Pacific Biosciences and Illumina substantially comply with the request. This time period may be further extended by a timing agreement entered into by the parties and the FTC. Pacific Biosciences and
Illumina have each agreed to supply as promptly as practicable any additional information and documentary material that may be requested by the FTC or DOJ and to use their reasonable best efforts to take all other actions necessary to cause the
expiration or termination of the applicable waiting periods under any applicable antitrust law as soon as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time before
or after consummation of the merger, notwithstanding the termination of the waiting period under the HSR Act, the FTC or the DOJ could take such action under the antitrust laws as it deems necessary or desirable, including seeking to enjoin the
completion of the merger, seeking divestiture of substantial assets of the parties or requiring the parties to license, or hold separate, assets or terminate existing relationships and contractual rights. At any time before or after the completion
of the merger, and notwithstanding the termination of the waiting period under the HSR Act, any state could take such action under the antitrust laws as it deems necessary or desirable. Such action could include seeking to enjoin the completion of
the merger or seeking divestiture of substantial assets of Pacific Biosciences or Illumina. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Competition Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina and Pacific Biosciences have agreed to file merger notifications, as applicable, with the appropriate regulatory agencies in the
required foreign jurisdictions as promptly as reasonably practicable and advisable and work cooperatively toward expedited regulatory clearances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina and Pacific Biosciences conduct business in several member states of the European Union. The thresholds that trigger a mandatory
notification to the European Commission pursuant to Council Regulation (EC) No.&nbsp;139/2004, as amended, are not met in the merger. Illumina and Pacific Biosciences are examining which European Union member state agencies have jurisdiction over
the proposed merger and whether the parties might be entitled to request the referral of the proposed merger to the European Commission for review. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Regulatory Approvals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more governmental bodies may impose a condition, restriction, qualification, requirement or limitation when it grants the necessary
approvals and consents to the merger. Third parties may also seek to intervene in the regulatory process or litigate to enjoin or overturn regulatory approvals, which actions could significantly impede or even preclude obtaining required regulatory
approvals. There is currently no way to predict how long it will take to obtain all of the required regulatory approvals or whether such approvals will ultimately be obtained, and there may be a substantial period of time between the approval by
Pacific Biosciences stockholders and the completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we expect that all required regulatory clearances and
approvals will be obtained, we cannot assure you that these regulatory clearances and approvals will be timely obtained, obtained at all or that the granting of these regulatory clearances and approvals will not involve the imposition of additional
conditions on the completion of the merger or require changes to the terms of the merger agreement. These conditions or changes could result in the conditions to the merger not being satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delisting and Deregistration of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, our common stock will no longer be traded on Nasdaq and will be deregistered under the Exchange Act. We will no
longer be required to file periodic reports, current reports and proxy and information statements with the SEC on account of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_55"></A>PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are asking you to approve the adoption of the merger agreement. For a summary of and detailed information regarding this proposal, see the
information about the merger agreement throughout this proxy statement, including the information set forth under the sections of this proxy statement captioned &#147;The Merger&#148; and &#147;The Merger Agreement.&#148; A copy of the merger
agreement is attached as Annex A to this proxy statement. You are urged to read the merger agreement carefully and in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The
Pacific Biosciences Board unanimously recommends that you vote &#147;FOR&#148; this proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_56"></A>PROPOSAL 2: ADJOURNMENT OF THE SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are asking you to approve a proposal to adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit
additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting. If stockholders approve this proposal, we can adjourn the special meeting and any adjourned session of the special meeting and use
the additional time to solicit additional proxies, including soliciting proxies from stockholders that have previously returned properly signed proxies voting against adoption of the merger agreement. Among other things, approval of the adjournment
proposal could mean that, even if we received proxies representing a sufficient number of votes against adoption of the merger agreement such that the proposal to adopt the merger agreement would be defeated, we could adjourn the special meeting
without a vote on the adoption of the merger agreement and seek to convince the holders of those shares to change their votes to votes in favor of adoption of the merger agreement. Additionally, we may seek stockholder approval to adjourn the
special meeting if a quorum is not present, and the chairperson of the special meeting may also adjourn the special meeting for such purpose even if the stockholders have not approved the proposal to adjourn the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Pacific Biosciences Board unanimously recommends that you vote &#147;FOR&#148; this proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_57"></A>PROPOSAL 3: APPROVAL, ON A
<FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY BASIS, OF CERTAIN MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14A of the Exchange Act, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010,
requires that we provide stockholders with the opportunity to vote, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, on the compensation that will or may become payable by Pacific Biosciences to our named executive officers
in connection with the merger, as disclosed in the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger&#151;Golden Parachute Compensation,&#148;
including the additional disclosures referenced therein that otherwise are disclosed in the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are asking Pacific Biosciences stockholders to approve the compensation that will or may become payable by Pacific Biosciences to our
named executive officers in connection with the merger. These payments are set forth in the section of this proxy statement captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers of in the
Merger&#151;Golden Parachute Compensation&#148; and the accompanying footnotes. The various plans and arrangements pursuant to which these compensation payments may be made generally have previously formed part of Pacific Biosciences&#146; overall
compensation program for our named executive officers and previously have been disclosed to stockholders as part of the Compensation Discussion and Analysis and related sections of our annual proxy statements. These historical arrangements were
adopted and approved by the Compensation Committee of the Pacific Biosciences Board, which is composed solely of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and are believed to be reasonable and in line with marketplace norms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, we are seeking approval of the following resolution at the special meeting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the stockholders of Pacific Biosciences approve the compensation that will or may become payable to Pacific
Biosciences&#146; named executive officers in connection with the merger as disclosed pursuant to Item 402(t) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> in the section captioned &#147;The Merger&#151;Interests of Pacific
Biosciences&#146; Directors and Executive Officers in the Merger&#151;Golden Parachute Compensation&#148; in Pacific Biosciences&#146; proxy statement for the special meeting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences stockholders should note that this proposal is not a condition to completion of the merger, and as a <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory vote, the result will not be binding on Pacific Biosciences, the Pacific Biosciences Board or Illumina. Further, the underlying plans and arrangements are contractual in nature and not, by
their terms, subject to stockholder approval. Accordingly, regardless of the outcome of the advisory vote, if the merger is consummated our named executive officers will be eligible to receive the compensation that is based on or that otherwise
relates to the merger in accordance with the terms and conditions applicable to those payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Pacific Biosciences Board
unanimously recommends that you vote &#147;FOR&#148; this proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_58"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary describes the material provisions of the merger agreement. The descriptions of the merger agreement in this summary
and elsewhere in this proxy statement are not complete and are qualified in their entirety by reference to the merger agreement, a copy of which is attached to this proxy statement as Annex&nbsp;A and incorporated by reference. We encourage you to
read the merger agreement carefully and in its entirety because this summary may not contain all the information about the merger agreement that is important to you. </I><B><I>The rights and obligations of the parties are governed by the express
terms of the merger agreement, and not by this summary or any other information contained in this proxy statement.</I></B><I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
representations, warranties, covenants and agreements described below and included in the merger agreement (1)&nbsp;were made only for purposes of the merger agreement and as of specific dates; (2)&nbsp;were made solely for the benefit of the
parties to the merger agreement; (3)&nbsp;may be subject to important qualifications, limitations and supplemental information agreed to by Pacific Biosciences, Illumina and Merger Sub in connection with negotiating the terms of the merger
agreement; and (4)&nbsp;may also be subject to a contractual standard of materiality different from those generally applicable to reports and documents filed with the SEC and in some cases were qualified by confidential matters disclosed to Illumina
and Merger Sub by Pacific Biosciences in connection with the merger agreement. In addition, the representations and warranties may have been included in the merger agreement for the purpose of allocating contractual risk between Pacific Biosciences,
Illumina and Merger Sub rather than to establish matters as facts, and may be subject to standards of materiality applicable to such parties that differ from those applicable to investors. Further, the representations and warranties were negotiated
with the principal purpose of establishing the circumstances in which a party to the merger agreement may have the right not to consummate the merger if the representations and warranties of the other party prove to be untrue due to a change in
circumstance or otherwise. Pacific Biosciences stockholders are not third-party beneficiaries under the merger agreement and should not rely on the representations, warranties, covenants and agreements or any descriptions thereof as
characterizations of the actual state of facts or condition of Pacific Biosciences, Illumina or Merger Sub or any of their respective affiliates or businesses. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the merger agreement. None of the representations and warranties will survive the closing of the merger, and, therefore, they will have no legal effect under the merger agreement after the effective time. In addition,
you should not rely on the covenants in the merger agreement as actual limitations on the respective businesses of Pacific Biosciences, Illumina and Merger Sub, because the parties may take certain actions that are either expressly permitted in the
confidential disclosure letters to the merger agreement or as otherwise consented to by the appropriate party, which consent may be given without prior notice to the public. The merger agreement is described below, and included as Annex A, only to
provide you with information regarding its terms and conditions, and not to provide you with any other factual information regarding Pacific Biosciences, Illumina, Merger Sub or their respective businesses. Accordingly, the representations,
warranties, covenants and other agreements in the merger agreement should not be read alone, and you should read the information provided elsewhere in this document and in our filings with the SEC regarding Pacific Biosciences and our business.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_59"></A>Closing and Effective Time of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the merger will take place on (1)&nbsp;a date that is as soon as possible, but no later than the third business day after the
satisfaction or waiver of all of the conditions to closing of the merger (described in the section of this proxy statement captioned &#147;The Merger Agreement&#151;Conditions to the Closing of the Merger&#148;), other than conditions that by their
terms are to be satisfied at the closing of the merger, but subject to the satisfaction or waiver of each of such conditions; or (2)&nbsp;such other time agreed to by Pacific Biosciences and Illumina. On the closing date, the parties will file a
certificate of merger with the Secretary of State of the State of Delaware as provided under the DGCL. The merger will become effective upon the filing and acceptance of that certificate of merger, or at a later time as may be agreed to in writing
by the parties and specified in such certificate of merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_60"></A>Effects of the Merger; Certificate of Incorporation; Bylaws; Directors and
Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, subject to the terms and conditions of the merger agreement, and in accordance with the
DGCL, at the effective time of the merger: (1)&nbsp;Merger Sub will be merged with and into Pacific Biosciences; (2)&nbsp;the separate existence of Merger Sub will cease; and (3)&nbsp;Pacific Biosciences will continue as the surviving corporation in
the merger and a wholly owned subsidiary of Illumina. From and after the effective time of the merger, all of the property, rights, privileges, powers, immunities, licenses, franchises and authority of Pacific Biosciences and Merger Sub will vest in
the surviving corporation, and all of the liabilities, obligations, restrictions and disabilities of Pacific Biosciences and Merger Sub will become the liabilities, obligations, restrictions and disabilities of the surviving corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger, the certificate of incorporation of Pacific Biosciences as the surviving corporation will be amended and
restated in its entirety to conform to the certificate of incorporation of Merger Sub as in effect immediately prior to the effective time of the merger, and the bylaws of Pacific Biosciences as the surviving corporation will be amended and restated
in its entirety to conform to the bylaws of Merger Sub, as in effect immediately prior to the effective time of the merger, in each case, until thereafter amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the effective time of the merger, the board of directors of the surviving corporation will consist of the directors of Merger
Sub as of the effective time of the merger, to hold office in accordance with the certificate of incorporation and bylaws of the surviving corporation until their successors are duly elected or appointed and qualified. From and after the effective
time of the merger, the officers of Merger Sub as of the effective time of the merger will be the officers of the surviving corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the surviving corporation
until their successors are duly appointed and qualified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_61"></A>Conversion of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the effective time of the merger, each outstanding share of common stock (other than shares: (1)&nbsp;held by Pacific Biosciences as treasury stock; (2)&nbsp;owned by Illumina or Merger Sub; (3)&nbsp;owned by any direct or indirect wholly owned
subsidiaries of Pacific Biosciences or Illumina (other than Merger Sub); or (4)&nbsp;owned by each Pacific Biosciences stockholder who has properly made a demand for appraisal under Delaware law and has neither effectively withdrawn, failed to
perfect, waived or otherwise lost such stockholder&#146;s right to appraisal will be canceled and automatically converted into the right to receive cash in an amount equal to $8.00 per share, without interest thereon and subject to applicable
withholding taxes (or, in the case of a lost, stolen or destroyed certificate, upon delivery of an affidavit (and if required, bond) in accordance with the terms of the merger agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger, each outstanding share of common stock that is (1)&nbsp;held by Pacific Biosciences as treasury stock or
(2)&nbsp;owned by Illumina or Merger Sub will be canceled and retired without any payment thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger,
each share of common stock that is owned by any direct or indirect subsidiary of Pacific Biosciences, Illumina (other than Merger Sub) or Merger Sub as of immediately prior to the effective time of the merger will be converted into such number of
shares of capital stock of the surviving corporation such that each such subsidiary owns the same percentage of the outstanding capital stock of the surviving corporation as of immediately following the effective time of the merger as such
subsidiary-owned in Pacific Biosciences as of immediately prior to the effective time of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the effective time of the
merger, each share of common stock of Merger Sub outstanding immediately prior to the effective time of the merger will be converted into and become one fully paid and nonassessable share of common stock of the surviving corporation with the same
rights, powers and privileges as the shares so converted and will constitute the only outstanding shares of capital stock of the surviving corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Awards; ESPP </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that Pacific Biosciences&#146; equity awards that are outstanding immediately prior to the effective time of the
merger will be subject to the following treatment at the effective time of the merger: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, each
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option award will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the excess of the merger
consideration over the applicable per share exercise price of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option, multiplied by (2)&nbsp;the aggregate number of shares of common stock
subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option immediately prior to the effective time of the merger. Any company option that is not an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> company option will be canceled as of the effective time of the merger without any amount payable in exchange. Holders of unvested company options (including company options that are not <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> company options) will be given an opportunity to exercise any unvested company options prior to, and contingent upon the consummation of the transactions
contemplated by the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company RSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, each company RSU award will be canceled and converted into the right to receive a
cash amount equal to the product of (1)&nbsp;the merger consideration, multiplied by (2)&nbsp;the total number of shares of common stock subject to such company RSU award immediately prior to the effective time of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company PRSUs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
or immediately prior to the effective time of the merger, each company PRSU award will be canceled and converted into the right to receive a cash amount equal to the product of (1)&nbsp;the merger consideration, multiplied by (2)&nbsp;the number of
shares of company common stock that would be payable if such company PRSU award had vested at target performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock
Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP (and all outstanding rights thereunder) will be terminated no later than as of immediately prior to the
effective time of the merger, contingent upon the consummation of the transactions contemplated by the merger agreement. From and after the date of the merger agreement, no new participants are permitted to participate in the ESPP and participants
may not increase their payroll deductions or purchase elections from those in effect on the date of the merger agreement, and except for the final offering period, no new offering or purchase period shall be authorized, continued or commenced
following the date of the merger agreement. In addition, from and after the date of the merger agreement, both the maximum number of shares of common stock that a participant in the ESPP can purchase and the total number of shares available under
the ESPP will not be increased. Unless otherwise agreed between Illumina and us, the final offering period will terminate no later than as of immediately following the next scheduled purchase date (to occur on March&nbsp;1, 2019), and the exercise
date under the final offering period will accelerate and occur on such termination date with respect to any then-outstanding purchase rights. Additionally, shares of common stock purchased under the terms of the ESPP for the final offering period
will be canceled at the effective time of the merger in exchange for the right to receive the merger consideration in accordance with the merger agreement. As promptly as practicable following the purchase of shares of common stock under the final
offering period, Pacific Biosciences will return to each participant the funds, if any, that remain in such participant&#146;s account after such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_62"></A>Payment Agent, Exchange Fund, and Exchange and Payment Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the merger, Illumina will appoint an agent reasonably acceptable to Pacific Biosciences, which we refer to as the
&#147;payment agent,&#148; to make payments of the merger consideration to Pacific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biosciences stockholders. At or prior to the closing of the merger, Illumina will deposit (or cause to be deposited) with the payment agent cash that is sufficient in the aggregate to pay the
aggregate per share merger consideration to Pacific Biosciences stockholders in accordance with the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly (and in
any event within five business days) following the effective time of the merger, Illumina will, or will cause the payment agent to mail to each holder of record (as of immediately prior to the effective time of the merger) of a certificate that
immediately prior to the effective time of the merger represented outstanding shares of common stock, a letter of transmittal and instructions advising stockholders how to surrender stock certificates in exchange for the per share merger
consideration. Upon receipt of (1)&nbsp;surrendered certificates for cancellation (or an appropriate affidavit for lost, stolen or destroyed certificates, together with any required bond); and (2)&nbsp;a duly completed and signed letter of
transmittal and such other documents as may be reasonably requested by the payment agent, the holder of such certificate will be entitled to receive an amount in cash equal to the product of (i)&nbsp;the number of shares represented by such
certificate and (ii)&nbsp;the per share merger consideration in exchange therefor. The amount of any per share merger consideration paid to Pacific Biosciences stockholders will not include interest and may be reduced by any applicable withholding
taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, any holder of shares of common stock held in book-entry form (which we refer to as
&#147;uncertificated shares&#148;) will not be required to deliver a certificate or an executed letter of transmittal (as both are described above) to the payment agent to receive the consideration payable in respect thereof. Each holder of record
(as of immediately prior to the effective time of the merger) of uncertificated shares that immediately prior to the effective time of the merger represented an outstanding share of common stock will, upon receipt of an &#147;agent&#146;s
message&#148; in customary form at the effective time of the merger, be entitled to receive, and the payment agent will pay and deliver as promptly as practicable, an amount in cash equal to the product of (1)&nbsp;the number of uncertificated
shares held by such stockholder; and (2)&nbsp;the per share merger consideration in exchange therefor. The amount of consideration paid to such Pacific Biosciences stockholders will not include interest and may be reduced by any applicable
withholding taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any cash deposited with the payment agent is not claimed within six months following the effective time of the
merger, such cash will be returned to Illumina upon demand, and any Pacific Biosciences stockholders as of immediately prior to the merger who have not complied with the exchange procedures in the merger agreement will thereafter look only to
Illumina for satisfaction of payment of the merger consideration (subject to abandoned property law, escheat law or similar law). None of Illumina or any of its affiliates will be liable to any Pacific Biosciences stockholder with respect to any
cash amounts properly paid to a public official pursuant to any applicable abandoned property law, escheat law or similar law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The letter
of transmittal will include instructions if a stockholder has lost a share certificate or if such certificate has been stolen or destroyed. In the event that any share certificates have been lost, stolen or destroyed, then the payment agent will
issue the per share merger consideration to such holder upon the making by such holder of an affidavit for such lost, stolen or destroyed certificate. Illumina or the payment agent may, in its discretion and as a condition precedent to the payment
of the per share merger consideration, require such stockholder to deliver a bond in such reasonable amount as Illumina or the payment agent may direct as indemnity against any claim that may be made against Illumina, the surviving corporation or
the payment agent with respect to such certificate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_63"></A>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement contains representations and warranties of Pacific Biosciences, Illumina and Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the representations and warranties in the merger agreement made by Pacific Biosciences are qualified as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect.&#148; For purposes of the merger agreement, &#147;Company Material Adverse Effect&#148; means, with respect to Pacific Biosciences, any event, circumstance, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change, occurrence, development, condition or effect that, individually or in the aggregate, has or would reasonably be expected to result in a material adverse change in, or material adverse
effect on, the financial condition, business, assets, liabilities or results of operations of Pacific Biosciences and its subsidiaries, taken as a whole, but excluding any such effect to the extent resulting from: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in general economic conditions in the United States or global credit, currency, financial or capital
markets (except to the extent that such changes have had a disproportionate effect on Pacific Biosciences and its subsidiaries, taken as a whole, relative to other participants in the industry in which Pacific Biosciences and its subsidiaries
operate, in which case only the incremental disproportionate adverse impact may be taken into account in determining whether there has occurred a Company Material Adverse Effect ); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in United States or global regulatory, legal, legislative or political conditions, including changes or
proposed changes in applicable law or GAAP (except to the extent that such changes have had a disproportionate effect on Pacific Biosciences and its subsidiaries, taken as a whole, relative to other participants in the industry in which Pacific
Biosciences and its subsidiaries operate, in which case only the incremental disproportionate adverse impact may be taken into account in determining whether there has occurred a Company Material Adverse Effect); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or conditions generally affecting the industry in which Pacific Biosciences and its subsidiaries operate
(except to the extent that such changes or conditions have had a disproportionate effect on Pacific Biosciences and its subsidiaries, taken as a whole, relative to other participants in the industry in which Pacific Biosciences and its subsidiaries
operate, in which case only the incremental disproportionate adverse impact may be taken into account in determining whether there has occurred a Company Material Adverse Effect); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">geopolitical conditions, acts of war, sabotage or terrorism, outbreak or escalation of hostilities or war or
epidemics, pandemics or natural disasters (except to the extent that such conditions have had a disproportionate effect on Pacific Biosciences and its subsidiaries, taken as a whole, relative to other participants in the industry in which Pacific
Biosciences and its subsidiaries operate, in which case only the incremental disproportionate adverse impact may be taken into account in determining whether there has occurred a Company Material Adverse Effect); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the announcement or pendency of the transactions contemplated by the merger agreement, including the impact
thereof on relationships of Pacific Biosciences or its subsidiaries, contractual or otherwise, with customers, suppliers, distributors, partners, employees or regulators, it being understood that termination, change of control and other similar
rights of third parties that are required to be disclosed in the confidential disclosure letter provided by Pacific Biosciences to Illumina and Merger Sub in connection with the merger agreement will not be deemed to be events, circumstances,
changes, occurrences, developments, conditions or effects related to the announcement or pendency of the transactions contemplated by the merger agreement for purposes of the references to Company Material Adverse Effect in the merger agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any decline, in and of itself, in the market price, or change in trading volume, of any capital stock of Pacific
Biosciences (it being understood that any cause of such decline or change may be taken into consideration when determining whether a Company Material Adverse Effect has occurred); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure, in and of itself, of Pacific Biosciences to meet any internal or public projections, forecasts,
budgets or estimates of revenue, earnings, cash flow or cash position (it being understood that any cause of such failure may be taken into consideration when determining whether a Company Material Adverse Effect has occurred); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action taken by Pacific Biosciences that is expressly required by the merger agreement or taken at the prior
written request of or with the prior written consent of Illumina. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the merger agreement, Pacific Biosciences has made customary representations and
warranties to Illumina and Merger Sub that are subject, in some cases, to specified exceptions and qualifications contained in the merger agreement. These representations and warranties relate to, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due organization and qualification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the certificate of incorporation and bylaws of Pacific Biosciences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate power and authority; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due execution, delivery, and performance of the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requisite vote of Pacific Biosciences stockholders in connection with the merger agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval and recommendation of the Pacific Biosciences Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required consents and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of, among other things, various implications of the merger under any organizational documents,
existing material contracts or laws applicable to Pacific Biosciences or its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the capitalization of Pacific Biosciences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of all securities and stock awards of Pacific Biosciences and its subsidiaries being in compliance
with all applicable laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any contract relating to the voting, registration of, or transfer of any securities of Pacific
Biosciences or its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity and capitalization of each subsidiary of Pacific Biosciences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy and sufficiency of Pacific Biosciences&#146; SEC filings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of SEC reporting obligations for any Pacific Biosciences subsidiary since the date of the merger
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences&#146; and its subsidiaries&#146; internal controls, disclosure controls and procedures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of Pacific Biosciences&#146; and its subsidiaries&#146; internal controls;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy and sufficiency of Pacific Biosciences&#146; financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance by Pacific Biosciences in all material respects with all applicable listing and corporate governance
rules, regulations and requirements of Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance by Pacific Biosciences, and Pacific Biosciences&#146; principal executive officer and principal
financial officer, with the Sarbanes-Oxley Act of 2002 since January&nbsp;1, 2015; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of untrue statement or omission of a material fact required to be stated in this proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) the absence of any Company Material Adverse Effect prior to the date of the merger agreement; and
(2)&nbsp;the conduct of the business of Pacific Biosciences and its subsidiaries in the ordinary course consistent with past practices, in each case, since December&nbsp;31, 2017; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of specified undisclosed liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with applicable laws, including export control laws and anti-corruption laws, by Pacific Biosciences
and its subsidiaries since January&nbsp;1, 2015; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the validity and effectiveness of consents, approvals, waivers, permits, registrations, licenses or consents
necessary for Pacific Biosciences and its subsidiaries to conduct its business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of legal proceedings or orders pending or threatened against Pacific Biosciences or any of its
subsidiaries, officers or directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real property leased or subleased by Pacific Biosciences and its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trademarks, patents, copyrights and other intellectual property matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer and supplier matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privacy and data matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee and labor matters and benefit plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">environmental matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences&#146; material contracts, including, (1)&nbsp;the existence and enforceability of such
material contracts; and (2)&nbsp;the absence of breaches or defaults under its material contracts by Pacific Biosciences or its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than Centerview, the absence of financial advisors and similar advisors retained or authorized to act on
behalf of Pacific Biosciences or its subsidiaries or who is entitled to fees or commissions in connection with the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rendering of Centerview&#146;s fairness opinion to the Pacific Biosciences Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inapplicability of anti-takeover statutes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">related party matters; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the merger agreement, Pacific Biosciences acknowledges that Illumina and Merger Sub have not made any representations or
warranties other than those expressly set forth in the merger agreement, and expressly disclaims reliance on any representation, warranty or other information regarding Illumina and Merger Sub, except Illumina and Merger Sub&#146;s express
representations in the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the merger agreement, Illumina and Merger Sub have made customary representations and
warranties to Pacific Biosciences that are subject, in some cases, to specified exceptions and qualifications contained in the merger agreement. These representations and warranties relate to, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due organization and qualification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate power and authority; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due execution, delivery, and performance of the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required consents and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of, among other things, various implications of the merger under any organizational documents,
existing material contracts or laws applicable to Illumina or its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of untrue statement or omission of a material fact required to be stated in this proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">matters with respect to Illumina&#146;s financing, including Illumina&#146;s sufficiency of funds; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of capital stock of Pacific Biosciences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the merger agreement, Illumina and Merger Sub acknowledge that Pacific Biosciences has not made any representations or
warranties other than those expressly set forth in the merger agreement, and expressly disclaim reliance on any representation, warranty or other information regarding Pacific Biosciences, except Pacific Biosciences&#146; express representations in
the merger agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties contained in the merger agreement will not survive the
consummation of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_64"></A>Conduct of Business Pending the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, during the period of time between the date of the merger agreement and the effective time of the merger (or
the earlier termination of the merger agreement), Pacific Biosciences will, and will cause each of its subsidiaries to, conduct its business in the ordinary course consistent with past practice and in material compliance with applicable law and all
material contracts. In addition, Pacific Biosciences has also agreed that, without limiting the generality of the foregoing, Pacific Biosciences will, and will cause each of its subsidiaries to use its reasonable best efforts to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preserve intact its present business organization (including preserving all assets material to the conduct of its
business in good repair and condition); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain in effect all of its foreign, federal, state and local permits that are used in, and material to, the
conduct of its business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">keep available the services of its directors, officers, employees and consultants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain the goodwill and existing relationships with its customers, lenders, suppliers and others having
significant business relationships with it. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Pacific Biosciences has also agreed that, except as
(1)&nbsp;expressly contemplated by the merger agreement; (2)&nbsp;approved by Illumina (which approval will not be unreasonably withheld, conditioned or delayed with respect to certain of the actions specified in the merger agreement, but with
respect to the remaining actions specified in the merger agreement, Illumina&#146;s consent may be conditioned, delayed or withheld in its sole discretion); or (3)&nbsp;as specified in the disclosure schedule which was delivered by Pacific
Biosciences to Illumina in connection with the merger agreement, during the period of time between the date of the merger agreement and the effective time of the merger (or the earlier termination of the merger agreement), Pacific Biosciences will
not, and will cause each of its subsidiaries not to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend its organizational documents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) split, combine, subdivide, or reclassify any shares of its capital stock or other securities;
(2)&nbsp;declare, set aside or pay dividends or make other distributions of capital stock, except for dividends payable to Pacific Biosciences or any of its subsidiaries; or (3)&nbsp;redeem, repurchase or otherwise acquire any shares of capital
stock or other securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) issue, pledge, dispose of, transfer, encumber, sell, grant or otherwise deliver or authorize the issuance,
pledge, disposal of, transfer, encumbrance, grant, sale or other delivery of any securities of Pacific Biosciences or any of its subsidiaries, except as required under the loan arrangements of Pacific Biosciences, or the issuance of (i)&nbsp;shares
upon the exercise of options; (ii)&nbsp;shares upon the exercise of purchase rights under the ESPP; (iii)&nbsp;any shares upon the vesting of any Company RSUs; or (iv)&nbsp;securities of the subsidiaries of Pacific Biosciences to Pacific Biosciences
or any other wholly owned subsidiary of Pacific Biosciences; or (2)&nbsp;amend the terms of any securities of Pacific Biosciences or any of its subsidiaries, except as may be required by applicable law or the terms of any employee plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur capital expenditures or any obligations or liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, directly or indirectly, any assets, securities, properties, interests or businesses, except in the
ordinary course of business consistent with past practice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">merge or consolidate Pacific Biosciences or any of its subsidiaries with any entity or adopt a complete or
partial plan of liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, assign, lease or otherwise transfer, abandon, dispose of or permit to lapse, or create or incur any lien,
except as permitted by the merger agreement, on any of Pacific Biosciences&#146; or its subsidiaries&#146; assets, securities, properties, interests or businesses, except in the ordinary course of business consistent with past practice;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) extend, grant, amend, waive, cancel, abandon or allow to lapse or modify any rights in or to intellectual
property that would result in a Company Material Adverse Effect; (2)&nbsp;fail to diligently prosecute any material patent application; or (3)&nbsp;divulge, furnish, or make accessible any trade secrets, other than in the ordinary course of business
consistent with past practice to a third party that is subject to a written agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans, advances or capital contributions to, or investments in, any third party, other than advances of
travel and business expense for directors, officers or employees in the ordinary course of business consistent with past practice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create, incur, assume, suffer to exist or become liable with respect to any indebtedness for borrowed money, or
guarantees thereof (except with respect to obligations of wholly owned subsidiaries of Pacific Biosciences), or issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of Pacific Biosciences or
any of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) renew, amend, modify in any material respect any material contract, or enter into or terminate any contract
that would constitute a material contract if it were in effect on the date of the merger agreement (except the expiration or renewal of any material contract in accordance with its terms); or (2)&nbsp;waive, release or assign any material rights,
claims, or benefits under any material contract; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to any current or former employee or independent contractor, (1)&nbsp;grant or increase any
compensation, bonus, severance, retention, change in control, termination pay, welfare or other benefits to (or amend any existing severance pay or termination arrangement); (2) grant any equity or equity-based awards to, or discretionarily
accelerate the vesting or payment of, any such awards held by any current or former employee or independent contractor; or (3)&nbsp;enter into, establish, adopt, amend or terminate any employment, consulting services, severance, retention, change in
control, termination pay, retirement, deferred compensation or other similar agreement or arrangement, except the entry into, establishment or adoption of a consulting services agreement (or similar agreement or arrangement) to replace a terminating
or expiring consulting agreement or arrangement on the same or more favorable terms to Pacific Biosciences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, adopt, enter into, amend (except as required by applicable law), or become obligated to contribute to
any employee plan or collective bargaining agreement, other than routine amendments that do not result in materially increased administrative costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognize any new union, works council or similar employee representative with respect to any current or former
employee or independent contractor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, adopt or enter into any plan, agreement or arrangement, or otherwise commit to, gross up or indemnify,
or otherwise reimburse any current or former employee or independent contractor for any tax incurred by such employee or independent contractor, including under Section&nbsp;409A or Section&nbsp;4999 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire any employee except to fill vacancies (other than at the level of vice president or above) in the ordinary
course of business, consistent with past practice or terminate any employee except for &#147;cause&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any accounting methods or practices or internal controls in any material respect, except as required by a
change in GAAP or applicable law, after consultation with its independent public accountants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commence, compromise, settle, or offer or propose to settle (1)&nbsp;any action (except for immaterial monetary
damages or in the ordinary course of business consistent with past practice); (2) any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stockholder action dispute against Pacific Biosciences or any of its officers or directors; or (3)&nbsp;any action or dispute with a third party that relates to the transactions contemplated by
the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or change any material tax election, change any material tax accounting period, adopt or change any material
method of tax accounting, amend any federal income or other material tax returns, enter into any closing agreement with respect to material taxes, settle any material tax claim, audit or assessment, surrender any right to claim a material tax
refund, offset or other reduction in tax liability, or consent to any extension or waiver of the statute of limitations period applicable to any material claim or assessment in respect of taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain insurance at less than current levels or otherwise in a manner inconsistent with past practice;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assign, transfer, lease, cancel, fail to renew or fail to extend any permit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forgive any loans to directors, officers, employees or any of their respective affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend or modify the letter of engagement of the financial advisor or engage other advisors or consultants in
connection with the transactions contemplated by the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-pay</FONT> any long-term indebtedness for borrowed money;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement any plant closing, relocation or mass layoff of employees that could implicate the WARN Act or any
comparable foreign, state or local law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">until August&nbsp;1, 2019, (1) solicit or enter into or continue any discussions or negotiations or enter into
any contract with any third party; or (2)&nbsp;afford access to any third party to the business, properties, assets, books, records or other <FONT STYLE="white-space:nowrap">non-public</FONT> information of Pacific Biosciences or any of its
subsidiaries, in each case in connection with certain specified matters; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree, resolve or commit to do any of the foregoing actions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_65"></A>No Solicitation of Other Offers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, from the date of the merger agreement until the effective time of the merger (or the earlier termination of the
merger agreement), Pacific Biosciences has agreed to cease and cause to be terminated any activities, discussions or negotiations conducted on or prior to the date of the merger agreement with any person and its representatives (other than Illumina,
Merger Sub and their respective representatives) relating to an acquisition proposal (as defined below), and to instruct each such person and its representatives that is in possession of confidential information furnished by or on behalf of Pacific
Biosciences or its subsidiaries prior to the date of the merger agreement (and all analyses and other materials prepared by or on behalf of such person and its representatives (other than Illumina, Merger Sub and their respective representatives)
that contain, reflect or analyze that information) to return or destroy all such information as promptly as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms
of the merger agreement, from the date of the merger agreement until the effective time of the merger (or the earlier termination of the merger agreement), Pacific Biosciences and its subsidiaries and certain of its and their respective directors
and executive officers will not, and Pacific Biosciences will not authorize or direct any of its or its subsidiaries&#146; employees, consultants or other representatives to, directly or indirectly: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate, propose, seek or take any action for the purpose of the making, submission or announcement of,
or knowingly facilitate, assist, induce or encourage the making, submission or announcement of, any proposal that constitutes, or that would reasonably be expected to lead to an acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, engage in, participate in or maintain or continue any discussions or negotiations with, furnish any <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to Pacific Biosciences or any of its subsidiaries or afford </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
access to the business, properties, assets, books, records or other <FONT STYLE="white-space:nowrap">non-public</FONT> information of Pacific Biosciences or any of its subsidiaries to, or
otherwise knowingly cooperate in any way with, or knowingly assist, participate in, facilitate, induce or encourage, any effort by any person (other than Illumina, Merger Sub, and their respective representatives) concerning an acquisition proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make an adverse recommendation change; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve any transaction under, or any person becoming an &#147;interested stockholder&#148; under,
Section&nbsp;203 of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submit any acquisition proposal or any matter related thereto to the vote of Pacific Biosciences stockholders; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize or commit to do any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding these restrictions, prior to the adoption of the merger agreement by Pacific Biosciences stockholders, Pacific Biosciences
may, directly or indirectly through one or more of their representatives: (1)&nbsp;contact any third party or its representatives that has made (and not withdrawn) a bona fide written acquisition proposal that was not solicited in breach of the <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above to the extent necessary to clarify the terms and conditions of such acquisition proposal; (2)&nbsp;engage in discussions or negotiations with any third party or its
representatives that has made (and not withdrawn) a bona fide written acquisition proposal that was not solicited in breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above, but only if the Pacific Biosciences Board
(or a committee thereof) has reasonably determined in good faith (after consultation with its financial advisor and outside legal counsel) that such acquisition proposal either constitutes a superior proposal (as defined below) or is reasonably
expected to lead to a superior proposal; or (3)&nbsp;furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to Pacific Biosciences or any of its subsidiaries to any third party or its representatives that has made or
delivered to Pacific Biosciences a written acquisition proposal that was not solicited in breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above pursuant to a written confidentiality agreement, but only if, in the
case of (1)&nbsp;through (3) above, the Pacific Biosciences Board (or a committee thereof) has determined in good faith (after consultation with its financial advisor and outside legal counsel) that&nbsp;the failure to do so would be inconsistent
with its fiduciary duties pursuant to applicable law. In connection with the foregoing, Pacific Biosciences will (1)&nbsp;provide written notice to Illumina immediately following the Pacific Biosciences Board&#146;s determination referred to in the
prior sentence; and (2)&nbsp;substantially contemporaneously, make available to Illumina any <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning Pacific Biosciences and its subsidiaries that is provided to any such third party
or its representatives that was not previously made available to Illumina. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Pacific Biosciences or its representatives receives an
acquisition proposal (as defined below) or an inquiry from any person related to making a potential acquisition proposal, or if any <FONT STYLE="white-space:nowrap">non-public</FONT> information that would reasonably be expected to relate to the
making of an acquisition proposal is requested from, or any discussions or negotiations are sought to be initiated or continued with Pacific Biosciences or its representatives at any time prior to the earlier to occur of the termination of the
merger agreement and the effective time of the merger, Pacific Biosciences must promptly (and in all events by the later of 24 hours from the receipt thereof) advise Illumina of such acquisition proposal or request, including the identity of the
person making such proposal, inquiry, request or offer and the material terms and conditions thereof (including copies of any written documentation setting forth such terms). Thereafter, Pacific Biosciences must keep Illumina reasonably informed, on
a prompt basis, of the status and terms of any such offers or proposals (including any amendments thereto) and the status of any such discussions or negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this proxy statement and the merger agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an &#147;acquisition proposal&#148; means, other than the merger, any third party offer or proposal relating to,
in a single transaction or series of related transactions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any acquisition or purchase, direct or direct, of assets representing more than 15&nbsp;percent of the
consolidated assets of Pacific Biosciences and its subsidiaries or 15&nbsp;percent or more of any class </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of equity or voting securities of Pacific Biosciences or any of its subsidiaries whose assets, individually or in the aggregate, constitute 15&nbsp;percent or more of the consolidated assets of
Pacific Biosciences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any tender offer or exchange offer that, if consummated, would result in any third party beneficially owning
15&nbsp;percent or more of any class of equity or voting securities of Pacific Biosciences or any of its subsidiaries whose assets, individually or in the aggregate, constitute 15&nbsp;percent or more of the consolidated assets Pacific Biosciences;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">merger, consolidation, share exchange, business combination, sale of substantially all of the assets,
reorganization, recapitalization, liquidation, dissolution or other transaction involving Pacific Biosciences or any of its subsidiaries whose assets, individually or in the aggregate, constitute 15&nbsp;percent or more of the consolidated assets of
Pacific Biosciences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale or exclusive license of certain specified products or intellectual property rights of Pacific
Biosciences, other than commercial sales of such specified products in the ordinary course of business consistent with past practice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;superior proposal&#148; is a bona fide written acquisition proposal (substituting 50&nbsp;percent for all
percentages in the definition of &#147;acquisition proposal&#148; above) that was not solicited in breach of Pacific Biosciences&#146; <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions described above, on terms that the Pacific
Biosciences Board (or a committee thereof) has determined in good faith (after consultation with its financial advisor and outside legal counsel) would be more favorable, from a financial point of view, to the Pacific Biosciences stockholders (in
their capacity as such) than the merger (taking into account (1)&nbsp;any revisions to the merger agreement made or proposed in writing by Illumina prior to the time of such determination; and (2)&nbsp;those other factors and matters deemed relevant
in good faith by the Pacific Biosciences Board (or any committee thereof), including the identity of the person making the proposal, the likelihood of consummation in accordance with the terms of such proposal, and the legal, financial (including
financing terms), regulatory, timing and other aspects of such proposal). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_66"></A>The Pacific Biosciences
Board&#146;s Recommendation; Adverse Recommendation Change </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board has recommended that the holders of shares of
common stock vote &#147;FOR&#148; the proposal to adopt the merger agreement. The merger agreement provides that the Pacific Biosciences Board will not effect an adverse board recommendation change except as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth below, at no time after the date of the merger agreement may the Pacific Biosciences Board or a committee thereof (with
any action described in the following being referred to as an &#147;adverse recommendation change&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to make, qualify, withhold, withdraw, amend or modify in any manner adverse to Illumina or Merger Sub, or
publicly propose to qualify, withhold, withdraw, amend or modify, the Pacific Biosciences Board&#146;s recommendation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt, endorse, approve, or recommend, or publicly propose to adopt, endorse, approve or recommend, an
acquisition proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly make any recommendation in connection with a tender or exchange offer, other than a recommendation
against such offer or a &#147;stop, look and listen&#148; communication by the Pacific Biosciences Board (or a committee thereof) to Pacific Biosciences&#146; stockholders pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated
under the Exchange Act (or any substantially similar communication) (it being understood that the Pacific Biosciences Board (or a committee thereof) may refrain from taking a position with respect to an acquisition proposal until the close of
business on the 10th business day after the commencement of a tender or exchange offer in connection with such acquisition proposal without such action being considered a violation of the merger agreement); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the date on which any acquisition proposal or any material modification thereto is first made public,
fail to issue a press release reaffirming the Pacific Biosciences Board&#146;s recommendation within five business days after Illumina so requests in writing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to include the Pacific Biosciences Board&#146;s recommendation in this proxy statement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the restrictions described above, prior to the adoption of the merger agreement by stockholders, the
Pacific Biosciences Board may, upon compliance with the procedures described below, effect an adverse recommendation change (1)&nbsp;in response to an intervening event (as defined below) other than in connection with a written acquisition proposal
that constitutes a superior proposal; or (2)&nbsp;if Pacific Biosciences has received a bona fide written acquisition proposal that the Pacific Biosciences Board (or a committee thereof) has concluded in good faith (after consultation with its
financial advisor and outside legal counsel) is a superior proposal, in each case, if the Pacific Biosciences Board (or a committee thereof) determines in good faith (after consultation with its financial advisor and outside legal counsel) that a
failure to effect an adverse recommendation change would be inconsistent with the Pacific Biosciences Board&#146;s fiduciary duties pursuant to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pacific Biosciences Board may effect an adverse recommendation change, but may not terminate the merger agreement, in response to an
intervening event if and only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences has provided prior written notice to Illumina at least four business days in advance to the
effect that the Pacific Biosciences Board (or a committee thereof) has (1)&nbsp;made the determination described above; and (2)&nbsp;resolved to effect an adverse recommendation change pursuant to the merger agreement, which notice must describe the
applicable intervening event in reasonable detail; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to effecting such adverse recommendation change, Pacific Biosciences and its representatives, during such
four business day period, have negotiated with Illumina and its representatives in good faith to make such adjustments to the terms and conditions of the merger agreement so that the Pacific Biosciences Board (or a committee thereof) no longer
determines in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to make an adverse recommendation change in response to such intervening event would be inconsistent with its fiduciary duties
pursuant to applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Pacific Biosciences Board may effect an adverse recommendation change or
terminate the merger agreement to enter into a definitive, written agreement in respect of an acquisition proposal that was not solicited in breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions above, only if the
Pacific Biosciences Board (or a committee thereof) has concluded in good faith (after consultation with its financial advisor and outside legal counsel) that such acquisition proposal is a superior proposal, and: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Pacific Biosciences Board (or a committee thereof) has determined in good faith (after consultation with its
financial advisor and outside legal counsel) that the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences has provided prior written notice to Illumina at least four business days in advance to the
effect that the Pacific Biosciences Board (or a committee thereof) has (1)&nbsp;received a written acquisition proposal that has not been withdrawn; (2)&nbsp;concluded in good faith (after consultation with its financial advisor and outside legal
counsel) that such acquisition proposal constitutes a superior proposal; and (3)&nbsp;resolved to effect an adverse recommendation change or to terminate the merger agreement, which notice will describe the basis for such adverse recommendation
change or termination, including the identity of the person making such acquisition proposal, the material terms of such acquisition proposal and a copy of the current version of the proposed agreement under which such acquisition proposal is
proposed to be consummated; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to effecting such adverse recommendation change or termination, Pacific Biosciences and its
representatives, during the four business day notice period described above, have negotiated with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Illumina and its representatives in good faith to make such adjustments to the terms and conditions of the merger agreement so that such acquisition proposal would cease to constitute a superior
proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any material revision, amendment, update or supplement to any such acquisition proposal
described above, Pacific Biosciences has also agreed to deliver a new written notice to Illumina and to comply with the above procedures with respect to such new written notice (with the notice period being two business days from the date of such
notice) and no adverse recommendation change or termination will be permitted by Pacific Biosciences unless, at the end of such two day notice period, the Pacific Biosciences Board (or a committee thereof) has in good faith (after consultation with
its financial advisor and outside legal counsel) reaffirmed its determination that such acquisition proposal is a superior proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of this proxy statement and the merger agreement, an &#147;intervening event&#148; means any positive material change, effect, development, circumstance, condition, event or occurrence that, as of the date of the merger agreement was not
known to Pacific Biosciences Board, or the consequences of which (based on facts known to the Pacific Biosciences Board as of the date of the merger agreement) were not reasonably foreseeable to the Pacific Biosciences Board as of the date of merger
agreement, other than: (1)&nbsp;changes in the financial or securities markets or general economic, political or business conditions in the United States or other jurisdictions in which Pacific Biosciences or its any of its subsidiaries has
operations; (2)&nbsp;changes (including changes of applicable law) or conditions generally affecting the industry in which Pacific Biosciences and its subsidiaries operate; (3)&nbsp;changes in GAAP or other applicable accounting rules; or
(4)&nbsp;the receipt, existence or terms of any acquisition proposal or any inquiry, offer, request or proposal that would reasonably be expected to lead to an acquisition proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_67"></A>Stockholder Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to take all action necessary to establish a record date for, duly call, give notice of, convene and hold the
special meeting as promptly as reasonably practicable following the mailing of this proxy statement. Pacific Biosciences is permitted to postpone or adjourn the special meeting in certain circumstances related to soliciting additional proxies or
requirements of applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_68"></A>Employee Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period commencing on the effective time of the merger and ending one year later (or, if shorter, during the period of employment),
Illumina will provide continuing employees with (1)&nbsp;an aggregate base salary or base wages and cash target bonus opportunity no less than the aggregate base salary or base wages and cash target bonus opportunity provided to such continuing
employee immediately before the effective time of the merger; and (2)&nbsp;benefits (other than any equity or equity-based and change in control or transaction-based compensation or benefits or severance pay or benefits) that are substantially
comparable in the aggregate to either (i)&nbsp;those offered to similarly situated employees of Illumina or its affiliates; or (ii)&nbsp;those offered by Pacific Biosciences to the continuing employees as of immediately before the effective time of
the merger. The determination of the employee benefits under clause (2)&nbsp;will be made by Illumina, based on Illumina&#146;s evaluation of the nature and scope of the continuing employees&#146; duties, principal locations, grade level and
performance, among other things. However, Illumina will not have any obligation to issue, or adopt any plans or arrangements providing for the issuance of, shares of capital stock, warrants, options, stock appreciation rights or other rights in
respect of any shares of capital stock of any entity or any securities convertible into, or exchangeable or exercisable for, such shares pursuant to any such plans or arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any employee benefit plan maintained by Illumina in which any continuing employee will participate on or after the effective
time of the merger, but excluding (1)&nbsp;any retiree healthcare or life insurance plans or programs maintained by Illumina or its affiliates; and (2)&nbsp;any equity compensation arrangement, Illumina will recognize all service with us or any
subsidiary of ours provided before the effective time of the merger by continuing employees who are active Pacific Biosciences employees immediately before the closing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the merger for purposes of vesting and eligibility (but not benefit accrual), to the extent such continuing employees otherwise would be eligible to participate or vest under the terms of such
Illumina benefit plans. The service of a continuing employee before the effective time of the merger will not be recognized for the purpose of any entitlement to participate in, or receive benefits with respect to, (1)&nbsp;any retiree medical
programs or other retiree welfare benefit programs maintained by Illumina or its affiliates; or (2)&nbsp;for purposes of early retirement subsidies under any Illumina benefit plan. In no event will these benefits result in any duplication of
benefits for the same period of service. In addition, Illumina will use commercially reasonable efforts to (i)&nbsp;waive any limitations on benefits relating to <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions to the same extent such
limitations are waived under any comparable plan of Pacific Biosciences applicable to such continuing employee before the effective time of the merger and (ii)&nbsp;recognize, for purposes of satisfying the deductibles, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets, <FONT STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments under
its medical, dental and vision plans, the deductibles, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets, <FONT STYLE="white-space:nowrap">co-payments,</FONT>
<FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments recognized under the corresponding employee plan with respect to a continuing employee (and his or her eligible dependents) for the plan year in which the effective
time of the merger occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless Illumina chooses otherwise, effective as of the date immediately before the closing date of the merger,
Pacific Biosciences will terminate its 401(k) plan, subject to the completion of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_69"></A>Efforts to Close the Merger
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, Illumina, Merger Sub and Pacific Biosciences agreed to use reasonable best efforts to take, or cause to be taken,
all actions and to do, or cause to be done, and assist and cooperate with the other parties hereto in doing, all things necessary, proper or advisable under applicable law to consummate the merger, including: (1)&nbsp;preparing and filing as
promptly as practicable with any governmental authority or other third party as promptly as practicable, all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents; and
(2)&nbsp;obtaining and maintaining all permits required to be obtained from any governmental authority or other third party that are necessary, proper or advisable to consummate the transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to, at the request of Illumina, divest, hold separate or otherwise take or commit to take any action with
respect to, any of the businesses, services, or assets of Pacific Biosciences or any of its subsidiaries, if requested to do so by Illumina, if and to the extent such action is necessary to obtain clearance of the merger pursuant to the HSR Act any
other competition laws applicable to the merger, but only so long as any such action is conditioned upon the consummation of merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, nothing in the merger agreement requires Illumina to (1)&nbsp;enter into any settlement, undertaking, consent decree, stipulation or
agreement with any governmental authority in connection with the merger; (2)&nbsp;agree, propose, negotiate, offer, sell, divest, lease, license, transfer, dispose of or otherwise encumber or hold separate (including by establishing a trust,
licensing any intellectual property rights or otherwise), or take any other action (including by providing its consent to permit Pacific Biosciences or any of its subsidiaries to take any of the foregoing actions), or otherwise proffer or agree to
do any of the foregoing, with respect to any of the businesses, assets or properties of Illumina, Pacific Biosciences or the surviving corporation or any of their respective affiliates or subsidiaries; (3)&nbsp;terminate any existing relationships
or contractual rights or obligations; or (4)&nbsp;otherwise offer to take or offer to commit to take any action that would limit Illumina&#146;s or any of its affiliates&#146; freedom of action with respect to, or ability to retain, operate or
otherwise exercise full rights of ownership with respect to, businesses, assets or properties of Illumina, Pacific Biosciences, the surviving corporation, or any of their respective affiliates or subsidiaries (or equity interests held by Illumina or
any of its affiliates in entities with businesses, assets or properties). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_70"></A>Indemnification and Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, during the six year period commencing at the effective time of the merger, the surviving corporation will
(and Illumina will cause the surviving corporation to) indemnify and hold harmless each the current and former directors and officers of Pacific Biosciences (whom we refer to as the &#147;indemnified persons&#148;), to the fullest extent permitted
by law, from and against all costs, expenses (including reasonable attorneys&#146; fees), judgments, fines, losses, claims, damages, liabilities and amounts paid in settlement in connection with any claim, action, suit, proceeding or investigation,
of whatever nature, in respect of, arising out of or related to such indemnified person&#146;s service as a director or officer of Pacific Biosciences in respect of acts or omissions occurring at or prior to the effective time of the merger
(including, for the avoidance of doubt, in connection with the merger and the other transactions contemplated by the merger agreement), whether asserted or claimed prior to, at or after the effective time of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, without limiting the foregoing but subject to the immediately forthcoming sentence, the merger agreement requires Illumina to
cause the surviving corporation to maintain in effect Pacific Biosciences&#146; directors&#146; and officers&#146; insurance policies in respect of acts or omission occurring at or prior to the effective time, on terms that are at least as favorable
to the indemnified persons as those policies that were in effect on the date of the merger agreement, for a period of at least six years commencing at the effective time of the merger. The surviving corporation is not required to pay premiums for
such policy to the extent such premiums exceed 300&nbsp;percent of the annual premiums currently paid by Pacific Biosciences, and if the premium for such insurance coverage would exceed such amount, the surviving corporation will be obligated to
obtain the greatest coverage available for a cost not exceeding such amount. In lieu of the foregoing, prior to the effective time of the merger, Pacific Biosciences may purchase (or, if Illumina requests, Pacific Biosciences will purchase) a
prepaid &#147;tail&#148; policy so long as the annual cost for such &#147;tail&#148; policy does not exceed 300&nbsp;percent of the aggregate annual premiums currently paid). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement also provides that the indemnified parties are third party beneficiaries of the indemnification and insurance provisions
in the merger agreement and are entitled to enforce such provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information, refer to the section of this proxy statement
captioned &#147;The Merger&#151;Interests of Pacific Biosciences&#146; Directors and Executive Officers in the Merger.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_71"></A>Conditions to the Closing of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Illumina, Merger Sub and Pacific Biosciences to consummate the merger are subject to the satisfaction or waiver (where
permitted by law) of certain conditions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adoption of the merger agreement by the requisite affirmative vote of Pacific Biosciences stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expiration or termination of the waiting period under the HSR Act and the affirmative approval or clearance
under the competition laws of the European Union or one or more competent European Union member states; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of (1) any applicable law in key jurisdictions and (2)&nbsp;any injunction, order or decree that a
governmental authority in any key jurisdiction has enacted, issued, promulgated, enforced or entered, that, in each case, remains in effect and makes illegal, enjoins or otherwise prohibits the consummation of the merger or the other transactions
contemplated by the merger agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the obligations of Illumina and Merger Sub to consummate the merger are subject
to the satisfaction or waiver of each of the following additional conditions, any of which may be waived exclusively by Illumina: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences having performed in all material respects all obligations under the merger agreement required
to be performed and complied with by it prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as specified in the following bullets, the representations and warranties of Pacific Biosciences being
true and correct (without giving effect to any materiality or Company Material Adverse Effect qualifications set forth therein) as of the date on which the closing occurs as if made at and as of such date (except to the extent that any such
representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall have been true and correct as of such earlier date), except for such failures to be true and correct that have not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Pacific Biosciences relating to certain aspects of Pacific
Biosciences&#146; capitalization being true and correct as of 5:00 p.m., Pacific time, on October&nbsp;30, 2018, except for such inaccuracies that are de minimis in the aggregate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Pacific Biosciences relating to corporate existence and power, corporate
authorization, certain aspects of capitalization, finders&#146; fees, the opinion of Pacific Biosciences&#146; financial advisor, and antitakeover laws being true and correct in all material respects as of the date on which the closing occurs as if
made at and as of such date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall have been true and correct in all material respects as of such
earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt by Illumina and Merger Sub of a customary closing certificate of Pacific Biosciences;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any Company Material Adverse Effect having occurred after the date of the merger agreement that is
continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of (1) any applicable law in specified jurisdictions or other jurisdictions and (2)&nbsp;any
injunction, order or decree that a governmental authority in any specified jurisdiction or other jurisdiction has enacted, issued, promulgated, enforced or entered, that, in each case, remains in effect and makes illegal, enjoins or otherwise
prohibits the consummation of the merger or the other transactions contemplated by the merger agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the obligations of Pacific Biosciences to consummate the merger are subject to the satisfaction or waiver (where permitted by applicable law) of each of the following additional conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina and Merger Sub having complied in all material respects all obligations under the merger agreement
required to be performed by Illumina and Merger Sub prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as specified in the following bullet, the representations and warranties of Illumina being true and
correct (without giving effect to any materiality or material adverse effect qualifications set forth therein) as of the date on which the closing occurs as if made at and as of such date (except to the extent that any such representation and
warranty expressly speaks as of an earlier date, in which case such representation and warranty shall have been true and correct as of such earlier date), except for such failures to be true and correct that have not had and would not reasonably be
expected to have, individually or in the aggregate, a material adverse effect on Illumina&#146;s ability to consummate the transactions contemplated by the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Illumina relating to corporate authorization being true and correct in all
material respects as of the date on which the closing occurs as if made at and as of such date </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall have been true and correct in all
material respects as of such earlier date); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt by Pacific Biosciences of a customary closing certificate of Illumina and Merger Sub.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_72"></A>Termination of the Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement may be terminated at any time prior to the effective time of the merger, whether before or after the adoption of the
merger agreement by Pacific Biosciences stockholders (except as otherwise provided in the merger agreement), in the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by mutual written agreement of Pacific Biosciences and Illumina; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Pacific Biosciences or Illumina if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger has not been consummated on or before the termination date, provided that a party may not terminate
the merger agreement pursuant to this provision if such party&#146;s action or failure to act constitutes a breach of the merger agreement and has resulted in the failure to satisfy the conditions to the closing of the merger or the failure to
consummate the merger by the termination date; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pacific Biosciences stockholders do not adopt the merger agreement at the special meeting, except that a party
may not terminate the merger agreement pursuant to this provision if such party&#146;s action or failure to act constitutes a breach of the merger agreement and results in the failure to obtain the approval of the Pacific Biosciences stockholders at
the special meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Pacific Biosciences if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after a <FONT STYLE="white-space:nowrap">30-day</FONT> cure period, Illumina or Merger Sub has materially
breached or failed to perform any of its respective representations, warranties, covenants or other agreements in the merger agreement, such that the related closing condition would not be satisfied; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the adoption of the merger agreement by Pacific Biosciences stockholders: (1)&nbsp;the Pacific
Biosciences Board has made an adverse recommendation change in compliance with the terms of the merger agreement in order to enter into a definitive, written agreement in respect of a superior proposal; and (2)&nbsp;Pacific Biosciences pays or
causes to be paid to Illumina a $43.0&nbsp;million termination fee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Illumina if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) after a <FONT STYLE="white-space:nowrap">30-day</FONT> cure period, Pacific Biosciences has materially
breached or failed to perform any of its representations, warranties, covenants or other agreements in the merger agreement such that the related closing condition would not be satisfied; or (2)&nbsp;Pacific Biosciences has materially breached its <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions, as described in more detail under the sections of this proxy statement captioned &#147;The Merger Agreement&#151;No Solicitation of Other Offers&#148; and &#147;The Merger
Agreement&#151;The Pacific Biosciences Board&#146;s Recommendation; Adverse Recommendation Change&#148;; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Pacific Biosciences Board has effected an adverse recommendation change. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the merger agreement is terminated pursuant to the termination rights above, the merger agreement will be of no further
force or effect without liability of any party to the other parties (or their representatives), as applicable, except certain sections of the merger agreement will survive the termination of the merger agreement in accordance with their respective
terms. Notwithstanding the foregoing, nothing in the merger agreement will relieve any party from any liability resulting from the (1)&nbsp;intentional failure of any party to fulfill a condition to the performance of the obligations of another
party under the merger agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(2)&nbsp;material breach by any party of the covenants required to be performed by such party pursuant to the merger agreement; or (3)&nbsp;willful and intentional breach by any party of the
representations and warranties made by such party pursuant to the merger agreement. In addition, no termination of the merger agreement will affect the rights or obligations of any party pursuant to the confidentiality agreement between Pacific
Biosciences and Illumina, which rights, obligations and agreements will survive the termination of the merger agreement in accordance with their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_73"></A>Termination Fees and Remedies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has agreed to pay Illumina a termination fee of $43.0&nbsp;million if the merger agreement is terminated in specified
circumstances. Illumina will be entitled to receive the termination fee from Pacific Biosciences if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger agreement is validly terminated by Illumina because the Pacific Biosciences Board has effected an
adverse recommendation change; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger agreement is validly terminated by Pacific Biosciences in order to enter into a definitive, written
agreement with respect to a superior proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) the merger agreement is validly terminated by (i)&nbsp;either Illumina or Pacific Biosciences because Pacific
Biosciences stockholders do not adopt the merger agreement at the special meeting or (ii)&nbsp;Illumina because Pacific Biosciences has either (a)&nbsp;breached or failed to perform its representations, warranties, covenants or other agreements in
the merger agreement (and has not cured such breach or failure to perform during a cure period), such that the related closing condition would not be satisfied or (b)&nbsp;materially breached its
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions; (2)&nbsp;following the date of the merger agreement and prior to its termination under certain circumstances, an acquisition proposal has been publicly announced or otherwise
communicated to Pacific Biosciences, the Pacific Biosciences Board, or Pacific Biosciences&#146; stockholders; and (3)&nbsp;within one year of such termination of the merger agreement, either an acquisition proposal is consummated or Pacific
Biosciences enters into a definitive agreement providing for the consummation of an acquisition proposal (provided that, for purposes of the termination fee, all percentages in the definition of &#147;acquisition proposal&#148; are deemed to be
references to &#147;50 percent&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of the merger agreement under specified circumstances, Illumina
will be required to pay Pacific Biosciences a termination fee of $98.0&nbsp;million. Pacific Biosciences will be entitled to receive the termination fee from Illumina if: the merger agreement is terminated by either Illumina or Pacific Biosciences
if (1)&nbsp;the merger has not been consummated on or before the termination date; and (2)&nbsp;all of the conditions applicable to Illumina, Merger Sub and Pacific Biosciences&#146; obligations to close the merger have been satisfied or waived
(other than (i)&nbsp;those conditions relating to antitrust or competition laws in the United States and the key jurisdictions and (ii)&nbsp;those conditions that by their terms are to be satisfied at the closing of the merger, each of which is then
capable of being satisfied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (1)&nbsp;the merger has not been consummated on or before the termination date; (2)&nbsp;all of the
conditions applicable to Illumina, Merger Sub and Pacific Biosciences&#146; obligations to close the merger have been satisfied or waived (other than those conditions (i)&nbsp;relating to legal restraints (other than antitrust laws) in the specified
jurisdictions; and (ii)&nbsp;that by their terms are to be satisfied at the closing of the merger, each of which is then capable of being satisfied); and (3)&nbsp;the merger agreement is terminated by Illumina or Pacific Biosciences, Pacific
Biosciences may be entitled to a specific remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Illumina nor Pacific Biosciences is required to pay to the other its
termination fee on more than one occasion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina&#146;s receipt of the termination fee payable by Pacific Biosciences is the sole
and exclusive monetary remedy of Illumina and Merger Sub and each of their affiliates in respect of all losses, damages, costs or expenses in respect of the merger agreement. Pacific Biosciences&#146; receipt of the termination fee payable by
Illumina is the sole and exclusive monetary remedy of Pacific Biosciences in respect of all losses, damages, costs or expenses in respect of the applicable termination of the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_74"></A>Specific Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences, Merger Sub and Illumina agree that irreparable damage would occur if any provision of the merger agreement were not
performed in accordance with the terms of the merger agreement and that Pacific Biosciences, Merger Sub and Illumina will, in addition to any other remedy to which they are entitled at law or in equity, be entitled to an injunction or injunctions to
prevent breaches of the merger agreement or to enforce specifically the performance of the terms and provisions of the merger agreement (and each of Pacific Biosciences, Merger Sub and Illumina further agrees to waive any requirement for the
securing or posting of any bond in connection with such remedy). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_75"></A>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in specified circumstances, whether or not the merger is completed, Pacific Biosciences, on the one hand, and Illumina and Merger Sub,
on the other hand, are each responsible for all of their respective costs and expenses incurred in connection with the merger agreement and the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_76"></A>No Third Party Beneficiaries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement is binding upon and inures solely to the benefit of each party thereto, and nothing in the merger agreement, express or
implied, is intended to or will confer upon any other person any right, benefit or remedy, except, at and after the effective time (1)&nbsp;benefits to the directors and officers who are intended to be third-party beneficiaries of the
indemnification and insurance provisions; (2)&nbsp;the rights of Pacific Biosciences stockholders to receive the merger consideration in accordance with the merger agreement; and (3)&nbsp;the rights of the holders of Pacific Biosciences stock awards
and participants in the ESPP to receive treatment pursuant to the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_77"></A>Amendment and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law, the merger agreement may be amended or waived in writing by the parties prior to the effective time of the merger,
whether before or after adoption of the merger agreement by stockholders. However, after adoption of the merger agreement by stockholders, no amendment that requires further approval by such stockholders pursuant to the DGCL may be made without such
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the effective time, any party may extend the time for the performance of any of the obligations or other
acts of the other parties, waive any inaccuracies in the representations and warranties in the merger agreement or waive compliance with any of the agreements or conditions contained in provisions of the merger agreement (subject to compliance with
applicable law). Any agreement by a party to any such extension or waiver will be valid only if set forth in an instrument in writing signed by such party. Any delay in exercising any right pursuant to the merger agreement will not constitute a
waiver of such right. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_78"></A>Governing Law; Venue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement is governed by Delaware law. The venue for disputes relating to the merger and the guarantee is the Delaware Court of
Chancery of the State of Delaware or, to the extent that the Delaware Court of Chancery of the State of Delaware does not have jurisdiction, any state or federal court in the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_79"></A>Waiver of Jury Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties irrevocably waived any and all right to trial by jury in any action arising out of or relating to the merger agreement, or
the transactions contemplated by the merger agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_80"></A>THE VOTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary describes the material provisions of the voting agreement. The descriptions of the voting agreement in this summary
and elsewhere in this proxy statement are not complete and are qualified in their entirety by reference to the voting agreement, a copy of the form of which is attached to this proxy statement as Annex&nbsp;D and incorporated by reference. We
encourage you to read the voting agreement carefully and in its entirety because this summary may not contain all the information about the voting agreement that is important to you.</I><B><I>&nbsp;The rights and obligations of the parties are
governed by the express terms of the voting agreement and not by this summary or any other information contained in this proxy statement.</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the merger agreement, Illumina entered into a voting agreement with each of Susan K. Barnes, David
Botstein, Ph.D., William W. Ericson, Christian Henry, Michael Hunkapiller, Ph.D., Randall Livingston, John Milligan, Ph.D., Marshall Mohr, Kathy Ordo&ntilde;ez, Michael Phillips, and Lucy Shapiro, Ph.D. As of the record date, these stockholders
hold, in the aggregate, approximately [&#9679;] percent of the outstanding shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_81"></A>Voting Provisions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under each voting agreement, each stockholder agreed, during the term of the voting agreement, to vote his or her shares of common
stock (1)&nbsp;for the approval of the merger agreement and the approval of the transactions contemplated thereby, including the merger; (2)&nbsp;in favor of any proposal to adjourn or postpone a meeting of the stockholders to a later date if there
are not a sufficient number of votes to adopt the merger agreement; (3)&nbsp;against any action, proposal, transaction or agreement that relates to an acquisition proposal; and (4)&nbsp;against any action, proposal, transaction or agreement that
would result in any breach of any covenant, representation or warranty or any other obligation or agreement of Pacific Biosciences under the merger agreement or of the stockholder under the voting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_82"></A>Restrictions on Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the voting agreement, each stockholder agreed that, until the earlier of (1)&nbsp;the end of the term of the voting agreement; and
(2)&nbsp;the conclusion of the special meeting, he or she will not (i)&nbsp;sell, transfer, assign, tender in any tender or exchange offer, pledge, encumber, hypothecate or similarly dispose of (by merger, by testamentary disposition, by operation
of law or otherwise) (which we refer to as a &#147;transfer&#148;), or enter into any contract, option or other arrangement or understanding providing for any of the foregoing of any common stock other than any transfer made solely for estate
planning or philanthropic purposes; (ii)&nbsp;deposit any shares of common stock into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with the voting
agreement; or (iii)&nbsp;agree (whether or not in writing) to take any of the actions prohibited by the foregoing clause&nbsp;
(i) or (ii). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc646626_83"></A>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting agreement terminates upon the earliest of (1)&nbsp;the consummation of the merger; (2)&nbsp;the termination of the merger agreement;
and (3)&nbsp;the entry without the prior written consent of the stockholders into any amendment or modification of the merger agreement or any material waiver of any of Pacific Biosciences&#146; rights under the merger agreement, in each case, that
results in a decrease in, or change in the composition of, the per share merger consideration or imposes any material restrictions or additional constraints on the payment of the merger consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_84"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our common stock as of November 26, 2018, as to (1)
each person who is known by us to beneficially own more than five percent of our outstanding common stock; (2) each of the named executive officers; (3) each director; and (4) all directors and executive officers as a group. Unless otherwise
indicated, the address of each listed stockholder is c/o Pacific Biosciences of California, Inc., 1305 O&#146;Brien Drive, Menlo Park, California 94025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 149,342,128 shares of common stock outstanding as of November 26, 2018. In computing the number of
shares of stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares subject to company options held by that person that are currently exercisable or are exercisable within 60 days of
November 26, 2018. However, we did not deem these shares to be outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable<BR>Company<BR>Options (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackrock Inc.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,155,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Maverick Capital Ltd(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,223,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Oracle Investment Management Inc.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,453,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Capital World Investors(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,128,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Magnetar Financial LLC(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,421,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan K. Barnes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Botstein, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Corcoran(9).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Ericson(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,598,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hunkapiller, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,937,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,982,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Randy Livingston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Milligan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marshall Mohr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathy Ordo&#241;ez(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Phillips</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lucy Shapiro, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and Section&nbsp;16 executive officers as a group (12 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,347,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,300,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown in this column do not include company PRSUs since none of these will vest for any of the
respective beneficial owners within 60 days after November 26, 2018, and thus the beneficial owners of such awards do not currently have the right to dispose of or to vote the underlying shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown in this column do not include company RSUs since none of these will vest for any of the
respective beneficial owners within 60 days after November 26, 2018, and thus the beneficial owners of such awards do not currently have the right to dispose of or to vote the underlying shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of common stock that may be acquired within 60 days after November 26, 2018, upon the exercise
of company options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information taken from Schedule 13G/A filed on January 29, 2018, reporting on ownership as of
December 31, 2017 by Blackrock Inc., which has sole&nbsp;voting power as to 7,977,124 of these shares and sole dispositive power as to 8,155,624 of these shares. The address of this entity is 55 East 52nd&nbsp;Street, New York, New York 10055.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information taken from Schedule 13G/A filed on February 12, 2018, reporting on ownership as of
December 31, 2017. This Schedule 13G is being filed on behalf of each of the following persons: Maverick Capital, Ltd.; Maverick Capital Management, LLC; Lee S. Ainslie III (&#147;Mr. Ainslie&#148;); and Andrew H. Warford (&#147;Mr. Warford&#148;).
According to the Schedule 13G/A, each of the Maverick Capital, Ltd., Maverick Capital Management, LLC, Lee S. Ainslie III (&#147;Mr. Ainslie&#148;) and Andrew H. Warford (&#147;Mr.&nbsp;Warford&#148;) has sole voting power as to 11,223,094 of these
shares and sole dispositive power as to 11,223,094 of these shares. The address of the principal business office of (i) Maverick Capital, Ltd. and Maverick Capital Management, LLC is 300 Crescent Court, 18th Floor, Dallas, Texas 75201, and
(ii)&nbsp;Mr.&nbsp;Ainslie and Mr.&nbsp;Warford is 767 Fifth Avenue, 11th Floor, New York, New York 10153. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information taken from Schedule 13G/A, Amendment No. 2 filed on February 14, 2018, reporting on
ownership as of December 31, 2017 by Oracle Associates, LLC and direct or indirect subsidiaries. Oracle Associates, LLC has shared voting power as to 7,646,875 of these shares and shared dispositive power as to 7,646,875 of these shares; Oracle
Investment Management, Inc. has shared voting power as to 7,836,875 of these shares and shared dispositive power as to 7,836,875 of these shares; Oracle Partners, L.P. has shared voting power as to 5,683,437 of these shares and shared dispositive
power as to 5,683,437 of these shares; Oracle Institutional Partners, L.P. has shared voting power as to 838,818 of these shares and shared dispositive power as to 838,818 of these shares; Oracle Ten Fund Master, L.P. has shared voting power as to
1,124,620 of these shares and shared dispositive power as to 1,124,620 of these shares; Oracle Investment Management Employees Retirement Fund has shared voting power as to 190,000 of these shares and shared dispositive power as to 190,000 of these
shares; The Feinberg Family Foundation has shared voting power as to 41,500 of these shares and shared dispositive power as to 41,500 of these shares. The addresses of these entities are not reported on Schedule 13G. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information taken from Schedule 13G filed on February 14, 2018 reporting on ownership as of
December 31, 2017. Capital World Investors divisions of CRMC and Capital International Limited collectively provide investment management services under the name Capital World Investors. Capital World Investors has sole&nbsp;voting power as to
8,128,077 of these shares and sole dispositive power as to 8,128,077 of these shares.&nbsp;The address of this entity is 333 South Hope Street, Los Angeles, California 90071. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information taken from Schedule 13D filed on November 16, 2018 reporting on ownership as of
November 6, 2018, by Magnetar Financial LLC and direct or indirect subsidiaries. Each of Magentar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, and Alec N. Litowitz, has shared voting power as to 9,421,984 of these shares
and shared dispositive power as to 9,421,984 of these shares. The address of each of the reporting persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On February 10, 2018, the Pacific Biosciences Board determined that Mr. Corcoran no longer met the definition
of an executive officer under the Exchange Act. Mr. Corcoran&#146;s employment with Pacific Biosciences terminated on November 23, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of shares owned includes 5,598,397 shares held of record by funds affiliated with Mohr Davidow Ventures
where Mr. Ericson is a managing partner. Mr. Ericson disclaims beneficial ownership of any shares held of record by funds affiliated with Mohr Davidow Ventures except to the extent of his pecuniary interest therein. Based on information taken from
Schedule 13G filed on February 17, 2015. Shares of record includes (1) 5,074,066 shares held by MDV VII, L.P. as nominee for MDV VII, L.P., MDV VII Leaders&#146; Fund, L.P., MDV ENF VII(A), L.P. and MDV ENF VII(B), L.P.; (2) 370,333 shares held by
MDV VII Leaders&#146; Fund, L.P.; (3) 101,267 shares held by&nbsp;MDV ENF VII(A), L.P. and (4) 52,731 shares held by MDV ENF VII(B), L.P. The address of these entities is c/o Mohr Davidow Ventures, 3000 Sand Hill Road, Building 3, Suite 290, Menlo
Park, California 94025. Each of Jonathan Feiber, Nancy Schoendorf, and Seventh may be deemed to share voting and dispositive power over the shares held by MDV. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of shares owned includes 2,637,246 shares held of record by funds affiliated with Alloy Ventures where
Dr. Hunkapiller is a general partner. Dr. Hunkapiller disclaims beneficial ownership of any shares held of record by funds affiliated with Alloy Ventures except to the extent of his pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On October 30, 2018, Kathy Ordo&#241;ez resigned from her role as chief commercial officer and executive vice
president. Ms. Ordo&#241;ez will continue to serve as a Class III director on the Pacific Biosciences Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_85"></A>FUTURE STOCKHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, we will have no public stockholders and there will be no public participation in any future meetings of
stockholders of Pacific Biosciences. However, if the merger is not completed, stockholders will continue to be entitled to attend and participate in stockholder meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences will hold an annual meeting of stockholders in 2019 only if the merger has not already been completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who intend to have a proposal considered for inclusion in our proxy materials for presentation at our 2019 annual meeting of
stockholders, if held, pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> of the Exchange Act must submit the proposal to us no later than December&nbsp;6, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences&#146; bylaws establish an advance notice procedure with regard to specified matters to be brought before an annual meeting
of stockholders but not included in our proxy materials. In general, written notice must be received by Pacific Biosciences&#146; Corporate Secretary not less than 90 days nor more than 120 days prior to an annual meeting and must contain specified
information concerning the matters to be brought before such meeting and concerning the stockholder proposing such matters. Therefore, to be presented at the 2019 annual meeting of stockholders, such a proposal must be received by our Corporate
Secretary no earlier than 120 days nor later than 90 days prior to that meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_86"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this proxy statement, which means that we can disclose important
information to you by referring you to other documents filed separately with the SEC. The information incorporated by reference is deemed to be part of this proxy statement, except for any information superseded by information in this proxy
statement or incorporated by reference subsequent to the date of this proxy statement. This proxy statement incorporates by reference the documents set forth below that we have previously filed with the SEC. These documents contain important
information about us and our financial condition and are incorporated by reference into this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following Pacific
Biosciences filings with the SEC are incorporated by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31,
2017; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended
September&nbsp;30, 2018; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on February&nbsp;12, 2018,
February&nbsp;15, 2018, February&nbsp;20, 2018, May&nbsp;8, 2018, May&nbsp;23, 2018, July&nbsp;31, 2018, September&nbsp;10, 2018, September&nbsp;14, 2018 and November&nbsp;5, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this proxy statement additional documents that we may file with the SEC between the date of this proxy
statement and the earlier of the date of the special meeting or the termination of the merger agreement. These documents include periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and proxy soliciting materials. The information provided on our website is not part of this proxy statement, and
therefore is not incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information furnished under Item 2.02 or Item 7.01 of any Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> including related exhibits, is not and will not be incorporated by reference into this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may read and copy any reports, statements or other information that we file with the SEC at its public reference room at the following
location: 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of those documents at prescribed rates by writing to the Public Reference Section&nbsp;of the SEC at that address. Please call the SEC at <FONT
STYLE="white-space:nowrap">(800)&nbsp;SEC-0330</FONT> for further information on the public reference room. These SEC filings are also available to the public from commercial document retrieval services and at <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may obtain any of the documents we file with the SEC, without charge, by requesting them in writing or by telephone from us at the
following address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1305
O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo Park, California 94025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to request documents from us, please do so as soon as possible to receive them before the special meeting. If you request
any documents from us, we will mail them to you by first class mail, or another equally prompt method. Please note that all of our documents that we file with the SEC are also promptly available through the &#147;Investor Relations&#148; section of
our website, <I>www.pacb.com</I>. The information included on our website is not incorporated by reference into this proxy statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions concerning the merger, the special meeting or the accompanying
proxy statement, would like additional copies of this proxy statement or need help voting your shares of common stock, please contact our proxy solicitor: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Innisfree M&amp;A Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501
Madison Avenue, 20th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders may call toll-free: (888) <FONT STYLE="white-space:nowrap">750-5834</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers may call collect: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_87"></A>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences has supplied all information relating to Pacific Biosciences, and Illumina has supplied, and Pacific Biosciences has not
independently verified, all of the information relating to Illumina and Merger Sub contained in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOU SHOULD RELY
ONLY ON THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROXY STATEMENT IN VOTING YOUR SHARES OF COMMON STOCK AT THE SPECIAL MEETING. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT FROM WHAT IS
CONTAINED IN THIS PROXY STATEMENT. THIS PROXY STATEMENT IS DATED [&#9679;], 2018. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS PROXY STATEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THAT DATE (OR AS OF AN EARLIER DATE IF SO INDICATED
IN THIS PROXY STATEMENT), AND THE MAILING OF THIS PROXY STATEMENT TO STOCKHOLDERS DOES NOT CREATE ANY IMPLICATION TO THE CONTRARY. THIS PROXY STATEMENT DOES NOT CONSTITUTE A SOLICITATION OF A PROXY IN ANY JURISDICTION WHERE, OR TO OR FROM ANY PERSON
TO WHOM, IT IS UNLAWFUL TO MAKE A PROXY SOLICITATION. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc646626_88"></A>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">dated as of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">November 1, 2018
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PACIFIC
BIOSCIENCES of CALIFORNIA, INC., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ILLUMINA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FC OPS CORP.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE <A NAME="toc"></A>OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><U>PAGE</U></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_1">ARTICLE 1 DEFINITIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_2">Definitions</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_3">Other Definitional and Interpretative Provisions</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_4">ARTICLE 2 THE MERGER </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_5">The Merger.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_6">Conversion of Shares</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_7">Surrender and Payment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_8">Dissenting Shares</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_9">Company Stock Options and Company RSUs</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_10">Employee Stock Purchase Plan</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_11">Adjustments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_12">Withholding Rights</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.09.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_13">Lost Certificates</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_14">ARTICLE 3 THE SURVIVING CORPORATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_15">Certificate of Incorporation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_16">Bylaws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_17">Directors and Officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_18">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE
COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_19">Corporate Existence and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_20">Corporate Authorization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_21">Governmental Authorization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_22"><FONT STYLE="white-space:nowrap">Non-contravention</FONT></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_23">Capitalization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_24">Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_25">SEC Filings and the Sarbanes-Oxley Act</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_26">Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_27">Disclosure Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_28">Absence of Certain Changes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_29">No Undisclosed Liabilities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_30">Compliance with Laws, Permits and Court Orders</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_31">Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_32">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_33">Intellectual Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_34">IT Systems; Privacy and Data Security</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_35">Taxes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_36">Employee Benefit Plans; Labor Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_37">Environmental Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_38">Material Contracts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_39">Finders&#146; Fees</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_40">Opinion of Financial Advisor</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.23.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_41">Antitakeover Statutes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_42">Regulatory</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_43">Transactions with Affiliates</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.26.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_44">Insurance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.27.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_45">Exclusivity of Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><U>PAGE</U></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_46">ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBSIDIARY
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_47">Corporate Existence and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_48">Corporate Authorization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_49">Governmental Authorization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_50"><FONT STYLE="white-space:nowrap">Non-contravention</FONT></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_51">Disclosure Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_52">Financing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.07.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_53">Ownership of Company Capital Stock</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_54">Exclusivity of Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_55">ARTICLE 6 COVENANTS OF THE COMPANY </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_56">Conduct of the Company</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_57">Access to Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_58">Company Stockholder Meeting</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_59">No Solicitation; Other Offers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_60">Section&nbsp;16 Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.06.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_61">Stock Exchange Delisting; 1934 Act Deregistration</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.07.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_62">Takeover Statutes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.08.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_63">Interim Communications by the Company</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.09.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_64">Cooperation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_65">Golden Parachute Payments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_66">WARN Act</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_67">Employee Plans</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_68">Tax Sharing Agreements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_69">ARTICLE 7 COVENANTS OF PARENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_70">Obligations of Merger Subsidiary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_71">Voting of Shares</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_72">Director and Officer Liability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_73">Employee Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_74">ARTICLE 8 COVENANTS OF PARENT AND THE COMPANY </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_75">Reasonable Best Efforts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_76">Company Proxy Statement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_77">Public Announcements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_78">Further Assurances</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_79">Notices of Certain Events </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_80">ARTICLE 9 CONDITIONS TO THE MERGER </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_81">Conditions to the Obligations of Each Party</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_82">Conditions to the Obligations of Parent and Merger Subsidiary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_83">Conditions to the Obligations of the Company</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_84">ARTICLE 10 TERMINATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_85">Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_86">Effect of Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex2_1647083_87">ARTICLE 11 MISCELLANEOUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_88">Notices</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><U>PAGE</U></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_89">Survival of Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_90">Amendments and Waivers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_91">Expenses</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_92">Disclosure Schedule and SEC Document References</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.06.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_93">Binding Effect; Benefit; Assignment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.07.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_94">Governing Law</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.08.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_95">Jurisdiction</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.09.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_96">WAIVER OF JURY TRIAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_97">Counterparts; Effectiveness</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_98">Entire Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_99">Severability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_100">Specific Performance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#ex2_1647083_101">No Third Party Beneficiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc646626_88"></A>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGREEMENT AND PLAN OF MERGER (this &#147;<B>Agreement</B>&#148;) dated as of November&nbsp;1, 2018, among Pacific Biosciences of California,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), Illumina, Inc., a Delaware corporation (&#147;<B>Parent</B>&#148;), and FC Ops Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (&#147;<B>Merger
Subsidiary</B>&#148;). Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in Article 1 hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W I T N E S S E T H : </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of the Company (the &#147;<B>Board of Directors</B>&#148;) and the respective boards of directors of each of
Parent and Merger Subsidiary have approved and declared advisable the acquisition of the Company by Parent on the terms and subject to the conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition and inducement to Parent&#146;s and Merger Subsidiary&#146;s willingness to enter into this Agreement and to
consummate the Merger, following approval thereof by the Board of Directors, Parent has entered into voting agreements, each dated as of the date of this Agreement, with certain stockholders of the Company (collectively the &#147;<B>Voting
Agreements</B>&#148;), pursuant to which, subject to the terms thereof, such stockholders have agreed, among other things, to vote Shares held by them in favor of the adoption of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, at the Effective Time, the parties intend that Merger Subsidiary will be merged with and into the Company, with the Company surviving
the Merger on the terms and subject to the conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and
the mutual representations, warranties, covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree
as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_1"></A>ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC<A NAME="ex2_1647083_2">
</A>TION&nbsp;1.01. <I>Definitions</I>. (a)&nbsp;As used herein, the following terms have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>1933
Act</B>&#148; means the Securities Act of 1933. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>1934 Act</B>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition Proposal</B>&#148; means, other than the transactions contemplated by this Agreement, any Third Party offer or proposal
relating to, or any Third Party indication of interest in, in a single transaction or a series of related transactions, (i)&nbsp;any acquisition or purchase, direct or indirect, of assets representing 15% or more of the consolidated assets of the
Company and its Subsidiaries or 15% or more of any class of equity or voting securities of the Company or any of its Subsidiaries whose assets, individually or in the aggregate, constitute 15% or more of the consolidated assets of the Company,
(ii)&nbsp;any tender offer or exchange offer that, if consummated, would result in any Third Party beneficially owning 15% or more of any class of equity or voting securities of the Company or any of its Subsidiaries whose assets, individually or in
the aggregate, constitute 15% or more of the consolidated assets of the Company and its Subsidiaries, (iii)&nbsp;a merger, consolidation, share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange, business combination, sale of substantially all of the assets, reorganization, recapitalization, liquidation, dissolution or other similar transaction involving the Company or any of
its Subsidiaries whose assets, individually or in the aggregate, constitute 15% or more of the consolidated assets of the Company or (iv)&nbsp;any sale or exclusive license of any Key IP or Key Product, other than commercial sales of Key Products in
the ordinary course of business consistent with past practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Action</B>&#148; means any action, suit, investigation, audit
(including Tax audit), litigation, arbitration, mediation, complaint, claim (including any cross-claim or counterclaim), enforcement action or proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), in each
case by or before a Governmental Authority, arbitrator, mediator or other tribunal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to
any Person, any other Person directly or indirectly controlling, controlled by or under common control with such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Antitrust Law</B>&#148; means the HSR Act and any other Applicable Law designed or intended to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Law</B>&#148; means, with respect to any Person, any transnational, domestic or foreign, federal, state, local or
provincial law (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by a Governmental
Authority that is binding on or applicable to such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day, other than Saturday, Sunday or
other day on which commercial banks in New York, New York or San Francisco, California are authorized or required by Applicable Law to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collective Bargaining Agreement</B>&#148; means any written or oral agreement, memorandum of understanding or other contractual
obligation between the Company or any of its Subsidiaries and any labor organization or other authorized employee representative (including a works council) representing Service Providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company <FONT STYLE="white-space:nowrap">10-K</FONT></B>&#148; means the Company&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
<FONT STYLE="white-space:nowrap">10-Q</FONT></B>&#148; means the Company&#146;s quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended June&nbsp;30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Balance Sheet</B>&#148; means the audited consolidated balance sheet of the Company as of the Company Balance Sheet Date and
set forth in the Company <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Balance Sheet Date</B>&#148; means
December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Disclosure Schedule</B>&#148; means the disclosure schedule dated the date of this Agreement
related to this Agreement that has been provided by the Company to Parent and Merger Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Employee</B>&#148;
means, as of any time, any employee of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Interim Balance Sheet</B>&#148; means the
unaudited consolidated balance sheet of the Company as of June&nbsp;30, 2018, and set forth in the Company <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Material Adverse Effect</B>&#148; means any event, circumstance, change, occurrence, development, condition or effect that,
individually or in the aggregate, has or would reasonably be expected to result in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material adverse change in, or material adverse effect on, the financial condition, business, assets, liabilities or results of operations of the Company and its Subsidiaries, taken as a whole,
but excluding any such effect to the extent resulting from (i)&nbsp;changes in general economic conditions in the United States or global credit, currency, financial or capital markets, (ii)&nbsp;changes in United States or global regulatory, legal,
legislative or political conditions (including changes or proposed changes in Applicable Law or GAAP), (iii) changes or conditions generally affecting the industry in which the Company and its Subsidiaries operate, (iv)&nbsp;geopolitical conditions,
acts of war, sabotage or terrorism, outbreak or escalation of hostilities or war or epidemics, pandemics or natural disasters, (v)&nbsp;the announcement or pendency of the transactions contemplated by this Agreement, including the impact thereof on
relationships of the Company or its Subsidiaries, contractual or otherwise, with customers, suppliers, distributors, partners, employees or regulators, it being understood that termination, change of control and other similar rights of Third Parties
that are required to be disclosed in the Company Disclosure Schedule will not be deemed to be events, circumstances, changes, occurrences, developments, conditions or effects related to the announcement or pendency of the transactions contemplated
by this Agreement for purposes of the references to Company Material Adverse Effect in this Agreement, (vi)&nbsp;any decline, in and of itself, in the market price, or change in trading volume, of any capital stock of the Company (it being
understood that any cause of such decline or change may be taken into consideration when determining whether a Company Material Adverse Effect has occurred), (vii) any failure, in and of itself, of the Company to meet any internal or public
projections, forecasts, budgets or estimates of revenue, earnings, cash flow or cash position Company (it being understood that any cause of such failure may be taken into consideration when determining whether a Company Material Adverse Effect has
occurred), or (viii)&nbsp;any action taken by the Company that is expressly required by this Agreement or taken at the prior written request of or with the prior written consent of Parent except, in the case of clauses (i), (ii), (iii) and (iv), to
the extent not having a disproportionate effect on the Company and its Subsidiaries, taken as a whole, relative to other participants in the industry in which the Company and its Subsidiaries operate (in which case on the only incremental
disproportionate adverse impact may be taken into account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Related Parties</B>&#148; means, collectively, the Company,
its Subsidiaries and their respective Affiliates, and any of their respective former, current or future general or limited partners, stockholders, equityholders, members, managers, directors, officers, employees, agents, Affiliates or other
Representatives, or any former, current or future general or limited partner, stockholder, equityholder, member, manager, director, officer, employee, agent or Affiliate of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidentiality Agreement</B>&#148; means the <FONT STYLE="white-space:nowrap">One-Way</FONT>
<FONT STYLE="white-space:nowrap">Non-disclosure</FONT> Agreement dated as of September&nbsp;11, 2018, by and between the Company and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consulting Agreement</B>&#148; means each consulting agreement or Contract between the Company or a Subsidiary of the Company and any
Independent Contractor relating to the provision of services to the Company or a Subsidiary of the Company and that provides for compensation to be paid or provided to the Independent Contractor for providing such services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Continuing Employee</B>&#148; means each Company Employee employed by the Company or any of its Subsidiaries immediately prior to the
Effective Time whose employment with the Surviving Corporation, Parent or any of their respective Affiliates continues after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contract</B>&#148; means, with respect to any Person, any contract, agreement, lease, sublease, license, sublicense commitment, sale
or purchase order, indenture, note, bond, loan, mortgage, deed of trust, concession, franchise, instrument or other arrangement, commitment or undertaking, including any exhibits, annexes, appendices or attachments thereto, whether written or oral,
that, in each case, is legally binding on such Person or by which such Person or such Person&#146;s properties or assets are bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Deerfield Agreements</B>&#148; means the Facility Agreement, dated as of February&nbsp;5, 2013, between the Company and the lenders
set forth on the signature pages thereto, together with any security agreements entered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into in connection therewith or notes issued pursuant thereto, in each case as amended, restated, modified, supplemented from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Law</B>&#148; means the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Employee Plan</B>&#148; means any (i) &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA,
(ii)&nbsp;compensation, employment, consulting, independent contractor, severance, termination protection, change in control compensation, transaction bonus, retention or similar plan, agreement, arrangement, program or policy or (iii)&nbsp;other
plan, agreement, arrangement, program or policy providing for compensation, bonuses, profit-sharing, equity or equity-based compensation or other forms of incentive or deferred compensation, vacation benefits, insurance benefit (including any
self-insured arrangement), medical, dental, vision, prescription or fringe benefits, life insurance, relocation or expatriate benefits, perquisites, disability or sick leave benefits, employee assistance program, supplemental unemployment benefits
or post-employment or retirement benefits (including compensation, pension, health, medical or insurance benefits), in each case (x)&nbsp;whether or not written, and (y)&nbsp;(1) that is sponsored, maintained, administered, contributed to, required
to be contributed to or entered into by the Company or any of its ERISA Affiliates for the current or future benefit of any current or former Service Provider or (2)&nbsp;for which the Company or any of its Subsidiaries has or would be reasonably
expected to have any material current or future liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Employment Agreement</B>&#148; means each management, employment,
severance, consulting, retention, relocation, repatriation, expatriation, change in control compensation or similar agreement or offer letter between the Company or a Subsidiary of the Company and any current or former Company Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; means any Applicable Laws or any legally binding agreement with any Governmental Authority relating to
pollution, human health and safety (as it relates to exposure to Hazardous Substances), protection of the environment, and natural resources, or to Hazardous Substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Permits</B>&#148; means all Permits relating to, pursuant to, or required by Environmental Laws and affecting, or
relating to, the business of the Company or any of its Subsidiaries as currently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the Employee
Retirement Income Security Act of 1974. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA Affiliate</B>&#148; of any entity means any other entity that, together with such
first entity, would be (or at any relevant time was or will be) treated as a single employer under Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Government Bid</B>&#148; means any quotation, bid, offer or proposal by the Company or any of its Subsidiaries that, if accepted or
awarded, could result in a Government Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Government Contract</B>&#148; means any Contract that (i)&nbsp;is between the
Company or any of its Subsidiaries and a Governmental Authority or (ii)&nbsp;is entered into by the Company or any of its Subsidiaries in connection with a Contract between another entity and a Governmental Authority. A task, purchase or delivery
order under a Government Contract shall not constitute a separate Government Contract for purposes of this definition, but shall be part of the Government Contract (if any) to which it relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any transnational, domestic or foreign federal, state, provincial, local or other
governmental, regulatory or administrative authority, department, court, agency, commission or official, including any political subdivision thereof, or any other governmental or self-regulatory authority or instrumentality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Substance</B>&#148; means any pollutant, waste or chemical, or any toxic, radioactive, ignitable, caustic, corrosive,
reactive or otherwise hazardous substance, waste or material, or any substance, waste or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material having any constituent elements displaying any of the foregoing characteristics, including but not limited to any medical or biological waste, petroleum product or byproduct, asbestos,
lead, polychlorinated biphenyls or any substance, waste or material regulated, categorized, or controlled pursuant to any Environmental Law based on its dangerous or deleterious properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; means, collectively, the Health Insurance Portability and Accountability Act of 1996, Public Law <FONT
STYLE="white-space:nowrap">104-191,</FONT> as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and Reinvestment Act of 2009, Public Law
<FONT STYLE="white-space:nowrap">111-5,</FONT> and their implementing regulations, including but not limited to, the Standards for Privacy of Individually Identifiable Health Information at 45 C.F.R. Part 160 and Part 164, Subparts A and E, the
Security Standards for the Protection of Electronic Protected Health Information at 45 C.F.R. Part 160 and Part 164, Subparts A and C, and the Notification of Breach of Unsecured Protected Health Information requirements at 45 C.F.R. Part 160 and
Part 164, Subpart D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HSR Act</B>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Independent Contractor</B>&#148; means any independent contractor, director or consultant (other than an employee) of the Company or
a Subsidiary of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property Rights</B>&#148; means any and all (i)&nbsp;trademarks, service marks, trade
names, business marks, brand names, certification marks, trade dress, logos, corporate names, trade styles, domain names and other indications of origin, the goodwill associated with the foregoing and registrations in any jurisdiction of, and
applications in any jurisdiction to register, the foregoing, including any extension, modification or renewal of any such registration or application (&#147;<B>Trademarks</B>&#148;), (ii) national and multinational statutory invention registrations,
patents and patent applications issued or applied for in any jurisdiction, including all certificates of invention, provisionals, nonprovisionals, substitutions, divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, extensions, supplementary protection certificates, reexaminations, patents of addition, utility models, inventors&#146; certificates and the equivalents of any of
the foregoing in any jurisdiction, and all inventions disclosed in each such registration, patent or patent application (&#147;<B>Patents</B>&#148;), (iii) Trade Secrets, technical data, specifications, processes, methods, knowledge, experience,
formulae, skills, techniques, schematics, drawings, blue prints, utility models, designs, technology, software, inventions, discoveries, ideas and improvements, including manufacturing information and processes, assays, engineering and other manuals
and drawings, standard operating procedures, flow diagrams, regulatory, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality assurance, quality control and clinical data, technical information, research
records and similar data and information, (iv)&nbsp;writings and other works (including literary, pictorial and graphic works), whether copyrightable or not, in any jurisdiction (domestic and foreign), and any and all copyright rights, whether
registered or not, and registrations or applications for registration of copyrights in any jurisdiction (domestic and foreign), and any renewals or extensions thereof (&#147;<B>Copyrights</B>&#148;), (v) moral rights, sui generis database rights,
design rights, industrial property rights, publicity rights and rights of personality, (vi)&nbsp;all forms and types of computer software (including source code, object code, firmware, development tools, files, records and technical data, and all
documentation related to any of the foregoing), and (vii)&nbsp;other intellectual property or proprietary rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IRS</B>&#148;
means the Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IT Assets</B>&#148; means computers, computer software, firmware, middleware, servers,
workstations, routers, hubs, switches, data communications lines and all other information technology equipment, and all associated documentation owned by the Company or its Subsidiaries or licensed or leased by the Company or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Key Employee&#148; </B>means any Company Employee identified by Parent in a notice to the Company prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Key IP</B>&#148; means any Owned Intellectual Property Rights or Licensed
Intellectual Property Rights necessary to or used in (i)&nbsp;the Company&#146;s Single Molecule, Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) sequencing technology (i.e., that certain parallelized single molecule DNA
sequencing method enabled by utilization of both <FONT STYLE="white-space:nowrap">zero-mode</FONT> waveguides and phospholinked nucleotides) or (ii)&nbsp;any Key Product (including the making, use, offer for sale, sale or importation thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Key Jurisdiction</B>&#148; means each jurisdiction set forth on Section&nbsp;1.01(a) of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Key Products</B>&#148; means those products identified as such on Section&nbsp;1.01(b) of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Knowledge</B>&#148; means, with respect to the Company, the actual knowledge of each individual listed in Section&nbsp;1.01(c) of the
Company Disclosure Schedule, after reasonable inquiry of those persons who would reasonably be expected to have actual knowledge of the matters in question. With respect to matters involving the Intellectual Property Rights of the Company, Knowledge
does not require the Company or any of its directors, officers or employees to have conducted or have obtained any freedom to operate opinions or any Patent, Trademark or other Intellectual Property Rights clearance searches. If not conducted or
obtained, no knowledge of any Patents, Trademarks or other Intellectual Property Rights of any Third Party that would have been revealed by such opinions or searches will be imputed to the Company or any of its directors, officers or employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Legal Restraint</B>&#148; means an injunction, order or decree enacted, issued, promulgated, enforced or entered by any Governmental
Authority of competent jurisdiction that has become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> that (i)&nbsp;prohibits or makes illegal consummation of the Merger or (ii)&nbsp;prohibits, enjoins or permanently restrains the
Company, Parent or Merger Subsidiary from consummating the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Intellectual Property Rights</B>&#148; means all
Intellectual Property Rights licensed or sublicensed by a Third Party to the Company or any of its Subsidiaries or for which the Company or any of its Subsidiaries has obtained a covenant not to be sued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Registered Intellectual Property Rights</B>&#148; means Registered Intellectual Property Rights that constitute Licensed
Intellectual Property Rights, it being understood that Licensed Intellectual Property Rights excludes Intellectual Property Rights to which the Company or any of its Subsidiaries receives such license or sublicense pursuant to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> license Contract or other similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; means, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, encumbrance or
other adverse claim of any kind in respect of such property or asset. For purposes of this Agreement, a Person shall be deemed to own, subject to a Lien, any property or asset that it has acquired or holds subject to the interest of a vendor or
lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such property or asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nasdaq</B>&#148; means the Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Jurisdiction</B>&#148; means each jurisdiction which is not a Key Jurisdiction or Specified Jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Owned Intellectual Property Rights</B>&#148; means all Intellectual Property Rights owned or purported to be owned by the Company or
any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Owned Registered Intellectual Property Rights</B>&#148; means any Owned Intellectual Property Rights
that constitute Registered Intellectual Property Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Material Adverse Effect</B>&#148; means a material adverse effect on
Parent&#146;s ability to consummate the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Related Parties</B>&#148; means,
collectively, Parent, Merger Subsidiary and their respective Affiliates, and any of their respective former, current or future general or limited partners, stockholders, equityholders, members, managers, directors, officers, employees, agents or
Affiliates or any former, current or future general or limited partner, stockholder, equityholder, member, manager, director, officer, employee, agent or Affiliate of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permit</B>&#148; means each grant, license, franchise, permit, easement, variance, exception, exemption, waiver, consent,
certificate, registration, accreditation, approval, authorization, concession, decree, confirmation, qualification or other similar authorization of any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Liens</B>&#148; means (i)&nbsp;Liens for Taxes not yet due or delinquent or the validity or amount of which is being
contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP, provided no notice of any such Lien has been filed or recorded under the Code and the Treasury Regulations thereunder,
(ii)&nbsp;materialmen&#146;s, mechanics&#146;, carriers&#146;, workers&#146;, warehousemen&#146;s, repairers&#146; and similar Liens arising in the ordinary course of business consistent with past practice securing obligations as to which there is
no default and which are not yet delinquent, or the validity or amount of which is being contested in good faith by appropriate proceedings which have the effect of preventing the forfeiture or sale of the property subject thereto and for which
adequate reserves have been established in accordance with GAAP, (iii)&nbsp;Liens to secure payment of workers&#146; compensation, unemployment insurance, social security or other social security legislation (other than Liens imposed by ERISA), (iv)
with respect to real property, any nonmonetary Lien or other requirement or restriction arising under any zoning, entitlement, building, conservation restriction and other land use and environmental Applicable Law, and nonmonetary encumbrances of
record affecting any real property, in each case that would not, individually or in the aggregate, reasonably be expected to materially impair the operation of the business of the Company or its Subsidiaries at such real property or to materially
detract from the value of the real property subject thereto, (v)&nbsp;Liens imposed on the underlying fee or other interest in real property subject to a real property lease (exclusive of any Liens arising by reason of actions or inactions of the
Company or its Subsidiaries), (vi) statutory or common law Liens to secure landlords, lessors or renters under leases or rental agreements but only to the extent that the Company or any of its Subsidiaries, as applicable, is not in material default
of any obligation under any such lease or rental agreement, (vii)&nbsp;Liens in favor of financial institutions arising in connection with accounts maintained in the ordinary course of business consistent with past practice held at such institutions
to secure standard fees for services charged by, but not financing made available by, such institutions, (viii)&nbsp;deposits to secure the performance (but only to the extent that the Company or any of its Subsidiaries, as applicable, is not in
material default of any such obligation to perform) of tenders, bids, trade contracts, licenses and leases, statutory obligations, surety bonds, performance bonds, bank guaranties and other obligations of a like nature incurred in the ordinary
course of business consistent with past practice (including earnest money deposits in respect of any acquisition), (ix) licenses (not relating to any Leased Real Property) granted to others not interfering in any material respect with the business
of the Company and its Subsidiaries, and (x) <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> and other rights of the U.S. government pursuant to the Bayh-Dole Act (35 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;200-212</FONT>
and 37 C.F.R. 401). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, corporation, partnership, limited liability company, association,
trust or other entity or organization, including a government or political subdivision or a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal
Information</B>&#148; means any information that allows the identification of an individual, including name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number, driver&#146;s
license number, passport number or customer or account number, or any information that is otherwise considered personal information, personal data, protected health information, or personally identifiable information under Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy and Information Security Requirements</B>&#148; means (i)&nbsp;all
Applicable Laws relating to the Processing of Personal Information, including, without limitation, HIPAA and any Applicable Laws relating to data security, breach notification, direct marketing, telemarketing, or online behavioral advertising;
(ii)&nbsp;all provisions of contracts to which the Company or any of its Subsidiaries is a party or is otherwise bound that relate to the Processing of Personal Information, including without limitation any such contractual obligations to comply
with the Payment Card Industry&#151;Data Security Standard; and (iii)&nbsp;applicable policies and notices of the Company or any of its Subsidiaries relating to their Processing of Personal Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148; means the collection, use, storage, processing, recording, distribution, transfer,
import, export, protection (including security measures), disposal or disclosure or other activity regarding data (whether electronically or in any other form or medium). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registered Intellectual Property Rights</B>&#148; means any Intellectual Property Rights that have been filed or registered with or
issued or granted by the applicable Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></B>&#148;
means Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT></B>&#148; means Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> promulgated under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Representatives</B>&#148; of a Person means such Person&#146;s directors, officers, employees, investment bankers, attorneys,
accountants, consultants or other agents, auditors, advisors or other representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Research Use Only</B>&#148;<B> </B>or
&#147;<B>RUO</B>&#148; means an (i)&nbsp;in vitro diagnostic product that is in the laboratory research phase of development and is being shipped or delivered for an investigation that is not subject to 21 C.F.R. Part 812 (such a product is not
represented as an effective in vitro diagnostic product or intended for clinical diagnostic use) or (ii)&nbsp;certain products, such as instruments, systems, and reagents that are labeled for research use only and intended for use in the conduct of <FONT
STYLE="white-space:nowrap">non-clinical</FONT> laboratory research with goals other than development of a commercial in vitro diagnostic product, i.e., these products are used to carry out research and they are not themselves the object of the
research (these include products intended for use in discovering and developing medical knowledge related to human disease and conditions; for example, instruments and reagents intended for use in research attempting to isolate a gene linked with a
particular disease may be labeled for research use only when such instruments and reagents are not intended to produce results for clinical use). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sarbanes-Oxley Act</B>&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Service Provider</B>&#148; means any director, officer, employee or individual Independent Contractor of the Company or any of its
Subsidiaries (including any Company Employee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Specified Termination Actions</B>&#148; means those actions set forth on
Section&nbsp;1.01(d) of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Specified Jurisdiction</B>&#148; means each jurisdiction set forth on
Section&nbsp;1.01(e) of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any other
Person of which (i)&nbsp;such Person or any of its Subsidiaries is a general partner or holds a majority of the voting interests of a partnership or (ii)&nbsp;securities or other ownership interests having ordinary voting power to elect a majority
of the board of directors or other Persons performing similar functions (or, if there are no such ownership interests having ordinary voting power, 50% or more of the equity interests of which) are at any time directly or indirectly owned or
controlled by such Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means (i)&nbsp;any and all domestic and foreign, federal, state,
provincial, local, municipal, and other taxes and like assessments or charges in the nature of a tax imposed by any Taxing Authority (including taxes and other charges on, or measured by, net or gross income, and alternative minimum or <FONT
STYLE="white-space:nowrap">add-on</FONT> minimum, withholding, estimated, gross receipts, sales, use, ad valorem, value added, goods and services, transfer, franchise, fringe benefit, capital stock, profits, license, registration, payroll, social
security (or equivalent) or any other applicable social contribution, employment, unemployment, disability, excise, severance, stamp, license, occupation, premium, property (real, tangible or intangible), environmental, windfall profit, or unclaimed
property taxes), together with any interest, penalty, addition to tax or additional amount (including as a result of a failure to timely file any Tax Return), whether disputed or not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Return</B>&#148; means any report, return, document, declaration or other information or filing filed or required to be filed
with any Taxing Authority with respect to Taxes (and any amendments thereof and any schedule or attachment thereto), including information returns, and any documents with respect to or accompanying payments of estimated Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Sharing Agreement</B>&#148; means any agreement or arrangement (whether or not written), entered into prior to the Closing,
binding the Company or any of its Subsidiaries and providing for the allocation, apportionment, sharing or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts or gains for the purpose of
determining any Person&#146;s Tax liability, other than any agreement or arrangement entered into in the ordinary course consistent with past practices the primary purpose of which does not relate to Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Taxing Authority</B>&#148; means any Governmental Authority responsible for the collection or administration of Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Party</B>&#148; means any Person, including as defined in Section&nbsp;13(d) of the 1934 Act, other than Parent or any of its
controlled Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trade Secrets</B>&#148; means trade secrets and all other confidential
<FONT STYLE="white-space:nowrap">know-how</FONT> and confidential information and rights in any jurisdiction (domestic and foreign), including confidential recipes, ideas, formulae, formulations, compositions, specifications, techniques, data,
results, methods, processes, schematics, prototypes, models, designs, customer lists and supplier lists, but excluding Personal Information or rights therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of the following terms is defined in the Section set forth opposite such term: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adverse Recommendation Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Section&nbsp;6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.05(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.05(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.20(a)(xv)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charter Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.01(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Board Recommendation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.02(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Outbound License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.15(j)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Proxy Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.09</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Related Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Restricted Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.05(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.05(a)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company SEC Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.07</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.05(c)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stock Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.05(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.05(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stockholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stockholder Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;6.03</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Subsidiary Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.06(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;11.04(b)(i)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Copyrights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D&amp;O Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;7.03(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.01(c)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;10.01(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.06</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.24(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FCPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.12(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final Offering Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.06</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Advisor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.21</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Person</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;7.03(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intervening Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;6.04(b)(ii)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.14(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leased Real Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.14(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed Registered Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.20(a)(xv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Owned Registered Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Benefit Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;7.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Related Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paying Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.03(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.05</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Privacy Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.16(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registered Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.25</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reverse Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;11.04(b)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanctions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.12(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specified Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;6.04(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Superior Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;6.04(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tail Policy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;7.03(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;1.01(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UK Bribery Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.12(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uncertificated Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;2.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WEEE Directive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Section&nbsp;4.19</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION<A NAME="ex2_1647083_3"></A>&nbsp;1.02. <I>Other Definitional and Interpretative
Provisions</I>. The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions
herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Articles, Sections, Exhibits, Annexes and Schedules are to Articles, Sections, Exhibits, Annexes and Schedules of
this Agreement unless otherwise specified. All Exhibits, Annexes and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any
Exhibit, Annex or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words
&#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation,&#148; whether or not they are in fact followed by those words or words of like
import. &#147;Writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any Applicable Law shall be deemed to refer to such
Applicable Law as amended from time to time and to any rules, regulations or interpretations promulgated thereunder. References to any agreement or Contract are to that agreement or Contract as amended, modified, supplemented, extended or renewed
from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or
through and including, respectively. References to &#147;law,&#148; &#147;laws&#148; or to a particular statute or law shall be deemed also to include any Applicable Law. Unless otherwise specifically indicated, all references to &#147;dollars&#148;
and &#147;$&#148; will be deemed references to the lawful money of the United States of America. Documents or other information or materials will be deemed to have been &#147;made available&#148; (or words of similar import) by the Company if such
documents, information or materials have been, at any time least 24 hours prior to the execution and delivery of this Agreement, (i)&nbsp;posted and available to Parent and its Representatives in the virtual data room managed by the Company at
www.rrdvenue.com, and remain in such virtual data room at all times from the time posted through the Closing; or (ii)&nbsp;filed with or furnished to the SEC and available on EDGAR. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_4"></A>ARTICLE 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE MERGER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_5">
</A>SECTION&nbsp;2.01. <I>The Merger</I>. (a)&nbsp;At the Effective Time, Merger Subsidiary shall be merged with and into the Company (the &#147;<B>Merger</B>&#148;) in accordance with the Delaware Law, whereupon the separate existence of Merger
Subsidiary shall cease, and the Company shall be the surviving corporation (the &#147;<B>Surviving Corporation</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Subject to
the provisions of Article 9 the closing of the Merger (the &#147;<B>Closing</B>&#148;) shall take place in Palo Alto, California at the offices of Covington&nbsp;&amp; Burling LLP, 5 Palo Alto Square, 10th Floor, Palo Alto, CA 94306-2112 as soon as
possible, but in any event no later than three Business Days after the date the conditions set forth in Article 9 (other than conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent
permissible, waiver of those conditions at the Closing) have been satisfied or, to the extent permissible, waived by the party or parties entitled to the benefit of such conditions, or at such other place or time as Parent and the Company may
mutually agree. The date on which the Closing occurs is referred to in this Agreement as the &#147;<B>Closing Date</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) At the
Closing, the Company and Merger Subsidiary shall execute and file a certificate of merger with the Secretary of State of the State of Delaware in accordance with the Delaware Law and shall make all other filings or recordings required by the
Delaware Law in connection with the Merger. The Merger shall become effective at such time (the &#147;<B>Effective Time</B>&#148;) as such certificate of merger has been duly filed with the Secretary of State of the State of Delaware (or at such
later time as may be agreed by the parties in writing and specified in such certificate of merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) From and after the Effective
Time, the Surviving Corporation shall possess all the properties, rights, powers, privileges, immunities, licenses, franchises and authority and be subject to all of the obligations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities, restrictions and disabilities of the Company and Merger Subsidiary, all as provided under this Agreement and the Delaware Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC<A NAME="ex2_1647083_6"></A>TION&nbsp;2.02. <I>Conversion of Shares</I>. At the Effective Time, without any action on the part of Parent,
Merger Subsidiary or the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise provided in Section&nbsp;2.02(b), Section&nbsp;2.02(c) or Section&nbsp;2.04,
each issued and outstanding share of common stock, par value $0.001 per share, of the Company (the &#147;<B>Common Stock</B>&#148; or the &#147;<B>Shares</B>,&#148; and each, a &#147;<B>Share</B>&#148;) immediately prior to the Effective Time shall
be converted into the right to receive $8.00 in cash, without interest (the &#147;<B>Merger Consideration</B>&#148;). As of the Effective Time, each certificate formerly representing any Shares (each, a &#147;<B>Certificate</B>&#148;) or any
book-entry shares which immediately prior to the Effective Time represented Shares (each, an &#147;<B>Uncertificated Share</B>&#148;) shall automatically be canceled and retired and all Shares represented thereby shall cease to exist, and shall
thereafter represent only the right to receive the Merger Consideration to be paid in accordance with Section&nbsp;2.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each Share
held by the Company as treasury stock or otherwise owned by Parent or Merger Subsidiary immediately prior to the Effective Time shall be canceled and retired, and no payment shall be made with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Each Share held by any Subsidiary of the Company or Parent (other than Merger Subsidiary) immediately prior to the Effective Time, if any,
shall be converted into such number of shares of stock of the Surviving Corporation such that each such Subsidiary owns the same percentage of the outstanding capital stock of the Surviving Corporation immediately following the Effective Time as
such Subsidiary owned in the Company immediately prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Each share of common stock of Merger Subsidiary
outstanding immediately prior to the Effective Time shall be converted into and become one fully paid and nonassessable share of common stock of the Surviving Corporation with the same rights, powers and privileges as the shares so converted and
shall constitute the only outstanding shares of capital stock of the Surviving Corporation (except for any such shares resulting from the conversion of Shares pursuant to Section&nbsp;2.02(c)). From and after the Effective Time, all certificates
representing shares of common stock of Merger Subsidiary shall be deemed for all purposes to represent the number of shares of common stock of the Surviving Corporation into which they were converted in accordance with the immediately preceding
sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_7"></A>Section&nbsp;2.03. <I>Surrender</I> <I>and</I> <I>Payment</I>. (a)&nbsp;Prior to the Effective
Time, Parent shall appoint an agent reasonably acceptable to the Company (the &#147;<B>Paying</B> <B>Agent</B>&#148;) for the purpose of exchanging for the Merger Consideration (i)&nbsp;the Certificates and (ii)&nbsp;the Uncertificated Shares. On
the Closing Date, Parent or one of its Affiliates shall deliver, or cause to be delivered to, the Paying Agent, as needed, the aggregate Merger Consideration payable in respect of all the Shares of the Company represented by the Certificates and the
Uncertificated Shares in accordance with this Agreement (such cash, the &#147;<B>Consideration</B> <B>Fund</B>&#148;). In the event the Consideration Fund shall be insufficient to pay the Merger Consideration (including on account of any Merger
Consideration returned to Parent pursuant to Section&nbsp;2.03(g)), Parent shall promptly deliver, or cause to be delivered, additional funds to the Paying Agent in an amount equal to the deficiency required to make such payments. The Consideration
Fund shall not be used for any other purpose. Promptly after the Effective Time (and in any event within five Business Days), Parent shall send, or shall cause the Paying Agent to send, to each record holder of Shares at the Effective Time a letter
of transmittal and instructions (which shall be in customary form and shall specify that the delivery shall be effected, and risk of loss and title shall pass, only upon proper delivery of the Certificates or transfer of the Uncertificated Shares to
the Paying Agent) for use in such exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each holder of Shares that have been converted into the right to receive the Merger
Consideration shall be entitled to receive, upon (i)&nbsp;surrender to the Paying Agent of a Certificate (or such other materials as contemplated in Section&nbsp;2.09), together with a properly completed and validly executed letter of transmittal
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such other documents as may be reasonably requested by the Paying Agent, or (ii)&nbsp;receipt of an &#147;agent&#146;s message&#148; by the Paying Agent (or such other evidence, if any, of
transfer as the Paying Agent may reasonably request) in the case of a book-entry transfer of Uncertificated Shares, the Merger Consideration payable for each Share represented by such Certificate or for each such Uncertificated Share. Until so
surrendered or transferred, as the case may be, and subject to the terms of Section&nbsp;2.04, each such Certificate or Uncertificated Share shall represent after the Effective Time for all purposes only the right to receive the Merger Consideration
payable in respect thereof. No interest shall be paid or shall accrue on the cash payable upon the surrender or transfer of any Certificate or Uncertificated Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If any portion of the Merger Consideration is to be paid to a Person other than the Person in whose name the surrendered Certificate or
the transferred Uncertificated Share is registered, it shall be a condition to such payment that (i)&nbsp;such Certificate shall be properly endorsed or shall otherwise be in proper form for transfer or such Uncertificated Share shall be properly
transferred and (ii)&nbsp;the Person requesting such payment shall pay to the Paying Agent any transfer or other Taxes required as a result of such payment to a Person other than the registered holder of such Certificate or Uncertificated Share or
establish to the satisfaction of the Paying Agent and Parent that such Tax has been paid or is not payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Until disbursed in
accordance with this Agreement, the cash in the Consideration Fund will be invested by the Paying Agent as directed by Parent; <I>provided</I>, <I>however</I>, that any such investments shall be short-term obligations of or fully guaranteed by the
United States or backed by the full faith and credit of the United States with a maturity of no more than 30 days. No losses with respect to any investments of the Consideration Fund will affect the amounts payable to the holders of Certificates or
Uncertificated Shares under this Agreement. Any earnings, interest or other income from investment of the Consideration Fund shall be the sole and exclusive property of Parent and shall be paid as Parent directs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) From and after the Effective Time, there shall be no further registration of transfers of Shares. If, after the Effective Time,
Certificates or Uncertificated Shares are presented to the Surviving Corporation or the Paying Agent, they shall be canceled and exchanged for the Merger Consideration provided for, and in accordance with the procedures set forth, in this Article 2.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Any portion of the Consideration Fund (and any earnings, interest or other income earned thereon) that remains unclaimed by the
holders of Shares six months after the Effective Time shall be returned to Parent or one of its Affiliates, upon demand, and any such holder who has not exchanged its Shares for the Merger Consideration in accordance with this Section&nbsp;2.03
prior to that time shall thereafter look only to Parent (subject to abandoned property, escheat or similar laws), as general creditors thereof, for payment of the Merger Consideration in respect of such Shares without any interest thereon.
Notwithstanding the foregoing, neither Parent nor any of its Affiliates shall be liable to any holder of Shares for any amounts paid to a public official pursuant to applicable abandoned property, escheat or similar laws. Any amounts remaining
unclaimed by holders of Shares shall, immediately prior to the time when such amounts would otherwise escheat to or become property of any Governmental Authority, become, to the extent permitted by Applicable Law, the property of Parent free and
clear of any claims or interest of any Person previously entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Any portion of the Merger Consideration made available to
the Paying Agent pursuant to Section&nbsp;2.03(a) to pay for Shares for which appraisal rights have been perfected shall be returned to Parent or one of its Affiliates upon demand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) All Merger Consideration paid upon the surrender of Certificates or transfer of Uncertificated Shares in accordance with the terms hereof
shall be deemed to have been paid in full satisfaction of all rights pertaining to the Shares formerly represented by such Certificate or Uncertificated Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SE<A NAME="ex2_1647083_8"></A>CTION&nbsp;2.04. <I>Dissenting Shares</I>. Notwithstanding Section&nbsp;2.02 or any other provision of this
Agreement to the contrary, Shares outstanding immediately prior to the Effective Time (other than shares canceled in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with Section&nbsp;2.02(b) or Section&nbsp;2.02(c)) and held by a holder who has not voted in favor of the Merger or consented thereto in writing and who has properly demanded appraisal
for its Shares in accordance with Section&nbsp;262 of the Delaware Law and who has otherwise complied with all applicable provisions of Section&nbsp;262 of the Delaware Law shall not be converted into the right to receive the Merger Consideration,
but shall be entitled only to such rights as are granted by Section&nbsp;262 of the Delaware Law, unless such holder fails to perfect, waives, withdraws or otherwise loses the right to appraisal under Section&nbsp;262 of the Delaware Law, or a court
of competent jurisdiction shall determine that such holder is not entitled to the relief provided by Section&nbsp;262 of the Delaware Law. If, after the Effective Time, such holder fails to perfect, waives, withdraws or otherwise loses the right to
appraisal under Section&nbsp;262 of the Delaware Law, or if a court of competent jurisdiction shall determine that such holder is not entitled to the relief provided by Section&nbsp;262 of the Delaware Law, such Shares shall be treated as if they
had been converted pursuant to Section&nbsp;2.02(a) as of the Effective Time into, and shall represent only, the right to receive the Merger Consideration in accordance with Section&nbsp;2.03 upon surrender of such Certificate formerly representing
such Share or transfer of such Uncertificated Share, as the case may be. The Company shall give Parent prompt written notice of any demands received by the Company for appraisal of Shares, any waiver or withdrawal of any such demand, and any other
demand, notice or instrument delivered to the Company prior to the Effective Time that relates to such demand, and Parent shall have the right to participate in and, following the Effective Time, to direct all negotiations and proceedings with
respect to such demands. The Company shall not, without the prior written consent of Parent, make any payment with respect to, offer to settle or settle any such demands, or agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTI<A NAME="ex2_1647083_9"></A>ON&nbsp;2.05. <I>Company Stock Options and Company RSUs</I>. (a)&nbsp;At or immediately prior to the
Effective Time, each option to acquire Shares granted or issued pursuant to any Employee Plan that is outstanding immediately prior to the Effective Time, whether vested or unvested (collectively, the &#147;<B>Company Stock Options</B>&#148;), shall
be, by virtue of the Merger and without any action on the part of the holder thereof, canceled and converted into the right to receive, at or promptly after the Effective Time, solely an amount in cash equal to the product of (i)&nbsp;the excess, if
any, of the Merger Consideration over the applicable per Share exercise price of such canceled Company Stock Option multiplied by (ii)&nbsp;the aggregate number of Shares subject to such Company Stock Option immediately prior to the Effective Time.
For the avoidance of doubt, if the per Share exercise price under any Company Stock Option is equal to or greater than the Merger Consideration, such Company Stock Option shall be canceled as of the Effective Time without payment therefor and shall
have no further force or effect. Holders of unvested Company Stock Options shall be afforded an opportunity to exercise such Company Stock Options prior to, and contingent upon the consummation of the transactions contemplated by this Agreement. At
or immediately prior to the Effective Time, each restricted stock unit granted or issued pursuant to any Employee Plan that is outstanding immediately prior to the Effective Time (collectively, the &#147;<B>Company RSUs</B>&#148;) shall be, by
virtue of the Merger and without any action on the part of the holder thereof, canceled and converted into the right to receive, at or promptly after the Effective Time, solely an amount in cash equal to the product of (i)&nbsp;the Merger
Consideration multiplied by (ii)&nbsp;(A) for Company RSUs subject to time-based vesting, the total number of Shares subject to such Company RSU immediately prior to the Effective Time; and (B)&nbsp;for any other Company RSUs, the number of Shares
that would be payable if such Company RSU was vested at target performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At or immediately prior to the Effective Time, each
restricted Share granted or issued pursuant to any Employee Plan that is outstanding immediately prior to the Effective Time (collectively, the &#147;<B>Company</B> <B>Restricted Shares</B>&#148; and, together with Company Stock Options and Company
RSUs, &#147;<B>Company Stock Awards</B>&#148;) shall be, by virtue of the Merger and without any action on the part of the holder thereof, converted into the right to receive, at or promptly after the Effective Time, solely an amount in cash equal
to the Merger Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Prior to the Effective Time, the Company, the Board of Directors and the compensation committee of the
Board of Directors, as applicable, shall take all actions necessary or appropriate to effectuate the treatment of Company Stock Awards as contemplated in this Section&nbsp;2.05 (including obtaining any required consents from
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of Company Stock Awards) and to terminate any equity incentive plans maintained or sponsored by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S<A NAME="ex2_1647083_10"></A>ECTION&nbsp;2.06. <I>Employee Stock Purchase Plan</I>. The Company shall take all actions necessary to terminate
its 2010 Employee Stock Purchase Plan (the &#147;<B>ESPP</B>&#148;) and all outstanding rights thereunder (including providing requisite notice to participants in the ESPP pursuant to the terms of the ESPP) no later than as of immediately prior to
the Effective Time, contingent upon the consummation of the transactions contemplated by this Agreement; provided that, from and after the date of this Agreement, the Company shall take all actions necessary to ensure that (i)&nbsp;no new
participants are permitted to participate in the ESPP and that participants may not increase their payroll deductions or purchase elections from those in effect on the date of this Agreement, (ii)&nbsp;except for any offering or purchase period
under the ESPP that is in effect on the date of this Agreement (the &#147;<B>Final Offering Period</B>&#148;), no new offering or purchase period shall be authorized, continued or commenced following the date of this Agreement, and (iii)&nbsp;both
the maximum number of shares that a participant in the ESPP can purchase and the total number of share available under the ESPP cannot be increased. Unless otherwise agreed to by Company and Parent, the Final Offering Period shall terminate no later
than as of immediately following the next scheduled purchase date (to occur on March&nbsp;1, 2019), and the Company shall cause the exercise date applicable to the Final Offering Period to accelerate and occur on such termination date with respect
to any then-outstanding purchase rights. Notwithstanding anything to the contrary herein, (A)&nbsp;all amounts allocated to each participant&#146;s account under the ESPP at the end of the Final Offering Period shall thereupon be used to purchase
whole Shares under the terms of the ESPP for such offering period, which Shares shall be canceled at the Effective Time in exchange for the right to receive the Merger Consideration in accordance with Section&nbsp;2.02(a), and (B)&nbsp;as promptly
as practicable following the purchase of Shares in accordance with the foregoing clause (A), the Company shall return to each participant the funds, if any, that remain in such participant&#146;s account after such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTIO<A NAME="ex2_1647083_11"></A>N&nbsp;2.07. <I>Adjustments</I>. If at any time during the period between the date of this Agreement and
the Effective Time, the outstanding Shares (or securities convertible into, or exchangeable or exercisable for, Shares) shall have been changed into a different number of shares or into a different class (including by reason of any reclassification,
recapitalization, stock split (including a reverse stock split) or combination, exchange or readjustment of shares or similar transaction, or stock dividend or distribution thereon with a record date during such period, but excluding any change that
results from any issuance of Shares permitted by Section&nbsp;6.01(c)), the Merger Consideration and any other amounts payable pursuant to this Agreement shall be appropriately adjusted to reflect such change. Nothing in this Section&nbsp;2.07 shall
be construed to permit the Company to take any action with respect to its securities that is prohibited by the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_12">
</A>SECTION&nbsp;2.08. <I>Withholding Rights</I>. Notwithstanding any provision contained herein to the contrary, each of the Paying Agent, Merger Subsidiary, the Surviving Corporation and Parent shall be entitled to deduct and withhold from the
consideration otherwise payable to any Person pursuant to this Agreement (including the Merger Consideration or payments pursuant to Section&nbsp;2.04 or Section&nbsp;2.05) any amount that is required to be deducted and withheld with respect to the
making of such payment under applicable Tax law. Any amount that the Paying Agent, Merger Subsidiary, the Surviving Corporation or Parent, as the case may be, so deducts or withholds and pays over to the appropriate Governmental Authority shall be
treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_13"></A>SECTION&nbsp;2.09. <I>Lost Certificates</I>. If any Certificate shall have been lost, stolen or destroyed, upon
the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Parent or the Paying Agent, the posting by such Person of a bond, in such reasonable amount as Parent or the Paying
Agent may direct, as indemnity against any claim that may be made against it with respect to such Certificate, the Paying Agent shall pay, in exchange for such lost, stolen or destroyed Certificate, the Merger Consideration to be paid in respect of
the Shares represented by such Certificate, as contemplated by this Article 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<A NAME="ex2_1647083_14"></A>RTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE SURVIVING CORPORATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECT<A NAME="ex2_1647083_15">
</A>ION&nbsp;3.01. <I>Certificate of Incorporation</I>. The certificate of incorporation of the Surviving Corporation shall be amended at the Effective Time to be in the form of the certificate of incorporation of Merger Subsidiary in effect
immediately prior to the Effective Time and, as so amended, shall be the certificate of incorporation of the Surviving Corporation until thereafter amended as provided therein and under the Delaware Law, except that the name of the Surviving
Corporation may be changed to a name to be specified by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTI<A NAME="ex2_1647083_16"></A>ON&nbsp;3.02. <I>Bylaws</I>. The bylaws
of Merger Subsidiary in effect at the Effective Time shall be the bylaws of the Surviving Corporation, except that references to Merger Subsidiary&#146;s name shall be replaced with references to the Surviving Corporation&#146;s name, until
thereafter amended in accordance with the terms thereof, the certificate of incorporation of the Surviving Corporation and Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTIO<A NAME="ex2_1647083_17"></A>N&nbsp;3.03. <I>Directors and Officers</I>. From and after the Effective Time, until successors are duly
elected or appointed and qualified in accordance with certificate of incorporation and bylaws of the Surviving Corporation and Applicable Law, the directors and officers of Merger Subsidiary at the Effective Time shall be the directors and officers,
respectively, of the Surviving Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_18"></A>ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;11.05, except (i)&nbsp;as disclosed in any Company SEC Documents filed with the SEC on or after January&nbsp;1, 2018,
and prior to the date of this Agreement (but only to the extent that it is reasonably apparent from such disclosure in the Company <FONT STYLE="white-space:nowrap">10-K</FONT> that it is applicable to one or more specified Sections of the Company
Disclosure Schedule, and excluding any disclosures set forth under the headings &#147;Forward-Looking Statements and Market Data,&#148; &#147;Risk Factors,&#148; &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; or any similar
section and any disclosures under such headings that are predictive, cautionary or forward-looking in nature); <I>provided</I> that this clause (i)&nbsp;shall not apply to Section&nbsp;4.02 (Corporate Authorization), Section&nbsp;4.04 <FONT
STYLE="white-space:nowrap">(Non-contravention),</FONT> Section&nbsp;4.05 (Capitalization), Section&nbsp;4.10 (Absence of Changes), Section&nbsp;4.22 (Opinion of Financial Advisor) or Section&nbsp;4.23 (Antitakeover Statutes) or (ii)&nbsp;as set
forth in the correspondingly numbered Section of the Company Disclosure Schedule, the Company represents and warrants to Parent and Merger Subsidiary that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC<A NAME="ex2_1647083_19"></A>TION&nbsp;4.01. <I>Corporate Existence and Power</I>. The Company is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of Delaware and has all corporate powers and all Permits required to carry on its business as now conducted, except for those Permits the absence of which has not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where such qualification is necessary,
except for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The Company has delivered or made available to Parent a
true, correct and complete copy of the certificate of incorporation (including any certificates of designation), bylaws or like organizational documents, each as in effect (collectively, the &#147;<B>Charter Documents</B>&#148;), of the Company and
each of its Subsidiaries. The Company is not in violation of any of the provisions of its Charter Documents. No Subsidiary of the Company is in violation of any of the provisions of its Charter Documents, except for those violations which have not
had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION<A NAME="ex2_1647083_20">
</A>&nbsp;4.02. <I>Corporate Authorization</I>. (a)&nbsp;The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby are within the Company&#146;s corporate
powers and, except for any approval required as a result of an inaccuracy of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representations of Parent and Merger Subsidiary set forth in Section&nbsp;5.07 and for the Company Stockholder Approval (as defined below), have been duly authorized by all necessary corporate
action on the part of the Company. The affirmative vote of the holders of a majority of the outstanding Shares (the &#147;<B>Company Stockholder Approval</B>&#148;) is the only vote of the holders of any class or series of capital stock of the
Company necessary to adopt this Agreement or approve or consummate the transactions contemplated hereby (including the Merger), except for any approval required as a result of an inaccuracy of the representations of Parent and Merger Subsidiary set
forth in Section&nbsp;5.07. The Company has duly executed and delivered this Agreement and, assuming due authorization, execution and delivery by each of Parent and Merger Subsidiary, this Agreement constitutes a valid and binding obligation of the
Company enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws affecting creditors&#146; rights generally and general principles of
equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At a meeting duly called and held, the Board of Directors has (i)&nbsp;determined that this Agreement and the transactions
contemplated hereby, including the Merger, are fair to and in the best interests of the Company and its stockholders, (ii)&nbsp;approved, adopted and declared advisable this Agreement and the transactions contemplated hereby, including the Merger,
in accordance with the requirements of the Delaware Law, and (iii)&nbsp;resolved, subject to Section&nbsp;6.04(b), to recommend the approval and adoption of this Agreement and the Merger by the stockholders of the Company (such recommendation, the
&#147;<B>Company Board Recommendation</B>&#148;). As of the date of this Agreement, the foregoing determinations and resolutions have not been rescinded, modified or withdrawn in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_21"></A>SECTION&nbsp;4.03. <I>Governmental Authorization</I>. The execution, delivery and performance by the Company of
this Agreement and the consummation by the Company of the transactions contemplated by this Agreement require no action by, Permit from or filing by or with any Governmental Authority other than (i)&nbsp;the filing of a certificate of merger with
respect to the Merger with the Secretary of State of the State of Delaware, (ii)&nbsp;compliance with any applicable requirements of any Antitrust Law, (iii)&nbsp;compliance with any applicable requirements of the 1933 Act, the 1934 Act any other
applicable U.S. state or federal securities laws and the rules and requirements of Nasdaq and (iv)&nbsp;any actions or filings the absence of which has not had and would not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_22"></A>SECTION&nbsp;4.04.
<I><FONT STYLE="white-space:nowrap">Non-contravention</FONT></I>. Assuming receipt of the Company Stockholder Approval, the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated
hereby do not and will not (i)&nbsp;contravene, conflict with or result in any violation or breach of any Charter Documents of the Company; (ii)&nbsp;contravene, conflict with or result in any violation or breach of any Charter Documents of the
Subsidiaries of the Company, (iii)&nbsp;assuming compliance with the matters referred to in Section&nbsp;4.03, contravene, conflict with or result in a violation or breach of any provision of any Applicable Law by the Company or any of its
Subsidiaries, except for any approval required as a result of an inaccuracy of the representations of Parent and Merger Subsidiary set forth in Section&nbsp;5.07, (iv) assuming compliance with the matters referred to in Section&nbsp;4.03, require
any consent or other action by any Person under, constitute a breach or default, or an event that, with or without notice or lapse of time or both, would constitute a breach or default, under, or cause or permit the termination, cancellation,
acceleration or other change of any right or obligation or the loss of any benefit to which the Company or any of its Subsidiaries is entitled under, any Material Contract or (v)&nbsp;result in the creation or imposition of any Lien (other than
Permitted Liens) on any asset of the Company or any of its Subsidiaries, with only such exceptions, in the case of each of clauses (ii), (iii), (iv) and (v), as have not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_23"></A>SECTION&nbsp;4.05. <I>Capitalization</I>. (a)&nbsp;The
authorized capital stock of the Company consists solely of (i) 1,000,000,000 shares of Common Stock and (ii) 50,000,000 shares of preferred stock, par value $0.001 per share, of the Company (the &#147;<B>Preferred Stock</B>&#148;). As of 5:00 p.m.,
Pacific time, on October&nbsp;30, 2018 (such date and time, the &#147;<B>Capitalization Date</B>&#148;), there were outstanding (A) 148,901,892 shares of Common Stock, (B)&nbsp;no shares of Preferred Stock, (C) 38,835,378 shares of Common Stock
reserved under the Employee Plans </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(excluding shares of Common Stock subject to issuance under the ESPP), of which there were outstanding 26,930,553 shares of Common Stock subject to issuance upon exercise of outstanding Company
Stock Options (which have a weighted average exercise price of $5.5892 and 18,861,777 of which are currently exercisable), (D) 957,181 shares of Common Stock subject to issuance upon settlement of Company RSUs, and (E) 1,952,507 shares of Common
Stock reserved for issuance under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) All outstanding shares of capital stock of the Company have been, and all shares that may
be issued pursuant to any Employee Plan or Company Security will be, when issued in accordance with the respective terms thereof and in compliance with the terms of this Agreement, duly authorized and validly issued, fully paid and nonassessable and
free of preemptive rights. Section&nbsp;4.05(b) of the Company Disclosure Schedule contains a complete and correct list, as of October&nbsp;30, 2018, of each outstanding Company Stock Award, including the holder, type of award (if applicable), date
of grant, exercise price (if applicable), expiration date (if applicable), vesting schedule (including whether vesting accelerates on specified &#147;change in control&#148; transactions), any early exercise or other special terms and the number of
Shares subject thereto. Each Company Stock Award has been granted in compliance in all material respects with all applicable securities laws or exemptions therefrom and all requirements set forth in the applicable Employee Plan and applicable award
agreements. The treatment of Company Stock Awards under this Agreement complies in all material respects with the terms of the applicable Employee Plan and applicable award agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) There are no outstanding bonds, debentures, notes or other indebtedness of the Company having the right to vote (or convertible into, or
exchangeable or exercisable for, securities having the right to vote) on any matters on which stockholders of the Company may vote. Except as set forth in this Section&nbsp;4.05 resulting from the exercise of Company Stock Options outstanding on
such date in accordance with the terms thereof on such date, the issuance of Shares pursuant to the vesting of Company RSUs outstanding on such date in accordance with the terms thereof on such date and the purchase of Shares pursuant to the ESPP in
accordance with its terms as in effect on such date, there are no issued, reserved for issuance or outstanding (i)&nbsp;shares of capital stock or other voting securities of, or ownership interests in, the Company, (ii)&nbsp;securities of the
Company convertible into, or exchangeable or exercisable for, shares of capital stock or other voting securities of, or ownership interests in, the Company, (iii)&nbsp;warrants, calls, options or other rights to acquire from the Company, or other
obligations of the Company to issue, any capital stock or other voting securities of, or ownership interests in, or any securities convertible into, or exchangeable or exercisable for, any capital stock or other voting securities of, or ownership
interests in, the Company or (iv)&nbsp;restricted shares, restricted stock units, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights that are derivative of, or provide
economic benefits based, directly or indirectly, on the value or price of, any capital stock or voting securities of, or ownership interests in, the Company (the items in clauses (i)&nbsp;through (iv), including, for the avoidance of doubt, the
Shares, being referred to collectively as the &#147;<B>Company</B> <B>Securities</B>&#148;). There are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the Company Securities.
Neither the Company nor any of its Subsidiaries is a party to any Contract with respect to the voting, registration or transfer of any Company Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in this Section&nbsp;4.05, none of the Shares or any Company Securities are owned by any Subsidiary of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_24"></A>SECTION&nbsp;4.06. <I>Subsidiaries</I>. (a)&nbsp;Each Subsidiary of the Company has been duly incorporated
or formed, is validly existing and (where applicable) in good standing under the laws of its jurisdiction of organization, has all organizational powers and all Permits required to carry on its business in the places and in the manner as now
conducted, except for those failures to be in good standing and Permits the absence of which has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Each Subsidiary of the
Company is identified in Section&nbsp;4.06(a) of the Company Disclosure Schedule. Section&nbsp;4.06(a) of the Company Disclosure Schedule also includes the jurisdiction of incorporation or formation of each Subsidiary of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares, capital stock or other voting securities of, or ownership
interests in, each Subsidiary of the Company have been duly authorized and validly issued, are fully paid up and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free of preemptive rights and are owned beneficially and legally, and solely,
by the Company, directly or indirectly, free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such share, capital stock or other voting securities or
ownership interests). There are no issued, reserved for issuance or outstanding (i)&nbsp;securities of the Company or any of its Subsidiaries convertible into, or exchangeable or exercisable for, shares, capital stock or other voting securities of,
or ownership or economic interests in, any Subsidiary of the Company, (ii)&nbsp;warrants, calls, options or other rights to acquire from the Company or any of its Subsidiaries, or other obligations of the Company or any of its Subsidiaries to issue,
any shares, capital stock or other voting securities of, or ownership interests in, or any securities convertible into, or exchangeable or exercisable for, any shares, capital stock or other voting securities of, or ownership or economic interests
in, any Subsidiary of the Company or (iii)&nbsp;restricted shares, restricted stock units, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights that are derivative of, or
provide economic benefits based, directly or indirectly, on the value or price of, any share, capital stock or other voting security of, or ownership interest in, any Subsidiary of the Company (the items in clauses (i)&nbsp;through (iii) being
referred to collectively as the &#147;<B>Company Subsidiary Securities</B>&#148;). There are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the Company Subsidiary Securities.
Except for the shares, capital stock or other voting securities of, or ownership interests in, its Subsidiaries, the Company does not own, directly or indirectly, any shares, capital stock or other voting securities of, or ownership interests in any
Person. Neither the Company nor any of its Subsidiaries have declared, made or paid any dividends or distributions. No shares, capital stock or other voting securities of the Subsidiaries of the Company have been issued and no transfer of any such
shares has been registered (where applicable), except in accordance with all Applicable Laws and the constitutional documents of the relevant Subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_25"></A>SECTION&nbsp;4.07. <I>SEC Filings and the Sarbanes-Oxley Act</I>. (a)&nbsp;The Company has filed with or
furnished to the SEC, and made available to Parent, all reports, schedules, forms, statements, prospectuses, registration statements and other documents required to be filed with or furnished to the SEC by the Company (collectively, together with
any exhibits and schedules thereto and other information incorporated therein, the &#147;<B>Company SEC</B> <B>Documents</B>&#148;). The Company has made available to Parent true, correct and complete copies of all material correspondence between
the SEC, on the one hand, and the Company and any of its Subsidiaries, on the other hand, including all comment letters from the staff of the SEC relating to the Company SEC Documents containing unresolved comments all written responses of the
Company thereto. To the Company&#146;s Knowledge, as of the date of this Agreement, no Company SEC Document is the subject of ongoing review, comment or investigation by the SEC. No Subsidiary of the Company is, or at any time has been, required to
file any reports, schedules, forms, statements or other documents with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) As of its filing date (or, if amended or superseded
by a filing prior to the date of this Agreement, as of the date of such filing), each Company SEC Document complied, and each Company SEC Document filed subsequent to the date of this Agreement will comply, as to form in all material respects with
the applicable requirements of Nasdaq, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) As of its filing
date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such filing), each Company SEC Document filed pursuant to the 1934 Act did not, and each Company SEC Document filed subsequent to the date of this
Agreement will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Each Company SEC Document that is a registration statement, as amended or supplemented, if applicable, filed pursuant to the 1933 Act, as
of the date such registration statement or amendment became effective, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Company and its Subsidiaries have established and maintain disclosure controls and
procedures and internal control over financial reporting (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act) as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act.
Such disclosure controls and procedures are reasonably designed to ensure (i)&nbsp;all information required to be disclosed by the Company, including its consolidated Subsidiaries, in the reports that it files or submits under the 1934 Act is
recorded, processed, summarized and reported to the individuals responsible for preparing such reports within the time periods specified in the rules and forms of the SEC, and (ii)&nbsp;all such information is accumulated and communicated to the
Company&#146;s management as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the principal executive officer and the principal financial officer of the Company required under the 1934 Act with
respect to such reports. For purposes of this Agreement, &#147;principal executive officer&#148; and &#147;principal financial officer&#148; shall have the meanings given to such terms in the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Company and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act) that is effective in providing reasonable assurance regarding the reliability of the Company&#146;s financial reporting and the preparation of Company financial statements for external
purposes in accordance with GAAP. Neither the Company nor, to the Knowledge of the Company, the Company&#146;s auditors has identified or has been made aware of (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation
of internal controls that are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information that has not been adequately remedied and (ii)&nbsp;any fraud, whether or not material,
that involves management or other employees who have a role in internal controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Section&nbsp;4.07(g) of the Company Disclosure
Schedule describes, and the Company has made available to Parent copies of the documentation creating or governing, all securitization transactions and other <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements (as defined in Item
303 of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> that existed or were effected by the Company or its Subsidiaries since January&nbsp;1, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The Company has complied with and is in compliance in all material respects with all applicable listing and corporate governance rules,
regulations and requirements of Nasdaq, and is in compliance in all material respects with all rules, regulations and requirements of the SEC and with the Sarbanes-Oxley Act. There are no outstanding loans or other extensions of credit made by the
Company or any of its Subsidiaries to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> under the 1934 Act) or director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2015, each of the principal executive officer and principal financial officer of the Company (or each former
principal executive officer and principal financial officer of the Company, as applicable) has made all certifications required by Rule <FONT STYLE="white-space:nowrap">13a-14</FONT> and <FONT STYLE="white-space:nowrap">15d-14</FONT> under the 1934
Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and Nasdaq, and the statements contained in any such certifications are complete and correct as of their respective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) There are no Contracts between the Company or any of its Subsidiaries, on the one hand, and any other Person (other than the Company and
its Subsidiaries), on the other hand, that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_26"></A>SECTION&nbsp;4.08. <I>Financial Statements</I>. The audited consolidated financial statements and unaudited
consolidated interim financial statements of the Company included or incorporated by reference in the Company SEC Documents (i)&nbsp;as of their respective dates of filing with the SEC complied as to form in all material respects with the rules and
regulations of the SEC with respect thereto, (ii)&nbsp;fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and their consolidated results of operations
and cash flows for the periods then ended (subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments in the case of any unaudited interim financial statements which are not material in the aggregate) and (iii)&nbsp;have
been prepared in accordance with GAAP applied on a consistent basis (except as may be expressly indicated in the notes thereto). The books and records of the Company and its Subsidiaries have been, and are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being, maintained in all material respects in accordance with GAAP or International Financial Reporting Standards, where and as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_27"></A>SECTION&nbsp;4.09. <I>Disclosure Documents</I>. (a)&nbsp;At the time the proxy statement to be filed with the SEC
in connection with the Merger (the &#147;<B>Company Proxy Statement</B>&#148;) or any amendment or supplement thereto is first mailed to stockholders of the Company, at the time such stockholders vote on approval and adoption of this Agreement and
at the Effective Time, the Company Proxy Statement, as supplemented or amended, if applicable, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing in
this Section&nbsp;4.09, the Company makes no representation with respect to statements made or incorporated by reference in the Company Proxy Statement based on information supplied by or on behalf of Parent or Merger Subsidiary for inclusion or
incorporation by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_28"></A>SECTION&nbsp;4.10. <I>Absence of Certain Changes</I>. (a)&nbsp;Since the
Company Balance Sheet Date through to the date of this Agreement, the business of the Company and its Subsidiaries has been conducted in the ordinary course consistent with past practices and there has not been any event, circumstance, change,
occurrence, development, condition or effect that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) From the date of the Company Interim Balance Sheet until the date of this Agreement, there has not been any action taken by the Company or
any of its Subsidiaries that, if taken during the period from the date of this Agreement through the Effective Time without Parent&#146;s consent, would constitute a breach of Section&nbsp;6.01, other than with respect to the following subsections:
Section&nbsp;6.01(c), Section&nbsp;6.01(d), Section&nbsp;6.01(k)(i), Section&nbsp;6.01(l)(i)(A), Section&nbsp;6.01(l)(i)(B), Section&nbsp;6.01(l)(i)(C) as it relates to actions taken under Section&nbsp;6.01(l)(v), Section&nbsp;6.01(l)(ii) as it
relates to actions taken under Section&nbsp;6.01(l)(v), Section&nbsp;6.01(l)(v) and, as it applies to the foregoing subsections, Section&nbsp;6.01(w). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_29"></A>SECTION&nbsp;4.11. <I>No Undisclosed Liabilities</I>. As of the date of this Agreement, there are no liabilities
or obligations of the Company or any of its Subsidiaries of a nature required to be reflected or reserved against on a balance sheet prepared in accordance with GAAP, other than: (i)&nbsp;liabilities or obligations disclosed and reserved for in the
Company Interim Balance Sheet or in the notes thereto, (ii)&nbsp;liabilities or obligations arising out of or in connection with this Agreement and the transactions contemplated hereby; and (iii)&nbsp;liabilities or obligations incurred in the
ordinary course of business consistent with past practice since the date of the Company Interim Balance Sheet that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_30"></A>SECTION&nbsp;4.12. <I>Compliance with Laws, Permits and Court Orders</I>. (a)&nbsp;Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and each of its Subsidiaries is, and since January&nbsp;1, 2015 has been, in compliance with all Applicable Laws. Since
January&nbsp;1, 2015, the Company has not been threatened to be charged with or given written or, to the Knowledge of the Company, oral notice of any material violation of, and to the Knowledge of the Company is not under investigation by any
Governmental Authority with respect to any material violation of, any Applicable Law. There is no judgment, decree, injunction, rule or order of any arbitrator or Governmental Authority outstanding against the Company or any of its Subsidiaries that
has had or would be reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) During the
past five years, none of the Company, any of its Subsidiaries, or any of their respective directors, officers, or to the Company&#146;s knowledge, consultants, agents or other Persons acting for or on their behalf has taken any action that would
result in a violation by such Person of (i)&nbsp;the Foreign Corrupt Practices Act of 1977 (15 U.S.C. &#167;&#167; 78m(b), <FONT STYLE="white-space:nowrap">78dd-1,</FONT> <FONT STYLE="white-space:nowrap">78dd-2,</FONT> 78ff) (the
&#147;<B>FCPA</B>&#148;), the Bribery Act of 2010 of the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Kingdom (the &#147;<B>UK Bribery Act</B>&#148;) or any other anti-corruption or anti-bribery Applicable Law, (ii)&nbsp;any economic sanctions administered or enforced by the U.S. Department of
Treasury&#146;s Office of Foreign Assets Control, the U.S. Department of State, Her Majesty&#146;s Treasury or any applicable prohibited party list maintained by any U.S. government agency, the European Union or Her Majesty&#146;s Treasury
(collectively, &#147;<B>Sanctions</B>&#148;) and (iii)&nbsp;any applicable export controls laws. Since January&nbsp;1, 2015, the Company has conducted its businesses in compliance with the FCPA (and any state or foreign equivalents), the UK Bribery
Act, any other anti-corruption Applicable Law, Sanctions and applicable export controls laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) None of the Company, any of its
Subsidiaries or any of their respective directors, officers, consultants, agents or other Persons acting for or on their behalf is a Person that is, or is owned or controlled by Persons that are: (i)&nbsp;the subject of any Sanctions or
(ii)&nbsp;located, organized or resident in a country or region that is the subject of Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Company and its Subsidiaries
hold all material Permits necessary to conduct their respective businesses in the places and in such manner in which such businesses are currently being conducted. Except as has not had or would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, (i)&nbsp;such Permits are valid and in full force and effect and are not subject to any pending or threatened Action by any Governmental Authority to suspend, cancel, modify, terminate or revoke any
such Permit, (ii)&nbsp;the Company and each of its Subsidiaries are in compliance with the terms and requirements of such Permits, (iii)&nbsp;the Company and each of its Subsidiaries is not in default under, and no condition exists that with notice
or lapse of time or both would constitute a default under or would reasonably be expected to result in any suspension, cancellation, modification, termination or revocation of, any such Permit and (iv)&nbsp;none of the Permits shall be terminated or
impaired or become terminable, in whole or in part, as a result of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) There is, and since
January&nbsp;1, 2015, the Company and each of its Subsidiaries has been in material compliance with the terms of any Government Contract or Government Bid. There is, and since January&nbsp;1, 2015, has been, no pending or threatened audits or
investigations by any Governmental Authority arising under or relating to a Government Contract or Government Bid. Since January&nbsp;1, 2015, none of the Company, any of its Subsidiaries or any of their respective Principals (as the term is defined
under 48 C.F.R. 2.101) has been debarred, suspended, or proposed for suspension or debarment or otherwise excluded from participation in the award of any Government Contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_31"></A>SECTION&nbsp;4.13. <I>Litigation</I>. As of the date of this Agreement, there is no material Action pending
against, or, to the Knowledge of the Company, threatened against, the Company, any of its Subsidiaries, or, to the Knowledge of the Company, any present or former officer or director of the Company or any of its Subsidiaries in their capacities as
such, or any Employee Plan (or any fiduciary thereof) or any Person for whom the Company or any of its Subsidiaries may, to the Knowledge of the Company, pursuant to contract or applicable Law, be liable before (or, in the case of threatened
Actions, would be before) or by any Governmental Authority or arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_32"></A>SECTION&nbsp;4.14.
<I>Properties</I>. (a)&nbsp;The Company and its Subsidiaries have good title to, or good and valid leasehold interests in, all property and assets reflected on the Company Balance Sheet or acquired after the Company Balance Sheet Date, except as
have been disposed of since the Company Balance Sheet Date in the ordinary course of business consistent with past practice and in compliance with this Agreement, in each case free and clear of all Liens (other than Permitted Liens). Except has not
had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the properties and assets owned or leased by the Company and its Subsidiaries constitute all of the properties and assets
necessary for and used in the conduct of their respective businesses in the places and in such manner in which such businesses are currently being conducted. Neither the Company nor any of its Subsidiaries owns or has ever owned any interest in real
property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) (i) Each lease, sublease, license or other use or occupancy agreement (each, a
&#147;<B>Lease</B>&#148;) under which the Company or any of its Subsidiaries leases, subleases, licenses or otherwise uses or occupies any real property (whether as lessor or lessee) is valid and in full force and effect and (ii)&nbsp;neither the
Company nor any of its Subsidiaries, nor to the Company&#146;s Knowledge any other party to a Lease, is in default under the provisions of such Lease and no event has occurred that and is continuing that with notice or lapse of time, or both, would
constitute a default, in each case except for those defaults that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Section&nbsp;4.14(b) of the Company Disclosure Schedule
sets forth, as of the date of this Agreement, a complete and correct list of all Leases to which the Company or any of its Subsidiaries is a party, including all amendments, extensions, renewals and guarantees with respect thereto, in each case
identifying the parties thereto, and the address of the real property associated with such Lease (such property, together with all rights, title and interest of the Company or any Subsidiary in and to leasehold improvements relating thereto,
including security deposits, reserves or prepaid rents paid in connection therewith, collectively, the &#147;<B>Leased Real Property</B>&#148;). The Company has made available to Parent (in each case, together with all amendments, modifications,
supplements, waivers or other changes thereto) complete and correct copies of all Leases. The performance by the Company of this Agreement and the transactions contemplated hereby will not result in the termination of, or in any increase of any
material amounts payable under, any Lease or any material rights under any Lease or will require the consent or approval from any party to any such Lease other than the Company. With respect to any Leased Real Property, the Company and any of its
Subsidiaries enjoys peaceful and undisturbed possession of the Leased Real Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The equipment and tangible personal property
owned, leased, licensed or otherwise used or held for use by the Company or any of its Subsidiaries have no material defects. To the Company&#146;s Knowledge, all improvements and other equipment used in connection with the business of the Company
and its Subsidiaries is located entirely on the Leased Real Property, except for improvements and equipment which have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the
Knowledge of the Company, none of the Company or any of its Subsidiaries has received any notice of any pending or threatened condemnation Action with respect to any of the real property it leases, licenses or otherwise occupies. Except as set forth
in Section&nbsp;4.14(c) of the Company Disclosure Schedule, no Person leases, subleases, licenses or otherwise has the right to use or occupy any of the Leased Real Property other than the Company or any Subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_33"></A>SECTION&nbsp;4.15. <I>Intellectual Property</I>. (a)&nbsp;Section&nbsp;4.15(a) of the Company Disclosure Schedule
sets forth as of the date of this Agreement a true, correct and complete list of all the Owned Registered Intellectual Property Rights and material Licensed Registered Intellectual Property Rights, specifying as to each such item, as applicable,
(i)&nbsp;whether such item is an Owned Registered Intellectual Property Right or a Licensed Registered Intellectual Property Right, (ii)&nbsp;the owner (and, if any, joint owners; and for any jointly owned item, the Contract pursuant to which such
item was invented or otherwise developed) thereof, (iii)&nbsp;the jurisdiction (foreign and domestic) in which such item is issued or registered or in which any application for issuance or registration has been filed, (iv)&nbsp;the respective
issuance, registration, or application number of such item, (v)&nbsp;the date of application and issuance or registration of such item and (vi)&nbsp;in the case of each of such item that is a Licensed Registered Intellectual Property Right, the
applicable Contract pursuant to which the Company or any of its Subsidiaries receives its rights from Third Party licensor(s) to such Licensed Registered Intellectual Property Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) (i) The Company and its Subsidiaries are the sole and exclusive owners of all Owned Intellectual Property Rights and hold all right, title
and interest in and to all Owned Intellectual Property Rights, free and clear of any Lien; (ii)&nbsp;the Owned Intellectual Property Rights and the Licensed Intellectual Property Rights, together, constitute all of the Intellectual Property Rights
necessary to, or used or held for, or used in, the conduct of the business of the Company and its Subsidiaries as currently conducted and as proposed by the Company or any of its Subsidiaries described in the Company SEC Documents; (iii)&nbsp;there
exist no material restrictions on the disclosure, use, license or transfer of the Owned Intellectual Property Rights or, to the Knowledge of the Company, Licensed Intellectual Property Rights; and (iv)&nbsp;the consummation of the transactions
contemplated by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Agreement will not (A)&nbsp;alter, encumber, impair or extinguish any Owned Intellectual Property Right or, Licensed Intellectual Property Rights, (B)&nbsp;impair the right of Parent to
develop, use, sell, license or dispose of, or to bring any Action for the infringement of, any Owned Intellectual Property Right or Licensed Intellectual Property Rights, that Parent had immediately prior to such consummation, in the case of clauses
(A)&nbsp;and (B) above, whether through the operation of any Contracts to which the Company or any of its Subsidiaries is a party or otherwise bound or otherwise, or (C)&nbsp;grant any right (license, covenant not to sue or otherwise) to a Third
Party under any of the Intellectual Property Rights owned by or licensed to Parent or its Affiliates (other than the Company and its Subsidiaries). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) To the Knowledge of the Company, (i)&nbsp;no funding, facilities or personnel of any Governmental Authority or any university, college,
research institute or other educational institution has been or is being used in any respect to create, in whole or in part, any Owned Intellectual Property Rights or Licensed Intellectual Property Rights that is Key IP, except for any such funding
or use of facilities or personnel that does not result in such Governmental Authority or educational institution obtaining ownership of, or use rights to, such Owned Intellectual Property Rights or Licensed Intellectual Property Rights, and does not
require or otherwise obligate the Company or any of its Subsidiaries to grant or offer to any such Governmental Authority or educational institution any license or other right to such Owned Intellectual Property Rights or Licensed Intellectual
Property Rights and (ii)&nbsp;no current or former employee, consultant or independent contractor of the Company or any of its Subsidiaries who contributed to the creation or development of the Owned Intellectual Property Rights that is Key IP
performed services related to the Company&#146;s business as presently conducted for a Governmental Authority or any university, college, research institute or other educational institution during a period of time during which such employee,
consultant or independent contractor was also performing services for the Company or any of its Subsidiaries. As it relates to any (A)&nbsp;Owned Intellectual Property Rights and (B)&nbsp;to the Knowledge of the Company, Licensed Intellectual
Property Rights, in the case of clauses (A)&nbsp;and (B) above, in which the United States Government has rights, the Company or its licensor(s) has taken all necessary steps to comply with the Bayh-Dole Act (35 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap">200-212)</FONT> and any regulations related thereto, including making all necessary disclosures to the relevant funding agencies and complying with the domestic manufacturing requirement as set forth in 35 U.S.C. &#167;
204. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) To the Knowledge of the Company, none of the Company or any of its Subsidiaries has infringed, contributed to the infringement
of, misappropriated or otherwise violated any Intellectual Property Right of any Person in any material respect. There is no Action pending against, or, to the Knowledge of the Company, threatened against, the Company or any of its Subsidiaries or
affecting the conduct of the respective businesses of the Company or any of its Subsidiaries as presently conducted (including the research, development, manufacture, marketing, promotion, offering for sale, sale or other commercialization,
shipment, import, export or distribution, as applicable, of any Key Products)&nbsp;(i) based upon, or challenging or seeking to deny or restrict, any right of the Company or any of its Subsidiaries in any of the Owned Intellectual Property Rights,
(ii)&nbsp;alleging that any of the Owned Intellectual Property Rights are invalid or unenforceable, (iii)&nbsp;alleging that the use of any of the Owned Intellectual Property Rights or manufactured, used, imported, offered for sale or sold by the
Company or any of its Subsidiaries do or may conflict with, misappropriate, infringe, contribute to the infringement of, or otherwise violate any Intellectual Property Right of any Person or (iv)&nbsp;alleging that the Company or any of its
Subsidiaries have infringed, misappropriated or otherwise violated any Intellectual Property Right of any Person, including in connection with an offer to grant a license or other rights to the Company or any of its Subsidiaries under such
Intellectual Property Rights of such other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) To the Knowledge of the Company, the operation of the business of the Company as
currently conducted does not infringe, misappropriate or otherwise violate any Intellectual Property of another Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) None of the
Owned Intellectual Property Rights has been adjudged invalid or unenforceable in whole or part by a court or administrative agency, or in the case of pending Patent applications included in the Owned Intellectual Property Rights, have been the
subject of a final and unappealable finding of unpatentability. All issued Patents, registered Trademarks and registered Copyrights included in the Owned Intellectual Property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rights are, to the Knowledge of the Company, valid, enforceable, in full force and effect and subsisting in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) To the Knowledge of the Company, no Person has infringed, misappropriated or otherwise violated any of the Owned Intellectual Property
Right or material Licensed Intellectual Property Right for the commercial manufacture, use, sale, offer for sale or importation any product or service, which Licensed Intellectual Property right the Company or its Subsidiary has the first right to
bring an enforcement action with respect to such infringement, misappropriation or violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The Company and its Subsidiaries have
taken commercially reasonable actions in accordance with current practice of the industry in which the Company and its Subsidiaries operate to maintain the confidentiality of all material Intellectual Property Rights of the Company or any of its
Subsidiaries (including any Trade Secrets owned, used or held for use by the Company or any of its Subsidiaries), the value of which to the Company or any of its Subsidiaries is contingent upon maintaining the confidentiality thereof, and no such
Intellectual Property Rights have been disclosed other than pursuant to written confidentiality agreements or other confidentiality obligations that protect such Intellectual Property Rights, or as required by Applicable Law or in accordance with
current practice of the industry in which the Company and its Subsidiaries operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) To the extent that any material Intellectual
Property Right has been developed or created by a Third Party (including any current or former officer, director, employee, independent contractor or consultant of the Company or any of its Subsidiaries) for the Company or any of its Subsidiaries,
the Company or one of its Subsidiaries, as the case may be, has a written agreement with such Third Party with respect thereto pursuant to which such Person has agreed to hold such Intellectual Property Right in confidence, and the Company or one of
its Subsidiaries thereby either (i)&nbsp;has obtained exclusive ownership of, or (ii)&nbsp;has obtained a valid and unrestricted right to exploit, sufficient for the conduct of its business as currently conducted, under such Intellectual Property
Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) Section&nbsp;4.15(j) of the Company Disclosure Schedule identifies, as of the date of this Agreement, each Contract pursuant
to which Company or its Subsidiaries has granted or is obligated to grant to any Third Party any material license or other right (including (i)&nbsp;any assignment or (ii)&nbsp;covenant not to sue, (iii)&nbsp;license to make, use, sell, offer for
sell or import any product or service, and (iv)&nbsp;as part of patent pool, standards-setting body, trade association or other organization) under any (a)&nbsp;Key IP or (b)&nbsp;other Intellectual Property Rights that are material to the business
of the Company (each, a &#147;<B>Company Outbound License</B>&#148;), in each case, other than any Contract granting <FONT STYLE="white-space:nowrap">(I)&nbsp;non-material,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses
entered into in the ordinary course of business consistent with past practice of the Company, (II)&nbsp;licenses or other rights (A)&nbsp;under Intellectual Property Rights or (B)&nbsp;for fields of use, in each case, that do not cover the Key
Products, (III)&nbsp;licenses, covenants not to sue, and similar rights (other than ownership) granted solely for the purpose of permitting the performance by a Third Party of its obligations to, for or on behalf of Company or its Subsidiaries, or
(IV)&nbsp;customary licenses or other rights (other than ownership) granted to a Third Party under Intellectual Property Rights constituting modifications to the background Intellectual Property Rights of such Third Party created or otherwise
developed in the course of the performance of activities under material transfer agreements and other similar Contracts entered into in the ordinary course of the business consistent with past practice of Company or its Subsidiaries; provided that,
Company and its Subsidiaries retain rights with respect to such created or developed Intellectual Property Rights necessary to, or that claim or cover the Key Products or their use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_34"></A>SECTION&nbsp;4.16. <I>IT Systems; Privacy and Data Security</I>. (a)&nbsp;The Company and each of its
Subsidiaries complies, and has complied since January&nbsp;1, 2015, in all material respects, with all Privacy and Information Security Requirements and material contractual requirements pertaining to Personal Information. Neither the Company nor
any of its Subsidiaries has, to the Knowledge of the Company, received written notice of any complaint, investigation, or other inquiry from any Governmental Authority with jurisdiction since January&nbsp;1, 2015, regarding any actual or suspected
material violation of, or material failure to comply with, any Privacy and Information Security Requirement by the Company or any of its Subsidiaries. To the Knowledge of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, there is not currently pending and there has not been since January&nbsp;1, 2015, any Action against the Company or any of its Subsidiaries alleging any material violation of, or
material failure to comply with, any Privacy and Information Security Requirement by the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At all
times since January&nbsp;1, 2015, the Company and each of its Subsidiaries has provided reasonable and accurate notice of the Company and its Subsidiaries&#146; privacy and personal data collection and use policies on its websites and otherwise as
required for compliance in all material respects with Applicable Law. The Company has made available to Parent copies of all of the current privacy and personal data collection and use policies on its websites and any other current public-facing
privacy notices or disclosures of the Company and its Subsidiaries as of the date of this Agreement (collectively, &#147;<B>Privacy Notices</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2015, to the Knowledge of the Company, no Person has, or is reasonably suspected by the Company to have, gained
unauthorized access to any Personal Information or other confidential information that the Company or any of its Subsidiaries has a legal obligation to protect, or gained unauthorized access to, or unauthorized acquisition of, any such Personal
Information or other confidential information, in each case as has required notification to any Third Party under any Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)
The transactions to be consummated hereunder as of the Closing will not cause or constitute a material breach or violation by the Company or any of its Subsidiaries of any Applicable Law relating to privacy or any Privacy Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Company and each of its Subsidiaries maintains commercially reasonable organizational, administrative, physical and technical
safeguards to (i)&nbsp;secure IT Assets in their possession and control that maintain any Personal Information and other confidential information of the Company and its Subsidiaries thereon from unauthorized access, acquisition, interruption,
alteration, modification, use or other processing; (ii)&nbsp;defend against or otherwise address or mitigate denial of service attacks, distributed denial of service attacks, hacking attempts and like attacks and activities directed to such IT
Assets by any other Person; and (iii)&nbsp;support the operation of such IT Assets, including employing commercially reasonable business continuity and disaster recovery measures except, in the case of any of (i), (ii), or (iii), for any failure to
maintain such safeguards as would not be material to the Company and its Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) To the Knowledge of the
Company, the IT Assets within the Company&#146;s possession and control contain no code (including what are sometimes referred to as &#147;viruses&#148;, &#147;worms&#148;, &#147;time bombs&#148; or &#147;back doors&#148;) designed to materially and
significantly disrupt, disable, harm, distort or otherwise impede the legitimate operation of such IT Assets that has not been removed or reasonably mitigated, except as would not be material to the Company and its Subsidiaries, taken as a whole.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_35"></A>SECTION&nbsp;4.17. <I>Taxes</I>. (a)&nbsp;Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect, all Tax Returns required by Applicable Law to be filed with any Taxing Authority by, or on behalf of, the Company or any of its Subsidiaries have been timely filed in
accordance with all Applicable Law. All such Tax Returns are true, correct and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Except as has not
had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and each of its Subsidiaries have timely paid all Taxes due and payable, or, where payment is not yet due, have
established in accordance with GAAP an adequate accrual for all Taxes through the end of the last period for which the Company and its Subsidiaries ordinarily record items on their respective books. The Company has made available to Parent all
federal and state, but not with any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or local, income, franchise and similar Tax Returns of each of the Company and its Subsidiaries for taxable years 2013 through 2017, in each case ending on
December&nbsp;31, filed with the United States Internal Revenue Service, any United States State Taxing Authority or any foreign Taxing Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Company and each of its Subsidiaries have properly withheld, and paid over to the
appropriate Taxing Authority, all material Taxes required to be withheld from any payment (including any dividend or interest payment) to any employee, independent contractor, creditor, shareholder, vendor or other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
there is no Action now pending or threatened in writing against or with respect to the Company or its Subsidiaries in respect of any Tax or Tax Return. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) No deficiency of material Taxes in respect of the Company or any of its Subsidiaries has been asserted in writing as a result of any audit
or examination by any Taxing Authority that remains outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) No extension or waiver of the statute of limitations with respect to
the time to assess material Taxes of the Company or any of its Subsidiaries has been granted that remains in effect, and no written request for such extension or waiver is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its Subsidiaries was a distributing corporation or a controlled corporation in a transaction intended to be
governed in whole or in part by Section&nbsp;355 or Section&nbsp;361 of the Code or any corresponding or similar provision of state, local or foreign Applicable Law since January&nbsp;1, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any of its Subsidiaries has entered into, or participated in, any &#147;reportable transaction&#148; within the
meaning of Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> or any similar provision of state or foreign law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries has received or applied for a Tax ruling or entered into a closing agreement pursuant to
Section&nbsp;7121 of the Code or any similar provision of state, local or foreign Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) The Company is not nor has been a
United States real property holding corporation (as defined in Section&nbsp;897(c)(2) of the Code) during the applicable period specified in Section&nbsp;897(c)(1)(A) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its Subsidiaries (i)&nbsp;is or has been a member of an affiliated, consolidated, combined or unitary group
other than one of which the Company was the common parent; (ii)&nbsp;has any liability for Taxes of any Person (other than the Company or any of its Subsidiaries) under U.S. Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or foreign Applicable Law) or as transferee or successor; or (iii)&nbsp;has any liability or potential liability to another Person under any Tax
Sharing Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its Subsidiaries is a party to any joint venture, partnership or other arrangement
that is treated as a partnership for U.S. federal, state, local or foreign income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) No material written claim has been
made by any Taxing Authority in a jurisdiction in which the Company or its Subsidiaries do not file Tax Returns to the effect that the Company or any of its Subsidiaries is or may be subject to taxation by, or required to file any Tax Return in,
such jurisdiction that remains outstanding. Section&nbsp;4.17(m) of the Company Disclosure Schedule contains a complete and correct list of all jurisdictions (foreign, U.S. federal and state) in which the Company and each of its Subsidiaries file
income, franchise or similar Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) Neither the Company nor any of its Subsidiaries has an office or fixed place of business
or, to the Company&#146;s Knowledge, a permanent establishment (within the meaning of any applicable Tax treaty or convention) in a country other than the country in which it is organized. Each Subsidiary of the Company that is a foreign corporation
for United States federal income tax purposes has at all times been wholly owned by, and a controlled foreign corporation within the meaning of Section&nbsp;957 of the Code with respect to, the Company. No Company Subsidiary organized outside the
United States is a surrogate foreign corporation within the meaning of Section&nbsp;7874(a)(2)(B) or (b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) Except as has not had and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, neither the Company nor any of its Subsidiaries will be required to include any item of income in, or to exclude any item of deductions from, taxable income from any taxable period (or portion
thereof) ending after the Closing as a result of any (i)&nbsp;change in method of accounting for a taxable period (or portion thereof) ending prior to the Closing, (ii)&nbsp;closing agreement as described in Section&nbsp;7121 of the Code (or any
corresponding or similar provision of state, local or foreign Tax Law) executed prior to the Closing, (iii)&nbsp;installment sale or open transaction disposition entered into prior to Closing, (iv)&nbsp;prepaid amount received prior to Closing,
(v)&nbsp;election under Section&nbsp;108(i) of the Code or (vi)&nbsp;application of Section&nbsp;965 of the Code. Neither the Company nor any of its Subsidiaries has made an election under Section&nbsp;965(h) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect:
(i)&nbsp;the Company and each of its Subsidiaries have duly kept and properly maintained all material records for all taxable years still open for audit that such Person is required to keep for Tax purposes under any Applicable Law; (ii)&nbsp;all
intercompany agreements have been adequately documented, and such documents have been duly executed in a timely manner; (iii)&nbsp;the prices for any property or services (or for the use of any property) provided by or to the Company or any of its
Subsidiaries are <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> prices for purposes of all applicable transfer pricing laws, including Section&nbsp;482 of the Code and any similar provision of state, local or foreign Applicable Law; and
(iv)&nbsp;all transactions and other dealings between the Company or any of its Subsidiaries, on the one hand, and a third party have been (and can be demonstrated to have been) conducted on <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT>
commercial terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_36"></A>SECTION&nbsp;4.18. <I>Employee Benefit Plans; Labor Matters</I>.
(a)&nbsp;Section&nbsp;4.18(a) of the Company Disclosure Schedule lists each material Employee Plan, other than Employment Agreements (i)&nbsp;providing for employment <FONT STYLE="white-space:nowrap">at-will</FONT> and no change in control benefits
or (ii)&nbsp;in a form made available or, except as noted in the sentence that immediately follows this sentence, will furnish or make available no later than 30 days following the date of this Agreement, to Parent. For each material Employee Plan,
the Company has furnished or made available to Parent a copy of such plan if reduced to writing (or a description, if such plan is not written) and all material amendments thereto, including a copy of (if applicable)&nbsp;(i) each existing trust
agreement, insurance contract, and administrative service agreement, (ii)&nbsp;each summary plan description and summary of material modifications, (iii)&nbsp;the three most recently filed IRS Forms 5500 for each Employee Plan required to file IRS
Forms 5500, (iv) the most recent favorable determination or opinion letter from the IRS, (v)&nbsp;the most recently prepared actuarial reports and financial statements, (vi)&nbsp;all discrimination tests for the three most recent plan years to the
extent required with respect to the Employee Plan, (vii)&nbsp;all material documents and correspondence relating thereto received from or provided to the Department of Labor, the Pension Benefit Guaranty Corporation, the IRS or any other
Governmental Authority since January&nbsp;1, 2015, and (viii)&nbsp;all current employee handbooks, manuals, policies and procedures that applies to any Company Employee. The Company has furnished or made available as of the date of this Agreement
each Employment Agreement and Consulting Agreement that is not terminable <FONT STYLE="white-space:nowrap">at-will</FONT> or that upon termination of the same could result in liability to the Company. No Employee Plan is sponsored or maintained by a
third party professional employer organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company has made available to Parent each (i)&nbsp;Employment Agreement (other
than <FONT STYLE="white-space:nowrap">at-will</FONT> offer letters with no severance or change in control benefits), and (ii)&nbsp;Consulting Agreement pursuant to which an Independent Contractor is entitled to receive (or is reasonably expected to
be entitled to receive) more than $100,000 during any <FONT STYLE="white-space:nowrap">12-month</FONT> period. Each current and former Company Employee and Independent Contractor has executed a nondisclosure and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">assignment-of-rights</FONT></FONT> agreement for the benefit of the Company (or a Subsidiary, where applicable), vesting all rights in work product created by the Company Employee or Independent Contractor during such
individual&#146;s affiliation with the Company (or a Subsidiary, where applicable), and a copy of each such agreement has previously been made available to Parent. To the Company&#146;s Knowledge, no current Company Employee or Independent
Contractor is a party to, or is otherwise bound in any way by, any Contract that in any way may adversely affect or restrict the performance of such Company Employee or Independent Contractor&#146;s duties to the Company or its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Company has made available to Parent a list of all former Company Employees whose
employment has been terminated within 90 days preceding the date of this Agreement, including for each such individual: name, site of employment, job title, date of hire, and date of employment loss, termination or layoff, if applicable. To the
Company&#146;s Knowledge, no executive officer of the Company intends to terminate his or her employment or services with the Company or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Company has made available to Parent a true, correct and complete list that sets forth, as of the date of this Agreement,
(i)&nbsp;each current Company Employee, including each such individual&#146;s name, employer, title, hire date, location, base salary or wage or commission rate and current annual bonus or incentive opportunity (including performance goals and
target and maximum amounts), and whether such individual is in active employment or on leave; and (ii)&nbsp;each current Independent Contractor, including for each such individual: name, location, description of services, consulting or contracting
term, consulting or contracting fee, and an indication of whether such individual has entered into a Contract. The employment of each current Company Employee and the services of each current Independent Contractor is terminable at will without
compensation or other penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company nor any of its ERISA Affiliates (nor any predecessor of any such entity) sponsors,
maintains, administers or contributes to (or has any obligation to contribute to), or has in the past six years sponsored, maintained, administered or contributed to (or had any obligation to contribute to), or has or is reasonably expected to have
any direct or indirect liability with respect to, (i)&nbsp;a &#147;defined benefit plan&#148; (as defined in Section&nbsp;3(35) of ERISA) that is subject to ERISA; (ii)&nbsp;a &#147;multiemployer plan&#148; (as defined in Sections 4001(a)(3) or
3(37)(A) of ERISA) that is subject to ERISA; (iii)&nbsp;a pension plan subject to Section&nbsp;302 or Title IV of ERISA or Section&nbsp;412 or 4971 of the Code, in any case, either directly or through any ERISA Affiliate; (iv)&nbsp;a multiple
employer welfare arrangement (as defined in Section&nbsp;3(40) of ERISA) that is subject to ERISA; (v)&nbsp;a &#147;multiple employer plan&#148; (as defined in Section&nbsp;413(c) of the Code) that is intended to be qualified under
Section&nbsp;401(a) of the Code; or (vi)&nbsp;any plan, program or arrangement that provides for post-retirement or other post-employment health or welfare benefits (other than health care continuation coverage as required by Section&nbsp;4980B of
the Code or similar Applicable Law (i)&nbsp;for which the covered individual pays the full cost of coverage, or (ii)&nbsp;as required by an employment agreement that has been made available to Parent). No Employee Plan is or has ever been, or
currently funds or has ever been funded by, a &#147;voluntary employees&#146; beneficiary association&#148; within the meaning of Section&nbsp;501(c)(9) of the Code or other funding arrangement for the provision of welfare benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Each Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and has been so qualified during
the period since its adoption, and, to the Knowledge of the Company, no event has occurred since the date of such determination that would adversely affect such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Each Employee Plan has been established, maintained, funded, and administered in compliance in all material respects with its terms and
with all Applicable Law, including ERISA and the Code. No Action (other than routine claims for benefits) is pending against or involves or, to the Company&#146;s Knowledge, is threatened against or threatens to involve, any Employee Plan before any
court or arbitrator or any Governmental Authority, including the IRS and the Department of Labor. There are no controversies pending or, to the Knowledge of the Company, threatened between the Company and its Subsidiaries, on the one hand, and any
Company Employees, on the other. No investigation, review, complaint or proceeding by any Governmental Authority or Company Employee with respect to the Company and its Subsidiaries in relation to the employment of any individual is pending or, to
the Company&#146;s Knowledge, threatened, nor has the Company or any of its Subsidiaries received any written notice from any Governmental Authority indicating an intention to conduct the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) No asset of any Employee Plan consists of employer securities (within the meaning of Section&nbsp;407(d)(1) of ERISA). Each Employee Plan
that provides health or life insurance benefits is fully insured by a third party insurance company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its ERISA Affiliates nor any of their directors,
officers, employees or agents, nor any fiduciary, trustee or administrator of any Employee Plan or trust created under any Employee Plan, has engaged in or been a party to any <FONT STYLE="white-space:nowrap">non-exempt</FONT> &#147;prohibited
transaction&#148; as defined in Section&nbsp;4975 of the Code and Section&nbsp;406 of ERISA, and to the Company&#146;s Knowledge, no <FONT STYLE="white-space:nowrap">non-exempt</FONT> &#147;prohibited transaction,&#148; within the meaning of
Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Employee Plan. No events have occurred with respect to any Employee Plan that would reasonably be expected to result in the assessment of any excise taxes
or penalties against the Company or any of its Subsidiaries in a material amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) There has been no amendment to, written
interpretation of or announcement (whether or not written) by the Company or any of its Affiliates relating to, or change in employee participation or coverage under, any Employee Plan that would materially increase the expense of maintaining such
plan above the level of expense incurred in respect thereof for the fiscal year ended on the Company Balance Sheet Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) All
contributions, premiums and payments that are due have been made for each Employee Plan within the time periods prescribed by the terms of such plan and Applicable Law, and all contributions, premiums and payments for any period ending on or before
the Closing Date that are not due are properly accrued to the extent required to be accrued under applicable accounting principles and have been properly reflected on the Company Balance Sheet or disclosed in the notes thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) Except as provided in Section&nbsp;4.18(l) of the Company Disclosure Schedule, neither the execution of this Agreement nor the
consummation of the transactions contemplated hereby (either alone or together with any other event) will (i)&nbsp;entitle any current or former Service Provider to any payment or benefit, including any bonus, retention, severance, retirement or job
security payment or benefit, (ii)&nbsp;accelerate the time of payment or vesting or trigger any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, or increase the amount payable or trigger any other
obligation under, any Employee Plan or (iii)&nbsp;limit or restrict the right of the Company or any of its Subsidiaries or, after the Closing, Parent or any of its Affiliates, to merge, amend or terminate any Employee Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) No Employee Plan or other compensation benefit or arrangement, individually or collectively, would reasonably be expected to result in the
payment of any amount that would not be deductible under Section&nbsp;280G of the Code. Neither the Company nor any of its Subsidiaries has any obligation to <FONT STYLE="white-space:nowrap">gross-up,</FONT> indemnify or otherwise reimburse any
current or former Service Provider for any Tax incurred by such Service Provider, including under Sections 280G,&nbsp;409A, or Section&nbsp;4999 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) Neither the Company nor any of its Subsidiaries is a party to or subject to, or is currently negotiating in connection with entering into,
any Collective Bargaining Agreement, and there is no, and, to the Knowledge of the Company, there never has been any, organizational campaign, petition or other unionization activity pending, or to the Knowledge of the Company, threatened, seeking
recognition of a collective bargaining unit relating to any Company Employee. No Company Employees belong, or have during the period of their engagement by the Company or one of its Subsidiaries belonged, to any trade union or similar body, and no
trade union or similar body is recognized by the Company or any of its Subsidiaries. There are no representatives representing all or any Company Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) There are no material unfair labor practice complaints pending or, to the Knowledge of the Company, threatened against the Company or any
of its Subsidiaries before the National Labor Relations Board or any other Governmental Authority. There is no, and there has never been, any labor strike, slowdown, stoppage, picketing, material interruption of work or lockout pending or, to the
Knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p) The Company and its Subsidiaries
are, and since January&nbsp;1, 2015 have been, in compliance in all material respects with all Applicable Laws relating to labor and employment, including, but not limited to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;those relating to labor management relations, wages, hours, overtime, mandatory employment-related benefits, employee classification, equal opportunity, discrimination, sexual
harassment, disability accommodation, protected leave, civil rights, affirmative action, work authorization, immigration, safety and health, information privacy and security, wage payment, the payment and withholding of Taxes and workers
compensation and (ii)&nbsp;the Worker Adjustment and Retraining Notification Act (the &#147;<B>WARN Act</B>&#148;) and any comparable foreign, state or local law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(q) The Company and/or its Subsidiaries have complied with any obligations to inform and consult with Company Employees as required by
Applicable Law (to the extent applicable in the jurisdictions in which the relevant Company Employees are employed) or any agreement, arrangement, custom or practice to which the Company and/or its Subsidiaries are subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(r) Each Employee Plan that is a &#147;nonqualified deferred compensation plan&#148; within the meaning of Section&nbsp;409A of the Code
satisfies in all material respects the requirements of Section&nbsp;409A of the Code and has been operated in compliance in all material respects with the terms of such plan and the requirements of Section&nbsp;409A of the Code, in each case such
that no Tax is, has been, or (if administered in accordance with its terms) could be due or payable under Section&nbsp;409A of the Code. The exercise price of each Company Stock Option is not less than the fair market value (within the meaning of
Section&nbsp;409A of the Code) of a Share on the date of grant of such Company Stock Option and all such Company Stock Options are exempt from Section&nbsp;409A of the Code. Each Company Stock Option (now outstanding or previously exercised)
intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code so qualified at all times prior to the exercise thereof. At all times, the ESPP has qualified as an &#147;employee stock purchase plan&#148; under
Section&nbsp;423 of the Code, and all options to purchase shares under the ESPP (now outstanding or previously exercised or forfeited) have satisfied Applicable Law, including the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(s) The Company and its Subsidiaries have properly accrued on the Company Balance Sheet all personal time off owed to Company Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(t) To the Company Knowledge, in the last ten years, (a)&nbsp;no allegations of sexual harassment have been made against any Company Employee
who is (i)&nbsp;an executive officer or (ii)&nbsp;at the level of senior vice president or above, and (b)&nbsp;the Company and its Affiliates have not entered into any settlement agreements related to allegations of sexual harassment or misconduct
by a Company Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_37"></A>SECTION&nbsp;4.19. <I>Environmental Matters</I>. (a)&nbsp;Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect: (i)&nbsp;since January&nbsp;1, 2015, no written notice, notification, demand, request for information, citation, summons or order has been
received, no complaint has been filed, no penalty has been assessed, and no Action or review is pending, or to the Knowledge of the Company, threatened by any Governmental Authority or other Person relating to the Company or any of its Subsidiaries
and relating to or arising out of any Environmental Law, (ii)&nbsp;the Company and its Subsidiaries are and, since January&nbsp;1, 2015, have been in compliance with all Environmental Laws and all Environmental Permits, (iii)&nbsp;neither the
Company nor any of its Subsidiaries has disposed, discharged, spilled, or released any Hazardous Substance at, from, in, on, under, to or about any property currently or formerly owned, leased or operated by the Company or any of its Subsidiaries,
(iv)&nbsp;to the Knowledge of the Company, there are no underground storage tanks that are located on any property currently or formerly owned, leased or operated by the Company or any of its Subsidiaries, (v)&nbsp;the Company and its Subsidiaries
have not assumed or retained by contract or, to the Knowledge of the Company, by operation of law, any liability under Environmental Law or regarding Hazardous Substances, and (vi)&nbsp;the Company is and, since January&nbsp;1, 2015, has been in
compliance with EU Directive 2012/19/EU on Waste Electrical and Electronic Equipment (the &#147;<B>WEEE</B> <B>Directive</B>&#148;) and the applicable requirements of the national laws implementing the WEEE Directive in the EU/EEA Member States, as
well as the applicable WEEE legislation of non EU/EEA countries, where the Company, its subsidiaries or representatives have marketed electrical and electronic equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) To the Knowledge of the Company, neither the execution of this Agreement by the Company
nor the consummation by the Company of the Merger will require any investigation, remediation, mitigation, <FONT STYLE="white-space:nowrap">clean-up</FONT> or other action with respect to any Hazardous Substance, or any notice to or consent of any
Governmental Authority, pursuant to any applicable Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Company has made available to Parent any Phase I and Phase
II site assessment reports and environmental, occupational, health and safety, or industrial hygiene audits, each in the possession of the Company, relating to environmental matters with respect to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_38"></A>SECTION&nbsp;4.20. <I>Material Contracts</I>. (a)&nbsp;As of the date of this Agreement, other than Employee
Plans (except for those Employee Plans specifically contemplated to be disclosed pursuant to Section&nbsp;4.20(a)(i) below), neither the Company nor any of its Subsidiaries is a party to or bound by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any (A)&nbsp;Employment Agreement or Consulting Agreement (with the exception of (1)&nbsp;Employment Agreements and
Consulting Agreements substantially on the Company&#146;s standard forms and on the Company&#146;s standard forms in all material respect and that are terminable <FONT STYLE="white-space:nowrap">at-will</FONT> and without liability on the part of
the Company and (2)&nbsp;any nondisclosure and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">assignment-of-rights</FONT></FONT> agreement on substantially on the Company&#146;s standard forms and on the Company&#146;s standard
forms in all material respect and that are terminable <FONT STYLE="white-space:nowrap">at-will</FONT> and without liability on the part of the Company), (B) Contract the terms of which obligate or may in the future obligate the Company or any of its
Subsidiaries to make any severance or termination to any Company Employee, or (C)&nbsp;that is a Collective Bargaining Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any Contract (A)&nbsp;that creates any partnership, joint venture, strategic alliance, or collaboration arrangement other
than in the ordinary course of business consistent with past practices, (B)&nbsp;pursuant to which any material research and development project for any Key Product is conducted or (C)&nbsp;comprises an arrangement similar to a Contract described in
(A)&nbsp;or (B) above; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any Contract (excluding licenses for commercial <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> computer software that are generally available on nondiscriminatory pricing terms) to which the Company or any of its Subsidiaries is a party or otherwise bound and pursuant to which the Company
or any of its Subsidiaries (A)&nbsp;obtains the right to use, or a covenant not to be sued under, any Key IP or (B)&nbsp;grants the right to use, or a covenant not to be sued under, any Key IP, in each case, other than in the ordinary course of its
business consistent with past practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any active Government Contract other than purchase order agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any Contract with sole-source or single-source suppliers of material tangible goods or services or pursuant to which either
the Company or any of its Subsidiaries has agreed to purchase a minimum quantity of goods in excess of $100,000 used for any Key Product or has agreed to purchase goods used for any Key Product on an exclusive basis from a Third Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) any Contract (A)&nbsp;for the research, development, distribution, marketing, supply, license, collaboration, <FONT
STYLE="white-space:nowrap">co-promotion</FONT> or manufacturing of the Key Products or (B)&nbsp;that otherwise provides for the purchase or sale of products or services by the Company or any of its Subsidiaries in excess of $100,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) any stockholders, investors rights, registration rights, tax receivables or similar or related Contract; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) any Contract pursuant to which the Company or any of its Subsidiaries grants to a Third Party any &#147;most favored
nation&#148; or similar preferential pricing provisions, any exclusive dealing arrangement or any arrangement that grants any right of first refusal, first offer, first negotiation or similar preferential right; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) any Contract (excluding Leases)&nbsp;(A) that obligates the Company (together with its Subsidiaries) to make aggregate
payments in excess of (x) $100,000 in the current or any future calendar year or (y) $200,000 in the aggregate, (B)&nbsp;related to an acquisition or divestiture of assets that contains continuing representations, covenants, indemnities or other
obligations (including &#147;earn out&#148; or other contingent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
payment obligations) or (C)&nbsp;pursuant to which the Company or any of its Subsidiaries has continuing obligations or interests involving the payment of royalties or other amounts calculated
based upon the revenues or income of the Company or any of its Subsidiaries or any other contingent payment obligations of the Company or any of its Subsidiaries, in each case that is not terminable by the Company or its Subsidiaries without penalty
without more than 60 days&#146; notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) any Contract that provides for indemnification of any current or former
officer, director or employee of the Company or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) any Contract (A)&nbsp;for the disposition of
all or any significant portion of the assets or business of the Company or any of its Subsidiaries or (B)&nbsp;for the acquisition, directly or indirectly, of a material portion of the assets or business of any other Third Party (whether by merger,
sale of stock or assets or otherwise), in each case; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) any Contract for indebtedness for borrowed money, any
guarantees thereof or the granting of Liens over any material property or assets of the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) any Contract pursuant to which the Company or any of its Subsidiaries made any loan to a Third Party (excluding, for the
purpose of clarity, a wholly owned Subsidiary of the Company), except for (1)&nbsp;advances to directors, officers and other employees for travel and other business-related expenses incurred in connection with such person&#146;s role at the Company
or one of its Subsidiaries in accordance with the Company&#146;s policies and in the ordinary course of business consistent with past practice, and (2)&nbsp;product loans, leases, evaluation Contracts and the like entered into by the Company or one
of its Subsidiaries in the ordinary course of business consistent with past practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) any Contract containing any
provision or covenant limiting (1)&nbsp;in any material respect the ability of the Company or any of its Subsidiaries (or, after the consummation of the Merger, Parent, the Surviving Corporation or any of their respective Subsidiaries) to
(A)&nbsp;sell any products or services of or to any other Person or in any geographic region, (B)&nbsp;engage in any line of business or (C)&nbsp;compete with or to obtain products or services from any Person, or (2)&nbsp;the ability of any Person
to provide products or services to the Company or any of its Subsidiaries (or, after the consummation of the Merger, Parent, the Surviving Corporation or any of their respective Subsidiaries); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) any Contract requiring the Company, or any successor thereto or acquirer thereof, to make any payment to another Person
related to, in connection with, or as a result of a change of control of the Company (a &#147;<B>Change of Control Payment</B>&#148;) or that gives a Third Party a right to receive or elect to receive a Change of Control Payment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) any Contract that is a Company Outbound License; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) all Contracts pursuant to which a Third Party supplies the Company with any material component of a Key Product or the
Company&#146;s Single Molecule, Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) sequencing technology (or any material component thereof); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) any &#147;material contract&#148; (as such term is defined in Item 601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K)</FONT> or any other Contract that is material to the Company and its Subsidiaries, taken as a whole (it being understood that all such contracts listed in the exhibit index to the Company <FONT
STYLE="white-space:nowrap">10-K</FONT> need not be listed on Section&nbsp;4.20(a)(xviii) of the Company Disclosure Schedule); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) any standstill or similar agreement with respect to any class of equity securities of the Company or any of its
Subsidiaries (all Contracts of the type described in this Section&nbsp;4.20(a) being referred to herein as &#147;<B>Material Contracts</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company has made available to Parent prior to the date of this Agreement a true, correct and complete copy of each Material Contract.
Each of the Material Contracts is valid, binding on the Company or the applicable Subsidiary and in full force and effect. Neither the Company nor any of its Subsidiaries, nor, to the Company&#146;s Knowledge, any other party to a Material Contract,
is in breach or violation in any material respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any provision of, or taken or failed to take any act that, with or without notice, lapse of time, or both, would allow any party to a Material Contract to terminate such Material Contract or
obtain any material remedy thereunder, and as of the date of this Agreement, neither the Company nor any of its Subsidiaries has received notice that it has breached, violated or defaulted in any material respect under any Material Contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_39"></A>SECTION&nbsp;4.21. <I>Finders</I><I>&#146;</I><I> Fees</I>. Except for Centerview Partners LLC (the
&#147;<B>Financial</B> <B>Advisor</B>&#148;), there is no investment banker, broker, finder or other intermediary that has been retained by or is authorized to act on behalf of the Company or any of its Subsidiaries who might be entitled to any fee
or commission from the Company or any of its Affiliates in connection with any of the transactions contemplated by this Agreement. The Company has made available to Parent prior to the date of this Agreement a copy of all agreements pursuant to
which the Financial Advisor is entitled to any fees, expenses or indemnification in connection with any of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_40"></A>SECTION&nbsp;4.22. <I>Opinion of Financial Advisor</I>. The Board of Directors has received the opinion of the
Financial Advisor, to the effect that, as of the date of such opinion, and based upon and subject to the various assumptions made, procedures followed, matters considered, and qualifications and limitations on the review undertaken in preparing such
opinion as set forth therein, the Merger Consideration to be paid in the Merger to the Company&#146;s stockholders (other than Shares owned by Parent, Merger Subsidiary or by the Company (as treasury stock) or dissenting Shares in accordance with
Section&nbsp;2.04) pursuant to this Agreement, is fair from a financial point of view, to such holders. The Company shall deliver a correct and complete copy of the written opinion of the Financial Advisor to Parent solely for informational purposes
promptly after receipt thereof by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_41"></A>SECTION&nbsp;4.23. <I>Antitakeover Statutes</I>. No
&#147;fair price&#148;, &#147;moratorium&#148;, &#147;control share acquisition&#148; or other similar antitakeover statute or regulation enacted under U.S. state or federal laws (with the exception of Section&nbsp;203 of the Delaware Law) is
applicable to the Company, the Shares, the Merger or the transactions contemplated hereby. The action of the Board of Directors in approving this Agreement, the Voting Agreements and the Merger prior to entry into such agreements, arrangements or
understandings is sufficient to render inapplicable to this Agreement, the Voting Agreements, the Merger and the transactions contemplated hereby the restrictions on &#147;business combinations&#148; (as defined in Section&nbsp;203 of the Delaware
Law) as set forth in Section&nbsp;203 of the Delaware Law, except for any approval required as a result of an inaccuracy of the representations of Parent and Merger Subsidiary set forth in Section&nbsp;5.07. As of the date of this Agreement, neither
the Company nor any of its Subsidiaries is a party to any stockholder rights agreement, rights plan, &#147;poison pill&#148; or other similar agreement or plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_42"></A>SECTION&nbsp;4.24. <I>Regulatory</I>. (a)&nbsp;To the Company&#146;s Knowledge, all activities of the Company and
its Subsidiaries that are subject to the jurisdiction of the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) or any comparable Governmental Authority, or subject to the Federal Food, Drug and Cosmetic Act and FDA regulations
promulgated thereunder or similar Applicable Law of any foreign jurisdiction have been conducted in compliance in all material respects with all applicable requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its Subsidiaries has received any written notice or other written communication from FDA or any other
Governmental Authority alleging any violation of any legal or regulatory requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) All products manufactured by the Company and
any of its Subsidiaries are appropriately labeled as &#147;Research Use Only&#148; or RUO pursuant to applicable FDA regulations, and, to the Company&#146;s Knowledge, are promoted, distributed and otherwise commercialized by the Company and its
Subsidiaries in a manner consistent with FDA&#146;s Guidance Document titled &#147;Distribution of In Vitro Diagnostics Products Labeled for Research Use Only or Investigational Use Only&#148; (November 25, 2013). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_43"></A>SECTION&nbsp;4.25. <I>Transactions with Affiliates</I>. No (a)&nbsp;present or former officer or director the
Company or any of its Subsidiaries, (b)&nbsp;beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of 5% or more of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class of securities of the Company or any of its Subsidiaries or (c)&nbsp;Affiliate or &#147;associate&#148; or any member of the &#147;immediate family&#148; (as such terms are respectively
defined in Rules <FONT STYLE="white-space:nowrap">12b-2</FONT> and <FONT STYLE="white-space:nowrap">16a-1</FONT> of the 1934 Act) of any Person described in the foregoing clauses (a)&nbsp;or (b) (each of the foregoing, a &#147;<B>Related
Party</B>&#148;) is a party to any actual or proposed transaction, agreement, commitment, arrangement, understanding or Contract with the Company or has engaged in any transaction with the Company or any of its Subsidiaries since January&nbsp;1,
2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_44"></A>SECTION&nbsp;4.26. <I>Insurance</I>. The Company has delivered or otherwise made available to Parent
prior to the date of this Agreement a copy (or summaries) of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets and operations of the Company and its Subsidiaries. Except as has
not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, all such insurance policies are in full force and effect, all premiums thereon have been timely paid or, if not yet due,
accrued. As of the date of this Agreement, there is no material claim pending under the Company&#146;s or any of its Subsidiaries&#146; insurance policies or fidelity bonds as to which coverage has been questioned, denied or disputed by the
underwriters of such policies or bonds. The Company and its Subsidiaries are in compliance in all material respects with the terms of such policies and bonds and the Company has no Knowledge of any threatened termination of, or material premium
increase with respect to, any of such policies or bonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_45"></A>SECTION&nbsp;4.27. <I>Exclusivity of
Representations and Warranties</I>. (a)&nbsp;The Company, on behalf of itself and its Subsidiaries, acknowledges and agrees that, except for the representations and warranties expressly set forth in ARTICLE 5: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) None of Parent, Merger Subsidiary or any of their respective Subsidiaries (or any other Person) makes, or has made, any
representation or warranty relating to Parent or Merger Subsidiary, their respective Subsidiaries or any of their businesses, operations or otherwise in connection with this Agreement or the Merger; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no Person has been authorized by Parent or Merger Subsidiary, their respective Subsidiaries or any of their respective
Affiliates or Representatives to make any representation or warranty relating to Parent or Merger Subsidiary, their respective Subsidiaries or any of their respective businesses or operations or otherwise in connection with this Agreement or the
Merger, and if made, such representation or warranty must not be relied upon by the Company or any of its Affiliates or Representatives as having been authorized by Parent or Merger Subsidiary, respective Subsidiaries or any of their respective
Affiliates or Representatives (or any other Person); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the representations and warranties made by Parent or Merger
Subsidiary in this Agreement are in lieu of and are exclusive of all other representations and warranties, including any express or implied or as to merchantability or fitness for a particular purpose, and each of Parent and Merger Subsidiary
disclaims any other or implied representations or warranties, notwithstanding the delivery or disclosure to the Company or any of its Affiliates or Representatives of any documentation or other information (including any financial information,
supplemental data or financial projections or other forward-looking statements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company, on behalf of itself and its
Subsidiaries, acknowledges and agrees that, except for the representations and warranties expressly set forth in ARTICLE 5, it is not acting (including, as applicable, by entering into this Agreement or consummating the Merger) in reliance on: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any representation or warranty, express or implied; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any estimate, projection, prediction, data, financial information, memorandum, presentation or other materials or
information provided or addressed to the Company or any of its Affiliates or Representatives, in connection with presentations by or discussions with Parent&#146;s management whether prior to or after the date of this Agreement or in any other forum
or setting; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the accuracy or completeness of any other representation, warranty, estimate, projection,
prediction, data, financial information, memorandum, presentation or other materials or information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_46"></A>ARTICLE 5 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBSIDIARY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Parent and Merger Subsidiary represents and warrants to the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_47"></A>SECTION&nbsp;5.01. <I>Corporate Existence and Power</I>. Each of Parent and Merger Subsidiary has been duly
organized and is validly existing and in good standing under the laws of its jurisdiction of organization and has all organizational powers and all Permits required to carry on its business as now conducted, except for those Permits the absence of
which would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_48">
</A>SECTION&nbsp;5.02. <I>Corporate Authorization</I>. The execution, delivery and performance by Parent and Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary of the transactions contemplated hereby are within
the organizational powers of Parent and Merger Subsidiary and have been duly authorized by all necessary organizational action, subject to the approval and adoption of this Agreement by Parent, in its capacity as the sole stockholder of Merger
Subsidiary, following the execution of this Agreement. Assuming due authorization, execution and delivery by the Company, this Agreement constitutes a valid and binding obligation of each of Parent and Merger Subsidiary, enforceable against Parent
and Merger Subsidiary in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws affecting creditors&#146; rights generally and general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_49"></A>SECTION&nbsp;5.03. <I>Governmental Authorization</I>. The execution, delivery and performance by Parent and
Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary of the transactions contemplated by this Agreement and the Voting Agreement require no action by or filing with respect to Parent or Merger Subsidiary by or
with any Governmental Authority, other than (i)&nbsp;the filing of a certificate of merger with respect to the Merger with the Secretary of State of the State of Delaware, (ii)&nbsp;compliance with any applicable requirements of any Antitrust Law,
(iii)&nbsp;compliance with any applicable requirements of the 1933 Act, the 1934 Act, any other U.S. state or federal or any foreign securities laws and the rules and requirements of Nasdaq and (iv)&nbsp;any actions or filings the absence of which
would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_50"></A>SECTION&nbsp;5.04. <I><FONT STYLE="white-space:nowrap">Non-contravention</FONT></I>. The execution, delivery and
performance by Parent and Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary of the transactions contemplated hereby do not and will not (i)&nbsp;contravene, conflict with, or result in any violation or breach
of any provision of the organizational documents of Parent or Merger Subsidiary, (ii)&nbsp;assuming compliance with the matters referred to in Section&nbsp;5.03, contravene, conflict with or result in a violation or breach of any provision of any
Applicable Law, (iii)&nbsp;assuming compliance with the matters referred to in Section&nbsp;5.03, require any consent or other action by any Person under, constitute a default, or an event that, with or without notice or lapse of time or both, would
constitute a default, under, or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which Parent or any of its Subsidiaries is entitled under any provision of any
Contract binding on Parent or any of its Subsidiaries or any Permit affecting, or relating in any way to, the assets or business of Parent and its Subsidiaries or (iv)&nbsp;result in the creation or imposition of any Lien on any asset of Parent or
any of its Subsidiaries, with only such exceptions, in the case of each of clauses (ii)&nbsp;through (iv), as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_51"></A>SECTION&nbsp;5.05. <I>Disclosure Documents</I>. (a)&nbsp;The information with respect to Parent or any of its
Subsidiaries that Parent supplies to the Company specifically for use in the Company Proxy Statement, at the time the Company Proxy Statement or any amendment or supplement thereto is first mailed to stockholders of the Company, at the time such
stockholders vote on approval and adoption of this Agreement and at the Effective Time, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing in this Section&nbsp;5.05, Parent makes no representation
with respect to statements included or incorporated by reference in the Company Proxy Statement based upon information supplied by or on behalf of the Company for inclusion or incorporation by reference therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_52"></A>SECTION&nbsp;5.06. <I>Financing</I>. Parent has, or will have at the Effective Time, sufficient cash, available
lines of credit or other sources of immediately available funds to enable it to consummate the Merger pursuant to the terms of this Agreement and to pay all fees and expenses of Parent and Merger Subsidiary pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_53"></A>SECTION&nbsp;5.07. <I>Ownership of Company Capital Stock</I>. During the three years prior to the date of this
Agreement, none of Parent, Merger Subsidiary or any of their respective directors, officers, general partners or Affiliates or, to the knowledge of Parent or any of its Affiliates, any employees of Parent, Merger Subsidiary or any of their
Affiliates (a)&nbsp;has &#147;owned&#148; any shares of the Company&#146;s capital stock (including the Shares); or (b)&nbsp;has been an &#147;interested stockholder&#148; (as defined in Section&nbsp;203 of the Delaware Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_54"></A>SECTION&nbsp;5.08. <I>Exclusivity of Representations and Warranties</I>. (a)&nbsp;Each of Parent and Merger
Subsidiary, on behalf of itself and its respective Subsidiaries, acknowledges and agrees that, except for the representations and warranties expressly set forth in ARTICLE 4: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) neither the Company nor any of its Subsidiaries (or any other Person) makes, or has made, any representation or warranty
relating to the Company, its Subsidiaries or any of their respective businesses, operations or otherwise in connection with this Agreement or the Merger; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no Person has been authorized by the Company, any of its Subsidiaries or any of its or their respective Affiliates or
Representatives to make any representation or warranty relating to the Company, its Subsidiaries or any of their respective businesses or operations or otherwise in connection with this Agreement or the Merger, and if made, such representation or
warranty must not be relied upon by Parent, Merger Subsidiary or any of their respective Affiliates or Representatives as having been authorized by the Company, its Subsidiaries or any of its or their respective Affiliates or Representatives (or any
other Person); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the representations and warranties made by the Company in this Agreement are in lieu of and are
exclusive of all other representations and warranties, including any express or implied or as to merchantability or fitness for a particular purpose, and the Company disclaims any other or implied representations or warranties, notwithstanding the
delivery or disclosure to Parent, Merger Subsidiary or any of their respective Affiliates or Representatives of any documentation or other information (including any financial information, supplemental data or financial projections or other
forward-looking statements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent and Merger Subsidiary, on behalf of itself and its respective Subsidiaries, acknowledges
and agrees that, except for the representations and warranties expressly set forth in ARTICLE 4, it is not acting (including, as applicable, by entering into this Agreement or consummating the Merger) in reliance on: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any representation or warranty, express or implied; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any estimate, projection, prediction, data, financial information, memorandum, presentation or other materials or
information provided or addressed to Parent, Merger Subsidiary or any of their respective Affiliates or Representatives, including (A)&nbsp;any materials or information made available in the virtual data room hosted by or on behalf of the Company in
connection with the Merger; (B)&nbsp;in connection with presentations by or discussion with the Company&#146;s management (whether prior to or after the date of this Agreement); or (C)&nbsp;in any other forum or setting; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the accuracy or completeness of any other representation, warranty, estimate, projection, prediction, data, financial
information, memorandum, presentation or other materials or information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_55"></A>ARTICLE 6 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS OF THE COMPANY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_56"></A>SECTION&nbsp;6.01. <I>Conduct of the Company</I>. During the period from the date of
this Agreement until the Effective Time, the Company shall, and shall cause each of its Subsidiaries to, conduct its business in the ordinary course consistent with past practice and in material compliance with Applicable Law and all Material
Contracts. Without limiting the generality of the foregoing, the Company shall, and shall cause its Subsidiaries to, use its reasonable best efforts to (i)&nbsp;preserve intact its present business organization (including preserving all assets
material to the conduct of its business in good repair and condition), (ii) maintain in effect all of its foreign, federal, state and local Permits that are used in, and material to, the conduct of its business, (iii)&nbsp;keep available the
services of its directors, officers, employees and consultants and (iv)&nbsp;maintain the goodwill and existing relationships with its customers, lenders, suppliers and others having significant business relationships with it. Except as expressly
permitted by this Agreement, with the prior written consent of Parent (not to be unreasonably withheld, conditioned or delayed in the cases of clauses (k), (n), (p) or (w)&nbsp;of this Section&nbsp;6.01 to the extent related to such clauses, and
which consent may otherwise be withheld, conditioned or delayed in Parent&#146;s sole discretion), or as set forth in the applicable subsection of Section&nbsp;6.01 of the Company Disclosure Schedule, during the period from the date of this
Agreement until the Effective Time, the Company shall not, nor shall it permit any of its Subsidiaries to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) amend its Charter Documents
(whether by merger, consolidation or otherwise); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) (i) split, combine, subdivide or reclassify any shares of its capital stock
(including the Shares), (ii) declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock, except for dividends payable to the Company or any of its
Subsidiaries or (iii)&nbsp;redeem, repurchase or otherwise acquire, or offer to redeem, repurchase or otherwise acquire, any Company Securities or any Company Subsidiary Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) (i) issue, pledge, dispose of, transfer, encumber, grant, sell or otherwise deliver, or authorize the issuance, pledge, disposal of,
transfer, encumbrance, grant, sale or other delivery of, any Company Securities or Company Subsidiary Securities, other than as required under the Deerfield Agreements or the issuance of (A)&nbsp;any Shares upon the exercise of Company Stock Options
in accordance with their respective terms, (B)&nbsp;any Shares upon the exercise of purchase rights under the ESPP that are outstanding on the date of this Agreement in accordance with their terms on the date of this Agreement, as modified by
actions taken in accordance with this Agreement, and in compliance with the terms of this Agreement, (C)&nbsp;any Shares upon the vesting of any Company RSUs or Company Restricted Shares, in each case in accordance with their respective terms, and
(D)&nbsp;any Company Subsidiary Securities to the Company or any other wholly owned Subsidiary of the Company, or (ii)&nbsp;amend any term of any Company Security or any Company Subsidiary Security (in each case, whether by merger, consolidation or
otherwise), except as may be required by Applicable Law or the terms of any Employee Plan, with respect to any Company Stock Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)
incur any capital expenditures or any obligations or liabilities in respect thereof, except for those contemplated by Section&nbsp;6.01(d) of the Company Disclosure Schedule; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, any assets, securities,
properties, interests or businesses, other than in the ordinary course of business consistent with past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) merge or
consolidate the Company or any Subsidiary of the Company with any Person or adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the Company or any
Subsidiary; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) sell, assign, lease, otherwise transfer, abandon, dispose of or permit to lapse, or
create or incur any Lien (other than Permitted Liens and Liens pursuant to the Deerfield Agreements) on, any of the Company&#146;s or its Subsidiaries&#146; assets (including any Owned Intellectual Property Rights or Licensed Intellectual Property
Rights), securities, properties, interests or businesses, except in the ordinary course of business consistent with past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h)
(i) extend, grant, amend, waive, cancel, abandon, allow to lapse or modify any rights in or to the Owned Registered Intellectual Property Rights in a manner that would not have and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect, (ii)&nbsp;fail to diligently prosecute any material Patent application within (A)&nbsp;the Owned Intellectual Property Rights or (B)&nbsp;the Licensed Intellectual Property Rights for which the Company
or any of its Subsidiaries controls the prosecution thereof as of the date of this Agreement or (iii)&nbsp;divulge, furnish or make accessible any Owned Intellectual Property Rights or Licensed Intellectual Property Rights, in either case that
constitute Trade Secrets the value of which to the Company or any of its Subsidiaries is contingent upon maintaining the confidentiality thereof, other than in the ordinary course of business consistent with past practice to any Third Party that is
subject to an enforceable written agreement or other obligation to maintain the confidentiality of such Trade Secrets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) make any
loans, advances or capital contributions to, or investments in, any Third Party, except for&nbsp;advances to directors, officers and other employees for travel and other business-related expenses incurred in connection with such person&#146;s role
at the Company or one of its Subsidiaries in accordance with the Company&#146;s policies and in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) create, incur, assume, suffer to exist or otherwise become liable with respect to any indebtedness for borrowed money, or guarantees
thereof (except with respect to obligations of wholly owned Subsidiaries of the Company), or issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) (i) renew, amend or modify in any material respect or terminate any Material Contract or enter into any Contract that would constitute a
Material Contract if it were in effect on the date of this Agreement (except the expiration or renewal of any Material Contract in accordance with its terms) or (ii)&nbsp;waive, release or assign any material rights, claims or benefits of the
Company or any of its Subsidiaries under any Material Contract; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) (i) with respect to any current or former Service Provider,
(A)&nbsp;grant or increase any compensation, bonus, severance, retention, change in control, termination pay, welfare or other benefits to (or amend any existing severance pay or termination arrangement), other than in a manner in compliance with
the guidelines set forth on Section&nbsp;6.01(l) of the Company Disclosure Schedule, (B)&nbsp;grant any equity or equity-based awards to, or discretionarily accelerate the vesting or payment of, any such awards held by any current or former Service
Provider, other than in a manner in compliance with the guidelines set forth on Section&nbsp;6.01(l) of the Company Disclosure Schedule or (C)&nbsp;enter into, establish, adopt, amend or terminate any employment, consulting services, severance,
retention, change in control, termination pay, retirement, deferred compensation or other similar agreement or arrangement, except the entry into, establishment or adoption of a consulting services agreement (or similar agreement or arrangement) to
replace a terminating or expiring consulting agreement or arrangement on the same or more favorable terms to the Company, (ii)&nbsp;establish, adopt, enter into, amend (except as required by Applicable Law), or become obligated to contribute to any
Employee Plan or Collective Bargaining Agreement, other than routine amendments that do not result in materially increased administrative costs, (iii)&nbsp;recognize any new union, works council or similar employee representative with respect to any
current or former Service Provider, (iv)&nbsp;establish, adopt or enter into any plan, agreement or arrangement, or otherwise commit to, gross up or indemnify, or otherwise reimburse any current or former Service Provider for any Tax incurred by
such Service Provider, including under Section&nbsp;409A or Section&nbsp;4999 of the Code or (v)&nbsp;hire or engage the services of any individual as a Service Provider, except to fill vacancies (other than at the level of vice president or above)
in the ordinary course of business, consistent with past practice, or terminate the service of any Service Provider other than for &#147;cause&#148;; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) change the Company&#146;s methods, principles, practices or policies of accounting, in
each case except as required by concurrent changes in Applicable Law, GAAP or in Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> after consultation with its independent public accountants; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) commence, compromise, settle, or offer or propose to settle, (i)&nbsp;any Action (except for immaterial monetary damages or in the
ordinary course of business consistent with past practice), (ii) any stockholder Action or dispute against the Company or any of its officers or directors in their capacities as such or (iii)&nbsp;any Action or dispute with a Third Party that
relates to the transactions contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) make or change any material Tax election, change any material Tax accounting period,
adopt or change any material method of Tax accounting, amend any federal income or other material Tax Returns, enter into any closing agreement with respect to material Taxes, settle any material Tax claim, audit or assessment, surrender any right
to claim a material Tax refund, offset or other reduction in Tax liability, or consent to any extension or waiver of the statute of limitations period applicable to any material claim or assessment in respect of Taxes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p) maintain insurance at less than current levels or otherwise in a manner inconsistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(q) assign, transfer, lease, cancel, fail to renew or fail to extend any Permit; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(r) forgive any loans to directors, officers, employees or any of their respective Affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(s) amend or modify the letter of engagement of the Financial Advisor or engage other advisors or consultants in connection with the
transactions contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(t) <FONT STYLE="white-space:nowrap">pre-pay</FONT> any long-term indebtedness for borrowed money; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(u) implement any plant closing, relocation or mass layoff of employees that could implicate the WARN Act or any comparable foreign, state or
local law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) from the date of this Agreement until August&nbsp;1, 2019, (A) solicit or enter into or continue any discussions or
negotiations or enter into any Contract with, any Third Party, or (B)&nbsp;afford access to any Third Party to the business, properties, assets, books, records or other <FONT STYLE="white-space:nowrap">non-public</FONT> information of the Company or
any of its Subsidiaries to any Third Party, in each case in connection with a transaction of the type set forth on Schedule 6.01(v); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(w) agree, resolve or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_57"></A>SECTION&nbsp;6.02. <I>Access to Information</I>. (a)&nbsp;From the date of this Agreement until the Effective
Time and subject to Applicable Law and the Confidentiality Agreement, the Company shall (i)&nbsp;give to Parent and its Representatives reasonable access during regular business hours upon reasonable advance notice to the offices, properties,
assets, books and records of the Company and its Subsidiaries, (ii)&nbsp;furnish to Parent and its Representatives such financial and operating data and other information as such Persons may reasonably request and (iii)&nbsp;instruct the
Representatives of the Company and its Subsidiaries to cooperate with Parent in its investigation of the Company and its Subsidiaries. Notwithstanding the foregoing, the Company shall not be required to provide access to or to disclose information
where such access or disclosure would (A)&nbsp;violate any of its obligations to third parties with respect to confidentiality agreements, (B)&nbsp;jeopardize the attorney-client privilege or attorney work product immunity or (C)&nbsp;contravene any
Applicable Law; provided that the Company has taken reasonable steps to permit inspection of or to disclose such information and to respond in a timely manner to all subsequent queries by Parent and its Representatives based on such information on a
basis that does not violate obligations to third parties, compromise the Company&#146;s attorney-client privilege or other attorney </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
work product immunity with respect thereto or contravene applicable law, including for example, pursuant to a &#147;clean room&#148; or &#147;clean team&#148; arrangement. Any investigation
pursuant to this Section&nbsp;6.02 shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the Company and its Subsidiaries and will be subject to the Company&#146;s reasonable security measures and
insurance requirements and will not include the right to perform invasive testing or soil, air or groundwater sampling, including any Phase I or Phase II environmental site assessments. No information or knowledge obtained in any investigation
pursuant to this Section&nbsp;6.02 shall affect or be deemed to modify any representation or warranty made by the Company hereunder. The information provided pursuant to this Section&nbsp;6.02 will be used solely for the purpose of the Merger and
the other transactions contemplated by this Agreement, and such information will be kept confidential by Parent and Merger Subsidiary and their respective Representatives in accordance with the terms of the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The terms and conditions of the Confidentiality Agreement will apply to any information obtained by Parent or any of its Representatives
in connection with any investigation conducted pursuant to the access contemplated by Section&nbsp;6.02(a). In furtherance of the foregoing, Parent and the Company shall comply with, and shall cause their respective Representatives to comply with,
all of their respective obligations under the Confidentiality Agreement, which shall survive the termination of this Agreement in accordance with the terms set forth therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_58"></A>SECTION&nbsp;6.03. <I>Company Stockholder Meeting</I>. (a)&nbsp;The Company shall take all action necessary to
cause a meeting of its stockholders (the &#147;<B>Company Stockholder Meeting</B>&#148;) to be duly called and held as promptly as reasonably practicable after the SEC or its staff advises that it has no further comments on the Company Proxy
Statement or that the Company may commence mailing the Company Proxy Statement for the purpose of voting on the approval and adoption of this Agreement and shall comply with all Applicable Laws with respect to such meeting and the solicitation of
proxies in connection therewith. The Company shall cause the Company Proxy Statement to be mailed to the stockholders of the Company as of the record date established for the Company Stockholders Meeting as promptly as reasonably practicable
thereafter. Unless an Adverse Recommendation Change shall have occurred, the Company shall use its reasonable best efforts to solicit from the Company&#146;s stockholders proxies in favor of the adoption of this Agreement and shall take all other
action necessary or advisable to secure the Company Stockholder Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;6.04, the Board of Directors shall
make the Company Board Recommendation and not effect an Adverse Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Any adjournment, delay or postponement of the
Company Stockholder Meeting shall require the prior written consent of the Parent, except that the Company shall, without obtaining such prior written consent, be permitted to adjourn, delay or postpone the Company Stockholder Meeting (i)&nbsp;if
there are not holders of a sufficient number of Shares present or represented by proxy at the Company Stockholder Meeting to constitute a quorum at the Company Stockholder Meeting or (ii)&nbsp;if the Company is required to postpone or adjourn the
Company Stockholder Meeting by Applicable Law, order or a request from the SEC or its staff, in each case, with respect to (i), on one occasion for no more than 10 Business Days (with the actual number of days selected by the Company following good
faith consultation with Parent). Without the prior written consent of Parent, the adoption of this Agreement and the transactions contemplated hereby (including the Merger) shall be the only matter (other than matters of procedure and matters
required by Applicable Law to be voted on by the Company&#146;s stockholders in connection with the approval of this Agreement and the transactions contemplated hereby) that the Company shall propose to be acted on by the stockholders of the Company
at the Company Stockholder Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_59"></A>SECTION&nbsp;6.04. <I>No Solicitation; Other Offers</I>.
(a)<U>&nbsp;General Prohibitions</U>. The Company, its Subsidiaries and the persons specified on Section&nbsp;6.04(a) of the Company Disclosure Schedule (such persons, the &#147;<B>Specified Persons</B>&#148;) shall not, and the Company and its
Subsidiaries shall not authorize or direct any of its or their other directors, officers, employees, investment bankers, attorneys, accountants, consultants or other agents, auditors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advisors or other representatives to, directly or indirectly, (i)&nbsp;solicit, initiate, propose, seek or take any action for the purpose of the making, submission or announcement of, or
knowingly facilitate, assist, induce or encourage the making, submission or announcement of, any proposal that constitutes, or that would reasonably be expected to lead to an Acquisition Proposal, (ii)&nbsp;enter into, engage in, participate in or
maintain or continue any discussions or negotiations with, furnish any <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries or afford access to the business, properties, assets, books,
records or other <FONT STYLE="white-space:nowrap">non-public</FONT> information of the Company or any of its Subsidiaries to, or otherwise knowingly cooperate in any way with, or knowingly assist, participate in, facilitate, induce or encourage, any
effort by any Third Party concerning an Acquisition Proposal, (iii)&nbsp;(A) fail to make, qualify, withdraw, withhold, amend or modify in a manner adverse to Parent or Merger Subsidiary, or propose publicly to qualify, withdraw, withhold, amend or
modify, the Company Board Recommendation, (B)&nbsp;adopt, endorse, approve or recommend, or propose publicly to adopt, endorse, approve or recommend, any Acquisition Proposal, (C)&nbsp;publicly make any recommendation in connection with a tender
offer or exchange offer other than a recommendation against such offer or a &#147;stop, look and listen&#148; communication by the Board of Directors (or a committee thereof) to the stockholders of the Company pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under the 1934 Act (or any substantially similar communication) (it being understood that the Board of Directors (or a committee thereof) may refrain from taking a position with respect to an
Acquisition Proposal until the close of business on the tenth Business Day after the commencement of a tender or exchange offer in connection with such Acquisition Proposal without such action being considered a violation of this Section&nbsp;6.04),
(D) subject to clause (C), following the date on which any Acquisition Proposal or material modification thereto is first made public, fail to issue a press release reaffirming the Company Board Recommendation within five Business Days after a
written request by Parent to do so (it being understood that the Company will not be obligated to issue such a press release on more than five occasions) or (E)&nbsp;fail to include the Company Board Recommendation in the Company Proxy Statement
that is mailed to the Company&#146;s stockholders (any of the foregoing in this clause (iii), an &#147;<B>Adverse Recommendation Change</B>&#148;), (iv) approve any transaction under, or any Person becoming an &#147;interested stockholder&#148;
under, Section&nbsp;203 of the Delaware Law, (v)&nbsp;submit any Acquisition Proposal or any matter related thereto to the vote of the stockholders of the Company, or (vi)&nbsp;authorize or commit to do any of the foregoing. It is agreed that
(a)&nbsp;any action taken by a Representative of the Company (other than a Specified Person) that is authorized or directed by the Company or any Specified Person or that a Specified Person is made aware of and does not take action to cease and
that, if taken by the Company, would constitute a breach of this Section&nbsp;6.04, will be deemed to constitute a breach by the Company of this Section&nbsp;6.04; and (b)&nbsp;any action taken by a Specified Person and that, if taken by the
Company, would constitute a breach of this Section&nbsp;6.04, will be deemed to constitute a breach by the Company of this Section&nbsp;6.04. Notwithstanding anything to the contrary in this Section&nbsp;6.04, neither (1)&nbsp;the determination in
itself by the Board of Directors (or any committee thereof) that an Acquisition Proposal constitutes or is reasonably likely to lead to a Superior Proposal nor (2)&nbsp;the delivery in itself by the Company to Parent of any notice contemplated by
Section&nbsp;6.04(c) will constitute an Adverse Recommendation Change or violate this Section&nbsp;6.04(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exceptions</U>.
Notwithstanding Section&nbsp;6.04(a), at any time prior to the receipt of the Company Stockholder Approval, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the
Company, directly or indirectly through its Representatives, may (A)&nbsp;contact any Third Party and its Representatives that, subject to the Company&#146;s compliance with Section&nbsp;6.04(a), has made (and not withdrawn) after the date of this
Agreement a <I>bona fide</I>, written Acquisition Proposal that was not solicited in breach of this Section&nbsp;6.04 to the extent necessary to clarify the terms and conditions of such Acquisition Proposal and engage in negotiations or discussions
with any Third Party and its Representatives that, subject to the Company&#146;s compliance with Section&nbsp;6.04(a), has made (and not withdrawn) after the date of this Agreement a <I>bona fide</I>, written Acquisition Proposal that was not
solicited in breach of this Section&nbsp;6.04 and that the Board of Directors (or a committee thereof) reasonably believes in good faith, after consultation with outside legal counsel and a financial advisor, is or would reasonably be expected to
lead to a Superior Proposal (as defined below) and (B)&nbsp;furnish to such Third Party or its Representatives <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries pursuant to a
confidentiality agreement (a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
copy of which shall be provided solely for informational purposes to Parent) with such Third Party on customary terms for transactions of this type; provided that all such information (to the
extent that such information has not been previously provided or made available to Parent) is provided or made available to Parent, as the case may be, prior to or substantially concurrently with the time it is provided or made available to such
Third Party or its Representatives; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) subject to compliance with Section&nbsp;6.04(d), the Board of Directors (or a
committee thereof) may make an Adverse Recommendation Change in response to any positive material change, effect, development, circumstance, condition, event or occurrence that as of the date of this Agreement was not known to the Board of
Directors, or the consequences of which (based on facts known to the Board of Directors as of the date of this Agreement) were not reasonably foreseeable as of the date of this Agreement (an &#147;<B>Intervening Event</B>&#148;); <I>provided</I>
that in no event shall any of the following constitute or contribute to an Intervening Event: (A)&nbsp;changes in the financial or securities markets or general economic, political or business conditions in the United States or other jurisdictions
in which the Company or any of its Subsidiaries has operations, (B)&nbsp;changes (including changes of Applicable Law) or conditions generally affecting the industry in which the Company and its Subsidiaries operate, (C)&nbsp;changes in GAAP or
other applicable accounting rules or (D)&nbsp;the receipt, existence or terms of any Acquisition Proposal or any inquiry, offer, request or proposal that would reasonably be expected to lead to an Acquisition Proposal; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that in each case referred to in the foregoing clauses (i)&nbsp;and (ii) only if the Board of Directors (or a
committee thereof) determines in good faith, after consultation with outside legal counsel, that the failure to take such action would be inconsistent with its fiduciary duties under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the Board of Directors (or a committee thereof) expressly reaffirms the Company Board Recommendation in such disclosure and public statement (other
than in a customary &#147;stop, look and listen&#148; communication to the Company&#146;s stockholders pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> promulgated under the Exchange Act): (i) nothing in this Agreement will prohibit
the Company or the Board of Directors (or a committee thereof) from taking and disclosing to the Company&#146;s stockholders a position contemplated by Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange Act or
complying with Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> promulgated under the Exchange Act, in each case in response to a tender offer, but, except as otherwise permitted under this Section&nbsp;6.04, such disclosure must be limited to:
(A)&nbsp;making a &#147;stop, look and listen&#148; communication by the Board of Directors (or a committee thereof) to the Company&#146;s stockholders pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under the 1934 Act
(or any substantially similar communication); (B) an express rejection of any applicable Acquisition Proposal complying with Item 1012(a) of Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> promulgated under the 1934 Act; or (C)&nbsp;informing
any Person of the existence of the provisions contained in this Section&nbsp;6.04; and (ii)&nbsp;it is understood and agreed that, for purposes of this Agreement, a factually accurate public statement by the Company or the Board of Directors (or a
committee thereof) that (A)&nbsp;describes the Company&#146;s receipt of an Acquisition Proposal; (B)&nbsp;identifies the Person making such Acquisition Proposal; (C)&nbsp;provides the material terms of such Acquisition Proposal; or
(D)&nbsp;describes the operation of this Agreement with respect thereto will not, in any case, be deemed to be (1)&nbsp;a qualification, withdrawal, withholding, amendment or modification, or proposal by the Board of Directors (or a committee
thereof) to qualify, withdraw, withhold, amend or modify the Company Board Recommendation; (2)&nbsp;an adoption, approval or recommendation with respect to such Acquisition Proposal; or (3)&nbsp;an Adverse Recommendation Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Required Notices</U>. The Board of Directors (or a committee thereof) shall not take any of the actions referred to in
Section&nbsp;6.04(b) unless the Company shall have delivered to Parent a prior written notice advising Parent that it intends to take such action. The Company shall notify Parent promptly (but in no event later than 24 hours) after receipt by the
Company (or, to the actual knowledge of the Specified Persons, any of its Representatives) of any Acquisition Proposal or inquiry from any Third Party related to making a potential Acquisition Proposal or if any
<FONT STYLE="white-space:nowrap">non-public</FONT> information that would reasonably be expected by the Company to relate to the making of a potential Acquisition Proposal is requested from, or any discussions or negotiations are sought to be
initiated or continued with, the Company or, to the actual knowledge of the Specified Persons, any of its Representatives in connection with any Acquisition Proposal. The Company shall provide such notice in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing and shall identify the Third Party making, and the material terms and conditions of, any such Acquisition Proposal, indication or request. The Company shall keep Parent reasonably
informed on a prompt basis concerning the status and details of any such Acquisition Proposal (including any amendments thereto), indication or request, and shall promptly (but in no event later than 24 hours after receipt) provide to Parent copies
of all correspondence and written materials sent by or provided to the Company or any of its Subsidiaries or any of their respective Representatives that describes any terms or conditions of any Acquisition Proposal (as well as written summaries of
any material oral communications addressing such matters). The Company shall provide Parent with at least 24 hours prior notice of any meeting of the Board of Directors (or such lesser notice as is provided to the Board of Directors) at which the
Board of Directors is reasonably expected to consider any Acquisition Proposal. Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of the Company&#146;s compliance with this
Section&nbsp;6.04(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Last Look</U>. Further, the Board of Directors (or a committee thereof) shall not make an Adverse
Recommendation Change pursuant to Section&nbsp;6.04(b) (or terminate this Agreement pursuant to Section&nbsp;10.01(d)(i)), unless (i)&nbsp;if such Adverse Recommendation Change is to be taken in circumstances involving or relating to an Acquisition
Proposal, such Acquisition Proposal constitutes a Superior Proposal, (ii)&nbsp;the Company provides written notice to Parent, at least four Business Days before taking such action of its intention to do so, containing (A)&nbsp;in the case of any
action intended to be taken in circumstances involving or relating to an Acquisition Proposal, the material terms of such Acquisition Proposal, including the most current version of the proposed agreement under which such Acquisition Proposal is
proposed to be consummated and the identity of the Third Party making the Acquisition Proposal or (B)&nbsp;in the case of any action intended to be taken in circumstances not involving or relating to an Acquisition Proposal (including an Intervening
Event), a reasonably detailed description of the underlying facts giving rise to, and the reasons for taking, such action and (iii)&nbsp;after the Company or its Representatives negotiates with Parent in good faith, Parent does not make, within four
Business Days after its receipt of that written notification, an offer that (1)&nbsp;in the case of any action intended to be taken in circumstances involving or relating to an Acquisition Proposal, is at least as favorable to the stockholders of
the Company as such Acquisition Proposal (it being understood and agreed that any amendment to the financial terms or other material terms of such Acquisition Proposal shall require a new written notification from the Company and a new <FONT
STYLE="white-space:nowrap">two-Business</FONT> Day period under this Section&nbsp;6.04(d)) or (2)&nbsp;in the case of any action intended to be taken in circumstances not involving or relating to an Acquisition Proposal (including an Intervening
Event), after receipt of such offer, the Board of Directors (or a committee thereof) determines in good faith, after consultation with outside legal counsel, that the failure to take such action would be inconsistent with its fiduciary duties under
Applicable Law. The Company agrees that, during any applicable four or <FONT STYLE="white-space:nowrap">two-Business</FONT> Day period referred to in this Section&nbsp;6.04(d), the Company and its Representatives shall negotiate in good faith with
Parent and its Representatives regarding any revisions proposed by Parent to the terms of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Definition of Superior Proposal</U>. For purposes of this Agreement, &#147;<B>Superior</B> <B>Proposal</B>&#148; means a <I>bona
fide</I>, written Acquisition Proposal that was not solicited in breach of this Section&nbsp;6.04 (with all percentages in the definition of Acquisition Proposal deemed to refer to 50%) on terms that the Board of Directors (or a committee thereof)
determines, in good faith, after consultation with a financial advisor and outside legal counsel, are more favorable from a financial point of view to the Company&#146;s stockholders than as provided hereunder (taking into account any revisions
proposed by Parent to amend the terms of this Agreement pursuant to Section&nbsp;6.04(d) or otherwise at the time of such determination and after taking into account those factors and matters deemed relevant in good faith by the Board of Directors
(or a committee thereof), including the identity of the Person making the proposal, the likelihood of consummation in accordance with the terms of such proposal and the legal, financial (including the financing terms), regulatory, timing and other
aspects of such proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Obligation of the Company to Terminate Existing Discussions</U>. The Company shall, shall cause its
Subsidiaries to, and shall direct its and their respective Representatives to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any Third Party and its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Representatives conducted on or prior to the date of this Agreement with respect to any Acquisition Proposal, and shall promptly after the date of this Agreement instruct any such Third Party and
its Representatives in possession of confidential information heretofore furnished to such Third Party and its Representatives by or on behalf of the Company or any of its Subsidiaries (and all analyses and other materials prepared by or on behalf
of such Third Party and its Representatives that contain, reflect or analyze that information) to return or destroy all such information as promptly as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_60"></A>SECTION&nbsp;6.05. <I>Section</I><I></I><I>&nbsp;16 Matters</I>. Prior to the Effective Time, the Company and the
Board of Directors (or a duly formed committee thereof satisfying the applicable requirements of the 1934 Act) shall take all such steps as may be reasonably required or appropriate to cause any dispositions of Shares (including derivative
securities with respect to such Shares) resulting from the transactions contemplated by this Agreement by each individual who is subject to the reporting requirements of Section&nbsp;16(a) of the 1934 Act with respect to the Company to be exempt
under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the 1934 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_61"></A>SECTION&nbsp;6.06.
<I>Stock Exchange Delisting; 1934 Act Deregistration</I>. Prior to the Effective Time, the Company shall cooperate with Parent and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things,
reasonably necessary, proper or advisable on its part under Applicable Law and rules and policies of Nasdaq to enable the delisting by the Surviving Corporation of the Shares from Nasdaq and the deregistration of the Shares under the 1934 Act as
promptly as practicable after the Effective Time, and in any event no more than 10 days after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_62"></A>SECTION&nbsp;6.07. <I>Takeover Statutes</I>. The Company and the Board of Directors shall, to the extent
permitted by Applicable Law, use their best efforts (a)&nbsp;to take all actions necessary so that no &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;moratorium&#148; or other antitakeover or similar statute or regulation
becomes applicable to any of the transactions contemplated by this Agreement and (b)&nbsp;if any such antitakeover or similar statute or regulation becomes applicable to the transactions contemplated by this Agreement, to grant such approvals and
take all actions necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms contemplated herein and otherwise to take all such other actions as are reasonably necessary to eliminate
or minimize the effects of any such statute or regulation on the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_63"></A>SECTION&nbsp;6.08. <I>Interim Communications by the Company</I>. Prior to making any communications generally
disseminated to the employees, customers, lenders, suppliers or other Persons having material business relationships with the Company or its Subsidiaries relating to the transactions contemplated by this Agreement, the Company shall provide Parent
with prior written notice of the intended communication sufficiently reasonably in advance of dissemination of such communication so that Parent shall have the reasonable opportunity to review such communication and provide comments, which the
Company shall consider in good faith. This Section&nbsp;6.08 will not apply to communications primarily related to an Acquisition Proposal or Superior Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_64"></A>SECTION&nbsp;6.09. <I>Cooperation</I>. On and after the date of this Agreement, the Company shall cooperate with
Parent in good faith to identify and retain Key Employees and cooperate, if requested by Parent, to take reasonable steps to attempt to retain such employees. In addition, on and after the date of this Agreement, the Company shall cooperate with
Parent to take all actions reasonably requested by the Parent to assist in the transition, job mapping, and onboarding of Company Employees, including, but not limited to, providing information to be used in creating and delivering of offers of
employment to Company Employees, encouraging such Company Employees to accept offers of employment with Parent and tracking such acceptances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_65"></A>SECTION&nbsp;6.10. <I>Golden Parachute Payments</I>. To the extent any payments or benefits made with respect to,
or which could arise as a result of, this Agreement or the transactions contemplated hereby, could be characterized as an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G(b)(1) of the Internal Revenue Code, the Company
shall, prior to the Closing Date, cooperate in good faith with Parent to effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable measures to identify and minimize any such payments or benefits from being characterized as &#147;excess parachute payments&#148; within the meaning of Section&nbsp;280G(b)(1) of the
Internal Revenue Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_66"></A>SECTION&nbsp;6.11. <I>WARN Act</I>. Not later than the Closing Date, the Company
shall provide Parent with a list of employees who have suffered an &#147;employment loss&#148; (as defined in the WARN Act or any similar term defined under comparable foreign, state or local law) in the 90 days preceding the Closing Date or had a
reduction in hours of a least 50% in the 180 days preceding the Closing Date, each identified by date of employment loss or reduction in hours, employing entity and facility location. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_67"></A>SECTION&nbsp;6.12. <I>Employee Plans</I>. Prior to the Effective Time, the Company shall take all actions that
may be necessary or appropriate to cause the Employee Plans set forth in Section&nbsp;6.12 of the Company Disclosure Schedule to terminate as of the date immediately preceding the Closing Date, unless notice is provided to the Company at least 30
days prior to the Effective Time that such Employee Plan shall not be terminated. Upon request by Parent in writing prior to the Closing Date, the Company shall consider in good faith any request by Parent to amend, freeze, terminate or modify any
other Employee Plan effective upon the Closing Date (or at such different time mutually agreed to by the parties) and consistent with Applicable Law. The Company shall reasonably cooperate with Parent to provide information relevant to this
Section&nbsp;6.12 regarding Employee Plans. The form and substance of the resolutions, plan amendments, notices and other documents prepared to effectuate the actions set forth in this Section&nbsp;6.12 shall be subject to the prior review and
written approval of Parent (which approval will not be unreasonably withheld, conditioned or delayed) and prior to the Closing Date, the Company shall provide Parent with the final documentation evidencing that the actions contemplated herein have
been effectuated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_68"></A>SECTION&nbsp;6.13. <I>Tax Sharing Agreements</I>. Any Tax Sharing Agreement to which the
Company or any of its Subsidiaries is party (other than any Tax Sharing Agreement to which only the Company or its Subsidiaries is party) shall be terminated with respect to the Company and each Subsidiary as of the Closing Date and have no further
effect thereafter. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_69"></A>ARTICLE 7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS OF PARENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent
agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_70"></A>SECTION&nbsp;7.01. <I>Obligations of Merger Subsidiary</I>. Parent shall take all action
necessary to cause Merger Subsidiary to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_71"></A>SECTION&nbsp;7.02. <I>Voting of Shares</I>. Parent shall vote all Shares beneficially owned or controlled by it
or any of its Subsidiaries in favor of adoption of this Agreement at the Company Stockholder Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_72"></A>SECTION&nbsp;7.03. <I>Director and Officer Liability</I>. Parent shall cause the Surviving Corporation, and the
Surviving Corporation hereby agrees, to do the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) For six years after the Effective Time, the Surviving Corporation shall
indemnify and hold harmless the present and former officers and directors of the Company (each, an &#147;<B>Indemnified Person</B>&#148;) against any costs, expenses (including reasonable attorneys&#146; fees), judgments, fines, losses, claims,
damages, liabilities and amounts paid in settlement incurred in connection with any claim, action, suit, proceeding or investigation, of whatever nature, in respect of, arising out of or related to such Indemnified Person&#146;s service as a
director or officer of the Company in respect of acts or omissions occurring at or prior to the Effective Time (including, for the avoidance of doubt, in connection with the Merger and the other transactions contemplated hereby), whether asserted or
claimed prior to, at or after the Effective Time, to the fullest extent permitted by the Delaware Law or any other Applicable Law or provided under the Company&#146;s certificate of incorporation and bylaws in effect on the date of this Agreement;
provided that such indemnification shall be subject to any limitation imposed from time to time under Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) For six years after the Effective Time, maintain in effect provisions in the Surviving
Corporation&#146;s certificate of incorporation and bylaws (or in such documents of any successor to the business of the Surviving Corporation) regarding elimination of liability and indemnification of, and advancement of expenses to, Indemnified
Persons that are no less advantageous to the intended beneficiaries than the corresponding provisions in existence on the date of this Agreement (it being understood that if any claim is asserted against any individual entitled to the protections of
such provisions within such <FONT STYLE="white-space:nowrap">six-year</FONT> period, then such provisions shall not be modified until the final disposition of such claims). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Surviving Corporation shall either (i)&nbsp;maintain in effect for a period of six years after the Effective Time, if available, the
directors&#146; and officers&#146; insurance policies and fiduciary liability insurance policies of the Company (collectively, &#147;<B>D&amp;O Insurance</B>&#148;) in place as of the date of this Agreement or (ii)&nbsp;purchase comparable D&amp;O
Insurance or &#147;tail&#148; insurance policies with a claims period of six years from the Effective Time, with terms, conditions, retentions and limits of liability that are at least as favorable as those contained in the Company&#146;s D&amp;O
Insurance policies in effect as of the date of this Agreement, in each case with respect to any claim related to any period of time at or prior to the Effective Time; provided that in no event shall Parent or the Surviving Corporation be required to
expend for such policies pursuant to this Section&nbsp;7.03(c) a premium amount in excess of 300% of the annual premium amount paid by the Company for such insurance in its last full fiscal year prior to the date of this Agreement, which amount is
set forth in Section&nbsp;7.03(c) of the Company Disclosure Schedule. If such insurance coverage cannot be obtained at an annual premium equal to or less than such amount, the Surviving Corporation will obtain directors&#146; and officers&#146;
insurance (or &#147;tail&#148; coverage) with the greatest coverage available, with respect to matters occurring prior to the Effective Time, for a cost not exceeding such amount from an insurance carrier with a comparable credit rating as the
Company&#146;s directors&#146; and officers&#146; liability insurance carrier as of the date of this Agreement. Prior to the Effective Time, and in lieu of maintaining the D&amp;O Insurance pursuant to this Section&nbsp;7.03(c), the Company may (or,
if the Parent requests, the Company will) purchase a prepaid &#147;tail&#148; policy (the &#147;<B>Tail Policy</B>&#148;) with respect to the D&amp;O Insurance from an insurance carrier with a comparable credit rating as the Company&#146;s current
directors&#146; and officers&#146; liability insurance carrier so long as the cost for the Tail Policy does not exceed 300% of the annual premium amount paid by the Company for such insurance in its last full fiscal year prior to the date of this
Agreement. If the Company purchases the Tail Policy prior to the Effective Time, then the Surviving Corporation will (and Parent will cause the Surviving Corporation to) maintain the Tail Policy in full force and effect and continue to honor its
obligations thereunder for so long as the Tail Policy is in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) If Parent, the Surviving Corporation or any of its
successors or assigns (i)&nbsp;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfers or conveys all or substantially all of its
properties and assets to any Person, then, and in each such case, to the extent necessary, proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, assume the obligations set forth
in this Section&nbsp;7.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The rights of each Indemnified Person under this Section&nbsp;7.03 shall be in addition to any other
rights such Person may have under the certificate of incorporation or bylaws of the Company or any of its Subsidiaries, under the Delaware Law or any other Applicable Law, or under any agreement of any Indemnified Person with the Company or any of
its Subsidiaries and are intended for the benefit of, and shall be enforceable by, such Indemnified Person and such Indemnified Person&#146;s heirs, executors or similar relatives. These rights shall survive consummation of the Merger and shall not
be amended in a manner that is adverse to the Indemnified Persons without the prior written consent of the Indemnified Persons affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_73"></A>SECTION&nbsp;7.04. <I>Employee Matters</I>. (a)&nbsp;For the period commencing on the Effective Time and ending
on the first anniversary thereof (or, if shorter, during the period of employment), Parent shall, or shall cause the Surviving Corporation to, provide Continuing Employees with (i)&nbsp;an aggregate base salary or base wages and cash target bonus
opportunity no less than the aggregate base salary or base wages and cash target bonus opportunity provided to such Continuing Employee immediately prior to the Effective Time and (ii)&nbsp;benefits </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(other than any equity or equity-based and change in control or transaction-based compensation or benefits or severance pay or benefits) that are substantially comparable in the aggregate to
either (A)&nbsp;those offered to similarly situated employees of Parent or Parent&#146;s Affiliates or (B)&nbsp;those offered by the Company to the Continuing Employees as of immediately prior to the Effective Time, with the determination of the
employee benefits under clause (ii)&nbsp;to be made by Parent from time to time in its sole and absolute discretion, based on Parent&#146;s evaluation of the nature and scope of the Continuing Employees&#146; duties, principal locations, grade level
and performance, among other things. Notwithstanding the foregoing, neither Parent nor any of its Affiliates shall have any obligation to issue, or adopt any plans or arrangements providing for the issuance of, shares of capital stock, warrants,
options, stock appreciation rights or other rights in respect of any shares of capital stock of any entity or any securities convertible into, or exchangeable or exercisable for, such shares pursuant to any such plans or arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) With respect to any &#147;employee benefit plan&#148; (as defined in Section&nbsp;3(3) of ERISA) maintained by Parent or any of its
Subsidiaries in which any Continuing Employee will participate on or after the Effective Time, but excluding (i)&nbsp;any retiree healthcare or life insurance plans or programs maintained by Parent or any of its Subsidiaries and (ii)&nbsp;any equity
compensation arrangement (the &#147;<B>Parent Benefit Plans</B>&#148;), Parent shall, or shall cause the Surviving Corporation to, recognize all service with the Company or any Subsidiary rendered prior to the Effective Time by Continuing Employees
who are active Company Employees immediately prior to the Closing, for purposes of vesting and eligibility (but not benefit accrual), to the extent such Continuing Employees otherwise would be eligible to participate or vest under the terms of such
Parent Benefit Plans; <I>provided</I> that service of a Continuing Employee prior to the Effective Time shall not be recognized for the purpose of any entitlement to participate in, or receive benefits with respect to, (i)&nbsp;any retiree medical
programs or other retiree welfare benefit programs maintained by Parent or its Affiliates in which any Continuing Employee participates after the Effective Time or (ii)&nbsp;for purposes of early retirement subsidies under any Parent Benefit Plan.
In no event shall anything contained in this Section&nbsp;7.04(b) result in any duplication of benefits for the same period of service. In addition, Parent shall use commercially reasonable efforts to (A)&nbsp;waive, or cause to be waived, any
limitations on benefits relating to <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions to the same extent such limitations are waived under any comparable plan of the Company or its Subsidiaries applicable to such Continuing Employee
prior to the Effective Time and (B)&nbsp;recognize, for purposes of satisfying the deductibles, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets,
<FONT STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments under its medical, dental and vision plans, the deductibles, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> limits, offsets, <FONT STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance,</FONT> or similar costs or payments recognized under the corresponding
Employee Plan with respect to a Continuing Employee (and his or her eligible dependents) for the plan year in which the Effective Time occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) This Section&nbsp;7.04 shall be binding upon and inure solely to the benefit of each of the parties to this Agreement, and nothing in this
Section&nbsp;7.04, express or implied, shall confer upon any Service Provider or former Service Provider (including any beneficiary or dependent of such Service Provider or former Service Provider), or any other Person any rights or remedies of any
nature whatsoever under or by reason of this Section&nbsp;7.04. Nothing contained herein, express or implied shall: (i)&nbsp;be construed to establish, amend or modify any Employee Plan; (ii)&nbsp;alter or limit the ability of the Surviving
Corporation, Parent or any of their respective Affiliates to amend, modify or terminate any Employee Plan at any time assumed, established, sponsored or maintained by any of them; or (iii)&nbsp;prevent the Surviving Corporation, Parent or any of
their respective Affiliates from terminating the employment of any Service Provider (including any Continuing Employee) following the Effective Time. This Section&nbsp;7.04 shall not create any right in any Service Provider (including any Continuing
Employee) or any other Person to any continued employment with the Company, Surviving Corporation, Parent or any of their respective Subsidiaries or Affiliates or compensation or benefits of any nature or kind whatsoever, or otherwise alter any
existing <FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship between any Service Provider and the Company or Surviving Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_74"></A>ARTICLE 8 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS OF PARENT AND THE COMPANY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto agree that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_75">
</A>SECTION&nbsp;8.01. <I>Reasonable Best Efforts</I>. (a)&nbsp;Subject to the terms and conditions of this Agreement, the Company and Parent shall use their reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to
be done, and assist and cooperate with the other parties hereto in doing, all things necessary, proper or advisable under Applicable Law to consummate the transactions contemplated by this Agreement, including (i)&nbsp;preparing and filing as
promptly as practicable with any Governmental Authority or other Third Party all documentation to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents and
(ii)&nbsp;obtaining and maintaining all Permits required to be obtained from any Governmental Authority or other Third Party that are necessary, proper or advisable to consummate the transactions contemplated by this Agreement. Nothing in this
Agreement shall require Parent or any of its Subsidiaries to, and, except with the prior written consent of Parent, the Company shall not take any action to, and shall not allow any of its Subsidiaries to, (A)&nbsp;enter into any settlement,
undertaking, consent decree, stipulation or agreement with any Governmental Authority in connection with the transactions contemplated by this Agreement, (B)&nbsp;agree, propose, negotiate, offer, sell, divest, lease, license, transfer, dispose of
or otherwise encumber or hold separate (including by establishing a trust, licensing any Intellectual Property Rights or otherwise), or take any other action (including by providing its consent to permit the Company or any of its Subsidiaries to
take any of the foregoing actions), or otherwise proffer or agree to do any of the foregoing, with respect to any of the businesses, assets or properties of Parent, the Company, the Surviving Corporation or any of their respective Affiliates or
Subsidiaries, (C)&nbsp;terminate any existing relationships or contractual rights or obligations or (D)&nbsp;otherwise offer to take or offer to commit to take any action that would limit Parent&#146;s or any of its Affiliates&#146; freedom of
action with respect to, or ability to retain, operate or otherwise exercise full rights of ownership with respect to, businesses, assets or properties of Parent, the Company, the Surviving Corporation or any of their respective Affiliates or
Subsidiaries (or equity interests held by Parent or any of its Affiliates in entities with businesses, assets or properties). At the request of Parent, the Company shall agree to divest, hold separate or otherwise take or commit to take any action
that limits its freedom of action with respect to, or its ability to retain, any of the businesses, services, or assets of the Company or any of its Subsidiaries (but, absent such request, the Company shall not take any such action), provided that
any such action shall be conditioned upon the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In furtherance and not in
limitation of the foregoing, each of Parent and the Company shall (i)&nbsp;make an appropriate filing of a Notification and Report Form pursuant to the HSR Act with respect to the transactions contemplated hereby as promptly as practicable, and in
any event within fifteen (15)&nbsp;Business Days after the date of this Agreement, (ii)&nbsp;make appropriate filings pursuant to any other Antitrust Law with respect to the transactions contemplated hereby as promptly as practicable after the date
of this Agreement and (iii)&nbsp;supply as promptly as practicable any additional information and documentary material that may be requested and to use their reasonable best efforts to take all other actions necessary to cause the expiration or
termination of the applicable waiting periods under any Antitrust Law as soon as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by Applicable
Law, each of Parent and the Company shall use its reasonable best efforts to (i)&nbsp;keep the other party apprised of the status of matters relating to the completion of the transaction and the other transactions contemplated by this Agreement and
cooperate in all respects with each other in connection with any filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party, (ii)&nbsp;promptly inform the other party of any
communication received from, or given to, any Governmental Authority and of any material communication received or given in connection with any proceeding by a private party, in each case regarding any of the transactions contemplated hereby, and
(iii)&nbsp;permit the other party to review any communication given by it to, and consult with each other in advance of any meeting or conference with, any such Governmental Authority or, in connection with any proceeding by a private party, with
any other Person, and to the extent reasonably practicable, give the other party the opportunity to attend and participate in such meetings and conferences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_76"></A>SECTION&nbsp;8.02. <I>Company Proxy Statement</I>. (a)&nbsp;As
promptly as reasonably practicable (but in any event by December&nbsp;3, 2018), the Company shall prepare and file the Company Proxy Statement with the SEC. The Company shall use its reasonable best efforts to cause the Company Proxy Statement to be
cleared by the SEC as promptly as reasonably practicable after the date of this Agreement and to be mailed to the Company&#146;s stockholders as promptly as reasonably practicable thereafter. The Company shall use its reasonable best efforts to
ensure that the Company Proxy Statement, and any amendments or supplements thereto, comply in all material respects with the rules and regulations promulgated by the SEC under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company and Parent shall cooperate with one another (i)&nbsp;in connection with the preparation of the Company Proxy Statement and
(ii)&nbsp;in determining whether any action by or in respect of, or filing with, any Governmental Authority is required, or any actions, consents, approvals or waivers are required to be obtained from parties to any material Contracts or in
connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company and Parent shall use their respective reasonable best efforts to take such actions or make any such filings and furnish information
required in connection therewith or with the Company Proxy Statement, and timely seek to obtain such actions, consents, approvals or waivers from parties under such material Contracts. Notwithstanding (i)&nbsp;any Adverse Recommendation Change,
(ii)&nbsp;the public proposal or announcement or other submission to the Company or any of its Representatives of an Acquisition Proposal or (iii)&nbsp;anything in this Agreement to the contrary, unless this Agreement is terminated in accordance
with its terms, the obligations of the Company under this Section&nbsp;
8.02 shall continue in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_77"></A>SECTION&nbsp;8.03. <I>Public Announcements</I>. The initial
press release concerning this Agreement and the transactions contemplated hereby shall be a joint press release to be reasonably agreed upon by the Company and Parent. Following such initial press release, Parent and the Company shall consult with
each other before issuing any additional press release, making any other public statement or scheduling any press conference, conference call or meeting with investors or analysts with respect to this Agreement or the transactions contemplated
hereby and, except as may be required by Applicable Law or any listing agreement with or rule of any national securities exchange or association, shall not issue any such press release, make any such other public statement or schedule any such press
conference, conference call or meeting before such consultation; <I>provided, however</I>, that the restrictions set forth in this Section&nbsp;8.03 shall not apply to any release or public statement (a)&nbsp;made or proposed to be made by the
Company in compliance with Section&nbsp;6.04 with respect to the matters contemplated thereby (or by Parent in response thereto) or (b)&nbsp;in connection with any dispute between the parties regarding this Agreement, the Merger or the other
transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_78"></A>SECTION&nbsp;8.04. <I>Further Assurances</I>. At and after the Effective
Time, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name and on behalf of the Company or Merger Subsidiary, any agreements, instruments, deeds, bills of sale, assignments, assurances or
other documents and to take and do, in the name and on behalf of the Company or Merger Subsidiary, any other actions and things to vest, perfect or confirm of record or otherwise in the Surviving Corporation any and all right, title and interest in,
to and under any of the rights, properties or assets of the Company acquired or to be acquired by the Surviving Corporation as a result of, or in connection with, the Merger. From and after the date of this Agreement, the Company and its
Subsidiaries shall cooperate with Parent in the preparation of any reports of Parent as may be required to be filed with the SEC with respect to the consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_79"></A>SECTION&nbsp;8.05. <I>Notices of Certain Events</I>. (a)&nbsp;At all times during the period commencing with the
execution and delivery of this Agreement and continuing until the earlier to occur of the (1)&nbsp;termination of this Agreement pursuant to ARTICLE 10 and (2)&nbsp;Effective Time, the Company will give prompt notice to Parent upon becoming aware
that any representation or warranty made by it in this Agreement has become untrue or inaccurate in any material respect, or of any failure by the Company to comply with or satisfy in any material respect any covenant, condition or agreement to be
complied with or satisfied by it pursuant to this Agreement, in each case if and only to the extent that such untruth, inaccuracy, or failure would reasonably be expected to cause any of the conditions to the obligations of Parent and Merger
Subsidiary to consummate the Merger set forth in Section&nbsp;9.02 (other than Section&nbsp;9.02(v) and Section&nbsp;9.02(vi)) to fail to be satisfied at the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At all times during the period commencing with the execution and delivery of this
Agreement and continuing until the earlier to occur of the (1)&nbsp;termination of this Agreement pursuant to ARTICLE 10 and (2)&nbsp;Effective Time, Parent will give prompt notice to the Company upon becoming aware that any representation or
warranty made by Parent or Merger Subsidiary in this Agreement has become untrue or inaccurate in any material respect, or of any failure by Parent or Merger Subsidiary to comply with or satisfy in any material respect any covenant, condition or
agreement to be complied with or satisfied by it pursuant to this Agreement, in each case if and only to the extent that such untruth, inaccuracy or failure would reasonably be expected to cause any of the conditions to the obligations of the
Company to consummate the Merger set forth in Section&nbsp;9.03 to fail to be satisfied at the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In no event shall
(i)&nbsp;the delivery of any notice by a party pursuant to this Section&nbsp;8.05 limit or otherwise affect the respective rights, remedies, obligations, representations, warranties, covenants or agreements of the parties or the conditions to the
obligations of the parties under this Agreement or (ii)&nbsp;disclosure by the Company or Parent be deemed to amend or supplement the Company Disclosure Schedule or constitute an exception to any representation or warranty of the disclosing party.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_80"></A>ARTICLE 9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONDITIONS TO THE MERGER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_81">
</A>SECTION&nbsp;9.01. <I>Conditions to the Obligations of Each Party</I>. The obligations of the Company, Parent and Merger Subsidiary to consummate the Merger are subject to the satisfaction or waiver of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) the Company Stockholder Approval shall have been obtained in accordance with the Delaware Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the waiting period (and any extension thereof) applicable to the Merger under the HSR Act shall have been terminated or shall have
expired, and all required filings shall have been made and all required approvals obtained (or waiting periods expired or terminated) under the Antitrust Laws of the Key Jurisdictions; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) (A) there shall be no Applicable Law in any Key Jurisdiction and (B)&nbsp;no Governmental Authority in any Key Jurisdiction having
jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any injunction, order or decree, whether temporary, preliminary or permanent, that, in each case, remains in effect and makes illegal, enjoins or
otherwise prohibits the consummation of the Merger or the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_82"></A>SECTION&nbsp;9.02. <I>Conditions to the Obligations of Parent and Merger Subsidiary</I>. The obligations of
Parent and Merger Subsidiary to consummate the Merger are subject to the satisfaction of the following further conditions: (i)&nbsp;the Company shall have performed in all material respects all of its obligations hereunder required to be performed
by it at or prior to the Effective Time; (ii)&nbsp;the representations and warranties of the Company contained in Section&nbsp;4.05(a) (Capitalization) and the first two sentences of Section&nbsp;4.05(c) (Capitalization) shall be true in all
respects (other than inaccuracies that are in the aggregate <I>de minimis</I>); (iii) the representations and warranties of the Company contained in Sections 4.01 (Corporate Existence and Power), Section&nbsp;4.02 (Corporate Authorization),
Section&nbsp;4.05 (Capitalization) (except as provided in Section&nbsp;9.02(ii)), Section&nbsp;4.21 (Finders&#146; Fees), Section&nbsp;4.22 (Opinion of Financial Advisor) and Section&nbsp;4.23 (Antitakeover Statutes) shall be true in all material
respects at and as of immediately prior to the Effective Time as if made at and as of such time (other than such representations and warranties that by their terms address matters only as of another specified time, which shall be true in all
material respects only at and as of such time); (iv) the other representations and warranties of the Company contained in this Agreement (disregarding all materiality and Company Material Adverse Effect qualifications contained therein) shall be
true at and as of immediately prior to the Effective Time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as if made at and as of such time (other than representations and warranties that by their terms address matters only as of another specified time, which shall be true only at and as of such
time), with, in the case of this clause (iv)&nbsp;only, only such exceptions as have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; (v)&nbsp;Parent shall have received a
certificate signed by an executive officer of the Company to the foregoing effect; (vi)&nbsp;from and after the date of this Agreement, there shall not have occurred any event, circumstance, change, occurrence, development, condition or effect that,
has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect that is continuing; and (vii)(A) there shall be no Applicable Law in any Specified Jurisdiction or Other Jurisdiction and
(B)&nbsp;no Governmental Authority in any Specified Jurisdiction or Other Jurisdiction having jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any injunction, order or decree, whether temporary,
preliminary or permanent, that, in each case, remains in effect and makes illegal, enjoins or otherwise prohibits the consummation of the Merger or the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_83"></A>SECTION&nbsp;9.03. <I>Conditions to the Obligations of the Company</I>. The obligations of the Company to
consummate the Merger are subject to the satisfaction of the following further conditions: (i)&nbsp;each of Parent and Merger Subsidiary shall have performed in all material respects all of its obligations hereunder required to be performed by it at
or prior to the Effective Time; (ii)&nbsp;(a) the representations and warranties of Parent contained in Section&nbsp;5.02 (Corporate Authorization) shall be true in all material respects at and as of immediately prior to the Effective Time as if
made at and as of such time (other than such representations and warranties that by their terms address matters only as of another specified time, which shall be true in all respects only at and as of such time) and (b)&nbsp;the other
representations and warranties of Parent contained in this Agreement (disregarding all materiality and Parent Material Adverse Effect qualifications contained therein) shall be true at and as of immediately prior to the Effective Time as if made at
and as of such time (other than representations and warranties that by their terms address matters only as of another specified time, which shall be true only at and as of such time), with, in the case of this clause (b)&nbsp;only, only such
exceptions as have not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect; and (iii)&nbsp;the Company shall have received a certificate signed by an executive officer of Parent to the
foregoing effect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_84"></A>ARTICLE 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TERMINATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_85">
</A>SECTION&nbsp;10.01. <I>Termination</I>. This Agreement may be terminated and the transactions contemplated hereby may be abandoned: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by mutual written agreement of the Company and Parent at any time prior to the Effective Time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either the Company or Parent, if: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Effective Time shall not have occurred on or before November&nbsp;1, 2019 (the &#147;<B>End Time</B>&#148;);
<I>provided</I> that the right to terminate this Agreement pursuant to this Section&nbsp;10.01(b)(i) shall not be available to any party whose breach of any representation, warranty, covenant, agreement or provision of this Agreement has resulted in
the failure of the Effective Time to occur by the End Time; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) at the Company Stockholder Meeting (including any
adjournment or postponement thereof), the Company Stockholder Approval shall not have been obtained; <I>provided </I>that the right to terminate this Agreement pursuant to this Section&nbsp;10.01(b)(ii) shall not be available to any party whose
breach of any representation, warranty, covenant, agreement or provision of this Agreement has resulted in the failure to obtain the Company Stockholder Approval at the Company Stockholder Meeting (including any adjournment or postponement thereof);
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Parent, if, prior to the Effective Time: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an Adverse Recommendation Change shall have occurred; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (A) the Company shall have breached or failed to perform any
representation, warranty, covenant or agreement set forth in this Agreement, which breach or failure to perform would cause the conditions set forth in Section&nbsp;9.01 or Section&nbsp;9.02 not to be satisfied, and such breach or failure is
incapable of being cured by the End Time or, if curable by the End Time, is not cured by the Company within 30 days of receipt by the Company of written notice of such breach or failure or (B)&nbsp;the Company shall have materially breached any of
its covenants and agreements under Section&nbsp;6.04; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the Company, if, prior to the Effective Time: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Board of Directors shall have made an Adverse Recommendation Change in compliance with the terms of this Agreement,
including Section&nbsp;6.04, in order to enter into a definitive, written agreement immediately following such termination in respect of a Superior Proposal; <I>provided</I> that such termination shall only occur if the Company shall have paid (or
caused to be paid) any amounts due pursuant to Section&nbsp;11.04(b) in accordance with the terms, and at the times, specified therein; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Parent or Merger Subsidiary shall have materially breached or failed to perform any representation, warranty, covenant or
agreement set forth in this Agreement, which breach or failure to perform would cause the conditions set forth in Section&nbsp;9.01 or Section&nbsp;9.03 not to be satisfied, and such breach or failure is incapable of being cured by the End Time or,
if curable by the End Time, is not cured by Parent within 30 days of receipt by Parent of written notice of such breach or failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The party desiring to
terminate this Agreement pursuant to this Section&nbsp;10.01 (other than pursuant to Section&nbsp;10.01(a)) shall give written notice of such termination to the other parties, which written notice shall specify the provision of this
Section&nbsp;10.01 pursuant to which such termination is being effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_86"></A>SECTION&nbsp;10.02. <I>Effect of
Termination</I>. If this Agreement is terminated pursuant to Section&nbsp;10.01, this Agreement shall become void and of no effect without liability of any party to this Agreement (or any stockholder, director, officer, employee, agent, consultant
or Representative of such party) to any other party hereto; <I>provided</I> that, if such termination shall result from the (a)&nbsp;intentional failure of any party to fulfill a condition to the performance of the obligations of another party,
(b)&nbsp;material breach by any party of the covenants required to be performed by such party pursuant to this Agreement or (c)&nbsp;willful and intentional breach by any party of the representations and warranties made by such party pursuant to
this Agreement, then such failing or breaching party shall be fully liable for any and all liabilities and damages incurred or suffered by another party as a result of such failure or breach. The provisions of Section&nbsp;6.02(b), and Article 11
(and any related definitions contained in any such Sections or Article) and this Section&nbsp;10.02 shall survive any termination hereof pursuant to Section&nbsp;10.01. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex2_1647083_87"></A>ARTICLE 11 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_88">
</A>SECTION&nbsp;11.01. <I>Notices</I>. All notices, requests and other communications to any party hereunder shall be in writing (including facsimile transmission and electronic mail <FONT STYLE="white-space:nowrap">(&#147;e-mail&#148;)</FONT>
transmission, so long as a receipt of such facsimile transmission or <FONT STYLE="white-space:nowrap">e-mail</FONT> is requested and received) and shall be given, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Parent or Merger Subsidiary or, after the Effective Time, the Company or the Surviving Corporation, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Illumina, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5200 Illumina Way
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92122 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Charles E. Dadswell, Senior Vice President and General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> CDadswell@illumina.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">legalnotices@illumina.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Covington&nbsp;&amp; Burling LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The New York Times Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">620
Eighth Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">New York, New York 10018 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Scott Smith </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jack Bodner </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bradley Chernin </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Facsimile&nbsp;No.:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-841-1079</FONT></FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-441-9079</FONT></FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-955-6541</FONT></FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ssmith@cov.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">jbodner@cov.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bchernin@cov.com </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to the Company prior to the Effective Time, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1305 O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stephen M. Moore, Vice President and General Counsel </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Facsimile&nbsp;No.:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(650) <FONT STYLE="white-space:nowrap">323-9420</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">smoore@pacificbiosciences.com </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Professional Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">650
Page Mill Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Donna M. Petkanics </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Martin W. Korman </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Douglas K. Schnell </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Facsimile&nbsp;No.:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-493-6811</FONT></FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">dpetkanics@wsgr.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mkorman@wsgr.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">dschnell@wsgr.com </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as such party may hereafter specify for the purpose by
notice to the other parties hereto. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a Business Day in the place of receipt. Otherwise, any
such notice, request or communication shall be deemed to have been received on the next succeeding Business Day in the place of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_89">
</A>SECTION&nbsp;11.02. <I>Survival of Representations and Warranties</I>. The representations and warranties contained herein and in any certificate or other writing delivered pursuant hereto shall not survive the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_90"></A>SECTION&nbsp;11.03. <I>Amendments and Waivers</I>. (a)&nbsp;Any provision of this Agreement may be amended or
waived prior to the Effective Time if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be
effective; <I>provided</I> that after the Company Stockholder Approval has been obtained, there shall be no amendment or waiver that would require the further approval of the stockholders of the Company under the Delaware Law without such approval
having first been obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No failure or delay by any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and
not exclusive of any rights or remedies provided by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_91"></A>SECTION&nbsp;11.04. <I>Expenses</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Except as otherwise provided herein, all costs, fees and expenses incurred in connection with the Merger and the
other transactions contemplated by this Agreement shall be paid by the party incurring such cost or expense, whether or not such transactions are consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Fees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If this Agreement is terminated by Parent pursuant to Section&nbsp;10.01(c)(i) or by the Company pursuant to
Section&nbsp;10.01(d)(i), then the Company shall pay (or cause to be paid) to Parent in immediately available funds $43,000,000 (the &#147;<B>Company Termination Fee</B>&#148;), in the case of a termination by Parent, within two Business Days after
such termination and, in the case of a termination by the Company, concurrently with such termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If
(A)&nbsp;this Agreement is terminated by Parent pursuant to Section&nbsp;10.01(c)(ii) or by either Parent or the Company pursuant to Section&nbsp;10.01(b)(ii), (B) after the date of this Agreement and prior to such termination, an Acquisition
Proposal shall have been publicly announced or otherwise communicated to the Company, the Board of Directors or the Company&#146;s stockholders (<I>provided</I> that in the case of a termination pursuant to Section&nbsp;10.01(c)(ii)(A), all
percentages in the definition of Acquisition Proposal will be deemed to refer to 50%), and (C)&nbsp;within 12 months following the date of such termination, the Company or any of its Subsidiaries shall have entered into a definitive agreement with
respect to an Acquisition Proposal or an Acquisition Proposal shall have been consummated (provided that for purposes of this clause (C), all percentages in the definition of Acquisition Proposal will be deemed to refer to 50%), then the Company
shall pay (or cause to be paid) to Parent in immediately available funds, prior to or concurrently with the occurrence of the applicable event described in clause (C), the Company Termination Fee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If this Agreement is terminated by Parent or the Company pursuant to&nbsp;Section&nbsp;10.01(b)(i) and at the time of
such termination, all of the conditions set forth in Section&nbsp;9.01 and Section&nbsp;9.02 shall have been satisfied or validly waived (other than one or both of (x)&nbsp;Section&nbsp;9.01(b), Section&nbsp;9.01(c) or Section&nbsp;9.02(vii) (but,
with respect to Section&nbsp;9.01(c) and Section&nbsp;9.02(vii), only if the applicable Legal Restraint or Applicable Law relates to an Antitrust Law; provided, that if there is additionally a failure to satisfy or waive any of Section&nbsp;9.01(b),
Section&nbsp;9.01(c) or Section&nbsp;9.02(vii) due to a Legal Restraint or Applicable Law relating to a Specified Jurisdiction, this subsection (x)&nbsp;shall nonetheless be satisfied) and (y)&nbsp;those conditions that by their nature are to be
satisfied at the Closing, provided that such conditions were then capable of being satisfied if the Closing had occurred on the date of such termination), then Parent shall pay to the Company in immediately available funds $98,000,000 (the
&#147;<B>Reverse Termination Fee</B>&#148;) within two Business Days after such termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) If this Agreement is
terminated by Parent or the Company pursuant to Section&nbsp;10.01(b)(i) and, at the time of such termination, all of the conditions set forth in Section&nbsp;9.01 and Section&nbsp;9.02 shall have been satisfied or validly waived (other than one or
both of (x)&nbsp;Section&nbsp;9.01(b), Section&nbsp;9.01(c) or Section&nbsp;9.02(vii) (but, with respect to Section&nbsp;9.01(c) and Section&nbsp;9.02(vii), only if the applicable Legal Restraint or Applicable Law does not relate to an Antitrust Law
and occurs in a Specified Jurisdiction) and (y)&nbsp;those conditions that by their nature are to be satisfied at the Closing, provided that such conditions were then capable of being satisfied if the Closing had occurred on the date of such
termination), then Parent shall take the Specified Termination Actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, in the event this Agreement is terminated by Parent
or the Company pursuant to Section&nbsp;10.01(b)(i) and, at the time of such termination, (i)&nbsp;the conditions set forth in Section&nbsp;9.01(b) have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfied, (ii)&nbsp;the conditions set forth in Section&nbsp;9.01(c) and Section&nbsp;9.02(vii) have been satisfied with respect to any Applicable Law or Legal Restraint relating to Antitrust
Law and (iii)&nbsp;the conditions set forth in Section&nbsp;9.01(vii) have been satisfied with respect to any Applicable Law or Legal Restraint relating to the Specified Jurisdiction, then Parent shall neither be obligated to pay the Reverse
Termination Fee or take the Specified Termination Actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Other Costs and Expenses</U>. Each of Parent and the Company
acknowledges and hereby agrees that the agreements contained in this Section&nbsp;11.04 are an integral part of the transactions contemplated by this Agreement and that, without these agreements, neither party would enter into this Agreement.
Accordingly, if either party fails to promptly pay any amount due pursuant to this Section&nbsp;11.04 to the other party when due, then the party failing to pay such amounts shall also pay any costs and expenses (including attorney&#146;s fees and
expenses) incurred by the other party in connection with an Action to enforce this Agreement that results in a judgment for such unpaid amount, together with interest on such amount of any unpaid fee, cost or expense at the prime lending rate
published in <I>The Wall Street Journal</I> from the date such fee, cost or expense was required to be paid to (but excluding) the payment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in this Agreement, the parties expressly acknowledge and agree that in no event shall the Company
be required to pay the Company Termination Fee on more than one occasion, and if Parent receives the Company Termination Fee from the Company pursuant to the terms of this Agreement (together with any payments required under Section&nbsp;11.04(c)),
then such payment shall constitute liquidated damages and be the sole and exclusive monetary remedy of the Parent Related Parties against the Company Related Parties for all losses, damages, costs or expenses in respect of this Agreement (or the
termination thereof) or the transactions contemplated by this Agreement (or the failure of such transactions to occur for any reason or for no reason) or any breach (whether willful, intentional, unilateral or otherwise) of any covenant or agreement
or otherwise in respect of this Agreement or any oral representation made or alleged to be made in connection herewith, and upon payment of the Company Termination Fee to Parent pursuant to Section&nbsp;11.04(b) (together with any payments required
under Section&nbsp;11.04(c)), none of the Company Related Parties shall have any further monetary liability or obligation to any of the Parent Related Parties relating to or arising out of this Agreement or the transactions contemplated hereby or
thereby, and none of the Parent, its Subsidiaries or any other Parent Related Party shall seek to recover any other monetary damages; <I>provided</I> that, notwithstanding the foregoing, the parties will remain obligated with respect to
Section&nbsp;11.04(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary in this Agreement, the parties expressly acknowledge and agree that
that in no event shall Parent be required to both (x)&nbsp;pay the Reverse Termination Fee and (y)&nbsp;take the Specified Termination Actions and, in the case of either (x)&nbsp;or (y), do so on more than one occasion. If the Company receives the
Reverse Termination Fee from Parent under circumstances where the Reverse Termination Fee is payable pursuant to the terms of this Agreement or Parent takes the Specified Termination Actions under circumstances where the Specified Termination
Actions are to be taken pursuant to the terms of this Agreement (in each case, together with any payments required under Section&nbsp;11.04(c)), then such payment or such actions, as applicable, shall constitute liquidated damages and shall
constitute the sole and exclusive monetary remedy of the Company Related Parties against the Parent Related Parties for all losses, damages, costs or expenses in respect of this Agreement (or the termination thereof) or the transactions contemplated
by this Agreement (or the failure of such transactions to occur for any reason or for no reason) or any breach (whether willful, intentional, unilateral or otherwise) of any covenant or agreement or otherwise in respect of this Agreement or any oral
representation made or alleged to be made in connection herewith, and upon payment of the Reverse Termination Fee to the Company pursuant to Section&nbsp;11.04(b)(iii) or Parent&#146;s taking of the Specified Termination Actions pursuant to
Section&nbsp;11.04(b)(iv) (in each case, together with any payments required under Section&nbsp;11.04(c)), none of the Parent Related Parties shall have any further monetary liability or obligation to any of the Company Related Parties relating to
or arising out of this Agreement or the transactions contemplated hereby or thereby, and none of the Company, its Subsidiaries or any other Company Related Party shall seek to recover any other monetary damages; <I>provided</I> that, notwithstanding
the foregoing, the parties will remain obligated with respect to Section&nbsp;11.04(a). In a situation where both the Reverse Termination Fee would be payable pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;11.04(b)(iii) and Parent would be required to take the Specified Termination Actions pursuant to Section&nbsp;11.04(b)(iv), only the Reverse Termination Fee will be payable and
Parent shall have no obligation with respect to Section&nbsp;11.04(b)(iv) or the Specified Termination Actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_92"></A>SECTION&nbsp;11.05. <I>Disclosure Schedule and SEC Document References</I>. The parties agree that any reference
in a particular Section of the Company Disclosure Schedule shall be deemed to be an exception to (or, as applicable, a disclosure for purposes of)&nbsp;(i) the representations and warranties (or covenants, as applicable) of the relevant party that
are contained in the corresponding Section of this Agreement and (ii)&nbsp;any other representations and warranties of such party that are contained in this Agreement, but, in the case of clause (ii), only if the relevance of that reference as an
exception to (or a disclosure for purposes of) such representations and warranties would be reasonably apparent to a reasonable person who has read that reference and such representations and warranties, without any independent knowledge on the part
of the reader regarding the matter(s) so disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_93"></A>SECTION&nbsp;11.06. <I>Binding Effect; Benefit;
Assignment</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Agreement shall be binding on and, except as provided in Section&nbsp;7.03, shall inure to the
benefit of the parties and their respective successors and assigns. Except as provided in Section&nbsp;7.03 and Section&nbsp;11.14, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities
hereunder upon any Person other than the parties hereto and their respective successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No party may assign, delegate or
otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of each other party, except that Parent or Merger Subsidiary may transfer or assign its rights and obligations under this Agreement, in whole
or from time to time in part, to (i)&nbsp;one or more of their Affiliates at any time and (ii)&nbsp;after the Effective Time, to any Person; <I>provided</I> that such transfer or assignment shall not relieve Parent or Merger Subsidiary of its
obligations hereunder or enlarge, alter or change any obligation of any other party hereto or due to Parent or Merger Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_94">
</A>SECTION&nbsp;11.07. <I>Governing Law</I>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_95"></A>SECTION&nbsp;11.08. <I>Jurisdiction</I>. The parties agree that any Action seeking to enforce any provision of,
or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby (whether brought by any party or any of its Affiliates or against any party or any of its Affiliates) shall be brought in the
Delaware Chancery Court or, if such court shall not have jurisdiction, any federal court located in the State of Delaware or other Delaware state court, and each of the parties hereby irrevocably consents to the exclusive jurisdiction of such courts
(and of the appropriate appellate courts therefrom) in any such Action and irrevocably waives, to the fullest extent permitted by law, any objection that you may now or hereafter have to the laying of the venue of any such Action in any such court
or that any such Action brought in any such court has been brought in an inconvenient forum. Process in any such Action may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting
the foregoing, each party agrees that service of process on such party as provided in Section&nbsp;11.01 shall be deemed effective service of process on such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_96"></A>SECTION&nbsp;11.09. <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY ACTION ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_97">
</A>SECTION&nbsp;11.10. <I>Counterparts; Effectiveness</I>. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the same instrument. This Agreement shall become effective when each party shall have received a counterpart hereof signed by all of the other parties. Until and unless each party has
received a counterpart hereof signed by the other parties, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_98"></A>SECTION&nbsp;11.11. <I>Entire Agreement</I>. This Agreement (including the Company Disclosure Schedule) and the
Confidentiality Agreement constitute the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the
subject matter of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_99"></A>SECTION&nbsp;11.12. <I>Severability</I>. If any term, provision, covenant
or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in
full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a
determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as
originally contemplated to the fullest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_100"></A>SECTION&nbsp;11.13. <I>Specific Performance</I>.
The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall, in addition to any other remedy to which they are entitled at law or in
equity, be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof (and each party further agrees to waive any requirement for the securing or
posting of any bond in connection with such remedy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="ex2_1647083_101"></A>SECTION&nbsp;11.14. <I>No Third Party
Beneficiaries</I>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except for:
(a)&nbsp;solely if the Effective Time occurs, (i)&nbsp;the right of the Company&#146;s stockholders to receive the Merger Consideration, as applicable, following the Effective Time, in each case in accordance with the terms of this Agreement, and
(ii)&nbsp;the right of the holders of Company Stock Awards and participants in the Company&#146;s ESPP to receive the applicable treatment pursuant to Article 2 in accordance with the terms of this Agreement and (b)&nbsp;the provisions set forth in
Section&nbsp;7.03 of this Agreement with respect to the Persons referred to therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally blank</I>] </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date
set forth on the cover page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Hunkapiller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Hunkapiller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, Chairman and President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>ILLUMINA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francis A. deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Francis A. deSouza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>FC OPS CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francis A. deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Francis A. deSouza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Merger Agreement] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc646626_89"></A>Annex B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g646626g30p56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Centerview Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">31 West 52nd Street New </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="right">York, NY 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:5%; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;1, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board
of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1305
O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board
of Directors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested our opinion as to the fairness, from a financial point of view, to the holders of the outstanding shares
of common stock, par value $0.001 per share (the &#147;Shares&#148;) (other than Excluded Shares, as defined below), of Pacific Biosciences of California, Inc., a Delaware corporation (the &#147;Company&#148;), of the $8.00 per Share in cash,
without interest, proposed to be paid to such holders pursuant to the Agreement and Plan of Merger proposed to be entered into (the &#147;Agreement&#148;) among Illumina, Inc., a Delaware corporation (&#147;Parent&#148;), FC Ops Corp., a Delaware
corporation and a wholly owned subsidiary of Parent (&#147;Merger Sub&#148;), and the Company. The Agreement provides that Merger Sub will be merged with and into the Company (the &#147;Merger&#148; and, collectively with the other transactions
contemplated by the Agreement, the &#147;Transaction&#148;), as a result of which the Company will become a wholly owned subsidiary of Parent and each issued and outstanding Share immediately prior to the effective time of the Merger (other than
(i)&nbsp;Shares owned by Parent, Merger Sub or by the Company (as treasury stock) and (ii)&nbsp;Shares that are held by stockholders of the Company who have properly exercised their respective demand for, and not effectively withdrawn, waived or
lost their rights to, appraisal pursuant to Section&nbsp;262 of the Delaware General Corporation Law with respect to such Shares (the shares referred to in clauses (i)&nbsp;and (ii), together with any Shares held by any affiliate of the Company or
Parent, &#147;Excluded Shares&#148;)) will be converted into the right to receive $8.00 per Share in cash, without interest, (the $8.00 per Share consideration to be paid in the Merger, the &#147;Consideration&#148;). The terms and conditions of the
Transaction are more fully set forth in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as financial advisor to the Board of Directors of the Company in
connection with the Transaction. We will receive a fee for our services in connection with the Transaction, a portion of which is payable upon the rendering of this opinion and a substantial portion of which is contingent upon the consummation of
the Merger. In addition, the Company has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial advisory and
merchant banking activities. In the past two years, we have not (except for our current engagement) been engaged to provide financial advisory or other services to the Company, and we have not received any compensation from the Company. In the past
two years, we have not been engaged to provide financial advisory or other services to Parent or Merger Sub, and we have not received any compensation from Parent. We may provide financial advisory and other services to or with respect to the
Company or Parent or their respective affiliates in the future, for which we may receive compensation. Certain (i)&nbsp;of our and our affiliates&#146; directors, officers, members and employees, or family members of such persons, </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">31 WEST 52ND STREET, 22ND FLOOR, NEW YORK, NY 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PHONE: (212) <FONT STYLE="white-space:nowrap">380-2650</FONT> FAX: (212) <FONT STYLE="white-space:nowrap">380-2651</FONT>
<U>WWW.CENTERVIEWPARTNERS.COM</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">NEW YORK&nbsp;&nbsp;&#9679;&nbsp;&nbsp;LONDON&nbsp;&nbsp;&#9679;&nbsp;&nbsp;SAN
FRANCISCO&nbsp;&nbsp;&#9679;&nbsp;&nbsp;PALO ALTO&nbsp;&nbsp;&#9679;&nbsp;&nbsp;LOS ANGELES </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 1, 2018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;of our affiliates or related investment funds and (iii)&nbsp;investment funds or other persons in which any of the foregoing may have financial interests or with which they may <FONT
STYLE="white-space:nowrap">co-invest,</FONT> may at any time acquire, hold, sell or trade, in debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, the Company,
Parent, or any of their respective affiliates, or any other party that may be involved in the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this
opinion, we have reviewed, among other things: (i)&nbsp;a draft of the Agreement dated November&nbsp;1, 2018 (the &#147;Draft Agreement&#148;); (ii) Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of the Company for the years
ended December&nbsp;31, 2017, December&nbsp;31, 2016 and December&nbsp;31, 2015; (iii) certain interim reports to stockholders and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the Company; (iv)&nbsp;certain publicly
available research analyst reports for the Company; (v)&nbsp;certain other communications from the Company to its stockholders; and (vi)&nbsp;certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities
and prospects of the Company, including certain financial forecasts, analyses and projections relating to the Company prepared by management of the Company and furnished to us by the Company for purposes of our analysis (the &#147;Forecasts&#148;)
(collectively, the &#147;Internal Data&#148;). We have also participated in discussions with members of the senior management and representatives of the Company regarding their assessment of the Internal Data. In addition, we reviewed publicly
available financial and stock market data, including valuation multiples, for the Company and compared that data with similar data for certain other companies, the securities of which are publicly traded, in lines of business that we deemed
relevant. We also compared certain of the proposed financial terms of the Transaction with the financial terms, to the extent publicly available, of certain other transactions that we deemed relevant and conducted such other financial studies and
analyses and took into account such other information as we deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed, without independent verification or any
responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied upon
such information as being complete and accurate. In that regard, we have assumed, at your direction, that the Internal Data (including, without limitation, the Forecasts) has been reasonably prepared on bases reflecting the best currently available
estimates and judgments of the management of the Company as to the matters covered thereby and we have relied, at your direction, on the Internal Data for purposes of our analysis and this opinion. We express no view or opinion as to the Internal
Data or the assumptions on which it is based. In addition, at your direction, we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative,
<FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of the Company, nor have we been furnished with any such evaluation or appraisal, and we have not been asked to conduct, and did not conduct, a physical inspection of the
properties or assets of the Company. We have assumed, at your direction, that the final executed Agreement will not differ in any respect material to our analysis or this opinion from the Draft Agreement reviewed by us. We have also assumed, at your
direction, that the Transaction will be consummated on the terms set forth in the Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term,
condition or agreement, the effect of which would be material to our analysis or this opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transaction, no
delay, limitation, restriction, condition or other change will be imposed, the effect of which would be material to our analysis or this opinion. We have not evaluated and do not express any opinion as to the solvency or fair value of the Company,
or the ability of the Company to pay its obligations when they come due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. We are not legal,
regulatory, tax or accounting advisors, and we express no opinion as to any legal, regulatory, tax or accounting matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 1, 2018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no view as to, and our opinion does not address, the Company&#146;s underlying
business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to the Company or in which the Company might engage.
This opinion is limited to and addresses only the fairness, from a financial point of view, as of the date hereof, to the holders of the Shares (other than Excluded Shares) of the Consideration to be paid to such holders pursuant to the Agreement.
We have not been asked to, nor do we express any view on, and our opinion does not address, any other term or aspect of the Agreement or the Transaction, including, without limitation, the structure or form of the Transaction, or any other
agreements or arrangements contemplated by the Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or aspect of the Transaction
to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any other class of securities, creditors or other constituencies of the Company or any other party. In addition, we express no
view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of the Company or any party, or class of such persons in
connection with the Transaction, whether relative to the Consideration to be paid to the holders of the Shares pursuant to the Agreement or otherwise. Our opinion is necessarily based on financial, economic, monetary, currency, market and other
conditions and circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or responsibility to update, revise or reaffirm this opinion based on circumstances, developments or
events occurring after the date hereof. Our opinion does not constitute a recommendation to any stockholder of the Company or any other person as to how such stockholder or other person should vote with respect to the Merger or otherwise act with
respect to the Transaction or any other matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial advisory services and the opinion expressed herein are provided for the
information and assistance of the Board of Directors of the Company (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. The issuance of this opinion was approved
by the Centerview Partners LLC Fairness Opinion Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, including the various assumptions
made, procedures followed, matters considered, and qualifications and limitations set forth herein, we are of the opinion, as of the date hereof, that the Consideration to be paid to the holders of Shares (other than Excluded Shares) pursuant to the
Agreement is fair, from a financial point of view, to such holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Centerview Partners LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">CENTERVIEW PARTNERS LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc646626_90"></A>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;262 of the DGCL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#167;
262. Appraisal rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a
demand pursuant to subsection (d)&nbsp;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger or consolidation, who has otherwise complied with subsection (d)&nbsp;of this section and
who has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#146;s shares of
stock under the circumstances described in subsections (b)&nbsp;and (c) of this section. As used in this section, the word &#147;stockholder&#148; means a holder of record of stock in a corporation; the words &#147;stock&#148; and &#147;share&#148;
mean and include what is ordinarily meant by those words; and the words &#147;depository receipt&#148; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a
corporation, which stock is deposited with the depository. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series
of stock of a constituent corporation in a merger or consolidation to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258,
&#167; 263 or &#167; 264 of this title: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Provided, however, that, except as expressly provided in &#167; 363(b) of this title, no
appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the
meeting of stockholders to act upon the agreement of merger or consolidation (or, in the case of a merger pursuant to &#167; 251(h), as of immediately prior to the execution of the agreement of merger), were either: (i)&nbsp;listed on a national
securities exchange or (ii)&nbsp;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for
its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding
paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or
consolidation pursuant to &#167;&#167; 251, 252, 254, 255, 256, 257, 258, 263 and 264 of this title to accept for such stock anything except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or depository receipts in
respect thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of
stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of
this section; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or
fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) In the event all of the
stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary
Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) In the event of an amendment to a corporation&#146;s certificate of incorporation contemplated by &#167; 363(a)
of this title, appraisal rights shall be available as contemplated by &#167; 363(b) of this title, and the procedures of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
section, including those set forth in subsections (d)&nbsp;and (e) of this section, shall apply as nearly as practicable, with the word &#147;amendment&#148; substituted for the words
&#147;merger or consolidation,&#148; and the word &#147;corporation&#148; substituted for the words &#147;constituent corporation&#148; and/or &#147;surviving or resulting corporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares
of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially all of the assets of the
corporation. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&nbsp;of this section, shall apply as nearly as is practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) If a proposed merger or consolidation for which appraisal rights are provided under this section is to be submitted for approval at a
meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167;
255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&nbsp;or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations, and shall
include in such notice a copy of this section and, if 1 of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Each stockholder electing to demand the appraisal of such stockholder&#146;s shares shall deliver
to the corporation, before the taking of the vote on the merger or consolidation, a written demand for appraisal of such stockholder&#146;s shares. Such demand will be sufficient if it reasonably informs the corporation of the identity of the
stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#146;s shares. A proxy or vote against the merger or consolidation shall not constitute such a demand. A stockholder electing to take such action must
do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or resulting corporation shall notify each stockholder of each constituent corporation who has complied
with this subsection and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has become effective; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) If the merger or consolidation was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a
constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such constituent corporation who
are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such notice a copy
of this section and, if 1 of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Such notice may, and, if given on or after the effective date of the merger or consolidation, shall, also notify such
stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of mailing of such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this
title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of mailing of such notice, demand in writing from the surviving or resulting corporation the appraisal of such
holder&#146;s shares. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#146;s shares. If such notice did not
notify stockholders of the effective date of the merger or consolidation, either (i)&nbsp;each such constituent corporation shall send a second notice before the effective date of the merger or consolidation notifying each of the holders of any
class or series of stock of such constituent corporation that are entitled to appraisal rights of the effective date of the merger or consolidation or (ii)&nbsp;the surviving or resulting corporation shall send such a second notice to all such
holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title,
later than the later of the consummation of the offer contemplated by &#167; 251(h) of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such
holder&#146;s shares in accordance with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required to give either notice that such notice has been given shall, in the absence of
fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record date that shall be not more than 10 days prior to
the date the notice is given, provided, that if the notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the
effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Within
120 days after the effective date of the merger or consolidation, the surviving or resulting corporation or any stockholder who has complied with subsections (a)&nbsp;and (d) of this section hereof and who is otherwise entitled to appraisal rights,
may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of
the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon
the merger or consolidation. Within 120 days after the effective date of the merger or consolidation, any stockholder who has complied with the requirements of subsections (a)&nbsp;and (d) of this section hereof, upon written request, shall be
entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor of the merger or consolidation (or, in the case of a merger approved
pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in,
the offer referred to in &#167; 251(h)(2)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of holders of such shares. Such written statement shall be mailed to the stockholder within 10
days after such stockholder&#146;s written request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&nbsp;of this
section hereof, whichever is later. Notwithstanding subsection (a)&nbsp;of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, in such person&#146;s
own name, file a petition or request from the corporation the statement described in this subsection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Upon the filing of any such
petition by a stockholder, service of a copy thereof shall be made upon the surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly
verified list containing the names and addresses of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition
shall be filed by the surviving or resulting corporation, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such
petition by registered or certified mail to the surviving or resulting corporation and to the stockholders shown on the list at the addresses therein stated. Such notice shall also be given by 1 or more publications at least 1 week before the day of
the hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs
thereof shall be borne by the surviving or resulting corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the Court shall determine the
stockholders who have complied with this section and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their
certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder. If
immediately before the merger or consolidation the shares of the class or series of stock of the constituent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise
entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&nbsp;the value of the consideration provided in the merger or
consolidation for such total number of shares exceeds $1&nbsp;million, or (3)&nbsp;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the
rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or
expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its
discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the
Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. At any time before the entry of judgment in the proceedings,
the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the
fair value of the shares as determined by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving or resulting corporation or by any stockholder entitled to participate in the appraisal
proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list filed by the surviving or resulting
corporation pursuant to subsection (f)&nbsp;of this section and who has submitted such stockholder&#146;s certificates of stock to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined
that such stockholder is not entitled to appraisal rights under this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Court shall direct the payment of the fair value of
the shares, together with interest, if any, by the surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of
holders of shares represented by certificates upon the surrender to the corporation of the certificates representing such stock. The Court&#146;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such
surviving or resulting corporation be a corporation of this State or of any state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by
the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding,
including, without limitation, reasonable attorney&#146;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal rights as provided in
subsection (d)&nbsp;of this section shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of record at a date
which is prior to the effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection (e)&nbsp;of this section, or if such stockholder shall deliver to the
surviving or resulting corporation a written withdrawal of such stockholder&#146;s demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or consolidation as provided in
subsection (e)&nbsp;of this section or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be
dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any stockholder who has not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon the merger or
consolidation within 60 days after the effective date of the merger or consolidation, as set forth in subsection (e)&nbsp;of this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The shares of the surviving or resulting corporation to which the shares of such objecting stockholders would have been converted had they
assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc646626_91"></A>Annex D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Voting Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This VOTING AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of November&nbsp;1, 2018, is by and between Illumina, Inc., a Delaware
corporation (&#147;<B>Parent</B>&#148;), and the stockholder whose name appears on the signature page to this Agreement (&#147;<B>Stockholder</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, Pacific Biosciences of California, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and FC Ops Corp., a
Delaware corporation and wholly owned subsidiary of Parent (&#147;<B>Merger Subsidiary</B>&#148;), propose to enter into an Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to time, the &#147;<B>Merger
Agreement</B>&#148;), which provides, among other things, for the merger of Merger Subsidiary with and into the Company (the &#147;<B>Merger</B>&#148;), with the Company being the surviving corporation, upon the terms and conditions set forth in the
Merger Agreement (capitalized terms used herein without definition shall have the respective meanings specified in the Merger Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Stockholder owns in Stockholder&#146;s personal capacity shares of common stock, par value $0.001 per share, of the Company
(&#147;<B>Common Stock</B>&#148;) (together with any other shares of capital stock of the Company acquired (whether beneficially or of record) by such Stockholder in such Stockholder&#146;s personal capacity after the date hereof, including any
shares of Common Stock acquired by means of purchase, dividend or distribution, or as a result of the exercise or vesting of Company Stock Awards or the conversion of any convertible securities or otherwise, the &#147;<B>Shares</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition to the willingness of Parent to enter into the Merger Agreement and as an inducement and in consideration therefor,
Stockholder is entering into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and agreements set
forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOTING </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01 <I>Voting</I>. From and after the date hereof until the earlier of (a)&nbsp;the consummation of the Merger, (b)&nbsp;the
termination of the Merger Agreement pursuant to and in compliance with the terms therein, and (c)&nbsp;the entry without the prior written consent of Stockholder into any amendment or modification of the Merger Agreement or any material waiver of
any of the Company&#146;s rights under the Merger Agreement, in each case, which results in a decrease in, or change in the composition of, the Merger Consideration or imposes any material restrictions or additional constraints on the payment of the
Merger Consideration (such earlier date, the &#147;<B>Expiration Date</B>&#148;), Stockholder hereby agrees that at any meeting (whether annual or special and each adjourned or postponed meeting) of the Company&#146;s stockholders, however called,
Stockholder will (i)&nbsp;appear at such meeting or otherwise cause all of the Shares to be counted as present thereat for purposes of calculating a quorum and (ii)&nbsp;vote or cause to be voted (including by proxy) all of the Shares (A)&nbsp;in
favor of the adoption of the Merger Agreement and the approval of the transactions contemplated thereby, including the Merger; (B)&nbsp;in favor of any proposal to adjourn or postpone such meeting of the Company&#146;s stockholders to a later date
if there are not sufficient votes to adopt the Merger Agreement and such adjournment or postponement is undertaken in compliance with the Merger Agreement; (C)&nbsp;against any action, proposal, transaction or agreement that relates to an
Acquisition Proposal; and (D)&nbsp;against any action, proposal, transaction or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of the Company contained in the Merger Agreement
or of Stockholder contained in this Agreement. Notwithstanding the foregoing, this Section&nbsp;1.01 shall not apply during any period in which the Board of Directors has qualified, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withheld, withdrawn or modified the Company Board Recommendation in response to a Superior Proposal or an Intervening Event in accordance with the terms of the Merger Agreement; <U>provided</U>,
that to the extent that the Board of Directors reinstates its recommendation of the Merger Agreement, this Section&nbsp;1.01 shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02 <I>Restrictions on Transfers</I>. Stockholder hereby agrees that, from the date hereof until the earlier of the Expiration
Date and the conclusion of the Company Stockholder Meeting, Stockholder shall not, directly or indirectly, (a)&nbsp;sell, transfer, assign, tender in any tender or exchange offer, pledge, encumber, hypothecate or similarly dispose of (by merger, by
testamentary disposition, by operation of law or otherwise) (a &#147;<B>Transfer</B>&#148;) or enter into any contract, option or other arrangement or understanding with respect to the Transfer of any Shares, other than any Transfer made solely for
estate planning purposes or philanthropic purposes, but only if, in each case, prior to or upon the effectiveness of such Transfer, the transferee agrees in writing to be bound by the terms hereof and notice of such Transfer is delivered to Parent
pursuant to Section&nbsp;5.02 hereof, (b)&nbsp;deposit any Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement, or
(c)&nbsp;agree (whether or not in writing) to take any of the actions referred to in the foregoing clause (a)&nbsp;or (b). Notwithstanding the foregoing, (i)&nbsp;nothing herein will prohibit the Stockholder from &#147;net exercising&#148; any
Company Stock Awards and (ii)&nbsp;if &#147;net exercising&#148; is not permitted with respect to a Company Stock Award, then nothing herein will prohibit the Stockholder from exercising such Company Stock Award and selling a number of shares of
Common Stock acquired from such exercise in an amount no greater than required to cover the exercise price in connection with the exercise of such Company Stock Award (but the actions permitted under this clause (ii)&nbsp;will only be permissible
for the first 10 Business Days following such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.03 <I>Inconsistent Agreements</I>. Stockholder hereby covenants
and agrees that, except for this Agreement, Stockholder (a)&nbsp;shall not enter into at any time while this Agreement remains in effect any voting agreement or voting trust with respect to the Shares and (b)&nbsp;shall not grant at any time while
this Agreement remains in effect a proxy, consent or power of attorney with respect to the Shares. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CAPACITY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01
<I>Capacity</I>. Stockholder is signing this Agreement solely in his, her or its capacity as a stockholder of the Company and nothing contained herein shall in any way limit or affect any actions taken or not taken by Stockholder or any of his or
her Representatives in his or her capacity as a director or officer of the Company, and no action taken or not taken in any such capacity as a director or officer shall be deemed to constitute a breach of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS,
WARRANTIES AND COVENANTS OF STOCKHOLDER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01 <I>Representations and Warranties</I>. Stockholder represents and warrants to
Parent as follows: (a)&nbsp;Stockholder has full legal right and capacity to execute and deliver this Agreement, to perform Stockholder&#146;s obligations hereunder and to consummate the transactions contemplated hereby, (b)&nbsp;this Agreement has
been duly executed and delivered by Stockholder and no other actions or proceedings on the part of Stockholder are necessary to authorize this Agreement or to consummate the transactions contemplated hereby, (c)&nbsp;assuming due authorization,
execution and delivery by Parent, this Agreement constitutes a valid and binding obligation of Stockholder, enforceable against Stockholder in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other laws affecting creditors&#146; rights generally and general principles of equity), (d) the execution, delivery and performance of this Agreement by Stockholder and the consummation of the transactions
contemplated hereby does not and will not contravene, conflict with or result in a violation or breach of any provision of any Applicable Law or require any consent or other action by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Person under, constitute a default, or an event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation,
acceleration or other change of any right or obligation or the loss of any benefit to which Stockholder is entitled under any provision of any Contract binding on Stockholder or the Shares, nor require any action by or in respect of, or filing with
respect to Stockholder by or with, any Governmental Authority, in each case, except as would not prevent or delay the consummation of the Merger or Stockholder&#146;s ability to perform its obligations hereunder, and (e)&nbsp;Stockholder
beneficially owns the Shares free and clear of any proxy, voting restriction, adverse claim or other Lien (other than any restrictions created by this Agreement or under Applicable Laws) and has sole voting power with respect to the Shares and sole
power of disposition with respect to all of the Shares, with no restrictions on Stockholder&#146;s rights of voting or disposition pertaining thereto, and no person other than Stockholder has any right to direct or approve the voting or disposition
of any of the Shares in each case, except as would not prevent or delay the consummation of the Merger or Stockholder&#146;s ability to perform its obligations hereunder, except in case of (e)&nbsp;for any spousal rights under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02 <I>Covenants</I>. Stockholder hereby: (a)&nbsp;irrevocably waives, and agrees not to exercise, any rights of appraisal or
rights of dissent from the Merger that Stockholder may have with respect to the Shares; (b)&nbsp;agrees that any Shares acquired by Stockholder in Stockholder&#146;s personal capacity after the date hereof and prior to the Expiration Date shall
automatically be subject to the terms of this Agreement as though owned by Stockholder on the date hereof and Stockholder shall promptly notify Parent of any such Shares; (c)&nbsp;agrees to permit the Company to publish and disclose in filings with
the Securities and Exchange Commission, this Agreement and Stockholder&#146;s identity and ownership of the Shares and the nature of Stockholder&#146;s commitments under this Agreement; (d)&nbsp;shall and does authorize Parent or its counsel to
notify the Company&#146;s transfer agent that there is a stop order transfer with respect to all of the Shares (and that this Agreement places limits of the voting and transfer of such Shares as described herein); <U>provided</U> that Parent shall,
or shall cause its counsel to, promptly notify the Company&#146;s transfer agent to lift and vacate the stop transfer order with respect to the Shares promptly (and in no event more than one (1)&nbsp;Business Day) following the Expiration Date; and
(e)&nbsp;agrees to execute and deliver such additional instruments and documents and take such further action as may be reasonably necessary to effectuate and comply with his, her or its respective obligations under this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TERMINATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall terminate and be of no further force or effect on the Expiration Date. Notwithstanding the preceding sentence, this
Article IV and Article V shall survive any termination of this Agreement. Nothing in this Article IV shall relieve or otherwise limit any party of liability for willful breach of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01 <I>Expenses</I>. All costs, fees and expenses incurred in connection with this Agreement and the transactions contemplated
by this Agreement shall be paid by the party incurring such cost or expense, whether or not the Merger is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02
<I>Notices</I>. All notices, requests and other communications to any party hereunder shall be in writing (including facsimile transmission and electronic mail (&#147;<B><FONT STYLE="white-space:nowrap">e-mail</FONT></B>&#148;) transmission, so long
as a receipt of such facsimile transmission or <FONT STYLE="white-space:nowrap">e-mail</FONT> is requested and received) and shall be given, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Parent, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Illumina, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">5200 Illumina Way
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92122 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charles E. Dadswell, Senior Vice President and General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legalnotices@illumina.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDadswell@illumina.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Covington&nbsp;&amp; Burling LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The New York Times Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">620
Eighth Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">New York, New York 10018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scott Smith </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Jack Bodner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bradley Chernin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile No.: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-841-1079</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;646-441-9079</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;415-955-6541</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> ssmith@cov.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jbodner@cov.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bchernin@cov.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Stockholder, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">as set
forth on the signature page to this Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as
such party may hereafter specify for the purpose by notice to the other parties hereto. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a
Business Day in the place of receipt. Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding Business Day in the place of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03 <I>Amendments; Waivers</I>. Any provision of this Agreement may be amended or waived if, but only if, such amendment or
waiver is in writing and signed, in the case of an amendment, by Parent and Stockholder, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04 <I>Binding Effect; Benefit;
Assignment</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Agreement shall be binding on and shall inure to the benefit of the parties hereto and their
respective successors and assigns. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than the parties hereto and their respective successors and assigns.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the prior written
consent of the other party, except that Parent may transfer or assign its rights and obligations hereunder, in whole or from time to time in part, to one or more of its Affiliates (including Merger Subsidiary) at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05 <I>Severability</I>. If any term, provision, covenant or restriction of
this Agreement is held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination, the parties
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to
the fullest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06 <I>Entire Agreement</I>. This Agreement and the Merger Agreement (including the Company
Disclosure Schedule) constitute the entire agreement between the parties with respect to the subject matter hereof and thereof, and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the
subject matter hereof and thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.07 <I>Jurisdiction</I>. The parties hereto agree that any Action seeking to enforce any
provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby (whether brought by any party or any of its Affiliates or against any party or any of its Affiliates) shall be brought
in the Delaware Chancery Court or, if such court shall not have jurisdiction, any federal court located in the State of Delaware or other Delaware state court, and each of the parties hereby irrevocably consents to the exclusive jurisdiction of such
courts (and of the appropriate appellate courts therefrom) in any such Action and irrevocably waives, to the fullest extent permitted by law, any objection that such party may now or hereafter have to the laying of the venue of any such Action in
any such court or that any such Action brought in any such court has been brought in an inconvenient forum. Process in any such Action may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court.
Without limiting the foregoing, each party agrees that service of process on such party as provided in Section&nbsp;5.02 shall be deemed effective service of process on such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08 <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
ACTION ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE MERGER AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.09 <I>Governing Law</I>. This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10 <I>Interpretation</I>. The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of like
import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or
interpretation hereof. References to Articles and Sections are to Articles and Sections of this Agreement unless otherwise specified. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular.
Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation,&#148; whether or not they are in fact followed by those
words or words of like import. &#147;Writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any Applicable Law shall be
deemed to refer to such Applicable Law as amended from time to time and to any rules, regulations or interpretations promulgated thereunder. References to any agreement or Contract are to that agreement or Contract as amended, modified,
supplemented, extended or renewed from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise
specified, from and including or through and including, respectively. References to &#147;law,&#148; &#147;laws&#148; or to a particular statute or law shall be deemed also to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include any Applicable Law. Unless otherwise specifically indicated, all references to &#147;dollars&#148; and &#147;$&#148; will be deemed references to the lawful money of the United States of
America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11 <I>Counterparts</I>. This Agreement may be signed in any number of counterparts, each of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by all of the other parties hereto.
Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement
or other communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ILLUMINA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STOCKHOLDER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print
Name:</P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile No.
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Voting Agreement] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc646626_92"></A>Annex E </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g646626v001.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">VOTE BY INTERNET &#150; [&#149;] Use the internet to transmit your voting instructions and for electronic delivery of information up
until 11:59 p.m., Eastern time, the day before the meeting date. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form. VOTE BY PHONE &#150;
[&#149;] Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m., Eastern time, the day before the special meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark,
sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to [&#149;]. Pacific Biosciences of California, Inc. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR
RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE &#147;FOR&#148; PROPOSALS 1, 2 AND 3. 1. To adopt the Agreement and Plan of Merger, dated as of
November&nbsp;1, 2018, as it may be amended from time to time, by and among Pacific Biosciences of California, Inc., Illumina, Inc., and FC Ops Corp. (the &#147;merger agreement&#148;). 2. To approve any proposal to adjourn the special meeting to a
later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the special meeting. 3. To approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the
compensation that will or may become payable by Pacific Biosciences to its named executive officers of in connection with the merger. NOTE: Such other business as may properly come before the special meeting or any postponement or adjournment
thereof. For Against Abstain This proxy should be marked, dated and signed by the stockholder(s) exactly as his/her name appears hereon, and returned promptly in the enclosed envelope. Persons signing in a fiduciary capacity should so indicate. If
shares are held by joint tenants or as community property, both should sign. Signature (PLEASE SIGN WITHIN BOX) Date Signature (Joint Owners) Date </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g646626img002v.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">PRELIMINARY FORM OF PROXY CARD &#150; SUBJECT TO COMPLETION Pacific Biosciences of California, Inc. PROXY FOR SPECIAL MEETING OF
STOCKHOLDERS THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder of Pacific Biosciences of California, Inc., a Delaware corporation, hereby acknowledges receipt of the Notice of Special Meeting of Stockholders and
Proxy Statement, each dated [&#149;], and hereby appoints Michael Hunkapiller, Ph.D. and Susan K. Barnes, and each of them, proxy and <FONT STYLE="white-space:nowrap">attorney-in</FONT> fact, will full power of substitution, on behalf and in the
name of the undersigned, to represent the undersigned at the Special Meeting of Stockholders, to be held on [&#149;], 2018, at the offices of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, located at 650 Page Mill Road, Palo
Alto, California, at [&#149;], Pacific time, and at any postponement or adjournment thereof, and to vote all shares of common stock that the undersigned would be entitled to vote if then and there personally present, on the matters set forth on the
reverse side, and, in their discretion, upon such other matter or matters that may properly come before the special meeting and adjournment(s) thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE STOCKHOLDER(S). IF NO
DIRECTION IS GIVEN, THIS PROXY WILL BE VOTED &#147;FOR&#148; PROPOSALS 1, 2 AND 3, AND IN THE DISCRETION OF THE PROXIES WITH RESPECT TO ANY OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE SPECIAL MEETING. PLEASE SIGN, DATE ON THE REVERSE SIDE AND
RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED REPLY ENVELOPE, OR FOLLOW THE INSTRUCTIONS ON THE REVERSE SIDE TO VOTE BY INTERNET OR BY TELEPHONE. CONTINUED AND TO BE SIGNED ON REVERSE SIDE </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g646626g30p56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646626g30p56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+(4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "]G8 .$))300E       0Q?IXWP(TE$Z[NN04
MZ>6OCSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             '$   +3          $                          0
M           "TP   '$                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   '$     4F=H=&QO;F<   +3    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !Q
M     %)G:'1L;VYG   "TP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      (4@    $   "@    &0   >
M "[@   (-@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ &0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M<0]]SV.]OJ[VM?ZG[Z-7@8E62<ME<9!K;2;227&MNK*W.<?=M=[E8224U\?
MP\:NVNBIK&7O?9:WD.?8=USW[OSK7?SB!=T/I-[:&68S-N)6:L8-EOIUN K?
M53Z9;Z;'5M;7[/S%?224U:^F=/JRF9==#&9%=(QF6-$$4@[FX_\ Q6[W;%6K
M^K?0JB#5AUUM;$5LEM<->[(8TT-/HN97D/??6ST_T=S_ %&+3224_P#_V3A"
M24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %^34T *@    @ # $   ,    !".$   $!  ,
M   ! 6(   $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5
M  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (
M  $Q  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (
M  @ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HQ,CHP,R Q-3HP,3HS,0     $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   +3H , !     $   !Q          8! P #
M 0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
M     0   7X" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!@$U- "H    (  P!   #     0CA   ! 0 #
M     0%B   ! @ #     P   )X!!@ #     0 "   !$@ #     0     !
M%0 #     0 #   !&@ %     0   *0!&P %     0   *P!*  #     0 "
M   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @
M"  (   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,3(Z,#,@,34Z,#$Z,S$     !)    <    $,#(R,: !  ,
M   !__\  * "  0    !   "TZ #  0    !    <0         & 0,  P
M  $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  D .<# 1$
M A$! Q$!_\0 '0   @(# 0$!              8'" 0%"0(!"O_$ "T0  $%
M 0$  00" @$#!0    4" P0&!P$(  D1$A,4%18A,2)"<2-!46&!_\0 &@$!
M 0$! 0$!              $"!08$ __$ #P1  $" P,+ @0#!P4       $
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M12EO"\/UQ@A7Y90+=03()EN.7B,-RXLU4X&&L7;U%Z;//LK%2"7R;<8F3_\
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MGZO7L ;0]HN&,G8_@OR>EHS3P.8V1R3+D:?Z53"<*C-+HMWC/1!3ZV97&!?
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?(^$1\(CX1'PB/A$?"(^$1\(CX1'PB/A$?"(^$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g646626g53x69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646626g53x69.jpg
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M 1$  A$! Q$!_\0 'P   @(" @,!              D("@8'!0L! P0"_\0
M3!   00" 0,"! (#"! $!P  ! (#!08!!P@ "1$2$PH4%2$6(B,Q.1<9)#)8
M=Y>W&!HS-S@Z05ES=7B6L[;6US1TD[@E45=VI;75_\0 '@$!  (" P$! 0
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M/TB-B68JAE+AFTC+?XB1P9''B51/@9D>=&LC=C<&'-D>XZ,8QQ<]Q#6@D@*
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MX$<EJIMJ'>D#Z!*O"U?<E+&=SEBW:].+;^H^T*M:&%6.N*S^(*H6I3*V98/
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M;%5D671A<@B4A"AI2(;G[$B*@!U9>'9DX[\2XRZX-&'M]6:.)/ ??WX*KCP
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MJ'DO['M3*V0*RV6-D0D:HQ))4@Z*_P#(J5$)EB"L*'ADXC(.-KT>^:$4+KZ
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M&,1H#);<N7B+V/WU)Z_P^NXZ_N/M,\4WH<T=^3UG 6/3EM :<0M^%G]?VJ7
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M?T9283Q:X$<OO4*.?-3O2;^[R&M++P1[8_#3=I\7N!R,KVT-EW,6'Q+1M/\
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MARN3U@^23RN^<^B0\A*_*?,9XW?+_,_(#O\ L>_[#WL^[Z/=]EWT>KVU^"B
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MQQST5%VB6G(TL,;]PZ\#H?JE$<8/B2]V<)X**XQ=V/BCOAO:&M &*ZULV B
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6>,8QC'VQC&/MC&/MC'1%YZ(CHB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g646626img002v.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646626img002v.jpg
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M$0$#$0'_Q "Z  $  @(# 0$!            !P@%!@,$"0(!"@$!  $% 0$
M              4! P0&!P(($   !@,  0,!! 0+!04%! L" P0%!@<  0@)
M$1(3%"$5%A<Q(I9705$CE3;6-W?76+C4=K<8>'$RDB0E89%"4AF!,]4F"J%3
M184G1V>7*$@1 0 " @(" @$# P(% P4    ! @,$$042!A,'(3$B%",5"$$R
M47$S)!9AL25"4G(U)O_:  P# 0 "$0,1 #\ _OXP& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M[4Y$*42L*=:F+-!H8!>TP 1:^W6MX%>-\&<2[UO6^2N==ZW]F]?D]!/T;_\
MX'@69CL=8(@PL\6BK*UQV-Q]N2-#$PLJ%.VM#.UH20IT3<VMZ0LI*B1)" :
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M:.(^.F!V:WYCY<H)H>V1Q1NS.[-M40E$XM;HW*"U:!P0+$[,6>E6HU103"C
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M2G3IR2]!+*((*!H( AUK00ZUK7V8$)V/S#SC<,@*E=KT54MD2<AM3LY,@F\
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M7;JX?%I<X[;6A,D2;6K-$ ^0SV>\?LUZ[WZ:P-]P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M*3_Q,P'YGVA_EML7]M*3_P 3,!^9]H?Y;;%_;2D_\3,!^9]H?Y;;%_;2D_\
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MX5))NME^S19A@2K@,!@,!@,!@5]Z7_L^BW_4%RG_ *G:CP+!8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M1.7)>9XQUB9O,<3QI,UZWYXKF9RB SBQTL9D<(3P!;,@NC!*RF.*(+2>=QV
M.4BEH6$<29FN3/VOHB5*A<60!3Z%FC />M;Q-GN^JT\^37VL],>7%&*;^7,1
M6,][8\,VM,>,1DO6U*S,\3:./U3W2_5_V!['U>IW/0]5L[FAO9-^FM.**WOG
MOU>MBW.QIBQ5M.7)?3U<V+8S5K2;5PWC)QX\RY&[K3GESGCA6A%DH$\Q:[,-
MIE8@=6:3L;=JURV,,E*KU-)'ED01A=*W!A%]4B1D+##5Y7KM-HW>MZU6O==5
M;9G4^>D;%<_P3$_C^M\<9?BB9B(F\XIC)%8F9FG[HB8B7G+]9>_8NEQ^PSU>
MU;I\O4_W2N2D1D_^-C<OU\[UJX[6O35KO8[ZE\]ZUQTV(C%>U;VK$V+R4:(A
MQQOZIVN1OD552<P;O&W4]@?M(&"2.K<U2--!S[*.C*UY;&A6T$R0,#3[=-(-
MG_5"3"!Z V,P 18L;NK.6V&MXG+2_C:(YGQMX1D\9XCB+?',7XG\^,Q/'YCF
M?MZOW]-##V>76OCT=G7^?%:\UI\N#^3;3^;'%[1:^&-NE]><E8FD9<>2DVYQ
MW\=+WV#SL&JVN[OS ,%53S7,AMMOF@(?.S&PVNHJX-;8_P H,*!&1+TB1O5O
M276RCB2U)A9P3 %"+]1:P_[[U/\ ;([GYJ_VN=><\9>+>/PUB+3DYX_VQ68G
M_C,?F(XY;%/U7]@Q[Q?ZUGK,W_GF/N,?56T?+%\\=CER7Q8]2*^?YRVRX[X^
M(F:UR1%+6BTUB1O8?-Y%?6A:"BS4:>&4L8V@M58IC\N3N\%"\MC4],RE^B9S
M "6IT+PSO:56C4!0C(5)C?E*&, 1""R=YU.'6V=O+GI77T_^O,\\XOV5R?OK
MQY5_IVK>.8_-9BT?B>5-/ZK^PNQ[OI/7='JMG+VWLLQ'54KX37?F=C)J<:N7
MR^++,;>'+K6BM^:9\=\-N,E9JRC9U+1[S,7R -4K=5\LC"ZL&Z3-:2!V&>".
M*KG3D*JPT_N1<4$TLY$O(4@V0<H/+)+WZZ.$6((M:NT[7K\FUETL>2+;>&<?
MG6(M,T^;_I^7X_$7XGB9_'XGGA@;'H'M^IT.E[/MZ=L70=E7=G5SWR8JTV/[
M?,1NQAF<D3>VO-J^=:Q-I\J^,6YAQ"ZLH?:5T<DTU4.C*TRUY@1\B8HC-9#&
ME<VCJ9R5/D499 QQUQ:) ^M>F=42:G0G*!Z5D#3:]5(1%:]4[30RUF^+)%\=
M<EL<S6)M'G3F+TB:Q,3:LUM6T1,S%ZVI/[XF%O:]%]LT<^/5[#3MK;>73P;=
M<>:^/#DC5VHQVUMB^/+>E\>'/CS8<^+)DK6N36RXMFLS@R4R3WZ_Z9I6T%<K
M10B5KG<^#.$[9Y7L^&3IE3LKW6#BUM-@,2E8_1EL1C?8HX/24M6B+,&J!\P1
M:+V'U%IJ=GH[TWC4R1?X[Y*6XB>(OBMXY*S,QQY4M^)C]>5/8/1O:_5::]_8
M=.VK_+U=39PQ>^/RR:^]BG/J9ZUK>;3BV,,3DQWX\9KQ^8YCG76?L;G)Z73%
MO3V$:@-KP@"F?J9'#)_$FJ#DFP$ZTB!R][E,69V:-[45\F,=2]+#R1&)2Q>W
M6Q!V'5FO=]5:<T3FK7^-_P!:;<UC%_2C-_4FT1%/Z5HO^Z8XK/,I'-]8>^XJ
M=9:O6Y\L]W_^OKAG'GOO?][?K?\ L\>&^2^SSOXLFK'PUOY9JS6O+=J\Z J6
MTWO\,PZ4B420<*8;)21UZ8I%$WUTKN3GGI6&=,S1*VEE<'B)N"M.(G2Y,6:0
M4?[2C1 ,$$.[^OV6CM9?X^#)$['Q5R>,\UM\=^8K?QM$3XS,3'/'',3$_G\(
MKN/2O:.AZ_\ N_::>2G4?SLVE\]9IEP1MZ\4MFUIS8K7QQGI2]+SCFT6G':M
MZQ-)BSI(>D:7<WAS9VR9!<MLT_W53H]-S')%T21604#8UD*.F:5G.BFG]K%K
M9:TG2S?T)^MDJ-EG:V7E<78Z6>UJX,D7\,LXYFO,UC)7\6I-HCQ\JS$UM'/[
M;1-9XM^'G?\ 3O9NJQ8<O::F36G8T:;N.F6:X\M]3+$6Q;%<-K1E^+-2U<N&
M_AQEPVKFQ^6*8O.N,77_ #I)"4*IGLA*I1/<.F=@11P&Q2A*WSR&5X/VS60U
MRM5,A*>PT,>!O1IWW*)<8),,"@L(R!@,%CX>[ZG8C'.#/2U<N*^7',?IDQTX
M\[XYX_J5CRK/E3RCBU;1^+5F9?LOJ[[!Z>^WC[/JMK!EZ_?U]+<K>(BVEN;4
M7G!J[M?+G3SY/BS5C%LQBO&3#GQ6B,F#+6G$A[(YH<XM1<T;;69W"-=+2,J(
MT<Y(FN2*=S^2&&JB!-*!&2RB7MBA,I1&E*-N!20"8X&RS1 '^KEO%[#TF?7U
M-O#LXK:^_>*Z]HGF,MIK:W%?Q^OC6TSSQQQ//$LW>^G?L_K.X]A]?['I-[!W
M'J>O;/V^+)6*VT,5,N+!.3/S:(BLY<^&M)K-OD^2DX_*L\M2.\@/(*9DEDA5
MW*WHFJ$,TID4C.71:>(5"9C@TX)K::.B!N5Q8EQ?D<3G*@MN<1-Y2KZ,XP&S
M?:6,(]VK^S]!CPY-C)M8ZXL-,M[S/,<5P9/BSVXF.9C#D_9DFL3%+3$6XYCG
M/UOHK[<W.RTNHU.BW<O8=AL=?KX*T\+>>?MM3^?U>&;5O-,>3L=/G9TJ9+4M
MLXJ9+8HO\>3QFF?7Q5E7HJX7SF1JF0BW)6QP:NPZC4K<U4EF,D;U3JQ1LA"S
ML;@M1.SH@0GC**5%D;WLD8=^@@[#DCM]CI:,X8V\D4G8RQBQ\\_OR6BUHI'X
M_6:UM/\ RB6F>O\ IOLWM->ROZ_J9-K'U'7Y-[<FDUXU]3%DQ8<FQDF;1'QU
MRYL5)F)G]V2O_%H3IV'SXRJ8HC<Y=($BV<2 $2B:(=7VN)8]RT::1K-11*D+
MA U&I,%)$G P3>,(%8 )_41>M&%>^WE[;0P6Q4S7FM\^3PQQ-;\WOXWOX1'C
M_NBN.]IK^L169F/T9O7_ %][;VN#?VNMU:YM;J]3^5MWIGUYK@UIS:NO&QDM
M\O$8+9]S5Q5R\_';)FK6MIF+<?)?9/-9B6;*OS-2$ZKR0U]$92E5QZ7H7,B6
MVLW-SM7,5:6E;'T[I)Y+,&YV3&HT#62L5#"=KU '?KK5J>]ZB/EBV>D3@RX\
M=XGF)C)FBEL6/B8YF^2,E/"E>;6F]8B.9B&=7ZJ^P\D=?;'U6S>G::.YNZMJ
M^%JY-/K\FSBWMN;5M-<>MJ7T]J-C/EFF+%77S7O>*4M:/QX[,YGCB-.NDMJ-
M<:3F6T@HI?N0-,D9S(U;3JD"O:X7-"ES,2.#KG1O&%0E/=](D2E,()I1PRQ!
M%OSF[_IM:.=C8QTC^377GRGCQSWB)ICMS_LM>+5M6+<>46I->8O69N]9]1_9
M?=7\.GZ;=VK3T>7N*?%6+QEZO7O?'L;N":S,;&#7R8LV+/;!.2<.3!L8\L5O
MKYJTGV/2EDE(7D;(I/4A8) ZQ9TV>W.3=\#VR&A(<DQ.G)&DVN((-'K05)'R
MIC?M^,P6M;R6K>M^?'_29C])C\Q_S_\ ?]&@9];+K36,T1$WI6\<6K;]MHYC
MGQF>)X_6L\6C_6(;#GI8,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5^I[^TWJ[^
M^^)_Z9^?L"P. P& P& P&!7WI?\ L^BW_4%RG_J=J/ L%@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@0%U35#[>W-5[TM&%[2U2"UZHG->M#H_&K"69M72Z/KF,
MEP<AMZ)P6[2(A+?D$$HD8QZ#[=>GKZZA?9>LS=UZ[O\ 3Z]JUS[>GFPUM;GQ
MBV7':D3;B)GB)MS/$3/#IWTG[OUWUE]R>I_9'<8L^?JO7_9.M[+-BPQ6<N3%
MH[F'9OCQ>=J4\[UQ36OE:M8M,3,Q"B5C>-4]_:.9D-;RA-5<B@4M5S>\;+C4
MMF!5ER.7*.>55'()9!Y2O0.Z\QVC'R$'-J=8-"A3(TFB"BB@FC#J [#U"=K^
M!_#O&ODP[-LV?)2UHRVM.CFTXO2\UMS>GGC\9OQ$4QQ7CCBKK7I_^15.CCVR
M/8M:W<:78]'BZWJ=+9P8KZ&#!C]IZ[V/)K;.O3-BC'J[$ZNU\U=:;9+;.W;-
MY^4VRM<K[Q\7!$Y'R'(G)3317_*W1,RJXUFKN3V!73/-I698L0G<0EBI.EA[
MM\3;)%4-+42M J^L)6+G!4(&C0[!O6+UWJ?8Z>QU>QEG6YZ[K\^O-<5LF*N2
M]\NM?'?B*SQ6\:_.6EO.(M>8CY(CF9[W/_(+TWV/J??>IT*]W-?<_;^J[>F7
M?PZ>_FU-;7T>ZUMS5F^3/7Y,VO;MXQ]?LXHP6M@U:6M_#MD^.EEZSH&^JXZ
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M6O%MW+..E<>2](F6_>>9;85_<E="PAZ80O7-4AM0#E#94H<T#)+(E<<$U"I
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M@O\ 36Z?]^8]_P *Z_P)1P& P& P& P(JN'^C4?_ +U:6_XM0S E7 8# 8#
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M707^FMT_[\Q[_A77^!*. P& P& P&!%5P_T:C_\ >K2W_%J&8$JX# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)%<BF+55(%M;="-]IQB*UM-B%Z6#AA:Q#T?$W9W5:8%Z%4@'MC$J:2$J<"D
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M;-W!9E)A;&HT3I9Z*9Q6TI%"FJ:B&%<SU#.K9A+?('-KTC-<0FB5)4CBE2*
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M4_\ 4[4>!8+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8%?J>_M-ZN_OOB?\ IGY^P+ X# 8# 8# 8%?>E_[/HM_U
M!<I_ZG:CP-^LVV*]IR-J)?9<E316-)$[PM6O"M(Y*TJ%OCT?=I6_N:_;8B7&
M(6IDC;$L6JU1H0)TZ=.(9@PZ]/4,+!;ZJ2RI*OAL*F:-XE39&VZ8KH^- \M3
MJ1%W9R7-+:^_1O+:W&F-RQ>W&@ 8#0M;U[!_]PPL0PE[ 8&KOLUBD9>89'G]
M^;FE[L-]71F$-JP[XE4F?VR,OTS7M+47Z;^H6)8K%W!>,/V>B=&8+_X<#:,#
M'$NJ(]T7,Q8S]N#:C;EZL D2TM.%,[&N)*(1*\Q.! K-&8U'^\LHT9A.@AV8
M$&C"]C#(X&K2Z;1.!-S>[3%^;XZV.DFBD-;USD;LE,JE$YD;9$8@R%F:"+6E
MTAD[RD0I@[]-&*5  >OJ+6!M.!UD:U&XI4ZYO5IEZ%64$]*L1GE*DJDD>O4!
MR=00,9)Q0]?;H0=[UO U]5-XDBFC-7*I_;B)S(HU(IBQQ<P[VNSG%XDY1IGD
MKXD3^G\HWLKI,6L@\?K^H8N*U_\ %@<<'G</LJ.)Y= Y"W2B-*W&0-*=Y:C1
M'(S7.*R%TBDC0Z&((!:4LTD9%:(\.]:V ].,/\&!TPV7 1/L[C&I6S_B"L61
MCDD_:=J?:LB;!)4CTN8'=X*$'7TZ!V21Q>,DS[0CTD-_A!O6!G(O)X_-HS'9
ME$W9&_1:6L31)XT^MQGS-[U'WYO3NK,[(3O37RHW%N5EG%"]->X ];P,[@:0
MX61!VN9ME>+9&@*FKNG1JT<>!I0H7!2.1,F4-*I?],2<2TIWD$+=](1JQD!6
MC;%0"-F#(,"$, .]*9+GAE7'6C!4]BER)%#Q0I3)6I-)!2URAI]BMT6*:E"D
MM4=)'"OTIKX0A $2HYH),5@!M. 9F@E; @]YZ-J!@7Q-I<Y&Z@>9KMB^XF))
M!I\Z/P29.XNS1'5K\Q-<76NT1;'IR8%Y294[$H4QHD2CVCWHDS80G# @A@Z;
MH:3RXV!L=E,2R7 E\YKTED&6YHU+C/:S0?>T_A#(8N0)DS_+HBSZ$L7-J(Q0
ML(1@&?LOX0"'H)D9'=#(&9I?VS:O;:]MB!W;]KVYQ9UVT+DE*6I-K&AX2('9
MK5[(.#\B9402I('Z@,+ ,(@Z#E<W%*SMK@[+MJ-(FM"K<5FTB):Y*M)42<Q2
MHVF;FY.K<%ZCXBM^PD@HTXT7H$ !"WK6P^V]<G<T")R2;.VE<$B9<FVI2JD*
MC:=62 \G9Z)<2F6HSOC,U[BCBRS2Q>H1A"+6]:#MX# 8$>1*UH#.I#*XO$I
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M691()2\(&)F3*&Y&:X.)X4Y&USRYHV5F;B?=^NI<GEZ<$Z-&F+T,]4K/+)*
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M#'G>^Y95LZ4*2W272Z,11PN"PDCP_25,1,8PH(F,;C&Y@_J26\]&:!0@0A(
M6((2]>@4(K[E'L=B?$K-.(["IY6JG5T'Q #GT!+6.0T"[K+VN^S8"X,S=#H*
MPL4\:)S6-H,T1<V4(FMJ:@1@I-LE8T&Z) $5-?CZ[%.YNK.E9>LACM,*V@EO
M1D^PV*V);%M3M3(^.RZOI,Y_9F5J1(FQ?3%KIVYM3#2%:1A;8^ED*8@ES5J$
M)03HKXKZLF::;[E5H!8YB='>C3&V>M4W?S0V#)9K-:SM/E(N4-*0A+MG(YID
M<-,:#]@ :6J:BS2D_P B9Y<2"PYD/$73I,-1M#Y8,1?I$W=95Q;4.=27-[VG
MKFM5,S<[UL5 A2O*54!_7P6YK$?6V+I#?C^>(L;(G.4$CT<$(5ZD_#';DOH!
MR@C_ !& N;_85.WQ5=K0IWZDL&4PI?=<EJ6LZ_K+K6,N+K6K<4R(C5L!==KX
MR4W 7$"DYKH8I6N0E6A!UVBONGK-LGH]SK>.RPV:-%@S$YN;I[9EA02,3VOF
M?K9BLE\J"S%$HIM(6PNLZKI(K8H&_-J20MR")%%H%!)S:HVJV%\N7^;KJI^Z
M4LD=%1Z6J3*820];$YM9SG=DEB\I;FRKD\>35W:3NU1V;KXOI(Q.B1^;I(2X
M)M.*%*YLAJ$+DYHMA$70_(G1DFM6^[?KQL8I<*6VE2RAI@CW>$O@)=@T"W4H
M&O[<K1.[$1F7L=6N(K&*02M+LIL5$/"IC( H-3#/V:2&H//*/:S4CLE#'FJ%
M2ISB[_73[4\T?^F[2 _VK2J9QI%;.N1;&$\0=])1F(4-9N:)#.G<F0FK_K '
MFHDYCT_ZP(^M/EJW(O)Z1C<CBDQE]13RQ^6Z^5U4AZ$M>:*B6F%<V=I-5F-4
MVL140SN 8B6[3&*HM.JP:9.[K$27Y"B#0(P""\W O,MJ<RI+@9[6<VN;/4T5
M4(\;M<J1N#Y([ =81R_3E-S ^6ENS>F=-.B285JN4EKCSU!SJG<0*#OC4".!
MH*IR7A7I^6L"M#,'R-S-R*E$"%+RG28+],%X'PKOV#='QFV7- H;51<1ET,H
M-@=(V2FT2,9JIVTUA/TTH$:C07WZPI:56POYF?(?'8W(U5,]!?F,\MT@>=L.
MP1MQHZZZL/6,JK36Z$J'5F?+';E^DQ@2@G$(S-!,T9H 1!Y90_Q]]B5]#*]K
MQN3QZ0U87%*,B-DUDU=*V!61X9.U<QP&J9S<<*G;/#)"[L[U!;*@NUJ),D+;
MU3HB<1.!!Z%R3%DFAZS]4\_LO24%AE4S2(M,\KM?/6]3932[NJAG,#%2HE+F
MS3XQ+4ON=$TL89&YMZ]K4)#TJY L3@6)E)2A.4+8>?RSB;M?\+.4.D%WM%BN
M"UBZ"BD;M9*].D"FT;FSXY4B'F3J62I6E 6C>;;KZ(5BK124+>).4L<U)JA"
M46E=5R4D,:/C+KR%LZPFI2H"T*XVJZX=$[ ?:$ACT1N35H>0&INH8;').C98
MNL*B!=AT='9+#G1R"D7J&(YW^, %B(TWT":*EYJZ CO2T E\IB;2UTNPQ./R
M.%-['TQ93POH*2 BDYC4WI17&G2*%ZO*%2%7+27-(O6NB%N2*R_33: +.R[V
M$H7?0%[3_H1),H[*2$D&*WRR[PM[3RAR9'NHG:F;SDDWOQK)CR5-])*6GI*H
MGTB,J-[.WH6DOPK2_I@D#"&>Y?Y]E-/</M//\IA5=N$L0PVTV1P@ZMR.>:TD
M*F7O\S<T+&_.?W*4K6QI\0OI"=RWM"(823#0:+,T$/N#S*GW&-M1!QI^A?;:
MDRH6:6A83)5E3O\ =\Z?7*F8?_R776V+8J_7VT?22Q=3,>N'<>.@Y$E7NCRQ
M&$:"D4 %MN:TP20W\A]\1A-+%CF[QBZK!A#Y6REEGDHZ%FT<9.L:D0S.O)3-
MZ5LNMP5\Y,-;2!(VQE>WHI"H,D9)X-@*^(A(]/118+VXK[$D+#8L>J1/'V1G
ME=>ULPPE MZ3M%4X57+H7S!;\ ;G9AD$D9'\]Z+8;/D;  QS<$YSHI(2?>R4
M*)T)).)#TIYAJZ<UB9T4MFZ%H1'6GTI/+;C21E>-O/LB\FC,&;D)+D>8@; )
MG<"Y@4A,*#HPO0/8+1F_?L(0\S%7C>O9'&_NIG4P,Z&&7?R3U TT\I?UJ=-$
M>AH7>E;/_4,N32<#.<WK6*7U55>EK"E C+-%+I8]G*!$ . >$/U[X[[<6$2-
M2\M3).UQ]L26/V,E3];6' T?3=&R$%WD0J>(TZ*K71OH.TZGW:30J&002ZJE
MXV72=*Z)RFUE,"'-/>".H!L]RQ^MU+(PZF4N[;?FE[071-&)=(3^A*-@,<JV
M1R1R2-7WX;)8K9+(H$L7*1J%R?2;ZX@TTQ485@1Y<5.7/7]G1&L#H]8;["7N
MT[WL&&1R%V!9",#7!Y%T/0=JP5B@$K*KV2Q!BMOV0B0MZYO7/").FBS^O2 -
M^E7'*4P>HG7]-6Q;NZT)@2Q$YPUJU:[39-?+)(OAPW_\<U7(XG )FV2%O*-.
M)=ZOFRU,O)+]2C"0'C<$@_O% B+,#%<:\\V-13]T*Z6<O9Y3(+/E5*/.['1K
M/D?+%5P'EJD*>F$LE39]$F"R/$AL:O7ETT0$U3H:=P+,$,)HC"BPF6GO[3>K
MO[[XG_IGY^P+ X# 8# 8# 8%?>E_[/HM_P!07*?^IVH\#2.S7ZZ6"M8FIH-7
M$UM@'VC%2PUK*)V55BV\8\C0OSQ)*@@UFGM;RG@UA2!I:S%C4K.(TG4FMPD1
MYZ,E48M3A16IO(9,'61UI$$P#'1AM6$<OLM?K[I;D48M"/69<TOZ_C\N4W:5
M"U*F(G(F!VYI!&T>X_L;>ZOS@C^D6'$+R3<"/[0\FLLM7EZ_'ZO26"D;)KVA
MBYF\Q!=/B"K]:'YVJ%JM>-S6IH@MC!R"PZQ>'09[&D<E&FPM<40H6!&6,G:(
M0;=)_(#.TULTU;$3/8I!4DWIDU5+:K,D:]M-C)SUW-1W.1:I<A4Q;3NBOJN4
M5C*V^1,BP25&@>T"MKV/8@!58')(/().[&'SVZQYE=8+&I?.>7K9+51!9M[<
M'ZN;3DU]PJ5<_3UM<&LH2.SVAPJOW'(D9@1*5NC4P?A$WF[4A%T.\I,M,GTL
MD"5VJV2)+XKOG.<<_P ,E5PQV(U7#5TIY\L6X72OWRR'=(A)9IO-_P .Z1A]
M0+/<-N6+BDP@IC$6PM8V]_6<4_('"855"&*JG?J*Q.<BIK&I=(9\LB1]>7<V
M4HG>[(8VR,MKU'FF?/KXE(1/"!&[,C(ZG)$KRH1IW$E<2&W]/]\G<^W,75C9
M&X)*_9#5[NO)6SI2QR)I?SZ*ZGNJ+E/2$QB/3H6-]_Y9QMI TNW)2=]Z'*#
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MZLH343_T3%&.!(7D(2)DSO+%&B7%N2)3/HTB<X#F+V$%;,P.U"+GH6U$%\6
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M$H9:NZ)!=E?-JFMJ[129CBXFZZDZ>J9;.F!.@DDZ0MJN[W3;>Z.(OJDZ9&F
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MB[JE"G]%#&\+"M&!V;ZZ"NB'QIL"&?II2SW2H+1F3^_7NQH*LK.OI$P26 =
M6RDO#\!-B=]*<E==/<"EZ;8&.1-H@+0MBDPLPDP\"-6D#IL7C$^ZZSA==.E_
MNC^9 XU;E:,\J%45;QU\=:ELFBG&AV1AF)D03L&I;.X4P&HE89(J%L:\]'L
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M*CB-$5-;:A&L>RY:^%OCV638#C[$Z)X(2J$I918$X#]C ,-X:/(%1,@.>4;
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M/<#Z?E9LFAXR*8:)HX2->S5(\"Z]LCH$J!L 3H.ZD1V"HX!+DD>3.:%*)6E
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M"E8L<L"JMD<*]'V#T-.Y^NW3WY;RFQ(L[*&M/84^1K)/#(CTQR3<S6*2QT^
MN?OD^Z\IV6QPXDQ[5MGR/!8$A:% J5D%AJ$7\?74,7D--Z7JJ3F$1JF=TA.X
MD!SG$V2.E1M=+W!?4E75[7:;57NQ:]GG5<6:R)@'_(V?0JFD:$TI4B(0'%AZ
M%W!7-JWO!.97@3 Q5_-(7=E,719$+=9@K<4K*W1I(Y&3F%M,D8X^8FEBW7WL
M8B3B/2H4:XOU&;\'KH&!$O W(U@<LMK^SS91"SFY]I/ER'N"2)/\@?DSQ:=3
M0"00RV)TZ D$>8]G&S?9C3HI:/Y5RY,A %6 G9)0=A3ZO?%Y>,-0U7MID]/5
MY*JQ@?-U:L<Z@+M*C7N/-521SKV*3R3QL@R 1P)#A,$W0+,N"V".+(5GMZ@A
M4K]I*8\T,B[^./H245()@4_DS!K#D%$]&5Q8.HW>%\R^(2.RK2@G.$-B]GM;
MA+(&C=(L2O64BI<G-N0("-MBA4 P![LM/6N!H7GZ/YFE,Q@M(02D&BKVJ 5M
M*G_<NI.6*7**UK,('(:?LRND+44JCL0E^TRJ RR:M\C;DAS2:C5J6H(1#2'_
M  *TX4\@?CQZ'B$.B307/ZZ026'2;FB1M"LE_?95 SP4YR]0-#3F/RVO)96)
MZ24L<L=JO<US8H0K(^_,QPT2](Y)E UR8T,O'?'Y;CZBHY!<J&CWAWK:T%[I
M9%AL$ML)^?;O9V*D;VKBO;HET2E,.01I+<()A8S"^N#0(U<E+6M U'WVMV4W
MITH1<7XX.B'JO(E^)V:BT=S(JZZ,K&>2U%<MQS%NF#_9?+3/1$;O]F5S.OQK
MJ_D\K?X@WK']@:TP=IBSAJAN[PM*ULP-GL_QV](V#'YXU"L2'Z?W,4Y-9)69
M+IBV*I-$IY5]6Q5JI69C;XZ<I21"I9W"SGEH7D!4C,^[F\PM,E4JW 0 OCR_
M75G46?(JE=XA&MUFZ3_HZUHI*(O*50FZ$-,^O1TEU=U01"UD5:"&\LJ(2U0<
M/;>K,0MJA -,66(HP@\8>;UV<9=%-T@1.JV)Q"RJZUT.A3-T4C,GGKN^R:#6
MUY-ZVZ<4*IM'4U=B:8O#(#4:U_87?0ECBD)1%F;]-HU9I1(;S&_&I=K!&TL1
M+M..#8V84 <*V.,D<T$\TK'(T]7@HDO.T24F-"L3Y3DIA=CML8,5J#DRC3:4
MH$8@.^E;B@!:7D3DR?\ /%;7! I"X1%>DGD8J1.RMT2E<P;D09;%^8*QIVR'
MA>\?A]K=V%=-)_!U3F)V1!/<5(%(5I^@KA& P*R,'C_Z>BRJ+IT5A5B^M;:O
MI-,<].CXZ1N:-L<I;KV"]"MRMX.A%0LT0LRQGJ"(GJ.K7W33%OKA:2F*TZ@:
MMP/V&IR;QK7_ &)4\4B,ZUSP&Q(M!KMA[_8+7,+0=-V],GWFB;TA4_04L;7J
M!A+B5F*))($#R]IT?WB<VJ$@E1#LZJ"T@4P7GZ9YLM.\&&H6I%)XRM;8U#+4
MBMG0N5/$D1L,I>; J19#8W8+:^-#0N<ARFM9?OZMO$<D)'LAP4J"CDRPE/O8
M4(D/BQNAP13)#J45))7@Y'TD\12R']YE;-+WFV+BC/)I<4MV5HVB KBF2:L,
MUH9X<%2Q*N<5(#5R92G,V<(T!(2@=X\K1FDW3.ENHJBFZ!OZCU/GV6+K0MYX
M7W-0 9G>\R8(G/ZA=HB&M([,8"FMQ*S$DIU#LD=T*#?JM;D@2FS033W%QA.N
MG9,VOL/<(.V[9*&GM?L2B3ODG:5[+9#Y=7.MDPV9M>V"//'W>9%66IWHDEQ)
M, XI5+F ! ?B-/, %7WSQN]#+I0H;FMVHMKJU+8MT.<90HY-.D3BRU5;S[V-
MI56*B*[KE?&QQEJCW1#$-.TMBIH;OG:E:97]<2!J/0A\)_'#?K(S;;6QJY[=
MF&2F46EM6M2[0M6MV.Q(W$.,O^5R8,1]@0.I]2II4065H$LIBJP"(W:_9AI)
MA3,K*3.  NI2?(<BJNH^IHDW/[%";4OR:WJZL=OQ!9()))F)FFZZ5'5&Y.[K
M*"T,@7/=9%2<9I20Q8J*)/T9LM68(XPW80)6_CVG3;=M*V?8JBL'2(P=T;Y3
M(ZN;7J6/448[!9*#A5=EV!!4#W%T*1Q?Y-8\23O2S:PM")(8W)%X3%#D8>/
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M<=-S&?-^TYKLB82'-2D4@V:-V<Q 3;(#ST_^GY>CS:,$K&3>TTN,4\L>81T
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MACTJ731NB^E<3'('>4'31\4.467*6%X1R&2JU:YP=)$TNK><D7B5G&+ *R#
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M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P(N@O\
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M&XDJ"#BP"*, /TT+W!%K08R"_P!-;I_WYCW_  KK_ E' 8# 8# 8# K[TO\
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M+)GWFU" TZ(UMTT]/+6IMNS*L.$B1E,T8N) R-ZEW; %)BM/:$:TLK7U@RR
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MY1M'H:Z>#K/KITKI$W\I7E95L3%MGZV0$[D2"6\\6C3S,T,J!EC;XF=?:^V
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ME>;(E5[;Z(N7R13^#4!3,GB[?-WB@H;QXKL?GZD064^0J/CF5A0.P6<]Z2N
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M66.KZ3@$RIJ,$]51:$3"+0_K&L9#-^S+'KN%=*0*&*HJ9#+\ASTSQD$2>(>
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MC'URX\RT/,8V^(KO+E;_ "YC5]#T[%YE=#M$36T(*V?#7R<KXBH2E$!2*48
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MO9H81!3OFBJ&X6AF<4%,V<U'RNDNS+MC*#[TA;Z,#3PY9[A5%K,$WVR/*LZ
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M  P/KZ^T8="#ZZ_1OT%K>O76!\B((%O>Q$E"WL/MWL18-[V'7_P[WO7K[?\
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M4>!8+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MG:CP*0>:.X[(HGB/\P*GGK[7,U#TOQW$D[_'GW4><%,?L#IZK8/-6 3@()@
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M]V:(=*IHYR%B;24VZT0Q"<%J6DQH8RF-*VIE)[:>5[R]?&'D90G3W1;MQ#X
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M,:9*I79"F_X!S+.I+$@LU4.SC)Q(C'$N,NK2G:)8X)#@#-;OO@Y1I.42,HG
M\SX_V/T^]VSP/7MEIK)YUL-7Y1)-S?T57B&\M6_4ECQIOX8<[7:=4W:VM%OT
MWIZ2OI+(_:2NQ@I POC@J:E8_0("Q!67F/N#L60U7RN\M%]6):2BV*U\UYO5
MASH[)Y)NIX-S#-K@2\IW>6\)DGU]6/;3)V-FBB$?SID,C3+1#,(4*4GU10>N
M_B$MV9=!<?TG([AN*0N=[VMQ[0DO?D2:X2[%>5K+(*V9U!_0@VE0W>RJYO-;
M!D[RA/;=%%HM&Q\L)1)OTQQHPH?8O078$%J7SP3;GZT+>LVVN&[8;(+S=%'&
M1+[)(BL*?>8Z'=9J]KH6X@="YT]5\ID<BER'2LH\XQW0"('HU+LU&,/0+GFW
M++_^I290]96;++WY 5^..L+IF4VDDH-L,F%]!NMI*8U 5B"P3=JE*1SO:I2U
M[RL8OJM)0A9R7!&F2EJ#/J @JH[&[EB(/(?SLM-M2WKBX1F-V7YSO.9&L>E"
M/IBN;DIN53SC6F7QQ0'MY4Q61B:+W5@?41(2_P"6B3<,STVO%L01]SK=M_V3
M//#_  R+WQ;EK-G7W$ENV7Y!%H9&:%XKN31J%U9,(]9B7Z% 5^0$CWT ^/$
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MKZ:]<#\#&XZ%8!Q"P,H7 LW9Y:\+4ATL+/W[O4X"K1'SA-W[]_K:%Z_;O^/
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M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!%T%_IK=/\
MOS'O^%=?X$HX# 8# 8# 8$57#_1J/_WJTM_Q:AF!*N P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P(N@O]-;I_WYCW
M_"NO\"4<!@,!@,!@,"*KA_HU'_[U:6_XM0S E7 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$707^FMT_[\Q[_A77
M^!*. P& P& P&!%5P_T:C_\ >K2W_%J&8$JX# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# BZ"_P!-;I_WYCW_  KK
M_ E' 8# 8# 8# BJX?Z-1_\ O5I;_BU#,"5<!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1=!?Z:W3_OS'O\ A77^
M!*. P& P& P&!%5P_P!&H_\ WJTM_P 6H9@2K@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"+H+_36Z?]^8]_PKK_
M  )1P& P& P& P(JN'^C4?\ [U:6_P"+4,P)5P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P&!%T%_IK=/^_,>_X5U_
M@2C@,!@,!@,!@15</]&H_P#WJTM_Q:AF!*N P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P(N@O]-;I_P!^8]_PKK_
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M_P#KM@/S2=/W/VW_ #7#_P"NV _-)T_<_;?\UP_^NV _-)T_<_;?\UP_^NV
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&!@,!@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g646626v001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646626v001.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X012:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,#0V-34Q.#E&-S4S,3%%.#DP.3-!-T5!0D$W
M,C4W.$8B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,#0V-34Q.#A&-S4S
M,3%%.#DP.3-!-T5!0D$W,C4W.$8B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HU13@Q13@T-T8W-3 Q,44X.3<V1D9#
M-4$S0C1%14(S12(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HU13@Q13@T
M.$8W-3 Q,44X.3<V1D9#-4$S0C1%14(S12(O/B \9&,Z8W)E871O<CX@/')D
M9CI397$^(#QR9&8Z;&D^<G(R,#8Q.3 \+W)D9CIL:3X@/"]R9&8Z4V5Q/B \
M+V1C.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!087)M82 M(%-P
M96-I86P@365E=&EN9R!0<F]X>2!#87)D("A74T=2(#$R+C,N,3@I("T@4T5.
M5"!43R!04DE.5$527RAP86PN+BXN9&]C>#PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(#
M P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" .L M<# 1$  A$!
M Q$!_\0 TP !  (" P$! 0$           <(!08!! D# @H+ 0$  00# 0
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M/A,>$P[_ %_UYR/BI4$(TRA6I-"2G2DFJ#SA[Z *)) (PTP>_D"  =[W^YK
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M"QH?V!>G<FMQ3#ZZT:F5I1F$CZ"UO0@]>X M;"+6MZWK V; 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# TI;9%?-LN!7[A-8NBG1D<63 J'*GQN(DQT4;C? <)*
M2R&* N)S$A/WHLY4$O9!0Q:"(6M[UK8:PLOVDFXUA(76M DALF0-CLQA42=J
M*\^TO2_W4RNH1#4Z 0V/+K_NB-0;L!*I5O1)0AF;T' _*F_Z01R@V$JK9K]/
M,258T)L5-E30"0@4ENGN,P&V?:KS^P ?-Z0['HOLTMWHCKXV^S R,)NBH[*4
ME)*]LJ$S<\]N4O"4,6DC4^ 6M2%R&S+G) <W*E!*]"@>"Q)#S21# 0IUX0]A
M'\W P!7)+CX<&3#*NRK!AAC=)'>6[#.HYO4::H6MTVS1Q>__  A_X-10MP%H
MAX--[0-1HM 5;)%O6MAO[3/82_'MJ=CED>>3GF*IIRSA:G9$X:=88L$G"CE3
M:-(<:6NCZS:PKP596Q$&Z,#L(MZ%K>PU!BOZCI.OCK7';>K9[<I>;)R(D@:Y
MG'UJN4J84+9<R2QM.0O&:^JXD9K87,I+HTQ (.]'A!O6^@=!QY(T"T*&](ZW
M)6[:K=R]&M*5=+F5*I= >74+!:;4YZL!RX92)(:>,)6AB+(*&:+6BP[%H.^W
MW[2+LZK&1JMBOW-W;USHU.#>WRIG6*D#LR-/OYX9UI2=69M(\MK'_OIR0SM4
MEI/Y;8-%_.P,>DY*<>ET;?9BCN^J5$3C#*V261R8J>QD3"QQEZ/$F9Y.Z.VG
M+R**,NJ@L1:=Q,&%$<, ] -WL N@9U^NNH(L7H^26;!V).,V*IRE+K)FE$E/
M43K:D,)3)E*A4 A4IEXT9H&LLL0AKQ@V$C0Q>S PR_D;0C46UFNEPUTV@>E(
MT+3Y^6,Z,3BY ?%\9]U) *%18SG@<C:E2 "/6O,F+4QI(0;,+&'02LSO#3(6
MIN?6)R1/#,[HD[BUNC<I*6('!"K*"<F5I%1 ADGISRAZ$$0=[UO6\#I&RJ,D
MR9+##I S%R]<T*9 CBXW)'I_4L*-24B5O1+1XWGQM*=:> D:C1?@A-%H'=W;
MUK .<KC#*\1^//$A96I]EAJ\B+L[BY(T;E(CVI,%:YD,:-0<6H=#T",6C3@$
MA&(LOYPM:#[<#/X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8&K3*71^ Q>13>7.R-AB418G:2R5[<#=$HFEC941S@YN*DS?Q$I$
M:<8]].N]].FO;O6=<EZX\4WF/#^Y5<?L-]RO(8>*X[%;-O=SDKCQTK&MK9+V
MBM:Q'SU?YN7J8^HO9OJ.WVI4IS'Y%2D9>%C?1E/( +%NA-J4TT@J:/3$@ ><
M[S22%D>.8+90](R1:(+Z:"/8OG<V[IFC]S<3,X]9]-8C6?AKT\9ZQY2WX?3I
M]/\ VS[#=HQDY.F._>.;#2V^W%YI2M:WCUSBQ6M/2F.T1X=>FL]9>=#S'Y'&
M1IB)3')-%U"KKY<N41UYCIJK>M?_ ,L%W0HM'] Z]O9UW^YD?:-K:?7C]49?
M#28TZ?C#(78\OPO*3DW/ 9\'(17IKBS4M--?'7TV]5NDST\EW/2TUU]27A)K
M6C!FAOZ(&[**+&:/10!*MFFB 5H0PDD Z[&+>NT&O;O>M:ZY[[:)C=XJ_P":
M;QT\_P#M\UG/J8C:U]A.[<M_RX)XK+3'>]O3%[^CK6(F8F9B>D=.LZ1YPU7G
M'35OP[DGR6E\TJ2RXU"WF^+27M\MD-?R1MBK@WJY<Y&)5)#ZK;0-9R=86,(B
MS/%\,P.];UO/+%AR?R-S%L<Q'JGK/6)CX^?3[U5[%]\]D[WV[[<X3:\MQNXY
M+%PN"ML&+<X:[BN2,58FMZ>J>D3K$^J(\)U>U?H'^J?):RL&,<)K[EJM\J6?
M*@-%%R=_5#4GUS,#@C,10,]P/$,SZ(2@8=@;PF#V%(MV$L&] .UH-7Q6\RX]
MQ&VRZS2VOIF9ZQ\OQ\?MUQ(^M7Z8>+Y+A-Y[N=B;6,?-;')$\G@QQTRTG2?Y
M-:1TUKXVFFL6KK,_IZ_VV@WO80[WKMWO6M[#UZZ#OI[=:WK73?3/J)\6I&8Z
MZ>+ 2_\ ]DY/T^K[S\?Q?_ERCX^OLSAP\K^!?(?BG$N(%#QN<6U2S%*V>(J$
MKPT/\ABR5X;E6Y"]G> O2K#0*DAPBS BV S6A:T+6_EUO85_?+.;/I_R_G'$
MXGRL(OMLJ'CQ7[I'VI2UQ*P.2LI<G1HD\QAB/:=,0[!AD%6C,<G1(3LDPTD'
M48MA[L"UU$PALX=\L0T&S)BV^J^0-1,4JANR2ADH0W!4S<G8;")[A_,]Z3)A
M,(=S@AWW'':,%TWOV:#/\#(PTVDDL/F#,D*:06;<=BS5 S.[J6!>HA%7PR2.
M,9AL'C E(3--#8E2MFU!X2- $I4'",,V(7Q!8FXN-$>LRP*>MIA=!5]:5135
M$^IIFPMJ03E)X4H*/1RZLY,+7@B<XQ)T9^OFF['M,H* :5T'K?4/).:/L<B<
M4G,HD^PIXW'O6K]]OINFM4]; V(S&LY89II0)5RUP, G"+^2*),,,^+0=[]F
M!Z41KF;P]EDE9(LPNZA2^R%V1L[20?2=DMQ"AQ7'!)2E&.+A $B%&$9HM=33
MC2RP?&(6L#S[L.22EF<>=T,ACRLC;[?'->CJ*#(FTW29R8VJ>P>/II$O;U(-
M@$G6_1U*H**'K?< 1NMZ]OQ![.US4M=51!F>N(!$F2/0]C;B&M&T(V]*$HXH
M@G10SW$7@]SBN6"UL9YYW>:<8(0A;WO>!&%'<<6:@YK<CI!GH]!75J2-OFK=
M5A"$A+&X#*S4.D\N71?1.PA2(9<M %8<D  !)2CNV#6N[>!9;KUP& P& P&
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M/Q:D:9UD2X4;CEAS=\>W>D'AP=A1]")1&K4I)K12E/H 0GE+) U-&MC/5;4
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MCA:__9[HMZ>-6L7.?7 /?(]'*[MW81-T0."/=H[)/M>7F,&GU<\1]<]J@#C
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M2O'@\'FTO<'=C8M%!3MJX81Z-$7HPLT(MB?$*8O_ "0N:[GYW8F)L!<C7:U
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M<174FN)6WNB!T)2M$V315]TK2$Z+4;*0&^ >08  \#00SCU!)I-Y*R$I.1<
M@KG:3$:0["K>($R:/Q0V+\X&Z6-;2Y+8\\, VA-*(K5RA$>2!Q#HM>G&%0<%
M4>$ ?>@M<N[.Y5<8)WR.K&RF1_K9DFJ9\<QPU V5<T1VQ.*-/+BW$E^3I=GA
MF+E<I,F;G1NVK,]WJB0D")"6%,<8$C*&_G\=;%AP&5$2"74$X$7;"TTKV1!P
M*W9K4HDMIUV_D,J9I+6";W%I6N-;* ;'XPE!:5;H.A>(9L( JD_G745>5)40
M&J_V6L@[I>'@EL?J*,3:>5.O<ZG;%1C,") )9RUU/1^>MYC6ZKE&U![20;U.
M5:+[30A;SBRX\NSK2GR&_GRR28 \UW.U:-YDD:B4>:X9)V6Z)TPQXZ-."!F
M4E,6U26V..@KAKR3-! ?K?38PB""VZ?<_7VGXTN1O$@?SAK+TJ9;9%;H(;*U
MDBE%3P%T8J-O%F:TS9IMU +YM)L6KW,&PB*2IC&M/K:<LP\W83[QOFW,M7R
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M<YQU*Z5G<:TSQ_\ /2-;:>7JK,_-2-K_ .RO,?O?6WSF))!L(1_- TUJSD/
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M-S^LHTT2"0D2Q$[-$?>/,L9?&ABY)1=4M<4[GK;(%[A<P0#+\/O&2X@&E4;
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M-31W-5+:T=VVPD?*J=-$_G\2ER)SK13X#2R.<=;D;*N:A-KXC:D1:0Q<>7K
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M:_E\&KI_L1>%[ALUB+9(SSS4+,4'28\M +P%I2D S ;[=AZ@8# 8# 8# 8#
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MMHQ]O;DCFTJ ,SNW2^!;V)>#O,4I%YA)P![)3#)"R]M<.T5IW$CMD=AO#%V
MXS#=(R0QL;@@=5O&"X9I;\2/,6K2!+DQ+^MG"M X%%B#KRP"QD;*-T(8@JPP
M>DZRQV"SJKTE^S!7 ; HYKJMU:G6OJL<W=HEC76K/3>[(BTL518<DC_O6MHZ
M@3K6(A3IF.<$WFM$@\=24<%FWKA<U/%*6K3(+">T":TK\D5\*GY.QL U+$XR
M2T$%HJXTV-QZ4QO-:2'!)M*68>$Q3X!FQ"'LWY^!&SGZ<$0<UYBPRS)8$33-
M9C)H(:8WLJE;%VBQ^0+)R2G437*CDXOI(WK9^T&%(#E(=*6]N5B*T,8RR32P
M^$8]-6",3Z)8Y6')Y-'G:91N=2Z,.C8S!1OCY [*F-C0?:)2E3E'L:9 9-5+
M:X%$]0N:( -CT$[9AHPDSCAP2K;C383U8T5E<ZD#L^Q(J**T$F<DBMI++0/K
MDK9'5,C3(TP2'1AAYZ&,I1AZ:"R-*4K>A""(8@BU]]-QC?GMW<U-NR4"-7-)
M_,&=L#&HP(++NP>7=;\PG!M L$D\TL+13&N@-)1HA:,VU+#-BWM2 L\(;S5/
M!A-6G'JZ>.JNV7V71VS81(JJC$F<H1731+X162V-/L8BC$ZN\=CC4.RWV'M<
M@-* [/NE2M8 DKQ^X>SQG!&JOTQX6X#D.WB>FR9%)T=F-[Y'Y3!XNZ1QX06=
M >.\ =$+FA(*1*S"VU#QV0*DAI*@A42L<#S0&A$4EV2&P0STZ66*2=A>E]SS
M^:-S,_&R10GF*1C?I&]NKEQV>^-[\H>9JM1FO[BH611S3JB5!XS59:Q&'9II
MX3#=##2X#Z9[S7$MKJ?1CE%8**7U^LA;+M1N!U@H8I'5$2AHH$.NWJ/+(VH1
MF*72/D)A^^0["O3+"A&%;"$S9>@SFO31CA:Y&X)[?F!"B,/"I]@0P,T> */N
M!%_J;^CP'8PE*29)$*!R<530J).V7I8WJ-F;V!864H 'S;_3&@[+("I"S6.]
MHU.Y7&)RM1*8K$75K6R5H9>1K>^^,W.+<H3"CTK<N23LH/;!Z&D*)1ITI8=)
MQ'@-"TW&GCN=QLB2*O&"=.;S7C7J1J&*&KD@AML0/D$J6OR5CA:M<O<W9BK^
M*-:H+8SL@E!Y#>C*" L>BP%@ %FL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@<=,!T^'_'\6!S@.F P& Z?#_B_+@<=/A^7Y=X'. Z>WK@<=-?#^
M+ Y^'Y<!T^'_  _'@<=-8'. Z8# 8# =/W\#CI\/W]]<#G 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%=I;RII*"WU%^-$JE"MIN&:U;-KDB4
M</CL@$CD4#KE2A2S5>TR$MM&P+'*/C<TXCT %.UVBC0F:*V#?=@13*_43XGP
MD,E-D]@KVE- (-7]DVHK51&4@2T[";35A20)]MT_;3H%=$2( O,EENGESBT'
M^]F  F_E<#8#.<_'H-U-O'LEYF:ZUGN)AG[''FVLI^XIWNOS)N371$^9WM''
MCF5QA2B7* )BW,H\20P ]'!'LG?B8&;XZ\R*)Y5LD<D](/<FE,5E[))G^,RI
M7 9I'8T](8=+3H/)2D3U(&-M0#<6J2$"),2['I1L'0T(-E;T/ A]+ZH/#-8X
MRYG*L5_T\PX')O2QG,K6Q"W5\7<-GA Q\EV2%MPHSI7-Y#4ZUS3B<4#6!4JV
M0:$XH!A6^_ LO57(>J+N9X3(JND"F7QNQ*AB=YQ*1MK(\[87.N9R4 Z*.>W8
MU"6B2.;T2(8RFXX8%_:2=U*UX1G:%8M>J;P?_4DIY""N$0*R1<B]\35RXR&3
M8I^;^0(96FAHZY7Q$<?#)T;H6]+2>IIB4*;24X"GQ/ $$S86XU=57BM];094
MR:#KB;JX)MM;7I!VSI$17BE_-BZ:3#1@UOHB/?B1)@:Z]XA]/9TWK>PK?4_J
M+\3KM=J$9:WGSP^K>3(+D-IGO@<W;$\H*H%V)8K7&>J<V%(0Q!C#HI+*WYX2
M?S/B!V1XFMZW@7AZ]?A_#@<X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8%%N8G"IMY3S3BM8[=.'6M)[QCN]'82&3,)(-
MN$FK:0,R^*7!42XW>M""Q69$7 20_8N\LL8 &=FQ!U@5'OGTMI9.EWJ0,=96
M/&HY O4S@M7Q:S R)L7J7VIG:$QG5:R)X@Z=*2J;9 WO]:B$!$@4;0EH'0(3
M.\9/4&PG.)\$G^!\[Z>Y01V7LA]9U#P%0<,&V'.@7,R:N*YEGI$K:98I="TV
MVD* 3:E F/!\X[9W4S6NF^W0:CZ8'!&U> E4Q2G'V35O*6<A-8+M84K8'"?*
MGF72]ZG)KO Q,<?DNO<,,C\=B*]2F7EHQ:\^N\,[10-^*8:$(<7O2DL^CN7C
M1R5?;9A7NQ!=OJ,6G(X[&VU]?%5AQ;G'9+?/XS6C@3,"!-,"2U>YHBERQW8=
M$.+\J2$IE.Q(]B!H+>>G-PN?.#U"SREG)[BKRF=+SO:>5T1%0/9;% ZGL6PI
M#,:UJ1N"^!VN1LU8MC^-O3IB.B,L/>,@ =FCU@4(NOT6Y+8+;<KE"K8C,/?[
MYM7AO<DTA"A$\JZO8[,XW6":\V'949++("Z_32WZ\0-;&>8(D@H&D@AF]_?K
M>@M+-^!=O/G-'CQSDB]BPQAM6N)O:\6M9K6ENZUGL'BE8+/Y1EJ= N(9T[@3
M(H>^MJ%V1J%@3D:98)5HK6@F:Z!6SC%Z4M]\:E_ =Z0V544N<^&;5SH1NJ56
M3,FA!-E7+&9-DJC(VU22V+U#8GB0&DLI?XI8Q';,'LG6^W74/<J#IY>DA\92
MV O9G6<$,C<7+7*.IE*)A6R *8O3HI9DBS>U:=L-6=^R0&[\30.G=[>N!M6
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M'>3NRM]D"\PLP1FS%#L[KSE!V][WW&&;W\7LP-U\$GN,'X1?>< (#1=@>XT
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M!< -JXXG0Q:%T 9O7Y,#>>T/7NZ:[M_&+Y=ZU\6M[^/>M?DP.<#\Z #0= T
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M88FK6I>M)&<-8(@L*,>S "&(LTL ;/\ ?;K=7QEE'*IAB%D2*O8&CN5;/VI
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MK#AK[*&IY@3);XVUT5-]CG4FP,A+1&5ZM*!P1I1G=II8#SRC@N3\N\#G 8#
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M& P'7 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M'Y8\ ]Z[=ZW@=65\P^)#I 9 M=+_ (^RQX<MA54NSBTNSPSR=EF]I(TJZN6
M*1.AU)&=YG:%:2<RCVG %Q+-").(S0M;V$;*4_%Q'2TGY#G<I+-W2D'0/SA,
M;%(O*5*V**IXBJ.0RH$C$E$>M9U\87)S27)*H)+4H32A@/++$ 6M!8JO[BI1
M,&)UQ&[+,D[DI]RL;.<[K'M]=5[F]P45G,K0]R)6B\N5*G2O-Z>@(EAQ2\;:
M,!_A>&, A!&]@V1QQLQ[LYH67I)61]XT/,<BEPL, E\JC;E"'RR$;0[PU#+6
MAF1><6J9$VK4Q[:8 LT!A!_< 6PBWO S#) *EB$Y>"2KLLMREE7L;-8$KASO
M;[X^F,\5>1OY;*]26*B/.4&L+N9%W()&S"M@/$B-"'KL&]8&?-Y?\9R: :>5
M)EQ1(/'A\*;5#3;6CEPHDX$/#\&,-9Y"H"$2@2=;(!Z2ECV5H.SM].OY0KX*
M5<1Y;;DDK8CE1/4EFDV$*!.T**N.7Q\#;9#FPE3))7:,E:4C:D\H51H_2Y&S
ME&[5FHPB&44((!["$O++'X\<45SK&Y[>#PF=W"*N%EN3;84R?YN[1ZOHT:4V
M/$Y7IPD.*F(P-O4F["I=%84[<$99HA&_R)VP!V9AR*XR35PLBFC[X:T,Q@M>
MPVVYLR0B4KV^=,=8RY06JBD_;#&0HYR<(B^#)T7YYOTI3=!^&8(.QAUL(QC3
M'QRFA5Q&17D7<S_KC_(W:'W(%LMJ>J3X!*6-B12EVC[RG G\<3LBCSBG6"((
M"<9LA04(.M^(#J%BZBO:E+/B%3NE3V2VV-%[-KTR;UE)FE4X/Y$V@K![H;5D
MJ*>M)1%J"@J75* TT\19IIY^M:UL>]ZT%;7.\N'E\RZ! 8^4#X4^SN06K64(
M9(#8<KBZ*232C#33[<C)2!&D3IARZ!!+%MQ(.V!264'KH(@ZZX&!;[RX64\]
M3*5//*V5@'4,'B-A6 WSNQYL[,T5@UHNNXU!93)69R0;**;).\A\NWFC#O8S
MNG;KVZWL+-L_*OCY(9L_5NQ64VN\WC,M:8!)&%M;)$J5,,T?X>=/6*,NQY#.
M-$W/#U#B!+T91IH1J2>WP^X0@AV%>*I'Q;OYEB,NIOE#:%C1ZQE4X*B;Q#[H
MF#BV.2VOG(MLG+;XI!?A-"V*N:D"92E5>7.*-WV=FQ:Z:"2VZ^^,="0R?JGV
M]5(XI7R6PIE-Y?/I#(Y2D8&BM'EHB-EJ02E6A4(U377LC6$(78I*:=IK6F&%
MGZ+&$P(0[MMW9QP>T'T4D]UKXRH0PQDN1R^@3[)&R0L5=N8Q%L4ME:B,H5:Z
M+Q1]'LS2<;EI*6L\N=X??Y<[PPAV++>*4PD,\C,2Y26G))14TVA,#L>--%QS
M=R>H?+Y\B1/$%9Y"S)R#%Z4$O;EI)Z(X1?E51!G< S8>N!,S1S<XHN<1D,U;
M+KCBZ%0ALL=?)I?Y>0BC[4BII>%HM Q8^FM 6\Q7!5X>QT) 8,]/OJ(0.WKO
M Q3"90?*5\D4EKB^)N[K69/'"Y P0&SY%& ,!#TQI7J,KUT0Z(ES4GE#"J)7
M(U1A 2G%.9H\D1@-]V!D&D^BZ.!<4_<KQES@VT4Q*AW05+[+>YLWUDVZBS38
MASE*F#6UREF4%0I<E= FC*T/3<?XNOY,6]X&1EO+WBTUU<FLM\O"*H*LE,,@
M,J:;':W%>?'%L3N5]#"ZW?V:4M*-6A%J7R52!$W#*,V:)6, >FMB#U"*&]AX
MVN%:3.VV_DM:ZZN*T,EB.P9.1=LN/*A"^!>)J9M<N1 WMU87N,A(V)<C5$%*
MR =!"+UH8=["9>/MQ\?YC"UJ6I+G364T11C8Y@\N3[*UKS)F^*SAG%*XG*7D
M;^!*]EQ>3,&Q*VI>85I&K3%C$08/18^T-)OJ[>+OZM8E9%A<@5,'K)>B-E;#
M84$F;ZU1QU935+>S!<UTEBB9<A&R&.#HF)(&>8 D:@X(0;$/?3 A\$_X?1J5
MLK:KY/V[J4$Q=7:Z2+.<^M)4X*(+%96"+O$G<XV-EVLW%6V3 \DN,/*"26+N
MT9O0.HL"T+%RXXUR2Q7&I6:Y(8JL5JGKQ5JR+FK3T"S5F,$=0S!WKY,H<$Z5
MO735'$7(IU]UD'&+1MHMJ@%B( ,P(9.4<?F"5/[I(54^N-K/=5 5!C?'K.D+
M,RI!!)+(T4WM20P*9$1T*UO8 ZZ;'O>_EP-FKRIVNN%+DJ;I58LB$Z$$$&ES
M>;.\K3I@D&#,"8A)<AB"C/'W]!B!K6Q:UK6_BP-\?V8F0LKHQJ%CHWDNR(]"
M:N95YS6ZI '@V#9S>X)MZ/1*B];Z@,!\X._;@5]^ZY&>S8=6??VNH=@[M7'*
M^[IO73KW>-U[NGR_EP+"LC24Q-#8SDJW%<4V(B$12QW6G.3FI G+T6$Y>O/W
MLY6K,UKJ,P6^X>_;O T6PZL:['&UF.,HL".;:0J@EAA$R=HH!7I5LG8]N(6P
M8-+A%>!K1??_ +&A"Z?'@:U$Z#8HA(6Z1I)W;[LH;1FC+;I)9<@?&11LY.<F
MV%<UK#1)U8 !.V(.A:^:,(1?'K G3 KP\<<(Z].SF\'6+=R,YU7J7 U(V6M)
M6]M2C5&;,&G;T)!NBD:(OKT+*#\T ?9KV8&U,[)$J%A$L?7B92Q3%&)$Z3"2
MR&?R9VE9C$S,S<8M=5FE:O2A2F:V] D&<8 L.]!T$0L"*9?R/XSS& R02ZZ0
ML#$F3URI>')B<)%%I8V(+0=VUOK-W2$EMQ$D(9YX\+"43:N*3[2KE!FR"S!&
M=P=!#+V9QACAC:G?.1-]M:IY>Q1IK2*9Y;1:U;(^^3 "P$(],NU6WM0&&.@R
M4G9H\XE$8:6 1?06PNVRV# %;Q&X2VS!H62=]@@[ 8(\>Y@W)W:!(%;*T*9>
M%L4[+<S6@AR?D1!RD9>@A4*@ %O0Q=,"K]KV'QGDIZ^6R>_IA$FJ)M4X)<'*
M&S281J'&IZR ZNE@J"E[.A$QO[C#RFM8%P$E./-3[1'%"UH9!H0!M]/M]/)+
M)=F2%7#8LUFC!"8Q+7B*2>>RF1(D$0L0M:9$I"I;G<D"'07P#0IVE'W;-UL@
MS6PAV$6!*K[>=/1QDM.0/-BQA*S4F6,5NK2'$*W]7!8&LMY-,EI+?I4I9=)V
M4X*PP1P ^$EZG"Z%ZV+056F";C1%"4#W)N25NMK=)DT,?65>DMN=+FAW06F\
M'M4!4,:IH3K42U)*W4H1#>$@8]&;UK0?9O6]A.< L>D833DSG#7;2R0UM5YL
MV76',9?(W:2.L(-A_FEDV12\3B1M_8CXD2E-&J1JR"CD90.H@:#[<#79W=O'
M.?0<(UUSKF%EW:48K$Q;#7J21N5IK.D")*OBT"<$C:@U)6]TDS:\I5*5(>G+
MTM3JDQI?>6<4(80T8Y\78^\QY*MY$7D4[.JYQTQM*V;VP<:[KHPC?'M[; MV
MV39BM6U-<4<%2U)L/C$I$PS# :+WH6PM:V\B*7>6 J4-4^:ET?/F<DKPMU3I
MG8:7Z:0Y0Y)9.PCWIOT,I4R*6=46>(6@E!&0,/?O>NF!6&56[P_L= YW IY1
MR./Q9$37J5V7,5G2F$19F26$K]UUX].#8-,B+:&B:N!NB$CH> M"K/WH.CMB
M]F!.<(:JSJYUL%:GLJRI"KAI#*US)OF4JETQ3L)KT0F=&8*-N4I%'CN+HE<"
M=@VC">8,)@0].N^F!PBY5\<Y@E:F]JM-":7-Y:"K(\J2HI(W#<IRZ"F#>7&6
M=Q/9TY89 2H@CR$00B[DIC8=XG9LO KT6JXI&*0)=\H[7(.&;<I'<MN*<MY!
M8^/#B4SW=XZI<G3I4P*T=3@IW49@P!(.%V==B]F!:!@M&H8%4DIE!\_<OH#3
M93J1/I5.C)(<]Q?W6W))0Z?2X3ZWD2$"A ROB=2+Q2.X*4TO?^STP-!G=J\=
M;1C[0:9=;TV)DTED#:017$DD[)*QOL9CY+W)&AY86!&9)R],$<<"'%44I2EA
M3(U!*D?0HTL8@C%#(^*41FD+(.Y0SP]V=6Z)3:.)'JWY6YQ1Y89>]CCL1<7!
MP-+'&ALTDD7^X)]*5( 'K-A(U_*[T'83XMY8<>FYVE#&OL=$B=82QK)-+4BE
MDE) H]'&]N?G=2^NAIC&$A*T!;8RX' 4"%X)H$AGAB%VX$0RESXVRJ0@D"SD
M/8;29+$\(>0$1^S9@R1=I26,!&1 !N!:4@+3"BYD)8GTW%. T@E9BHG1>A;.
M+T(-^IV741'T3VKA=SR">D+;7/I%V#)9H_397'+<C2IP;W" +$*THU=$I 0<
M$0E!*DM/H9.R3M[V482,8;S9=M4ZU"?:]F=DIXFXG-S.E?%#>YKVM;$TTT5J
M6B,K7>2H"3$<(-?%J4X"!0N/2^,,D8B]BT6+>@KNTQSCJ_)'A4R\C+C=2HY:
M"FDY$!!<$X4K8]:Z0272B!OJ$DH2]FD0"W!.;HI265WD*23@[V4<6,03:@Y$
M4#%:.C%OFVJB-II2L9XHT66]J'E>B<7)?)=09L"XNIZ#:T1ZV5ZTA$I4 +*V
MI%T$/776\#OR)FKZ\G]]86^PYR@>JL<2F&5(8!+9#$BV]V=VY*[IT+L<B*(1
MNBH+><69KPQF^!H?:+M%OI@=B)4$Q0^0MTC23RX7=0V[/$6VR6RY ^,:GS"<
MU,+2YI6&B3*] ";W T+7S1AT+7MU@3KT]G7777R^W][I^[[>F!7EWXX1UY=G
M-X.L2[D9SHO5N)J1KM:3(&U*8L/&H&G;T!)VB42(D0^THH&M! #6M:^+ DJO
MZ^05VVK&QOD$SD):U;M:-5-9.XRE>2/98"O 2K'(8S4Z3H#KX8?F]V][^7 R
MLPBJ69Q]?'%CI(&=.X:+T8XQAY5,#VG\,T)O5&ZHMA4I=CV'H+MW[0]=?+@0
M?]UV,_\ 2;?FO;_TQ2KV]-]=?_?8%DDQ&DR<A,$9I@4Y)1 3#S!&G&!* $L(
MSC1?.,-%H/40M^W>_;@118%.M%B.J-W<)?9D>-1H0MX4D+G;U%FTXL*@]1YA
M4A;1A)4+-B/V'9HOG; $(>O36L#JP6DF6!/NGY!-;4?E&DAZ/R$OL%]DK/V*
M.SN-]V+S!)MJ2^SYAG3N!UWT^/ F;>O^/7Q_%T^/KKV],"*894C5")"[R-%*
M[&?%#R!26<VRN;O$A9$85*P2X6VQI7#$E0#*&+L+V#6M@*^9KV8$KX# 8# 8
M# 8# \ZO4'XO6=R95<(%%8 B!8N/'/[C]R@L$R5/"QE,5UU5#98*%\;HX)"Q
MO0G.4GFS H2-,?Y5,/0#>]07UUW!YO\ +#TKN35TV?ZB4SA:JN$+;RAY$>EO
M9U4(5UCRAD1$Q#A2[P1=:::P&1NARYM(=74B(CU'R"]+RS#!E"-.2=F];#9Y
MQZ65NV,Y\Q#)60A8U-O^H ^\Q>.]MU!=THKN\J$<DO&2*4_!YU%GE)#_ '6C
MFFI/&CDSPT*MKVI9''0\L9AP^I6PGCDIP.Y#\AXCZ7L<GTQATY>^,MIQ^7\L
M9BC>'JM%DZ:#:5E%;SM37J:,M9Z@+M(W62F"&5H]I ),,T03"=BT5H*<W?Z.
M%U!Y$32?<:4=-1F@X/&/3T8*>XX2>3R!NKFVHEQ!ECNYR.J+A;VR).2N-,Z$
MAR3/$7>$BAT/]_MQ8EZ89)@\"3WGTJ[V=JYFO&[<IA>Z]G?JELWJ J+P6NCF
MLLIH@Q5MMM_.4'$RZ;"=+[00RQM#&4CN%<4B&RC$LV669K2+86$J'AGR&IOU
M"Y%R\A+#4K#5?+>.29NYE4V&5*C@PRQ(2I3MM,7A31Z:!ITTAF=BPI&4@L8E
M6)J"Y*B4RO1B@:4L&!*'IL<,YOPY8.3<%E14;20)_P"4=R2OBNPQ>2.3^FJK
MBW/7DN<Q:ITR=R96H,4"P6/(Y,X^[D@E:0@MR)* >,!!8"PZ?!+B_>'#>E9K
MQ_>&*OK/2-5^<@+=KZTSY&J0N\R:;;LB5VY'54]:5D;7J4=ELCY*=M"Q84>I
M3FID92PL0=B\H *'6KZ7?+E6@]16-5L^52YQ#U&^(:$NR6B62EQ9QQ[G0@"M
M9E4J2F-$%5 5UO)H8[:;5Z\(2W#_ ,$(1^4,Z;[ CYZ])'F*37\WKTIXJ&PU
M;WRX]/;DTS6S+YS(T%F+XAQD;HBEFM(38XF$+VMQ;ZQ#&3D<"<$P"M+&];V+
MBDQI>S3 M(Z^FA=V^!OJOTPW2:&*[K]1RQN4MJQN+JW]W35=5+E?#<!ACT6%
M)P1Q0Z*TS<B2EKGA>2T VL<CE RT^M"U@;K!. %SP_F!4W)Z%2#]3#F29"(S
MRA9(M9;W+ZJY/U? ^.H:XBBJ:U*_1]*U,M^0B;I&](T2MJ/2"U&$)A:@)@C]
M)B@L4^<)GC_ZB17,*)2Y"QUK8M",<#Y(59Y/>AVC:-&3Y!*^+E@^9+*#X#A!
M4,HDB98H$9XAR=,VI]@,)"+0 K@Y<)N4:/F_'N9D575Z2HN:H;ZX_P#+N#N,
MI5! 97!ZD;IQ=<(&X(8803(9!7+JV%:6;6@1[ E?74!)@]B#HP*U!].'FF;Z
M.%>^FD-BHLB:PJL("SN$W_6A)AQQQF\5OIHGQZ1L[:VTN)C6H<E.'I4<FTH,
M<.TC1 "][48';GOI/\B;9O?D2[O<@KR$5C<OJ:<6N<[/,F>2.[M83!#.-U<1
MUE/B">._1AM0MTRFDF91)!*@.9R9.S'G;WX@S/""%J^0'!VZW#E%S"Y"U29!
MYZDY?<#6[B:*+60^+VA-6$UBJBQ26%^(TF97H#O6LE0V08>\H2? 6:5H.H/%
MTJ[DX0$X^CW-6VG>-;-75BHHAR5X5PV@*KJ?D@!8IVLNFDF"N(!7G(VDKACF
MFX_>JZLYK87 QO1FGN0FIV A<2!EB >48%L.*''3DOQVMWFZ[K8K5;W#>6G/
MQUY"-[WN?O!BZ-4H[TY45>.)#G&/H00%78*A?6!VBD(%PD!9+B T:H>R!D&A
MF_3:X<SGATW\FX?*B(XGK]_Y06M->+4?C\H<9*CJ[CE82YNFZ:L42%R86<$+
M3I;7=Y*ZB:D1BI"26Y$%@-V$@ 0!2.YO1KLF271;MG4[=397#<JYH4=S5X]-
M!: 02JFL9>PF0+FB#RJ9%HE8W7U7:4E(!(,1B<"I2H4"" S>A8&I\Y?2=Y%<
M@+#]1E^JM16K5&N3'%GAG1M(('JP96Q!1/O'FV4TVEN[";VZ*.J=+'S(\3Y=
MM- )U-4&]0&DDA%X@0M/Q_X;\DJ1YF<O.1(VN+/4<Y#6O6+O%6DFY9$@8V&"
M1ZB:YKJ7R245X&"&-;G:*9_KW9+&:0LUHIO<1B-4ZT7M,,-JXN^GE)N-/+ K
MD! ) T06J;@IQX5<C^-C0;M?#4W+H6ZU:"[^K9:%N;24*R?PR-K44K*+3(BW
M1<D1+]@$>,[H%.+Q]*7D=)XCS_CU&R)EK6-<U^/W+>+S?C\\VQ)9'Q]=^2UV
M3!K.@/(*OD+G$'%]HUT?H]MS<;"1MP5:!W=5)(2$XA%;5;"7B^#_ #=I&4<\
M;&XURJJCK-YG5'Q)1PA^GZLMQ9Z,M'CS5Q532&+/C,\PR3M\YJ-]:=FNB$92
M4E2G<5*P DV]*PG$A*$S].J=NO+"H^9U9REDJ"Y(E;C%'[Z]TB NC_*SBHD:
MXL,V,V$U)6ML0H9O$)DQB=HJ;HHX3-O6TX%&B#Q! %5J=]-/EQ7/!OFIQ57$
M5XX2CE$EYSG-+TJNB5., B2B^Y+(W:IT3#&%%= ,C@W(B1>)+3TP=@">E (H
MI8(6A!"VO"+@O<5"\@[5Y.6,OA:=\E'$+BAQ;C=80UY<7!O<3^-T2=B7&>R^
M7K69K <ZR>1/AB)"$MM%M T)R]C$8,6RP!'T5X-\IZXY-7S><=,K:317FEQ'
M'&N4<&>9>I:=D\LX@L>$%=2R)^5@:MH=H4OKF4*(T\J5!*=68D:FT>B# EB*
M"$"W9Z.]OLM#<PN./&"81 =%73:_#^X.-]+3UX<(_'>,J^N^5";D1R7KF+O3
M8P2)2"KI6Y,Q+E%&LLCP6AS<E:8 24O:/86LCG .W&BGO5D\P]Q -F^HK.+0
MFD/@"!V<B:ZK8#O2$<I>&I79^&SB5JY')-1D#O)'%.W:+\92$HHHWR_BG!!O
M&KTSN1M72YMLF7O5?MKP?Z>7#7TY7V'Q"2+W-M4Q6GA!-NBYG-Y=XDC32%W4
M)-FMD99S&\G?DE!XU"LK9NB0!JZOTQ^5K7Z5?*[TV6!QJUY;-VVL1<,)&]S1
MW;R6WC<?=41MV/0VQ_)P)09%W:"EH'%J1IT('4@Y*%)U-!T'VA8B\>%/(>1\
M_P"H.7L$1Q9SB]5\(W&D2XH*V'^OG"2V^;9&IDVMDP*;(3($$@IM0D'O;D X
M0CS5198P)=B+ ;H*\K/2NY&3:\;&>Y*]5W$*ZD_K(UAZG37*&&6/3U-00FFZ
M/B,&9*O3,@XDRIF*4SV8QTQ.ZK]+U29+&E!Q02SSE&]%![N5.OL]TK:%.-U1
MR(1"V%L>0'V!&8!(W.7PMCDYA75R;HU)WADC;H]M*<WV%*#T*0PS7MV7K D/
M 8# 8# 8# 8$.\A(2_670=WUQ%PH!26P:CLB#Q[3LK-0M6GN6PYX8&L3FM*2
MK3TC>!:X V<8 @X0"M"V$ ]ZT'8>3EJ\ ^15I(H=)3"(!')+7/'KBC0+-%VR
M?/)6I7JIN1%77;9$ND$T30Y.<WDMC=7QB**(B4)QH%RLY4<>1H_9106_L>@;
M=G*/C(% V-*05.<RFJY7[4LLMZEL@45@W0NV8Z:J^E"R."4O$J$Y3Y.-.V&A
M+(3H@")\X(101&!K-C<9;TD'(JO>4L951A-.X'<Y\'U%5D@(2LJ_A=)HF="I
MK'@OZ.%^_P#4D.?#")XC9!F;;OI&VI$YBC10=GZ"/8OQ,Y!L7IV3/@LL8*T<
MY!$J'LBE*TM@4M<$R>QO>S,_QR'S.1-FXLK<H+)Y&WN@%,H- <YZTN&J$1XX
M#P^&$U\?^.EHT]>UT6:L):79DFG&SC)7L7+<)\^O[P=/:9:K()DR)T,=640F
MN.KUDN2>65$G';-$$\P28K?:$00Q'.'U_P &L*RIJU&PZ4M_)SC\]-?(N//D
MD2($YM_MSHH,A#JW>0@&BI9'3(8\*(TX+7'HJV@1)Q^";WC*"$</7IVW9"6%
MTKZIGZ%O=*--C<5)Y3%9RAY=&IUI=CK&UU]E6U5[/+"F=W+>J_3K%&S(>D-3
M -;RS]H1'!3DECP)K>.'UNO5+^J"6<;!T=H\]6JQTT0@:!V<2:_@QR_C:Q\>
M(7[_ ))MG,5KG5_#&B7F0KT[9K6CU0RBB3O!",P(B/X+7ZUQI;%4J>'RQ4HY
MS\;>6JZT76Q7MJM*8Q.ORX;J2P:<O26)G#=)74S'"$<4B3F2826YQ5&VDJ@)
M5"10>K"UKG1%L/MF<'ID>W,Z5GX_V'=<@L +W8#K+I6:PRZF+-JZ&JBGM;'$
MQLVE#FOEB-8Z&J1(M)BA'!"-2,L(C0T.MN+5NPF'2JJEJ>)*V)->_(BY8S,"
M7M4$Q^;[=<9C*X['W!A&U#&T.B"0S0U$M,\8\C21*$\OO&;LDL*ST'Z<UK5O
M54MJFTHA5%Q,MOU30D.L-5)Y6M<GAL05VN4-LPI(;HMA8!RRF$K.J,<HT+>D
M*M"K.-3F%BZE*2@O_P 0./EE\>$-J0Z>6$1:$1W-&D%)2)T"J.L!!4;%%VAI
MBL3LIS/"%/)91#1)!H2G8&@FKT1)!AP=':%O8528>%%VE5)QJA#M]%$#U5_J
M"V%R5FA[#.WI$,JK98\<AEK<&-OZ2-(W!5+B2+7;O,(=EI2!!"K+TJWK0-FA
MIC/P)N0AS:2)5#:KL.%DKO5L(D\.FE@R%Q03>*<Y[A:)_6<:DJS<1,<5B5TB
MZ50W2D7?LQ":;W)Q+0[ZZ"6R>(=[H>#7+WC 3-5<U/LAFLF(<;$]MSA=+)5"
M8)*:V88TQ0^R[C,9%4DFJ1AF!;H8WN"],YNR1A&C2&J%7ERPEADXSPG>:/Y"
MP_DO4;*T2=_?JNLB)7G%9G,'E2ZR2Q)\DIX:2S6N8.:5V"8M:T]+MT>-3^53
ME:8S-B)#H8/!,"G0O2XOIB,KC38\UU-6NKJOBNU4,E3^\I*^MZ: Y72CD7(*
MMET>!'W,QLKF*D28O4:==&J%*=V:R#AH@E#$6$+KVAQ>N"<V+SIE;>EAR1MY
M&<,6FC*\ KDR[S9%A%1>R6I87)R2HZ,IJCB=?,$V@K2!K#C"@FB\OK80A&$#
MJ> MX**,Y84&-9#1(.9C'3Q3Y-SW]<M<*37LM(U72]BI61'MF3&2GZ*E5N-W
MABDL:#PE2HDH\LK279IP3$U\)I]'>0$5OJ!/$:@PY'>4L?.3<(&>K=V.ZJ_:
M7NP'ND++0B(1(0QF^H,%Z;VI4JT682XQLT]N5FJ-HFL],&*NGA?;$R3^H; 8
MVNB*^)\_T\3V7-7U8M3OE-*2J:B=%RM*8SEI%6Y2S,S+"R) PDD*48MO#@L*
M-V2 03\#LD\)+*8+W9[VKI\C\-4/UPIC>0L,<EZI^;+ZJN&@1&59/W!8F;&S
M;%?\+<&T'AN6BS2U38I5(%(C2S"ADAM% <:K,9^&P.)%WUY6[HQF5I9\?D!R
M68JI(U/K[,)C+'IA;D*53$6@Q D0(WI,I$Y#UYA*N*UX!/4L!^PL1PWJB;4K
MQKJFO;/6)G:TF6,I 65("']?+#)+,NWP7)]6RIU0-CK)%JPDDK0UBD@LXW0-
M=P==,"SN P& P& P& P& P'7 8# 8# 8# 8$8V=;T&I]%'5LV52$.Y;(@1.,
MM<3@LZL:1/;\-H=G[R#?%Z[C<ID1P269B5J#3M)? )+)WWC#O8>X(X^]?5_U
M8Y&_@^Y9_8I@/O7U?]6.1OX/N6?V*8#[U]7_ %8Y&_@^Y9_8I@/O7U?]6.1O
MX/N6?V*8#[U]7_5CD;^#[EG]BF ^]?5_U8Y&_@^Y9_8I@/O7U?\ 5CD;^#[E
MG]BF ^]?5_U8Y&_@^Y9_8I@/O7U?]6.1OX/N6?V*8#[U]7_5CD;^#[EG]BF
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MY"_TH\//V@'C^PFX<"U6 P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M5$EA\N9])9#&HZ,()&_M1X50BE3/'!BZ.*@._"0=-^.(OIOH&Y[MRL/?;-'
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M:K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8%27[^^]7G[.-@?S^B.!;; 8# 8# 8# JKR%_I1X>?M /']A-PX%JL!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5
M)?O[[U>?LXV!_/Z(X%ML!@,!@,!@,"JO(7^E'AY^T \?V$W#@6JP& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P'7XM?EP& P& P& P& P& P& P&
M P& P& P& P'7K_G_CP& P& P& P& P& P& P.-[Z:WOIU_<UTZ[_<UUWK77
M>!5>F>9U!7\88.K9,YR%I)E%I0E1)11UX01E++Z6=?<EFQU:]+4I*5"X15RZ
MEF^-LLHW81;*&/MWT"R^GEGV-*5IU;?%7>#Y(OSR7Q%?F21J$_E0>+W*/,)R
MQ#!V=>\ =BUUUK>\#)8# _!A@"@#-,&$LLL C#!CWH(0 !K8A#$+?LT$(===
M[_)@1C7-UU-;E>-EM5Q8$8EE:/*]^;&J;-KF1]'G!=&)2[PI](2N*C9!)HD$
MJ8E:(6];Z".(%H.]ZZ;V'>G]IPJM8=(YS)'01C)%F/Z1NI3&E/D+Q[GVH E
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MG6(YS%)'VMRAM2QLQ6WL)F[%A[I3UO&VVRR"OI=IQ"0QJGM8=Y)7L241A98
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M@FQD<)MCE--WY@D-02]Z<Y.!T]3?4)AT?,D;R@$XLL;<^.$V/=&KRI8!$,R
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M.D\<ER]U:O=\'1MLA9^)\J8$\D1R^F+-G*F;%LTR XO3(X,THC3(@,2*PE%
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M!5[B2SV/43M37(N!5"*,R<N0N[/%))-;>KN8J)3"VX:UF(>A-VR"59A!P5
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M]0<<?4)Y*,ZLF5.E?J&"W*TATP<W=WB[*F<^!/%RX!0)I\@8F=2HN=/9&[!
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M!MCQU>6>Y/D+9:ZB=;N[PMDA((FY/3"R--?V5''<UU<MDIU#*X%K='&$!-,
M&?FO,BKXR^-$-@#>GF+\3?U/4W.V(:=XAAT-*M^P9E6[3.D9;K%Q)Y.@*F%>
M/)!&TX@$+=MIQI:GPMD&'!DIOS;XF578,WKZ9SOZ-S*,IEBJ;[W6ECJ&L"AH
MK];9'NA1+VN%*HT^2<ZO6U4X(FM.M4N*Q.D/ F),,*&6$/TEY?<4PI4YA;\-
M$2I9I$ZD)%%53YN<1ZBL7'.) P:CZB&$/@9@WP9-IZ$Q[2Z=AM6RU(4PBAEB
M$$?1BX^*<?B3;"8M+F)13MPU[.[(-?GMWLD^0SQJE#VWL*]Y:)&_L9J=^1/B
M^5%(TYICT4LUL91:0D91>]E!)_&:W.+TKC<5K3CF]$/T>@,0:BFA*@990>&(
MM&VMM,;6N1.KXVA5Q^0+&A>G. F<S"%RPD0A@";X9NP! S9<U:W9?O&YOB->
M1F;SQ@CMUV(Q3!.Z3^-0:(UZFLY#1]BA; +H0@][6+I:W%F#;7=M2D!,0F%D
M*@Z/*58&8C'J"4;+K<;8$KCSFPQ"9-AY+)/)'%Y*$QTLEFY,S'BT&)2-D21)
M<DBK<NL")$@:'IU<2$JTUP(3Z"2=T"(-[+YT<-%+ZG:4U@MKB[O#GY()[37T
MU>T1Q((T3-/I(XR%GB3@RH8>3$4NG(3TK5%-921,,8SP^ /0 D9#R;X^2BN9
M9;+?(RW^%1.0*(-)G))#Y([+4[VC(:W7;/IH3L2EW<R!I'=(K+,()-2B)/"9
MH?30MZ#0E?.;B&L3NIZF?%.+=%XZPRI6Z&5Y.U,>(;Y-'E\I8TS/(E$1^CKO
M(G"+-"I>6U(%2AT$E3#%HC?;K6PQEU6AQ?;W"F[(L5TC X2;#I[?[&\FD6">
M4M9H(D@CC].012*Q=T9929&@R]&I#[YV4X-PSM'(23!Z4[)#92N9'%->S/3D
M&6EG-\>9+$GDR0'5Y-0O,/9:L=)FS3R2S.)'10,FCJ9D>:^>4OFE:(L*A2D"
M42,PQ2D"H#1[3YFUW&I!&X35L8165*G9\M)([D'-LB86*/FTQ6,2M&;-R]R3
M0YY5:?W2NILV;9A%I3DJO:P -F]H!AT&+I_F]7]A193*;$:XW&D)T4J2?P"(
M1MHLB<6(*"7-6+[9T<&_PW=7MNTK^CBD6=]J4L>/?R0)&92I--) (!6@WE/S
M(XVMRE0HETUA+6L2V0^0>.^[&:7JW=(I GBVC#GE X0QJ>&)6L52M&0H4$E'
M-FQ*20Z6#$(80!'[QR2X8\BY'3$+*!))ZXO]S,;S"AHH+8$4);I[$X>[3:,R
MJ1C>6J+K3HTHCXU(DBHTM2W*C>I6][&'IH)^<.2O'(AVF"%QE38!]A$C75;*
MTJ^)R EP;I 7J)#U$AB6L!/G"'HVP64#?X(S$;J<Z)P)1G#,Z8$?I^:7%I8^
MJ8L!S& AIA+;)3EZZ%.+<SHE!=I3BGD=<F$.3>E<4%EM5BUV\H1Q\U*4M2F(
MS!; '01["$JU-R H>[2%I=2R)!,6D,=8)$Y+FB-O);$G;Y#$HG+V1"\JU+.F
M1MC\IA<S9UY;6M\%PVC5A$$C>B3]$A'\8Y=\<+!FT"KN(GN,E>K0?IG$DP P
M%Z;D;2YQNLF>W'5%-0R%J:E3&%]@#VW+$@3R=^="J+!T[@&A+"()!Z@%%Q^T
MVN).<3<&V%%OMQU7,;'=8I(O$BLDIS4$&N:_HTS1!\6*Z\<=3E-KWT<H2-R4
M1?\ *![!!,P)XWRHXX'(+I7L<C;I0;0,*>;"L)!&F)2YK"HRS(WA<K7,!Y:(
M#;)=F&QA4G#I$H-Z*T_AF=@NF!5RK[SX3<<$DHD2!4X09D4E-?NE&<Q7E.I;
M'6)TJ9%R->(ZLCYL2?2H.S,</D)[[Y!H/4-9:/1AFQ 4 .)+"Q"3FIQ,3%)5
M9=@-K.;]+T5: 2+X=*X^]HG9P>(:SM(3V-SC;>^I(JZ.MD,/E7/:?34:4\)U
M 3O+B&: -ZF'(BB:ZFJF'O#\A3SI0=[N-;VMB7K5*N3+H>^6"TPE0\-[<8W%
MS>4P^(K%[:U*% %B\E.7X98A')@FA ,>Y@,!M-TE;4IJU,V./)AI4N]!1YE2
MO#D)9'3:(>;Y;$ME.JJ'-QE=JB6%G=D2H19#DB[R0*"3!EJ1%DA]:]Y]<4I1
M4L*M.3OK/ G*4,==%R>(.D9DFI!%'B2PZ'S) TJ$:V)-+X]19D335$%,^$(O
M=!P3-#),UKNT )OLSDKQZK=XEB*PY,F(<JP96.03(U/$9'+C82W2M:D;XV8[
M;C; ^*FDZ3+%19:$O80C6"ZZ*T(0!:"$=H.<'#+;5'WC5DQQA0O;V^,H2I#$
M9)#G:,R!A'*6QX;YU'))&V>1UTO3&0UU3CV]I&_7<D$5L6MF%!,#.F\I:52.
MK1%R3?),AS+/#U$;<*YLQJDYR^$S:IH5Y:,Q(V :;7EIW(+9:P&J J"];TO2
M*$P5"7:E0F#Z5=RIKZS9A9&HHG;E581:@J(O]BM-H,<5NYK#+?5W<B(#N+AC
MR5[;C(P139P@%;VI4GZ6^'X))A6P##3HWSFX62D*4#7-T*5N7HS7].YR*KIY
M#XZ:4=5Y-THE(WR60ID925D@JAR&^MP3#@G.2 "G9&C!D'@ ';<^<?#]"UH'
M_P"F[4Y*#EDL+0-;?$GA5)B9'' O+<\-"AI$S <&1\<CHVK2)!*])RG'9/0D
MTPO8!;#5">;7%9H6)YY)UR2.:U#HDJB&DE:V<[V$TQB;5PDN5R0R-D8Z^7$1
MY*DBQH7(\2-6L2!3DF#/,+&7L&@GZ$\CJ"FMCZK"$RE$Y3<31(7%&0WQI]);
M'!JB3HB;)6!LE.V4F.+#(X].A)"U*!9L\D\W7<7\>\"=#&1F.)&F-:&PU.9Y
M?O3F($HR1^4.VH2]Y0BMEB\L?O8R^NOF#WU#TW[<#D]E9U.E^E+2V*-.FD^G
M/1Z!*;IQTD#H*72_Q"A>;TF"'6B_$[NS6O9TP/H)J:Q[,$-M0#$:<2H-$-&G
M$(U0G#H)!YF]E[V,XD.M: +?S@ZU[.F!\A,C.(9IWNQ $\\8S3%):1.6I$</
MIW'^8 6$[2CKK6^_N[];UK?7KK UFNZXB=61L$5AJ)4D:M.+H[J#')U='YW<
M79Y6FKW%R=GQZ5KW=U6J#S>GB*#C!A*  L.]  $.@VTIM;D_@^ @1$^6$:-/
MX24@ORXU'_.!D]@->$(__E[#TV+Y>N!HEBU'7UK,!L9G$>3NK2HD,-E"@LDU
M0V*E#W )?')W%%:A>V&I%QP6N51)N5>&(S99HDH F!$#7;@?MJJB!LMA2VTV
MYC+*FTWC$+ALB=1J59Y2F-U\;+3HDUIFX\\QN;B6LR<NN^J<HH1OG!^)L7S>
M@9Z0PZ.2AA=8V[MA)K4\L3C&EI2;N0*-,CJD,0KT*1:BVG6("SDINP]21E[#
M[-ZZ;U@=>'0*)0*(Q*#19F2M\9@T89H=&$ M"5B;8ZPLZ-@;&\*M8(]6>$EH
M;R2!#,&(PT(-=^Q;P,W[C9MB,'MI;-C-)TG,%[O2=QB?0 EZ(&+P>HR=%AT'
M0=]0]NM:Z8'071"+.1R10OCK,J.0O261I336Y*(PE_0ICD:)Y"/PN[;DD2*#
M"RSM]1@ +>M;UK RIC8W'&&&G-Z(TPTTD\PPU*0,9AZ8O92<X8A%[$,U.7O8
M0"WU$ .^FMZU@?8:1*8H*5F)DXU1 !EDJ1D%B4$@,_[H H[8=F%@,_Y6M;UK
M?RX'7TTM>BBR MK?H@D!Q9).D2?111:@/8> LO1>@  <#V#UK6M"U[-X#34U
MA-//"VH-'J1I3%!VD:?1IXT.NB(9QFB^\T2/7_<MBWO9?_)Z8':(3)TH/"3$
M$IR^\PS99!0"2]F&CV8:/8"]!#L9A@MB%OX][WUW[<#[8# 8# 8'G(P>FM7L
M-1G,T#Y%<T8)%M/<C?6R'Q7D_9+;&&$^4R)TE3HB9&O3D86B:_?+PH&4GUO9
M90!]@=:!K6M!;+CW0L%XT5/&:<KDV2JHO&-NAY#A,I*[3&5.K@]NJQ[>'9_D
MKXH5.CNY.+FO--,--'O?473736M:P)IP& P&!Y\*/3GKI-*)_)(9>W+JL4]D
M3Q_LJ012M^2%B16'$RV4:2;?5S-'T3EY-H3KSD0#-D$]I(3-BV$.N[?4+$\<
M^.4'XR0I\A<'=YU(P2F>RRS)5)[)F;W/9C(YG-5A:U^=G61OZA2N.\89  E%
M:V$DDL&@@#K6!/V P&!&ER5-#[WJN?4Y8!#DHA5DQ=TB4E*9W9<Q.VVIW3B3
MJ!MCRV')W%K7E:WH91Y(P&%##H0=ZWK I(_^F=!I9%G*$2KD_P YY#$7MHW'
MWU@<^5]H'(7IB-( E6-3AH+H TU(X) [*/Z"T(P Q:WOYV\#T08&-MC+$RQM
MG(VF:(^TMK&U)MF&&[3MK2C)0(2-FFB&:;LI*G"'N%O8A=.N][W@9; 8# 8%
M27[^^]7G[.-@?S^B.!;; 8# 8# 8# JKR%_I1X>?M /']A-PX%JL!@,"@,V]
M.JHYW9,HM9TL6[T<Q?9 1+&)>V2Z-%[KN3H9'#I:SN\)/70E>X:"PR"$ICT2
M)V/=6P@!ZDG2;9!XRL#!1;TQZ1ASPT.[)8%X$Z1/;9+7QJ/E41/9IG-F1FGT
M<9YE(T8X%WIGE P6.XI/":C&QO/*"1LY,:,D \#,#]-GC^KC8X2\.UE/L)5Z
MC&G:*.4B9 MKSN-<<9/Q7$)<K;HN@>RA/M32H\E;M*K3[TO))5)O+F WW!VY
M%Z=5)RQ"^%2"36@X/4KA=BP28RT;U%@2.6LMDU?5E-NAKV:"&:;!N+/7U.,B
M1 <0E([32SU!^CSU!I@@[#'Z>]2LLR=)P=/;D?W=VL:M[-4@D,FC#@2)[JBY
MK7O*%HCE9<*3/3@V-\MN5Y2C$K5J%QK3Y5+M3VI21!#59%P%:+4M7DQ*;>DB
MY7";=?8D]U^PQ)T2I7&).C533S4KQ*5VW*(G>#*"D<A5"0:TK7H ="CAD:.!
MK E(O@]41$N<9DF=YX2Y+WXN;%)=O#.I;&FR3*X05*[V2T)%T>5>4E,A@#80
MA6%[$-KWLO1Q2,H_^4P(V7^F7Q^50])!4,CMV/1V/L,PCU>$1Z9-C>KJI#*)
MRQV,U[KUQW&3US6* RQ@).8RU0UB8D@9J924J3&C)V$W0?B;!(=;$=O%=)YU
M.[5C=<*:O)G$U514Z2/,;<AL2IV+E#W&XE&G22%+'EBTXIT"PXUG9URM6-K1
MH0J3 ;#XU'Q"K2F)E'YO%'J<JW2-P^S(4C2OKJS+&U0V6M;*FY9*J6$(X\WJ
M!N1$K4[*2#+-+*)0AT6(LP?4W81NG]/*E4[LI<_I)9IY1\J;Y20T*7J,&M:$
M37RO5<RT3(F#]#@KSF0NXUIW72A0>K&TC\H(_?: P(=:+^G53D?B\/@[O/+N
ML&'5_&K,@$,C\_G3<\D1^K;*ARJ!"K%$Y(HRU/PXS"8NKVF9%)JLQ[*T63M6
MO6;((\,-]+X>1XWCRV\=7RYK]E;2V*V \JQI-,HVXV>L21<Q"!D9GEQ+A2:(
M/K(0V-Q*)0F6,IX7 K0C5>SU9ABD816G]-:H&R%DQ..V??<5=&F65I-8A84=
MF450SR#R"K&!YBC$='U@X(?'U:%SC$@5H7)(Z-KDE5$FZ'H #BRS0!-EV\1J
MWOMMCS9-7R>IP1RM;+JM.K97UO X+HW:Z2((Y6I=%CRR/1JIZV"$I!IU&NSP
MQC-V((]"UH(18_\ IR<?Y8L5J)2IFS^G4O\ ?4E*2K7"-)E;4Y\DV6>1RV2F
M&4-44;ILS,DE9;"5$*&PAS"VJ_)H#%1"@Q&2/09*(\!:PB;TDDN[!N"1R(AT
MLM[5O4C?8<>J=7>U::KZC9(O7)FR"-383M-$*T;3D1*5.F3$.'C&;+&69X.@
MP O3AJ!+]!%T:LB]H3*JS;:!9X3.8E-(\W2AF:^/4 GE6,#>,:F&+F5T1S6O
M[+>6V1%K$2@*L"H)R;2-242< -B(X#U:VVA^MF-V#=D3D;@^V.Y3!%'YNVDL
M=AL-FHXF0[P:;(W",N*IPC;2NA3>M;U"<](^$J0&Z-<#B#SR3 X@? &G:YDU
M>RZ-R:S0/-:KXDL8C%;W&CTZI/$8:\05.TNR8,0*+4-KLQ/(O-^%X)_C$EC(
M-(Z#T,-ML?A-1=GR^TI\^M\D;YA;K#4[/)GM@D:QN,2N%(S%%/*VE[&B$%2V
M()>QR)H;A&JQ$&A7I6Q(E5 .3$Z*V$:2WTXJ9E"A4[H9Q<<&EZM0GD0IQ Y-
M&&22DV6BNR87ZBMA/M3"G)E!,4\\L60EF)-HQ1Q8T/:EO5M:A+H@LD)HAO%.
MNX9:CM<Y+K+WNQ7FKB*?<).]+V8#XX0PC49.+3OC^Q,+(_RM<C=HT)<WGNZI
M>)D4NCD%L\DG7'$;"*J;]/JJ*2DL)ET<GMP/C_!I07*D2^6O\0<C'A9JE4="
MJDLBTWP5I"Y$ND(:4!RQ2'PG)6[(@K350CCUFU()5Z>E+2]TG+DYR6SR2I\]
M68^N34B?(R!L;%=N)(*FFA+/I3#E2\*1897R$XD"H]7L@P9V@;T69H 0WFNN
M', K>O+>J5#.;=D=:VREF[21#IA,DKPV5?&+"*=_I)$ZP.*8T+FVL9JY^5JD
M_O50[JTAAOA$G@3 +3@"/W+T[Z;>42U&[S&V'$3DUJ&MP6'/L2)5K"U7'#[K
M1RHS:*$)4Y:L59:T+J66 'O/7F.WIU+V':0^G_6#-:3+<,;LF\HM-6]X$I?%
M,=F;$V()W%38G5L4/K>9-Q</$0LAA@:>9UP!I/)/*9;M7Y=P*3+E2<T) E'#
MJI)9:;_;*\V5)WJ3R&$SMY9$CLC%&%%G5O"'^N8-9Q;<X-:]0FEL>A[\%*'1
M9X6Y0)N0FJ$IQJ4(]A^5_#^NEM9<>*L*DM@MK/QF:VQDKQX0.S!](5C0W5*_
MTD:@E"A;&%K6Z@=*_DJM.I,*2)CO''H\H91@=;T$3Q_TX:AATJA4VA5E7S#)
M1"RXDT>]8U.&)O,E4&B=:QRKM5O+T^X<<D<XB^,<2;U2L1):9U)<T^E"):DV
M(0=A].8'!QJY%ER>;QUY TW6?#&V!0F0/ FEL:(S'1S>&RF1(C7=DAR^8NS:
MOU%M*"6MR/=&0MT[5&D0#!#,P.VX>G;2CM*'^5*Y/;:0=DPZPH3?L;9YHA:(
MKR':+)5R=Q>1VDWM<;0*"7-I<IBX&-RN-FQP\@!H"![,3$DD%AW3>!4+7QRN
MV=_NWD7*7ZLXZ\Q=@L*23:)N<U6M+Q9%,V7M+(#=P$J-O*)*X4.P-VT9C;IO
M7M6E93@0L-6'GC#<:5X8UE1#"]1V'R.PG!"]TI Z$.-DCO'W%6D@U;.UKO$4
M,1G)(NW!T^(SKD=RS%!H3@'% 3Z&7L10A#"'W/TP..KU#BH&[/=L+(V2TQ5H
M G!+VQN7 +AG&=SXIQ]<0\-,:0.R)U15LZF*0J"#BAA>@ 5![0A\'8;R@X*Q
M$B3$2YUO#D?)GIUJ113MK&/L]CNT=\,193P5'7VU&QI@[4V_2J':?UON\^/%
M1],,"DPI6G5$C$7L-?,].2EE!(2UDQMM8=]"4D!.6G/L0 I4LB*E%5!$&':3
M05.FTX?J_5["(T!8=;6!T?V]>H=AJU$<++,JRY[2G"NTS&>,2I6I3LFXBHA[
MJ\K8\F=8XKC*4]%**3]\P=R;FQA-1.O@R>0(7G3@<<4F;C0$"*#TIP& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!4E^_OO5
MY^SC8'\_HC@6VP& P& P& P*J\A?Z4>'G[0#Q_83<.!:K 8# 8# 8# 8#I@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#CI_E^/]W YP& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*DO
MW]]ZO/V<; _G]$<"VV P& P& P&!57D+_2CP\_: >/[";AP+58# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# J2_?WWJ\
M_9QL#^?T1P+;8# 8# 8# 8%5>0O]*/#S]H!X_L)N' W#D%>9= Q5DF2V%O4P
M95LTAL3>=,;DQH5[03-)8Q0MN6H4;TM1;DCJ-[D:;1+6D%M8K!HWPM"&#0!A
M//7\GQ>S_3U_BP.<"J+AR>/;;Y_4.KJR2$.OT)=+0%(E#]&TS076C+,&2$.D
ML. >L+-("E=WL!GEAB";M&6,[V:UTV$NM5V5,^1V1RUIL",+8Y$%GN^3NI;F
M2$AD6B\#:=*X%F=B@@YQ K)$CUL'^^A.+$1XFC ;$&BG\NN,J9SBK,HO"NR'
M2;M@'B+(3G],6>\-QK<^NI*DD(^FB?,(8NY#* ;LL9HD"@ 0[&4,(0ZC-S&X
MN2+31MBO2NW<3]+]P)G+;WTI2<XRT*)@=!-*9.4$1X]Z9Y4W+_&[=)MMZTI5
MXGEQ>+@;0AY)4,Y*"$B*UX4<J4[D>DZ?3P0 \[Z)19#.9 (LHWL,$6@A+FG>
M-"Z=IS4<!65L9&]&8&TQFW:PF<F>(9%9Y%WZ6L#6A>WF-MKND4/3>SN)QJ5*
MYGMVC-*?("6$#3C-T'8"E(=DF;"9K8<#&26]J=ASN[,4JLF(Q]V86=:_/"1V
M=TZ+;>U-B72]R/4''""G":WMHM*CR>_9Y27^6&#17S\#II.0=++Z^56HCLJ*
M**^1N*MG42<MPUM 6\(31$K&C9?9YP3H0,&][3:*V=L.N[0=A^=@)IR&I"NH
M]&Y9-[1AL;C4P1GN,6>W!Y3A;W]N2)DRY:X-:@K9H%:! @6%J%!P>I:=/O9I
MFPEA$+0?-ZY%49'%CTWOMJ0MJ61[W5IV(6O*<D1 GJ2((:WED[%OM7'&2]V2
M-0P)]FC(<E9"8W0#CBP"#5+-Y35?75)1WD(0Z)IA5<CE=31Y/*8ZN3'-Q#9;
M%CQ>MD4H,.,]HVV/.<I+/7%:#YD!1!H- \4/9@=<GEW0AB<,@%:%?_0!?&8+
M(H],TLO;UY;]]/W66,[&@3LB0LQS(.6+X@K3I^NA&*%A"A-HL)R8T&@UVP^:
M5/0B25A&6][:)2;:D>ETH9WI#(&]#&6ACC=;K+.0.\C?E(#$+6TR1@2:VF.%
MO8M:- 9L&R^HM!(+/R>HAW4O347:4(#((JT$.\M92'],L/8 &*T#8>G-.)#H
MI:H(=W-.DT GO-&>H)#H'<:7H02/$['@<ZB!<_B,M8GZ%&DN"C4G1.!.V8LE
MI-/(=3%"TT192738<E-"H\7LV2(L6A]NP[Z!7ZV^:=&U;3,DNE+*6V=LT?4&
MH@,D6<$YKXZKT3S'&9T1I4I^@F$#;#)6@&:8>$LD(5B;J/6E)&QA(CCR%K M
M)&E#%,(D^F2>:(H6@)W)D+7HQ>"T4]0R0D@]6 1:EXC<Y$<V#;_FJ%#F0)&#
MH=OIH.X9R&I(A$VN2BS(HF;GAU"SMC@I7^61+E)H&<TA2G5'EED#9CRY$W[+
M<>[W>9YY/VG;\<KN##Q_E/QWE3E)&B.V]"W9QB"5Y72-,D<MB&VHXZ_EQ5_4
M[$(H)2DEDDQH6]6(D1FDRS>B3.T?S<#4S>8=--'(&9<<YE(FV"32,LL:?651
M*G5 V-\V1/T;=I0OU'S3S"PA41UL93QJ2SA ,& L8RPB" >PAO >1],KF8;N
MQ6%%GK0T<F4)2"'3PM>)$TKPI> .IPB![CJ9)M@6 ,4+0$E!VF,Z;%L M8&Q
MP.W(7/\ W<A:'UF52%5&VR2K69H<RWPEO2N3>T.>BPO2(G38M$4D?D9N^P>C
M/ 5D&[ $!Q>Q!!]P<VZ2IJ:$P1_=SUCTV3^LH+87E2%!2:M@VY$K&E\)?W\]
M0G"6O;W)%6RL'A(=J#P#.*[@ZZ[UH)P9+KJ.22AKA3!9$->96^18J;,C"W/S
M>J<7B*'(F9S _-9)1PO/M_NN1-ZK8RMB[4RY.=O6BSBQ"# J^2%%(")"I5VG
M#R28HXI&N0C$YA%[K5K0KS$^SP  (P2(132K'M2#0DP"TAXA&!"0;L 8-UY;
M<:F-_6QAUNJ I'UN4ID2UN&]%&&IU2I8U("BAF$A,(ZA4/R'Q-Z'O1(%9)AF
MPEF %L/LV<KN-SRIG"-INFOW%76Z4I=-TR1^3'',"0]8XMQ2A26#N&>6)R:%
M2;>R-&]JE,:5OH86(.@^K3RIXXO[F<SL5TUX].!+,)_V2TR1"XEG-0014W2A
M&J1F')%YII<Z91%DD#,/-T[(]@ +2@KN#'3/ESQR@+!)9+)[5CB%NB$+%8,@
M*+VM5NB&*!31Q6->)H2I#7(1Y*68-)IR;17F4Y+FE,-+ 6>6(09@CD55J90\
MIY-,H=&Q-]A.E>(1'2EO7:6.C45& JMN?@ +^C2E.Y2Q&D/(6]GESE*8)@]"
M5$A$'?CO(FDI>BGCA%;)C,C35BVK7B="9E@EYD>;6XQ](6JU9!)>SC2DRN,.
M! ME!,Z*$9Q6_P"4 (.@ANNN=O'ZQ9I)8BDEB%C(;HC!9_$9!(506ENL.$SJ
M# GZ60QTA>6E6D$-C,/7F"5("E'7>A!!L.];P)?B'(RF)_-$-?PN=-DFE+E
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M'L)9PWMG1"VA.UO:90+>NTS>M"WH(3J[G;7%INA\>;6S3)(4BKCL)0F>Y.P
M9U#7R8:7UZ@)3/(T1JQL=9L2ABZ[:R.:V6YDZ"0/ILE8E--"?D?(>D7()HFV
MS(JX[)=TS(,I O\ .*?.K&P;VC-"E3%FJ3&I6R%B6E+P@VA,1@$>$[901#T&
M-4<C*L,D37'&6:0QV6&RI1%'\!DL;6M2Q+"8_()"$PI&M#H;UXR.,K=ATG%V
M"+2J# C%H@W00Z*7EEQJ6KH^UH[MKM6XRAV,8F1$FD2,]0J>"G,#*:W&E%B$
M) I [&@3["I\'^5-+#\9@.X,LKY*T$WI'AP<;;@S>AC\@;XN]*USZE1D-KV[
M;;_=B568I$4$LA<%V2B*4?\ -AA4%BT9T$'>P^TDY$TS%*UL&WG>=M/ZNJM:
MU+Q-90@ L<VYM;4K<G==K$IB!,HV[I%"!6480:CT>4<$S6P"W[>@;1'[7KB5
M2=="X_,F%TEC:V#>%D>3+0[=2FTA4F;URL*4S0!G@:'):0F7:+[Q(%)Y1*C1
M1A@ B"0=;Z_N>W YP/,F$\][IM1E+F55<#[BF=?NC_*V:,2X5BU6Q%/Z6)R]
M[A:IXVUN;QI>U)5;FPGC* HT$SP.T>]:T+6!;7B_R!:.3]*Q6Y&>+/\ "2Y"
M>^MSA$90)$8^1U[C3ZXQUZ:EI[<<H0*A)7)L,T$TD>P& Z"U\>!8' 8# 8'F
MVEYWVG,))9:"G>%5MVK$JVM"65.IG""=5K'$+U)(5M 4_'M[.^.Q3J2V%J7#
M191IH0^-L MZUTU@60XN\B@\DH3+9&JKR2U7)(!:4ZJ&:P:5+F9U<F:6P%>2
MB==$NS I5M+FW*0J2S"#R1]!@%\6NF!93 8# B"_[D8N/5*V==\F;'5Z8:OA
MSS,7-G8BR37ET3M"81_N]L H,*(VL6&=I8.\00:$+KO>M8%')ASZOROX"^6?
M,_3WNMHA,6C8YA)70JRJE<#VR.)DI:]R6EMZ9Y\PM4-Z 8C!$ ^>+PQ!U[<#
MTEB\@0RV,QV5-FCM-LF8FB0-^E /#/TA>6].XI-'%]=]AVDZD/=KKOIOKK S
MN P& P*DOW]]ZO/V<; _G]$<"VV P& P& P&!57D+_2CP\_: >/[";AP,YR4
MH ODI#-5=))$2@K%_*5H[#CWT?;G%RD";S+2XL2^.R!5_O\ "Y+&7-KV>B<$
M?\NG/-T<7L)Q)(PA-[ @?&\MU"^OVG\:I^=U[69IM2-GNIC5J=F-3#VI-:"L
MVT)MZ+\R9_+'_P"T/VX&?P*B3_C9#[@N6;V&OL!>,#QQEF_%&40M@-:@F-+-
M8;\WRIPD0W8CQ'MIE)!20!:<HS>B/!,\39>Q=HL#2(EPB)AU86E$66V),BGM
MI,M/L+K9Q#''S%A""C&%ABD'ZQM8D4L:L]9&8^6D=1#!_O@3S! \+^3T *<L
MOIAR&/O,VAJEV13&JF:E:Z30-Q7HHNQ2666I!+#OFQVED5Z:68'T+C#*\V0V
M@\TGV8:K(),)&$(!G^,$ETOZ9+(EC%3R"VGXU/8*:FAUK;<?BB)B2,CJF=^-
ML9X\J6QF?$"!(O:UT=:F8]40[(]$*5!ZC0!=""2"BPW='Z;]3>7B*&8V1)'F
MQ6N5T1)DTH2"9(T\2J,\<Z\54X9%5S$W$E(U;-9=22MW8I@,@L.U:)]&4#9)
M9*,)0295G$Z>4=)I@\P*X4STU2ZYU\W2-<NKJ$:=H=6D\LEWM*V*S231D:4,
MJE*1TDLA7#8SG-08)E*. 2#O**!K0:9:GIS0JTW^U7)QL*4(FJQY?)K-0-6F
M]F<3(;9DQJYNJ*1/C4M7)C#'!B6Q5H2C"TJM&)2U18A:UL!@P;#8W'@V$ZF;
M"J)CM^0Q\FQ+G6VXZO*:*Q)6#2=W:FIE>H*>RK6\UM61U>B;=B\000JP'"T+
M1G0.@X&K2/@7#+ IBH:.!<+@?J@:BMRBU#VB8X6X.JPJWJ=6U6N<WEIVD/0L
M#ZR,;OIP2IRBRBC#>S1@!$[[=AC/_IHPP1T>V=9<G5IX%9+W95>:7M3&N/CZ
MN<<I*5Y;V/'W U2E'I^8Y#9-(H4R/2C0CFIK6GEE#V,!!A8?==Z?%)0RK$13
MI-QL<RBKA'UB>XY&-I1-Q+='N4A7*&-QMYB:X]/ !,VIYX+:8/RI:Q0W_P G
MH[1@M;T& 9. 5-JYBL+AUS%&N,;EM=RV50]I309V.;I?";ZNGD(YF.*(DHUQ
MCR>4SJ\'0D2382@H$:<@M-VBT,0@U)A])UMCS.FB"/D3.CH.F8Y$44PKH9 E
MIX)7+J3_ %$2.0$.A[4)4F;5D43I%)+6#_=$:Y/L1.@EG&@$'RMGTY9&V0>6
M.E4S%7+K 5;DQC6T.J2&14K1TSF=32=<](GE3&7Y&"10\RK$ZEFTJ3&)AJS-
M[.]NBQ "QU)5)8U54^HK>R;%A%?P^0P-5!XZ5&V:(1>1QVQIH_2W0Y'[V3(6
MV*/<R=4;XA$(DI#I.J>2#32R>PW9>PJ@7Z4C6]-$O0-7*N5#>)0"QX;9CBSP
MNLU"14V6&V4.HD;4*/%MI[<R2UNE=&-SH4L$'2G0')00:$184WA!:];P)@ 7
MBPW>/S"3,OZP>4-.<H3&LQ.UNK/%GNJIS$[4=H;$$2Y./W+&;/M)A<9$^;+W
MY@QVD"XXL8!;+[ A=N]*ROT#<[,NK)E8(O+(E9=<2N#(TB B#HJZM-PK*0R6
M.ULPF:4 K?0IG6!+RF\B/P$2QU7!3E%D[3@)#;B.$ VV6\;XTG")?#Z8F]U6
MP\VB!Q:&)ZD>K5GLJF2^CG^"MK)I+)(0YKICXQR@Y4  =M*<T91JH6S<#>;D
MX)1>X[,FUAN$\?V,Z9DPET*):VI@,=(I/:UB4UB,&F$:>U:$U62%L3S@]2H0
MG>*G5'DEZ%T+V, @@F$^FA$"Q%/9=Z+Y([)9=<[V=,(S&8:Q.X%UNL4HC=CP
M1:KC986YV@CB\OVG!8R.!2@L#HWDF \(>SN\);KKA"]4C*V^?5):9S=+"X+3
M55R(*^/MZ:-SZ&5PMKMM<'F?1]L\)"]6 17\/7L[,[D!2JD29U\$P1I*9-HL
M,S;G#F-2JY72^7BV5D3;U4MHJ;+X^Y-,5.CH))3$?MR$L^SG5Y(TH @DK?;N
M@G$B,WLM4WDB(V'9QNA!KG%;@LP<7I0J9VZYW&?QL%:PAE;())XO R93'W:.
M537M)2&9M<S;&XB;H8].(]6+8<H9BS0M29U\4PG6M; 66&DM/IV(8U&('#I!
MR0E<A^@LBM9BJHR2L$(1*R:EMV+2R,2"HGG2!"A4V K9X_+5>FUW5B-<DW@@
M'ON[E'C!]U'I>0+R:QG;+*DC:QCU/T[4F^C<37+VING<7JB)^6TZK&TQ2Y&L
M3=4Z49!JCO$:<J-V;W:"7H(0Y _3"DT@@ '.<SP537A#Y],72I93"V2(2YLC
M3 HMN:S9M'+F-Z9@L%C)Y7'Y>H2KVYS(&0E\7Q"=Z4@\;83<Z^F="G=Y>W=R
MFI#RDD3G.W!\B+O74+!#'I%8-54-4[U'5C*T(6L*-E*::&2*DVD0DQR-6X#$
M2,ORR3P@T9X]*<#\0X(GGDW9[^F'2TUI=E72:/0N02AH:)Q5M55\K5J94N:]
MNS]IK=Z?;'M.4L$9LQ4J6%'#,),+"6$@R7TTX=+I-:4B?;,E*TB[U-L([/8P
MM3(E;7**6X*CUSRT,@$Z< V1Y:'VBT*E$ZZV-6 +@I /8M@3C*"1:DX,1VJU
MT]5ES]]>BI_5,SJIP3"8X\U!2HIK:UH6LM>R3&Y&4,QQ1+K34HB0#[BO+I2A
MBULP1HA!#6O3)"%L8PI^0DS0R>-M==-[++$,+@I:]'JL*@6TW'AA2FM1R,12
MV/J0G+2]AWHTT(@A[ "Z:"7>,/!M)QGFB*8-5IO4JW]#9U#WIH716+,S>XE2
MZW)';Z%:C]SHR#6HU@>):O2A+*%V*4XBQ&ZV8#KL-0:_3,J5@D-G25BFLW0*
M;)KB\JO&TB$T'QB-QFVG>4.<42LK -#I  BD4U@29!&BAZV62WR)80;H81!T
M$-QKG@PUU[/H#.B;-D+L9!+3:K33M*EBCZ5*YN#5PJC/"DMJ5*$J4"DE =%H
MR6_"$7L)@74T16M^5T$K01U-?3*@LS6R,Y19$H3I%-CV59D+*/:&!W40YTN>
M<P*?6<S&GN20X,C8'-\A)FT!*T(]MX',S0-[TD1> $T<F.&C#R3DA$B=9JZ1
M<153RFIQ(T+!'G8O;;*9E!YDH=BCG=&H.3KTBF#DIP #O10BCQB%K8@@WH*^
MK_3D.8YX@M1NL]\GA,,L&>W$P4N\1BOFN-/\EF89:8^0?<F/8%RYDB\K(DNT
MBP8P*=B"7H8@[UL>A!)T"X1HD_#!3QEDLB>6ASE(T#^\/0%R*7.49<V^8M<X
MCL53NSLVEE26,PD3.D9TNE! 0C:TVB@Z+UL/:$<'^EW##IC.WXNTI"BC5XQ*
MR6/D!!T\4AJE#,9%8#E:SH7.:]?5[6I?Z7DT?.N5X) >Q'$B5)PIPG;$,)AA
MH9C?IRZDR1G%;E\2VT'UPKEFJ:UGPZ'PF'?K&AT/M",VG"%A35$FQN;8C,F5
MTC0DBAU0@"H6D+S!CZ&I4 DP8H'I?0XP@25?:LE4)E2R"JG022,1)K6*=0GE
M59_*S1:-<A;RE#2)VD=H*6@P:?81$H$Q9I?:I$88(/U,^$UCQG@'8O&.'S5!
M<5DO33$F*.S"5Q:#UV-Q:H>[1)%&-R\$58BVA]>V.)1LLM2YJ$YBMR-*UW;!
MKLT /P\^G(B:K&07 P3]WDHXU/Y3=^Z<6QR"ML4FEER9%(4TG:B7A6R+U4,C
M4_0NQ21>06%02$17B]N]F&Z$&$CWIL+UM8T)&76VI/#SJUDK=8#Y%=)(S8:,
MU]:K>@5NQ*/II3(&8EUVCKXB$%QE"I*T5K;,/M"6 19>]!LS+Z8->-R"(H5E
M@219N(&0:/%+DK4QM+@^5C DW().VPYX5-R9.,+LN%R/>S#GE/X*T!A";979
MVF;&&_QO@L-!Q,E'&"77"[3-4_CC0"K2_5[7<6D6T=?J(G] M2-EC3(BC\N=
M4+="4"9Q7+"1*7$K0@"$ L)0"PPL.X3MT6Y#0*:HFC;;'8&JN"RI#+4K\F 5
M;<_O>P%5@/,)>Z\3M9)#7%ZVF[6VR-D5[5FC)<4Y?87HTQ6><$ON7$MF<;6Y
M'6_]+UR677W7E>P-G<BH[&E#E41E=,%A,3=)(0YKT"M28ZN8;%4F*M*>\O?@
M% #H(!#T(*ZU!Z;SG3<TCLTCG(Z6''"4RXJSX^IKRNA1RRV"4"C;L6VB;!,Y
M@8BZM,NC@7$#FW;+5FA4&$#ZEZ!VAF&+TWX^QL4:CP;9DBM!&H3QOA*?S$:B
MW>>EXXWJ[7LV+S EH@@+52YV=A-RW0-! F1AT--X9V]BV$BUMPP7P;C?;/&E
MZNZ6SF+SN 2RHH1(GB+PMNE5;U<]1EXB<<81N+.TH]3QZB#4\"T6Z.VCE"S9
M1?C===VQ!%[+Z9\-;WE!(%5EOXG),=Q#3+DS-&8M'V1X9^'Q\P-BIRYJ;4)8
M!3.:$3,Y([/VA>?*;DB-&E$20E+#H,,B]+>$IV&!MYMGRH<EKR-43 HS9"!O
M:V6PF.&\;6">QBJE+"_M91 VR;%L=CN:1Z<>PPE\1'[3*$^R-:!H,B+TU4CO
M5T6J&:7Y.Y1%*_F$V7P!8&+PABE,=KJ21&:1..5X?(VAH(<GLR#)9L9M*[JA
M&+U(4A03MB\53LX/F=Z:J611M@:K NMSE+^CKEBK>5REKK"M80HER-DM%DL@
M3^:VQ1E;T#/)'@IB*;U:I+H)@P#$?K>C=%["'Z:/3FDC4VTVG.Y/2]]<Z4E<
MK2L3E(ZOJAZ3R"CY8;'A'5++F=9&Q-CX\,Y440>[Y48#WTC&4+8!]!B#@2.R
M\"XRST=R?I!#/7QI8>3!$C$H3L+8V((U6[U(XHGCKD_0&&' 4LC,8\NZ;WVX
MH !"VGN9QVP$E%F;!H-LI[ALQU9:*2SUDW?)<X,#CR1=X>C7HF]O"PK>6=CP
M^W+G3G*F\LH]W:CY]$='LZ<_8M-B14)-K8P$I]EA=# 8'D'Q,M:^>-U'16DI
M?P/Y5R!YA,GM$APD<-.X\N48=D3Y;DXDK4\1Y0[7RQ.BQO7L+TG/!I2D2'!$
M+98P!V'KL+,^G37UA5KQ4AS!:,+=*[F2Z3V3*E\*?%K*O?(\EEU@2.1-;>\J
M(XY/+'[S VN)6S@IE:DH ][#HP73K@7CP& P'[OY,#R)H2=WMQB5\A8,]\*.
M2MBER3E'<ED1N8UNIHA9$'^(31:SKV!Q;CY1=46?RC30%F@.)4MZ<9(R_P#E
M:WK>!8G@/%K%98??TILBM)54J^VN6%X6M&X5.%,6/ER*%RMU;=1U8_%PV12R
M/H5KBG0B-\N2X*=E!%K0A=?9@7MP& P*E\\*^FEK\..2%<UTPFRB=2^J9.SQ
M6.$*T* ]\>3DG>C:DZUT4)&U,H6C+\,L9YI96ABUWB#KKO04XY!7C?5M\7K3
MI>.>GUR]12F>5 [0-F4/1W&Y*SI7Q[8 ,Y1CLL3\@5IR9L1J3Q"..+).'X9>
M]A+%O>@X'I_5C&XQBL:YC3N4$AVCT#B#&Z$@,"< EQ:8^WH%I0#0;V T):E.
M+6A:]F]:ZZP-\P& P&!4E^_OO5Y^SC8'\_HC@6VP& P& P& P*J\A?Z4>'G[
M0#Q_83<.!:GIK YZ?#X?'@,#R#L1%RZ#?\E>&,NU6&&MER6BEB+W&(LQNT<^
MC[]QC3HX1(Y7$&AT8%UEQ5@M8LP(0K3]+BU A *.*UX1@ STI<N;4@XK4,2B
M061 +E<9O(VFV#H6K8Y4Y&11#7EH&M4F0K9DP)WQD8Y!-D+">C2+4VGI!I2%
M(J&< )IXP@U-8?J-/,@$@'&+XC!#C%*J;I$M/B5<*D3=)4-[4*DFKQ#E99BA
M"C;7BDY!+% R!I3EA&TAOBJ3%I1!0 P@I5ZD,&:S].:'D;.HBX(FIFFCJS1&
MMGNU8HS(K=Y/U^TRZM6$3K#$$@D^H8EK!Z?$PU.S%36-2M 6<KVM3#"8JG:>
M5$FYN59(+JA5HJ":C;>1T*#/W)HAC96CI YC7O'=95TJ#J+.HD)4SESW&'[3
M\D1$C"WOVE:<(--@&@T0:HNEGJ*O<3M:1,J"[(]<,*MPQ*CK%UAU6I*<F<1A
MDPL!S=3*TFP'60R)U9;2HLUL(:CE(&\*"5$(0G%%*!N.!VIS:W.E),K2>6NM
M>3:J&PMZ@_@0N+Q.K##9[QOF#;$SULKK>2NTP Z&\HX"I&ZE.3&86WD"."/?
M<>7I+O88*YG?U E^['K>$H>13G&W> OCA$YA[IK9DE(6IPH-(M;D+C)(^-B3
MM-BDV@A.3[(;@ ,+5&:!W;),V/822V%<ZBY6!QB;=,R8B[7>CKA^;7QLA3$Z
MI:<L.DZZV*\@.2HOWH^2.CIXP.R<DA7LU6Y'NP@J/&*3$[T$G4S*.:#V9RV4
M29FF[59428I[%ZFB$^CL):Z$DDZ9GNPU-23FMIRTOSI+WV,36)*8X4\EKD[:
M2@VFZF)PN(U^]A!B>&<G[8D=$[MMAM)XJM->C/(E;))FUL3R%IC\@X#6NQ6V
MQ6HTMYGNYWA2'DN_HT#5K05FM*5ZD*38V@A"<6$-UBU<P:!KBGD[73=W+XTJ
MX]\6&F_#8/'J_.OPB6[D4]C]ENC,].R\A9+IA#R#V(;@0I5JBRF HP;>$P[8
M@#"5I*\^H&_RF?172KD?#549GM11)"\1^%THKALZIJ2N<&"YV8S2\M0YC16F
MSHPO8)*A0-#>D1&FF#(+,( AW@3S&7SG SPOF,WMS,XSB8Q5(<?QKE\H+(C1
M<S\NWJ"@1M;"'SQ&]%.6<M)VA=T;@;&)"H.3GC)0"VI)P(]@]?7_ &'R+HAY
MN5CG\DIN/O/)A7'=2YM1E#11QU8N/;W6R*WV<S17FG5JL5ED?T>4'$&K )VX
MDP\8!B+&8&F6VLY^(G^V3JW3VHV(V:;\H)9""(S#ZX DF9L>F'$M90C0ZG'M
M^SW5A?V);8*36S3"E"U&E-TL,T,"00PLUR"E_*])>[A%:LAUCG,HZ12S"C95
M&B((93;M<K.FMU//:YY(K9"J')6!C=2E,*4,QS<EV<>("P"920<$[O"H$K=_
M4A4H53C$5EUHXZ""R>9P9M41J";G)UC-M,UJ\_0.Q KT*@(VK=WA=TK<628%
M(J+,7$Z.$U%MH\#]2F<^HO$S)@]IF*_IK$9"[3,4E;V&(UPKG,%B1')!?'8<
MX4RQG.$33NSXEI=S)<3D:E8(Y6D3:,'H:L&RA!GY<X<V9+'+;A[TW\IR)G7[
M_3RJ-2B+HJTC<#M^HQ6)6KH:_-AT8<125JNA-'R'LN3LR ;>A"7WEZ\P5LCJ
M&>8W3GUI["U(F&8,2$5@B>($ZG1^'-K,[H-\L9.BLINMIO:$HBTS8JXL*43B
MPJ=E$G*7((1!,VOT:2,)/XEH>9\I@EM1.[)?9D8E$MX_TTY1"P)C'X2G<H!>
MDOK)Z:[0#&D#&@+:E*6#S1N0K](%!)Z'2@T80;.)-$'00TB6>I*^U3;SK841
M>VJ1>#3<XK:(MGT EZ@U3/'NJF6S:P6MR@A0W+2ZF<:TE3R6K-'OO:)VB+),
M&J;1" $<,-?<PHU=D0LAG8;N/?HK(IU Y0_/Q;,^ZF=;OWJ:A>P,[FX/"I:L
M<8JBXK.8W%N&F&08E;R^TL05902=!(/+&K.2,OY+29=%&^ZE,=99O1-@55)X
M\-K<XW"C8_4EXM,W-BB=X.5H6EQ<)DK8B'(G:00U1:@ OG%Z&( 3GQ"E_,.8
M6\XE<BV6V(21'*^8?,-*J(5\72LU*?8W&%S3(6J6HY&Y2])9C*^A=DKTU$H4
M*8@8M=VS2M$#P*RQ59ZF*11#GLYTN%X?SRJT='*-3%AKU%"12M[?+ZBDO99#
MMC:TZY'"VQA;(4X*]IC-B2C/VI(V,TQ2# ZY=B<V_H*=:LRFG(VEF",T?RTM
M&7(;/@%&,K' +DKN$T^16T9>5:9_?Q2NKEDOW,G5O\P](TSL$'@;/3MP4&]A
MDJUN/EY/E58I&9VY!J()+;3FY#W*([ ZRE4BI61-SC1LJ@E86&\/L@0LLPJ&
M1UNKE8#I8E*<SDRQPVE/(*6I&X>P]!N%Z^VT].0%IOD^UWJX)'%!SV=O%A-#
M"B1L#TJ<0L9T'1FQ=*WLK<:@ @"I)1%EF"V2<,\1N]C[=!<77Y<!TU_G_P O
MQ]?RX'. ^+ =/A^_\>!QTP.>GP_R?PX''36 WKK@.F!S\/\ 3@,!@<=/X/WO
MX^F Z?#X?'@<],#CI[>N!S@,!@<=,#G 8#I@,#CI[.GP_P F!S@.F P& P..
MGP_)^]^_@<X# 8# 8# 8# 8# 8# ?%[-8# 8# 8%27[^^]7G[.-@?S^B.!;;
M 8# 8# 8# JKR%_I1X>?M /']A-PX%JL!@,!@,!@.F P'3X?+_'@<=/9T^'^
MK YP& P..FL#G]S =,#CI[.GQ_OX'/3 8''3X?#\N Z?#][_ "X'/3X?Y,!_
M'@<=/A_I_?P'37PW_G_+@<_NX#X?'@,!@,#XJ$R=60>E5$E*4RDDU.I3GE@.
M(4$' V6<0>48$19I)I8MA$$6MA$'?3>L#',; Q1AK2L<;9FJ/LJ$ @(6AD;D
MC4V(P#,$:,"5 A)(2IPC,'L6] #K6Q;WOX\#+X# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# J2_?WWJ\
M_9QL#^?T1P+;8# 8# 8# 8%5>0O]*/#S]H!X_L)N' M5@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"I+]_?>KS]G&P/
MY_1' MM@,!@,!@,!@55Y"_TH\//V@'C^PFX<"U77X?O_ +V!^=B"'740@AUL
M6@ZWO>M:WL6]! 'V[_VA;%K6M?+O _6!QU_C_)UUUZ?EP.-BUKIUZ>W?377>
MM==^WV:]OMW[,#GK\/9@<X''PW@<_#X?%@<;_<^/Y,#GX=?D_P ^!^=[Z=/;
MK77?377V==^W?37Y=]-?Q8'ZP..OP_B_S]<!^]\OPZ_'K YP.-;_ "^S7R?#
M]W 8'/PZ?N_'@<=?A\/EZX#K^3X?+_FP'MP'7X_^+I^_[<!U_@_?_>ZX'.!Q
MU_T_#\F!QWA[NSN#W].[LZZ[NWKT[NGQ]O7Y?BP.>O[G\'LZX#V]/D^'Y>N!
MS\/^/ 8''7_3\/R8#KKKTZ^W73V?+[?B]GQZP.<#CK\7R_NZ^+ >WI^[_'@<
M:%K>NNNF^F]ZWV[UOVZ]F]=?RZW@?KX?#]W X_+_ )L#G ==?Z?X,#CK\/A\
M>!S_ !_#77 X_>_=^'R8#X?%@<X''7X_W.O[O_'[<!^_\/\ -@/R?\.OXNN
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ML\3L,2G2Q66UJ7=M;"Y;6L\EC G3Q=8G/4G'$DGZ..V(90MAN-875RHG?(B
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M(P!=%)!"DH82SA",+-!K6RQB!V[P-]P& P& P& P& P& P& P& P& P& P&
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MW-;BDL0)C$HCD,DMKU<5;%?P=0_-S[MH6ADS*J3(4CZ0<8Q*'1644!2(OO-
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MJVS[3KIPX[V^[)JIG-HPEWE;?(*N*;',=.3JIX3.GEM;ELS3OFD"8=Q-2I*
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MSSGC_$9&Z1XI%)FY=*AV*@$YO$?<V_9Z5,B"G/5 [S-)Q![M_#X?NX'. P&
MP& P& P& P& P& P& P& P*DOW]]ZO/V<; _G]$<"VV P& P& P&!57D+_2C
MP\_: >/[";AP) ON.T'.ZZ>*YY'@KQSK*:%E$O<7LMV:F^,R0ID5HWX!"Q.[
M+42=Q);5B$A4(&]B" 10!BU\W6\".II4W#F6V-J:3QEIUXM.(-\(5F/C\^M
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M**N)*Z6W5)72,-$27MKPYI;6J*CJU;V98_&NANE:*-.%/#<@Z,+$ 9CCOM"
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M,!@1Q$/_ &RM/_Q_'OYGLN!(^ P& P& P&!&LP_]M*O_ /'#_P#S?4X$E8#
M8# 8%27[^^]7G[.-@?S^B.!;; 8# 8# 8# JKR%_I1X>?M /']A-PX%JL"%+
MM>7&,,T3DK?"IM/?<,Y9%JUAK]I1/DD$C,3.*(:TAO<'5E(-2I#E8!'BT=WE
ME=1: />NW CW[TB__##RM_JUCFO\\\U@/O2+_P###RM_JUCG^?Z>=,!]Z1?_
M (8.5O\ 5K'/T\P'WI%_^&#E;_5K'/T\P'WI%_\ A@Y6_P!6L<_3S ?>D7_X
M8.5O]6L<_3S ?>D7_P"&#E;_ %:QS]/,!]Z5?_A@Y6_U:QS]/,#G[TB[V_\
M5AY6^S_]VL<U_%UGGMP./O2+_P##!RM_JVC?Z>8#[TB__#!RM_JVC?Z>8#[T
MB_X_NP\K?ZMHW^GG7 ?>D7_X8.5O]6L<_3S ?>D7_P"&#E;_ %:QS]/,!]Z1
M?_A@Y6_U:QS]/,!]Z1?_ (8.5O\ 5K'/T\P'WI%_^&#E;_5K'/T\P'WI%_\
MA@Y6_P!6L<_3S ?>D7_X8.5O]6T<_3S ?>E7_P"&#E;_ %:QS]/,!]Z1?_AA
MY6_%_P!&T<_3SX\!]Z1?_A@Y6_U:QS]/,!]Z1?\ X8.5O]6L<_3S ?>D7_X8
M.5O]6L<_3S T^(<B'ED^E.U7&'E9T=I>Z/"7I6T9[MI%:5N++%O0+ ,[=>(G
M'K77>A>SKL.NNL#</O2+_P##!RM_JUCGZ>8#[TB__#!RM_JUCGZ>8#[TB_\
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MI%_^&#E;_5K'/T\P'WI%_P#A@Y6_U:QS]/,!]Z1?_A@Y6_U:QS]/,!]Z1?\
MX8.5O]6L<_3S ?>D7_X8.5O]6L<_3S ?>D7_ .&#E;_5K'/T\P'WI%_^&'E;
MK_\ QK'-_P#]^8&0K:S'1V<)](U=-W7&"7I_:]H4$HB3.WN9Y*"--*(U66F2
MRAP!Y7:@H0-"$((MB#OYO3IO82I^L4[_ */+)_\ ("'_ -,X#]8IW_1Y9/\
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MO4+FLLL*8 Q!3X%7ZYMCE77B![0UK7DU4M=EW5>=UUBHE4'D9Q5FM4UYXNS
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M6GURY(?BSY-?:O@?K7$RM]=.DTY):Z;UO73EIR;ZZWKVZZ;_ %L===-^W]_
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MBRC#.S6A"V'V8$\8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
L8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
